{"docstore/data": {"1ed17d67-b105-40aa-aa9f-92f69e7243dd": {"__data__": {"id_": "1ed17d67-b105-40aa-aa9f-92f69e7243dd", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.   (MCK ) \nQ3 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f2d747-2083-412e-b828-5d8506da8229", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcdb20b9d8977eae47e72164d7a18b0104bb4a2b2272e77fc3be5be79881ef7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da3260e5-2e9b-4e2c-a5ff-594401cd5af5", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.   (MCK ) \nQ3 2024 Earnings Call    ", "original_text": "(MCK ) \nQ3 2024 Earnings Call    "}, "hash": "d4d0da2197978c5821ebfca8bac8942a9f4d0430225ee84a48afc99da18d9d24", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da3260e5-2e9b-4e2c-a5ff-594401cd5af5": {"__data__": {"id_": "da3260e5-2e9b-4e2c-a5ff-594401cd5af5", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.   (MCK ) \nQ3 2024 Earnings Call    ", "original_text": "(MCK ) \nQ3 2024 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d9f2d747-2083-412e-b828-5d8506da8229", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcdb20b9d8977eae47e72164d7a18b0104bb4a2b2272e77fc3be5be79881ef7d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ed17d67-b105-40aa-aa9f-92f69e7243dd", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.   (MCK ) \nQ3 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20764046c330094694e1cf7859bdff815f7773b082d7d9de9546f82265296f1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ea85a50-bcbd-4c82-8ae3-ba8e736e8193", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "260d83a28bbf3dc47a3f72e36aee2a30c9da0262eb028800dc2b6e3f83e132df", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ea85a50-bcbd-4c82-8ae3-ba8e736e8193": {"__data__": {"id_": "5ea85a50-bcbd-4c82-8ae3-ba8e736e8193", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da3260e5-2e9b-4e2c-a5ff-594401cd5af5", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.   (MCK ) \nQ3 2024 Earnings Call    ", "original_text": "(MCK ) \nQ3 2024 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "774f3d5ed0663ffc12a40b00ffbc00d34d0dc42933739f04345125e0e0abc8f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbae45d9-e504-4467-82cb-d23db27285e7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n"}, "hash": "91a2b86b3c06f1a5883abee01072e64e1bd62e4946f6bdd79f933f1a1caf68fc", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbae45d9-e504-4467-82cb-d23db27285e7": {"__data__": {"id_": "dbae45d9-e504-4467-82cb-d23db27285e7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ea85a50-bcbd-4c82-8ae3-ba8e736e8193", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "049f455c6214dc38fb770aec4c56116bc6fdf2ea3b0a9acde552ad36c728a52a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b74f7142-7590-42b0-991a-8d033c1dc4c4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "04e116d938a992bad5c142bf81e37a3ecae1ba5b2fa9a4e2e845f5261776e770", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b74f7142-7590-42b0-991a-8d033c1dc4c4": {"__data__": {"id_": "b74f7142-7590-42b0-991a-8d033c1dc4c4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbae45d9-e504-4467-82cb-d23db27285e7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a12326d7fa1ceb7457ecd4984932808d12e819deceaa0e078c5d0e6ee339b97d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bdf596e-0915-4c87-84b2-8ee16df4d174", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n "}, "hash": "965f5acff15ac581af6eccf7e0a0dc2967e7ef2e24eecf932352194528b010cc", "class_name": "RelatedNodeInfo"}}, "text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bdf596e-0915-4c87-84b2-8ee16df4d174": {"__data__": {"id_": "2bdf596e-0915-4c87-84b2-8ee16df4d174", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b74f7142-7590-42b0-991a-8d033c1dc4c4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29277b49ef8706d6b81bfbb988b1c3d074093fab1c8faa9a2b0f55ebc2c97e92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4577a03-46f1-43a5-aa9e-28b480a738a1", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "e7742c905e0b33469ae2735ac2339903f27d93fdb924a9eb4e718b9185231480", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "start_char_idx": 355, "end_char_idx": 445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4577a03-46f1-43a5-aa9e-28b480a738a1": {"__data__": {"id_": "e4577a03-46f1-43a5-aa9e-28b480a738a1", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bdf596e-0915-4c87-84b2-8ee16df4d174", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cad6b37a6d501cd23a53dc1b127f96fb8b4b3466f1984868f37d7cd8aa90847", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb3f2d6a-5c5a-4172-8f8d-0e34d861ce06", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "af8f78ddcbe8f11ec9cbcba386fc3dbf94068f8908874c9064165de4edb0c8a6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 445, "end_char_idx": 779, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb3f2d6a-5c5a-4172-8f8d-0e34d861ce06": {"__data__": {"id_": "fb3f2d6a-5c5a-4172-8f8d-0e34d861ce06", "embedding": null, "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4577a03-46f1-43a5-aa9e-28b480a738a1", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "024e1e8ee788830950735d39cbbb2fed68a398c6746eeb7b9f5cf3d97a92df67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e888fe65-7d3f-4301-a92e-520cc8608087", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "e5a3d00f4f21af128c4f29117b40e71e402dc6b9e8130786f70d23d1aa0f1ce6", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 779, "end_char_idx": 928, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e888fe65-7d3f-4301-a92e-520cc8608087": {"__data__": {"id_": "e888fe65-7d3f-4301-a92e-520cc8608087", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb3f2d6a-5c5a-4172-8f8d-0e34d861ce06", "node_type": "1", "metadata": {"window": "Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "original_text": "LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91f8836bf35508dd856cbffd163d1a40ef3109b0b476cd121a6a2e80211f0aa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a36f826-14c0-4607-b3da-bd4e42c94ae3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. "}, "hash": "906e855a093a5b7087ce2d61346194458ac7b8be199ab4c6d857f39b052d9682", "class_name": "RelatedNodeInfo"}}, "text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 928, "end_char_idx": 1078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a36f826-14c0-4607-b3da-bd4e42c94ae3": {"__data__": {"id_": "1a36f826-14c0-4607-b3da-bd4e42c94ae3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e888fe65-7d3f-4301-a92e-520cc8608087", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "original_text": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7da4cb77c63f2d0c60f2125cd27425d084cb6cf09b0aed60fddfe90ab7de719e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65fa6068-4c5e-40d2-ad15-7d63fcea2345", "node_type": "1", "metadata": {"window": "LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n"}, "hash": "713dcf0a0c5099ff423506f1ed71ae39858f5ee542e3827b9461cf4173f799f4", "class_name": "RelatedNodeInfo"}}, "text": "Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1078, "end_char_idx": 1176, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65fa6068-4c5e-40d2-ad15-7d63fcea2345": {"__data__": {"id_": "65fa6068-4c5e-40d2-ad15-7d63fcea2345", "embedding": null, "metadata": {"window": "LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a36f826-14c0-4607-b3da-bd4e42c94ae3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1be14693990d71e4d8f7e8a6538c6aa16c5898a580f5d0863c1cf13b1d27b2f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e28b0354-df44-429e-a582-563a61577a78", "node_type": "1", "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n"}, "hash": "eb372f0fe9988828d0c616476ba34456a24c9ab4639ee76f8e31b9faa891655d", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "start_char_idx": 1176, "end_char_idx": 1244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e28b0354-df44-429e-a582-563a61577a78": {"__data__": {"id_": "e28b0354-df44-429e-a582-563a61577a78", "embedding": null, "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65fa6068-4c5e-40d2-ad15-7d63fcea2345", "node_type": "1", "metadata": {"window": "LLC  \nEric Percher  \nAnalyst, Nephron Research LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  \n Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f0a15872b9ec8a146ecc861a0bf0335e306540e9edddd9472f82df4e0dd29dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e720f6ed-9ac9-41d5-8ddd-de5b90b0130f", "node_type": "1", "metadata": {"window": "Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  "}, "hash": "fbd5494c978b3fdcd1056a21363863fad4339201e6e5411aa942eedcfdb70b93", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "start_char_idx": 1244, "end_char_idx": 1345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e720f6ed-9ac9-41d5-8ddd-de5b90b0130f": {"__data__": {"id_": "e720f6ed-9ac9-41d5-8ddd-de5b90b0130f", "embedding": null, "metadata": {"window": "Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e0f1ac8f8220b2e91f58a43e842d8cc30c7988cbe363243db83509da3468b06", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e28b0354-df44-429e-a582-563a61577a78", "node_type": "1", "metadata": {"window": "Brian Tanquilut  \nAnalyst, Jefferies LLC  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d377c7f94226fe235de7c047693c249fc7df729b753fb4c9f96749a724f4ef2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5d0010e-9a3c-43fe-a561-b6cd258d110d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  "}, "hash": "0210cc202c35531501f5e01ff5b286ab03e9ba8c8188ce8bf369b5f3d5118f55", "class_name": "RelatedNodeInfo"}}, "text": "Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "start_char_idx": 1345, "end_char_idx": 1398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5d0010e-9a3c-43fe-a561-b6cd258d110d": {"__data__": {"id_": "e5d0010e-9a3c-43fe-a561-b6cd258d110d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e720f6ed-9ac9-41d5-8ddd-de5b90b0130f", "node_type": "1", "metadata": {"window": "Stephanie July Davis  \nAnalyst, Barclays PLC  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  \n Elizabeth Anderson  \nAnalyst, Evercore ISI  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  \n Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "original_text": "Carol Wong  \nAnalyst, Wells Fargo Securities LLC  \n  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed2294df98cfe4095b0e8032138fd7af23e64de5eb82bb82a162f67dadf5c96c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c757f87-efed-4953-8fa4-224d384d9312", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call. "}, "hash": "9d94784a34edc8e1f819d625d0a1c689427eb5c73040818bd155a2049e37887a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c757f87-efed-4953-8fa4-224d384d9312": {"__data__": {"id_": "2c757f87-efed-4953-8fa4-224d384d9312", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5d0010e-9a3c-43fe-a561-b6cd258d110d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d7d4e0942c5633b970c84fe9b436814c16aab7d5a418b7d1da50c23c5342f60", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95f1eb72-06f4-4dcc-b928-a9c1af0c7820", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n"}, "hash": "e637cd24bd11ae4e2a522cc7c1793657e886a3e396cd08d3f0995bcb5a868c06", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call. ", "start_char_idx": 16, "end_char_idx": 302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95f1eb72-06f4-4dcc-b928-a9c1af0c7820": {"__data__": {"id_": "95f1eb72-06f4-4dcc-b928-a9c1af0c7820", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c757f87-efed-4953-8fa4-224d384d9312", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "121def87f77bdc05a2ffd050ffa3d2ebd37e03fef59111dfa288ae32c3a8d0aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e20da75a-bcb6-4ed4-ba44-845e57c2a67c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations. "}, "hash": "20286aa1d9049f587735d4653e507c35cace49cd6c9e99e2397fb4be05ad65a7", "class_name": "RelatedNodeInfo"}}, "text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "start_char_idx": 302, "end_char_idx": 368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e20da75a-bcb6-4ed4-ba44-845e57c2a67c": {"__data__": {"id_": "e20da75a-bcb6-4ed4-ba44-845e57c2a67c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95f1eb72-06f4-4dcc-b928-a9c1af0c7820", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n", "original_text": "Please be advised that \ntoday's conference is being recorded.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc2b1f0055da9544476c1ea3559f492f9f6a6bc43a5a36d073df19054c20d6cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "470da5ce-1946-4afc-99ca-c859ef20559d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go \nahead.  \n "}, "hash": "cf6b590c712ac285a3c55339b76da746ef5b7926180c6a7f017dec8bbf16542b", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations. ", "start_char_idx": 368, "end_char_idx": 470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "470da5ce-1946-4afc-99ca-c859ef20559d": {"__data__": {"id_": "470da5ce-1946-4afc-99ca-c859ef20559d", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go \nahead.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e20da75a-bcb6-4ed4-ba44-845e57c2a67c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator. ", "original_text": "At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8f3f103e203eddee5ab43c3414ac4c38a82aeace5d7b6709f80b1de25593fd9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91e8149b-7c19-43aa-80f3-28bd2601ddce", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n"}, "hash": "2d21ef6319a763b1d226a64b4577875556b06f7c22e4e9fb4536d5a7309ac1e2", "class_name": "RelatedNodeInfo"}}, "text": "Please go \nahead.  \n ", "start_char_idx": 470, "end_char_idx": 491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91e8149b-7c19-43aa-80f3-28bd2601ddce": {"__data__": {"id_": "91e8149b-7c19-43aa-80f3-28bd2601ddce", "embedding": null, "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "470da5ce-1946-4afc-99ca-c859ef20559d", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall. ", "original_text": "Please go \nahead.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c14866ccf0efdbf6ed9a6ab7a5bfb0ca48d4579a14a6e1ac8478246fc732cb36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75b3bbb6-fc6c-439d-963c-b6033cd307ab", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. "}, "hash": "6f8b54b55bfe19888a7d128aa177c6ad827aa769bd29c298ec6d8cb216b62344", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n", "start_char_idx": 491, "end_char_idx": 838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75b3bbb6-fc6c-439d-963c-b6033cd307ab": {"__data__": {"id_": "75b3bbb6-fc6c-439d-963c-b6033cd307ab", "embedding": null, "metadata": {"window": "At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91e8149b-7c19-43aa-80f3-28bd2601ddce", "node_type": "1", "metadata": {"window": "Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f90b98898931a66ce8b81588a4ae9b7580d7f607caf921917fd8d7aaabbc927", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74b0e77f-54fa-47f1-a17c-41675b580c34", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall. "}, "hash": "b931275c4e47e87255ea0bbb2d861ef72ba6e903d44f3c1750947070d9d23271", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, operator. ", "start_char_idx": 838, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74b0e77f-54fa-47f1-a17c-41675b580c34": {"__data__": {"id_": "74b0e77f-54fa-47f1-a17c-41675b580c34", "embedding": null, "metadata": {"window": "Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75b3bbb6-fc6c-439d-963c-b6033cd307ab", "node_type": "1", "metadata": {"window": "At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations.  Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, operator. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67e4d730f0ab4a7012f47a288b3bd3215ae35fa24c4ec3c7b7fa950ec163a3af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2c0de1b-41a5-4024-bccc-176c141ee85d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n"}, "hash": "f3cbb9b0b64f48ce1f660efc650f21f50b5e6693477e7166eee09cc97a0be59b", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall. ", "start_char_idx": 859, "end_char_idx": 951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2c0de1b-41a5-4024-bccc-176c141ee85d": {"__data__": {"id_": "e2c0de1b-41a5-4024-bccc-176c141ee85d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74b0e77f-54fa-47f1-a17c-41675b580c34", "node_type": "1", "metadata": {"window": "Please go \nahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "original_text": "Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a8199a09b1da3c6102d099c88455146267bd5ef1a3d84f679a0ebdb8e72c26f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9761ac16-9494-46f1-91b0-41ee90e0fffc", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "16439f7ae5c0017b5825534270ded40cccf2dc10bc145527faf7ee7239b4cd0a", "class_name": "RelatedNodeInfo"}}, "text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "start_char_idx": 951, "end_char_idx": 1064, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9761ac16-9494-46f1-91b0-41ee90e0fffc": {"__data__": {"id_": "9761ac16-9494-46f1-91b0-41ee90e0fffc", "embedding": null, "metadata": {"window": "Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2c0de1b-41a5-4024-bccc-176c141ee85d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice Presi dent of Investor Relations, McKesson Corp.  \n Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "original_text": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "214be3038f19241aeb16249ce82f40398e541997c2cae93a903da7ce29e3413d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3cda2dd-ddb4-4180-9303-64f3fe3e7923", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. "}, "hash": "27aabb162270d642e5ab7cb4d6fb93b21f587b3ee17a15624bd4957202a1fab5", "class_name": "RelatedNodeInfo"}}, "text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 1064, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3cda2dd-ddb4-4180-9303-64f3fe3e7923": {"__data__": {"id_": "c3cda2dd-ddb4-4180-9303-64f3fe3e7923", "embedding": null, "metadata": {"window": "Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9761ac16-9494-46f1-91b0-41ee90e0fffc", "node_type": "1", "metadata": {"window": "Thank you, operator.  Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides. ", "original_text": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a389e90ea60d692d28da631c0cecae1d80ae566399f4ce3843d93d5ce1cec4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc971383-5c5b-4646-a95c-a4ab499a4737", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n"}, "hash": "62ce75f66a2e80ac74f2ff08266c3260cad6ec3628e284316b1db33deae2e300", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "start_char_idx": 1165, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc971383-5c5b-4646-a95c-a4ab499a4737": {"__data__": {"id_": "cc971383-5c5b-4646-a95c-a4ab499a4737", "embedding": null, "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3cda2dd-ddb4-4180-9303-64f3fe3e7923", "node_type": "1", "metadata": {"window": "Good afternoon and welcome everyone to McKesson's third quarter fiscal 2024 earnings \ncall.  Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n", "original_text": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4544903940da59238839959bf91de383dddc77c2de0023a7ed676451612eb81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "519a1f76-b821-4d3e-b1eb-094f57ebf349", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides. "}, "hash": "7fc8779062c758b65e84b9fd3fb256912c7ee3db3f7d24cfe0cb44c8a8d7b95c", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 1292, "end_char_idx": 1683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "519a1f76-b821-4d3e-b1eb-094f57ebf349": {"__data__": {"id_": "519a1f76-b821-4d3e-b1eb-094f57ebf349", "embedding": null, "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc971383-5c5b-4646-a95c-a4ab499a4737", "node_type": "1", "metadata": {"window": "Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. \n Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n ", "original_text": "Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4fc7c9a906fdfc07c98b2498ee45f9859c35e4b23c511b65453a05e6b6ee19d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d9026ec-bcc5-4ca8-b15f-bdfd618c355e", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody. ", "original_text": "The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n"}, "hash": "21b49b167d19a8069eb3e404b4bf289575614f76fa5061da2c5a6374acfb7e59", "class_name": "RelatedNodeInfo"}}, "text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides. ", "start_char_idx": 1683, "end_char_idx": 1904, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d9026ec-bcc5-4ca8-b15f-bdfd618c355e": {"__data__": {"id_": "8d9026ec-bcc5-4ca8-b15f-bdfd618c355e", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody. ", "original_text": "The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "519a1f76-b821-4d3e-b1eb-094f57ebf349", "node_type": "1", "metadata": {"window": "Brian will lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f37e1fec1f4fac10d398b1923ab4bfb329298bf8f3d742586b4ab9ff908dc7fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c096161-6d51-424b-a692-e701dfa2d8be", "node_type": "1", "metadata": {"window": "Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call. ", "original_text": "With that, let me turn it over to Brian.  \n "}, "hash": "63b34468a742a0e7e156193c483086b0c4507425b6a0a48e97f7791926c68e1c", "class_name": "RelatedNodeInfo"}}, "text": "The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n", "start_char_idx": 1904, "end_char_idx": 2006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c096161-6d51-424b-a692-e701dfa2d8be": {"__data__": {"id_": "3c096161-6d51-424b-a692-e701dfa2d8be", "embedding": null, "metadata": {"window": "Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d9026ec-bcc5-4ca8-b15f-bdfd618c355e", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecasts about McKesson's operations and \nfuture results.  Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody. ", "original_text": "The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7710cffc1fa9efdd6e2c8ba02ebdaa43eb4399f3aaf0b4aada8ece1315e8b935", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "063e96f4-99e5-4654-a80c-464fe9730301", "node_type": "1", "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "8229c2eedec822227d1cc134c6f13fe9d079b0b923f0bd57de3f1d6be3e5d3e4", "class_name": "RelatedNodeInfo"}}, "text": "With that, let me turn it over to Brian.  \n ", "start_char_idx": 2006, "end_char_idx": 2050, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "063e96f4-99e5-4654-a80c-464fe9730301": {"__data__": {"id_": "063e96f4-99e5-4654-a80c-464fe9730301", "embedding": null, "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c096161-6d51-424b-a692-e701dfa2d8be", "node_type": "1", "metadata": {"window": "Please refer to  the cautionary statements in today's earnings release and presentation slides \navailable at our website at investor.mckesson.com and to the Risk Factors section of our most recent annual and \nperiodic SEC filings for additional information concerning risk f actors that could cause our actual results to \nmaterially differ from those in our forward -looking statements.  \n \n Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call. ", "original_text": "With that, let me turn it over to Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59b22cfa05261c0c3849855f301163533a4cf98e94086aed70e20c0868245054", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "958a958d-b042-47a4-9a33-eef8dcf5b2ef", "node_type": "1", "metadata": {"window": "The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80. ", "original_text": "Thank you, Rachel, and good afternoon to everybody. "}, "hash": "0c7a111e4b60c1cf21e4fe1e74aebc08834877d2044163ee1b4364724761452e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2050, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "958a958d-b042-47a4-9a33-eef8dcf5b2ef": {"__data__": {"id_": "958a958d-b042-47a4-9a33-eef8dcf5b2ef", "embedding": null, "metadata": {"window": "The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80. ", "original_text": "Thank you, Rachel, and good afternoon to everybody. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "063e96f4-99e5-4654-a80c-464fe9730301", "node_type": "1", "metadata": {"window": "Information about non -GAAP financial measures that we will discuss during this webcast, including a \nreconciliation of those measures to GAAP resu lts, may be found in today's earnings release and presentations \nslides.  The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b9bac6c9d88f192ee190cd3957bf4b2055f05d13261942128b920a91cd37058", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e8b187a-1724-4a7b-9835-b449aa2ef7a1", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n", "original_text": "Thanks for joining our call. "}, "hash": "e753cc30e947af057ff66fb93db0c6e1f6bc55241b9db346b128776b90717654", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Rachel, and good afternoon to everybody. ", "start_char_idx": 2395, "end_char_idx": 2447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e8b187a-1724-4a7b-9835-b449aa2ef7a1": {"__data__": {"id_": "9e8b187a-1724-4a7b-9835-b449aa2ef7a1", "embedding": null, "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n", "original_text": "Thanks for joining our call. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "958a958d-b042-47a4-9a33-eef8dcf5b2ef", "node_type": "1", "metadata": {"window": "The presentation slides also include summary of our results for the quarter and updated guidance.  \n \n With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80. ", "original_text": "Thank you, Rachel, and good afternoon to everybody. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b71136889d913bfc094fa8429cd7ebbf1713a956e49c1447c4948eb1a1d1222", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bad560c-29d8-4225-978b-22016fb3e583", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n", "original_text": "McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business. "}, "hash": "e4741c4a99fdc65dd76d13580841a46a0ec86c93b9775d4c38906a75bc48e47b", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for joining our call. ", "start_char_idx": 2447, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bad560c-29d8-4225-978b-22016fb3e583": {"__data__": {"id_": "1bad560c-29d8-4225-978b-22016fb3e583", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n", "original_text": "McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e8b187a-1724-4a7b-9835-b449aa2ef7a1", "node_type": "1", "metadata": {"window": "With that, let me turn it over to Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n", "original_text": "Thanks for joining our call. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0338485da1617a3fc5b1cd7ec8a8434e3f34c942bb2990de872cdaf93da7cf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82be3953-bb6f-410d-a593-9c3ec2ce645d", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n", "original_text": "We delivered total revenues \nof $80. "}, "hash": "88ddca69b0fff6dbd92d4bd59a4e54f606620b363f1b642e609d33ddf7cf5a1b", "class_name": "RelatedNodeInfo"}}, "text": "McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business. ", "start_char_idx": 2476, "end_char_idx": 2589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82be3953-bb6f-410d-a593-9c3ec2ce645d": {"__data__": {"id_": "82be3953-bb6f-410d-a593-9c3ec2ce645d", "embedding": null, "metadata": {"window": "Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n", "original_text": "We delivered total revenues \nof $80. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bad560c-29d8-4225-978b-22016fb3e583", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n", "original_text": "McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f734e4a772d4983a4e48850495e034b1580ce6be7de23a709322746eb2ce5c6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c912436-74e2-4b4f-8fab-bde3885c4b53", "node_type": "1", "metadata": {"window": "Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n", "original_text": "9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n"}, "hash": "71edd6a35e1df10fdccca5da9c1f27e2bbd9648232fe5e000889810fd8f036fa", "class_name": "RelatedNodeInfo"}}, "text": "We delivered total revenues \nof $80. ", "start_char_idx": 2589, "end_char_idx": 2626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c912436-74e2-4b4f-8fab-bde3885c4b53": {"__data__": {"id_": "4c912436-74e2-4b4f-8fab-bde3885c4b53", "embedding": null, "metadata": {"window": "Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n", "original_text": "9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82be3953-bb6f-410d-a593-9c3ec2ce645d", "node_type": "1", "metadata": {"window": "Thank you, Rachel, and good afternoon to everybody.  Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n", "original_text": "We delivered total revenues \nof $80. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dfa6ee63dac9bedafcb3770f90d8215aa600d1f5a1d569c55c9eae23159b1fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afae947c-0b23-499c-b346-6c07f0a3a5e8", "node_type": "1", "metadata": {"window": "McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services. ", "original_text": "As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n"}, "hash": "0f8f8ca4efe92922bc0d71d5fb0ca04beb853f4b19132923ff51779434b65ddf", "class_name": "RelatedNodeInfo"}}, "text": "9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n", "start_char_idx": 2626, "end_char_idx": 2761, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afae947c-0b23-499c-b346-6c07f0a3a5e8": {"__data__": {"id_": "afae947c-0b23-499c-b346-6c07f0a3a5e8", "embedding": null, "metadata": {"window": "McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services. ", "original_text": "As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c912436-74e2-4b4f-8fab-bde3885c4b53", "node_type": "1", "metadata": {"window": "Thanks for joining our call.  McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n", "original_text": "9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "354bb7c3df1fe03d01e59a3ebdcc96d403c1335b78d169db230c36db336075d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f76a5a03-9f51-4273-8719-fe840b64b2f5", "node_type": "1", "metadata": {"window": "We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n", "original_text": "This solid financial performance is driven by the focused execution against our company priorities.  \n \n"}, "hash": "6e69484ef37f5d7b0ec73319ae60437a4dc9c5fbf2d2a5dcad46651a6a15e2a3", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n", "start_char_idx": 2761, "end_char_idx": 2988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f76a5a03-9f51-4273-8719-fe840b64b2f5": {"__data__": {"id_": "f76a5a03-9f51-4273-8719-fe840b64b2f5", "embedding": null, "metadata": {"window": "We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n", "original_text": "This solid financial performance is driven by the focused execution against our company priorities.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afae947c-0b23-499c-b346-6c07f0a3a5e8", "node_type": "1", "metadata": {"window": "McKesson reported a really \nsolid fiscal third quarter, highlighting the continued momentum across the business.  We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services. ", "original_text": "As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3cb56fbe5852e5e16df9f466846b3cd457dfaa6ec6471ed0ce51f07bc4e32a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "898239d1-e0b2-4242-8c6a-57170aa5f562", "node_type": "1", "metadata": {"window": "9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture. ", "original_text": "As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n"}, "hash": "a1e27f349030b5cef74ef9dad65a082e14692d0e0d7d33fa32813931ecdf6ce3", "class_name": "RelatedNodeInfo"}}, "text": "This solid financial performance is driven by the focused execution against our company priorities.  \n \n", "start_char_idx": 2988, "end_char_idx": 3092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "898239d1-e0b2-4242-8c6a-57170aa5f562": {"__data__": {"id_": "898239d1-e0b2-4242-8c6a-57170aa5f562", "embedding": null, "metadata": {"window": "9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture. ", "original_text": "As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f76a5a03-9f51-4273-8719-fe840b64b2f5", "node_type": "1", "metadata": {"window": "We delivered total revenues \nof $80.  9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n", "original_text": "This solid financial performance is driven by the focused execution against our company priorities.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d1b2367fbf44523a58d87dee5066fdf9a039ba91a5d24820dbaeb691e32ce22", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4583013b-e567-4ee5-a2ad-c94c9445a9d8", "node_type": "1", "metadata": {"window": "As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson. ", "original_text": "This includes the areas of oncology and biopharma services. "}, "hash": "c124f899a62c57ecbde657d2d232f04b74fbda2043ce6b0a112acb597b6d60aa", "class_name": "RelatedNodeInfo"}}, "text": "As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n", "start_char_idx": 3092, "end_char_idx": 3207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4583013b-e567-4ee5-a2ad-c94c9445a9d8": {"__data__": {"id_": "4583013b-e567-4ee5-a2ad-c94c9445a9d8", "embedding": null, "metadata": {"window": "As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson. ", "original_text": "This includes the areas of oncology and biopharma services. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "898239d1-e0b2-4242-8c6a-57170aa5f562", "node_type": "1", "metadata": {"window": "9 billion and adjusted earnings per diluted share of $7.74, both of which grew by double -digits when \ncompared to the prior year.  \n \n As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture. ", "original_text": "As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d399801069e0cf75d95452c7bf2a99372710a6094dc5f664ffbbd142da93298", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e89f2dcd-35c4-46b2-bbb2-1e423f793d01", "node_type": "1", "metadata": {"window": "This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.  ", "original_text": "We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n"}, "hash": "c9acac64db01ef80b94da34befea500001288cb443c464726b3fbe676bd1af8e", "class_name": "RelatedNodeInfo"}}, "text": "This includes the areas of oncology and biopharma services. ", "start_char_idx": 3207, "end_char_idx": 3267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e89f2dcd-35c4-46b2-bbb2-1e423f793d01": {"__data__": {"id_": "e89f2dcd-35c4-46b2-bbb2-1e423f793d01", "embedding": null, "metadata": {"window": "This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.  ", "original_text": "We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4583013b-e567-4ee5-a2ad-c94c9445a9d8", "node_type": "1", "metadata": {"window": "As a result of the recent performance and our latest outlook, we are raising and narrowing our guidance range for \nfiscal 2024 adjusted earnings per diluted share from $26.80 to $27.40 to an updated range of $27.25 to $27.65. \n This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson. ", "original_text": "This includes the areas of oncology and biopharma services. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09fa2250590e66d52df10a0cc8fd1b13b62a0c84de622d197c8fe79d273b9aa7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01be4f8c-2743-4a82-8579-15b18c4c4e39", "node_type": "1", "metadata": {"window": "As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr. ", "original_text": "Let me start where I always like to start, and that's with our focus on people and culture. "}, "hash": "23aae9ae10ffcd45abcbbcdef79ecd3edb869d47a9ff95af83b02ab8fc33ee6c", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n", "start_char_idx": 3267, "end_char_idx": 3416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01be4f8c-2743-4a82-8579-15b18c4c4e39": {"__data__": {"id_": "01be4f8c-2743-4a82-8579-15b18c4c4e39", "embedding": null, "metadata": {"window": "As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr. ", "original_text": "Let me start where I always like to start, and that's with our focus on people and culture. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e89f2dcd-35c4-46b2-bbb2-1e423f793d01", "node_type": "1", "metadata": {"window": "This solid financial performance is driven by the focused execution against our company priorities.  \n \n As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.  ", "original_text": "We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "253071682a0ea68ec9452452456efd78156ae8be60a16a1edf39747aafbffe07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a23c9a20-aea0-4f90-b393-b3a9670685bd", "node_type": "1", "metadata": {"window": "This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "I start here because it is \nfoundational to everything we do at McKesson. "}, "hash": "ee8f24a1ca4c9f35f2dd2dc492d5c434b086aeba77c71a95bb3968c3ed1690a2", "class_name": "RelatedNodeInfo"}}, "text": "Let me start where I always like to start, and that's with our focus on people and culture. ", "start_char_idx": 3416, "end_char_idx": 3508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a23c9a20-aea0-4f90-b393-b3a9670685bd": {"__data__": {"id_": "a23c9a20-aea0-4f90-b393-b3a9670685bd", "embedding": null, "metadata": {"window": "This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "I start here because it is \nfoundational to everything we do at McKesson. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01be4f8c-2743-4a82-8579-15b18c4c4e39", "node_type": "1", "metadata": {"window": "As a diversified healthcare services company, we are uni quely positioned to improve healthcare in every setting. \n This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr. ", "original_text": "Let me start where I always like to start, and that's with our focus on people and culture. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5e45655064c211b1cc83d4f6f515bc8ff2a10b7b9bd876f31ec51e2f9b88e62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "068180f1-295f-4acb-a521-2dadae3705d3", "node_type": "1", "metadata": {"window": "We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.  "}, "hash": "5b975955a80deabbbcf91048d1db932675981e1a634ef8dfb6ed19dca45248bd", "class_name": "RelatedNodeInfo"}}, "text": "I start here because it is \nfoundational to everything we do at McKesson. ", "start_char_idx": 3508, "end_char_idx": 3582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "068180f1-295f-4acb-a521-2dadae3705d3": {"__data__": {"id_": "068180f1-295f-4acb-a521-2dadae3705d3", "embedding": null, "metadata": {"window": "We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.  ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a23c9a20-aea0-4f90-b393-b3a9670685bd", "node_type": "1", "metadata": {"window": "This includes the areas of oncology and biopharma services.  We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "I start here because it is \nfoundational to everything we do at McKesson. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a481980f2ded0cad3c7c455bfcb15f253afa0b7d53c099b7a3c02356a150f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4db31ef3-56d2-414c-9471-ec0981095eba", "node_type": "1", "metadata": {"window": "Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "As the former Chief Financial Officer of McDonald's Corporation, Mr. "}, "hash": "6674cbf6281f5c5f91a00eca747648c52b28a338291c15eaacfa6169cba2b1ca", "class_name": "RelatedNodeInfo"}}, "text": "In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.  ", "start_char_idx": 3582, "end_char_idx": 3670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4db31ef3-56d2-414c-9471-ec0981095eba": {"__data__": {"id_": "4db31ef3-56d2-414c-9471-ec0981095eba", "embedding": null, "metadata": {"window": "Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "As the former Chief Financial Officer of McDonald's Corporation, Mr. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "068180f1-295f-4acb-a521-2dadae3705d3", "node_type": "1", "metadata": {"window": "We continue to make significant progress in \nadvancing our strategy and priorities, and I'm pleased to share some of the updates with you to day. \n \n Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.  ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb3e4c1a871ccf66df83cb5fdea59576be9cc9fce68b8daa0a5e3eec7db8e8a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dcca84c6-b093-4ad6-ae00-1babff4c8db8", "node_type": "1", "metadata": {"window": "I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "Ozan has over two "}, "hash": "82b336362745c5c27e477c5285e25f64082bed45ea14c68561725ad822b63c99", "class_name": "RelatedNodeInfo"}}, "text": "As the former Chief Financial Officer of McDonald's Corporation, Mr. ", "start_char_idx": 3670, "end_char_idx": 3739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dcca84c6-b093-4ad6-ae00-1babff4c8db8": {"__data__": {"id_": "dcca84c6-b093-4ad6-ae00-1babff4c8db8", "embedding": null, "metadata": {"window": "I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "Ozan has over two ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5a9672ce8a5a31395c526db03846a148f3be24d10eed3332debccf1250561", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4db31ef3-56d2-414c-9471-ec0981095eba", "node_type": "1", "metadata": {"window": "Let me start where I always like to start, and that's with our focus on people and culture.  I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "As the former Chief Financial Officer of McDonald's Corporation, Mr. ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58c103de413a00c5331defa070b97039d05a7d280a14a1da8b5e701150387c84", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4db949f0-840f-4966-beee-7c6febe725ef", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations. ", "original_text": "McKesson Corp.  "}, "hash": "c507dae1a8c7a7d67ad33f2fe897da36d50afa4e93628387258a14736e4b5115", "class_name": "RelatedNodeInfo"}}, "text": "Ozan has over two ", "start_char_idx": 3739, "end_char_idx": 3757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4db949f0-840f-4966-beee-7c6febe725ef": {"__data__": {"id_": "4db949f0-840f-4966-beee-7c6febe725ef", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dcca84c6-b093-4ad6-ae00-1babff4c8db8", "node_type": "1", "metadata": {"window": "I start here because it is \nfoundational to everything we do at McKesson.  In January, our board of directors welcomed Kevin Ozan as a new \nindependent Director.   As the former Chief Financial Officer of McDonald's Corporation, Mr.  Ozan has over two ", "original_text": "Ozan has over two ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3866b5119360ca4f721a0cf96a70ce5c489c49b6803e56256d025cdc64c40f1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ad3adfe-9cf0-4899-8a69-b3ad13a01a94", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n"}, "hash": "69c0232d108bd3c94428843c654f9777d2fa93f28ab10d5eafc2a96737b24912", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ad3adfe-9cf0-4899-8a69-b3ad13a01a94": {"__data__": {"id_": "5ad3adfe-9cf0-4899-8a69-b3ad13a01a94", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4db949f0-840f-4966-beee-7c6febe725ef", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc3b689795573d110c99ab607d931927033092acf680025e8409f876eda0b74a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35e0c4e3-de74-4591-b3ee-e5d249885214", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n", "original_text": "We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n"}, "hash": "0a2895ca7ea33c6c2ad26216035df83ab1da16d65f1eb1a116f8dae1add11d30", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n", "start_char_idx": 16, "end_char_idx": 293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35e0c4e3-de74-4591-b3ee-e5d249885214": {"__data__": {"id_": "35e0c4e3-de74-4591-b3ee-e5d249885214", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n", "original_text": "We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ad3adfe-9cf0-4899-8a69-b3ad13a01a94", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef80194d0bcaa5e9ff45718551fcd5afae274e851b639c7027df501e9a0d12df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8583c636-c44e-4f87-ac63-d35a81449456", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer. ", "original_text": "Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations. "}, "hash": "a7fcf38c067a95e73ac9be5e8cf25fb0d548f5a56e4c85d0c75889e58b05ec2c", "class_name": "RelatedNodeInfo"}}, "text": "We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n", "start_char_idx": 293, "end_char_idx": 390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8583c636-c44e-4f87-ac63-d35a81449456": {"__data__": {"id_": "8583c636-c44e-4f87-ac63-d35a81449456", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer. ", "original_text": "Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35e0c4e3-de74-4591-b3ee-e5d249885214", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n", "original_text": "We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d2a6b3386f1490f72ac3265ab8caf61bb7c50c82ed9aa851ac8fe5d4b35b1e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "712d9ff8-61a9-4909-989d-4433e012db40", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign. ", "original_text": "It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions. "}, "hash": "365aa79d4ee8f43064df7accbdbd21abb30dd24998855ba1bc7329e0d8f0df0a", "class_name": "RelatedNodeInfo"}}, "text": "Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations. ", "start_char_idx": 390, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "712d9ff8-61a9-4909-989d-4433e012db40": {"__data__": {"id_": "712d9ff8-61a9-4909-989d-4433e012db40", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign. ", "original_text": "It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8583c636-c44e-4f87-ac63-d35a81449456", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer. ", "original_text": "Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cdf4d322d038333839069d6830cd9353bcfdec7d4be367f0c880b3f9b5e4e25a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "037a6082-9518-49ce-924b-2e34b3ef60c5", "node_type": "1", "metadata": {"window": "We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n", "original_text": "And I'm pleased to see our efforts being  recognized.  \n \n"}, "hash": "515f88fac5df07f6625d27cc5e6cf3c7d0c9392886a6111c5aaab8f81ea62d22", "class_name": "RelatedNodeInfo"}}, "text": "It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions. ", "start_char_idx": 707, "end_char_idx": 830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "037a6082-9518-49ce-924b-2e34b3ef60c5": {"__data__": {"id_": "037a6082-9518-49ce-924b-2e34b3ef60c5", "embedding": null, "metadata": {"window": "We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n", "original_text": "And I'm pleased to see our efforts being  recognized.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "712d9ff8-61a9-4909-989d-4433e012db40", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign. ", "original_text": "It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7ae943ae0221ce3298c3cb0ee2e7a9c101ba1c5bae27d3525a20dc2d351652", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7ad2ed6-42e1-4f90-a874-114cae606854", "node_type": "1", "metadata": {"window": "Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses. ", "original_text": "For the 11th consecutive year, McKesson was named as a Military Friendly Employer. "}, "hash": "998cdc614f29e6a66202d3fd03a484b1be92fef24bd8c0c17cf369dde5a488c6", "class_name": "RelatedNodeInfo"}}, "text": "And I'm pleased to see our efforts being  recognized.  \n \n", "start_char_idx": 830, "end_char_idx": 888, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7ad2ed6-42e1-4f90-a874-114cae606854": {"__data__": {"id_": "c7ad2ed6-42e1-4f90-a874-114cae606854", "embedding": null, "metadata": {"window": "Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses. ", "original_text": "For the 11th consecutive year, McKesson was named as a Military Friendly Employer. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "037a6082-9518-49ce-924b-2e34b3ef60c5", "node_type": "1", "metadata": {"window": "We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n", "original_text": "And I'm pleased to see our efforts being  recognized.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f747f9d0bf4228f05253016dab8891500820200aa2fb61bf65c27cf9defb775", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad397227-1d53-477a-a010-a50db9c77871", "node_type": "1", "metadata": {"window": "It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n", "original_text": "We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign. "}, "hash": "7aba1ad4b7df18eaaeb930b5e1525e21f407f2e4036e09ea51886ec5a8b7cc7c", "class_name": "RelatedNodeInfo"}}, "text": "For the 11th consecutive year, McKesson was named as a Military Friendly Employer. ", "start_char_idx": 888, "end_char_idx": 971, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad397227-1d53-477a-a010-a50db9c77871": {"__data__": {"id_": "ad397227-1d53-477a-a010-a50db9c77871", "embedding": null, "metadata": {"window": "It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n", "original_text": "We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7ad2ed6-42e1-4f90-a874-114cae606854", "node_type": "1", "metadata": {"window": "Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations.  It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses. ", "original_text": "For the 11th consecutive year, McKesson was named as a Military Friendly Employer. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e13cf734d048ff9c5136360306af1b2e58e43d6b00acb9107929122879b75c13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6ce17d9-5e19-434c-bbf7-1b3aba146892", "node_type": "1", "metadata": {"window": "And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology. ", "original_text": "I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n"}, "hash": "2c1508d3f21d25fdbcf0daf9e536b035484427598413e9bb9ea05dc69a3d42f7", "class_name": "RelatedNodeInfo"}}, "text": "We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign. ", "start_char_idx": 971, "end_char_idx": 1128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6ce17d9-5e19-434c-bbf7-1b3aba146892": {"__data__": {"id_": "f6ce17d9-5e19-434c-bbf7-1b3aba146892", "embedding": null, "metadata": {"window": "And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology. ", "original_text": "I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad397227-1d53-477a-a010-a50db9c77871", "node_type": "1", "metadata": {"window": "It's how \nwe build the support network for our employees and how we each live these values through everyday \ninteractions.  And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n", "original_text": "We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb957e35a2e3ed5439aa2fd0a12895632e768f8973c41cd04386d1d271d75bfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6689efc-be1d-4cd0-b2be-d262b3599f6e", "node_type": "1", "metadata": {"window": "For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n", "original_text": "Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses. "}, "hash": "965a533231660d78ab34b7bc9856f08ba130cdf888ac9287ffaefc62ebc66bcb", "class_name": "RelatedNodeInfo"}}, "text": "I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n", "start_char_idx": 1128, "end_char_idx": 1394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6689efc-be1d-4cd0-b2be-d262b3599f6e": {"__data__": {"id_": "c6689efc-be1d-4cd0-b2be-d262b3599f6e", "embedding": null, "metadata": {"window": "For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n", "original_text": "Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6ce17d9-5e19-434c-bbf7-1b3aba146892", "node_type": "1", "metadata": {"window": "And I'm pleased to see our efforts being  recognized.  \n \n For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology. ", "original_text": "I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cec6b8e234945e37842af166e2e0721a3f11acaab56a43b6dcf60a50d00442af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5798f00-c3d0-465e-8fde-3f67c3f35802", "node_type": "1", "metadata": {"window": "We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n", "original_text": "In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n"}, "hash": "4b6b1167e38c8c6fcd73542b1b73fa91be7f36b8d9323cc021dc96fc2bc2e4b6", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses. ", "start_char_idx": 1394, "end_char_idx": 1547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5798f00-c3d0-465e-8fde-3f67c3f35802": {"__data__": {"id_": "a5798f00-c3d0-465e-8fde-3f67c3f35802", "embedding": null, "metadata": {"window": "We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n", "original_text": "In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6689efc-be1d-4cd0-b2be-d262b3599f6e", "node_type": "1", "metadata": {"window": "For the 11th consecutive year, McKesson was named as a Military Friendly Employer.  We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n", "original_text": "Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b136a56d1b3e5ef4215084f28afbd260a5117b80efee1ce9019a856cd5e785c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47a5dba3-7e33-40af-9803-28d8a7d6d91d", "node_type": "1", "metadata": {"window": "I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers. ", "original_text": "We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology. "}, "hash": "b2ce408174fecc0205cebf1b4993f73442536cfe603bdfe0c3cdaae54322b6c5", "class_name": "RelatedNodeInfo"}}, "text": "In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n", "start_char_idx": 1547, "end_char_idx": 1663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47a5dba3-7e33-40af-9803-28d8a7d6d91d": {"__data__": {"id_": "47a5dba3-7e33-40af-9803-28d8a7d6d91d", "embedding": null, "metadata": {"window": "I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers. ", "original_text": "We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5798f00-c3d0-465e-8fde-3f67c3f35802", "node_type": "1", "metadata": {"window": "We were also recognized \nby Newsweek as one of America's Greatest Workplaces for Diversity, and the Equality 100 Award winner by the \nHuman Rights Campaign.  I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n", "original_text": "In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b851aef36673b4bb62bf9e42404cd62434709ab413fe1e66ea61d5caa75fe4b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04993d82-38a1-4914-a424-13b0e47fd946", "node_type": "1", "metadata": {"window": "Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n", "original_text": "Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n"}, "hash": "38cf8600a8e7bc4139b6c9f3359c873cc7f49b322d5907d6820c6a27024b8598", "class_name": "RelatedNodeInfo"}}, "text": "We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology. ", "start_char_idx": 1663, "end_char_idx": 1791, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04993d82-38a1-4914-a424-13b0e47fd946": {"__data__": {"id_": "04993d82-38a1-4914-a424-13b0e47fd946", "embedding": null, "metadata": {"window": "Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n", "original_text": "Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47a5dba3-7e33-40af-9803-28d8a7d6d91d", "node_type": "1", "metadata": {"window": "I'm proud of what we've achieved as a team, and I'm truly grateful to the McKesson \nemployees for upholding our culture, values and delivering for all of our stakeholders, our patients, our customers, \nour partners, our shareholders and importantly, each other.  \n \n Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers. ", "original_text": "We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fcbcc47f8252192f8f4b3ddc1a7281f895cd55803c95f695b34acc41487dd4a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d564e149-fd5d-46d4-9025-2c6b6a31bdf9", "node_type": "1", "metadata": {"window": "In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable. ", "original_text": "These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n"}, "hash": "40e3fa4e3a4302522bb5c2cc4c00f26998e00d9f57f85f36a9a67123a3584244", "class_name": "RelatedNodeInfo"}}, "text": "Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n", "start_char_idx": 1791, "end_char_idx": 1942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d564e149-fd5d-46d4-9025-2c6b6a31bdf9": {"__data__": {"id_": "d564e149-fd5d-46d4-9025-2c6b6a31bdf9", "embedding": null, "metadata": {"window": "In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable. ", "original_text": "These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04993d82-38a1-4914-a424-13b0e47fd946", "node_type": "1", "metadata": {"window": "Moving on to our next priority of driving sustainable core growth, in the fiscal third quarter, we saw good \nperformance in our distribution businesses.  In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n", "original_text": "Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c81bbc1b15239e98756b8a4e630e083b562b50014dbf44b065087d4033d9354d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a541701-3166-4789-9242-d89259953431", "node_type": "1", "metadata": {"window": "We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n", "original_text": "The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers. "}, "hash": "4db16ac2a16bab6abaa1c3e8ee034522cab5f6c24f6e000ad1a5942293eb7188", "class_name": "RelatedNodeInfo"}}, "text": "These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n", "start_char_idx": 1942, "end_char_idx": 2148, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a541701-3166-4789-9242-d89259953431": {"__data__": {"id_": "5a541701-3166-4789-9242-d89259953431", "embedding": null, "metadata": {"window": "We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n", "original_text": "The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d564e149-fd5d-46d4-9025-2c6b6a31bdf9", "node_type": "1", "metadata": {"window": "In US Pharmaceutical, adjusted operating profit grew 6%, reflecting \nbroad -based momentum within the seg ment.  \n \n We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable. ", "original_text": "These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "63295614d497df9f45abbf8205c8c3916bf573091ad8eea8acee38367b5af0bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "320e8bd5-163d-4e4a-97f6-6d674025f9d7", "node_type": "1", "metadata": {"window": "Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n", "original_text": "During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n"}, "hash": "120018747d60c08bba6a2f19f3db71997820f1714dcd7da5197e7acc8dd0e4ce", "class_name": "RelatedNodeInfo"}}, "text": "The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers. ", "start_char_idx": 2148, "end_char_idx": 2287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "320e8bd5-163d-4e4a-97f6-6d674025f9d7": {"__data__": {"id_": "320e8bd5-163d-4e4a-97f6-6d674025f9d7", "embedding": null, "metadata": {"window": "Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n", "original_text": "During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a541701-3166-4789-9242-d89259953431", "node_type": "1", "metadata": {"window": "We continue to enhance our scaled distribution network, improving efficiency through investments in automation \nand technology.  Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n", "original_text": "The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e3910fbca68eb308388f886997a6442ceb88a1d51cc9884071a97d7d99e8b15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8652407-689e-46d3-8749-8c926f811986", "node_type": "1", "metadata": {"window": "These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter. ", "original_text": "At the consolidated level, prescription volume growth remains stable. "}, "hash": "7ede8844fd2fa44482f992c0e2282f3588e53bd3a65b460364c320a56c5efc77", "class_name": "RelatedNodeInfo"}}, "text": "During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n", "start_char_idx": 2287, "end_char_idx": 2441, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8652407-689e-46d3-8749-8c926f811986": {"__data__": {"id_": "f8652407-689e-46d3-8749-8c926f811986", "embedding": null, "metadata": {"window": "These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter. ", "original_text": "At the consolidated level, prescription volume growth remains stable. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "320e8bd5-163d-4e4a-97f6-6d674025f9d7", "node_type": "1", "metadata": {"window": "Over the past year, we opened two new distribution centers in the US that are equipped with \ninnovative technology and empl oyee -friendly design.  \n \n These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n", "original_text": "During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91797f020fe7bec1d1dc8a2ad7a839075522502e1423ae272b4395e45e91f395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71517e23-39d6-48ed-9c8d-95f8f216a5a1", "node_type": "1", "metadata": {"window": "The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits. ", "original_text": "Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n"}, "hash": "7ae4d7c02ef48f7baac0f24847dea9dbf68163604a46170a31aeaa857b269618", "class_name": "RelatedNodeInfo"}}, "text": "At the consolidated level, prescription volume growth remains stable. ", "start_char_idx": 2441, "end_char_idx": 2511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71517e23-39d6-48ed-9c8d-95f8f216a5a1": {"__data__": {"id_": "71517e23-39d6-48ed-9c8d-95f8f216a5a1", "embedding": null, "metadata": {"window": "The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits. ", "original_text": "Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8652407-689e-46d3-8749-8c926f811986", "node_type": "1", "metadata": {"window": "These enhancements will enable our facilities to pick, pack and ship medications to customers faster, while \nsimultaneously helping to optimize employee productivity levels by reducing redundant tasks.  \n \n The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter. ", "original_text": "At the consolidated level, prescription volume growth remains stable. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7a76e6a1e3144f48dab3ef85efccb64a3f83e62fd3319c91bd7f91744653417", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79d667f6-b30a-465a-bdf1-eed6dfbed2c0", "node_type": "1", "metadata": {"window": "During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n", "original_text": "As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n"}, "hash": "fba57d697a35adff97e42d3cb31474809751095f677842fe0f10b27201a9e831", "class_name": "RelatedNodeInfo"}}, "text": "Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n", "start_char_idx": 2511, "end_char_idx": 2690, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79d667f6-b30a-465a-bdf1-eed6dfbed2c0": {"__data__": {"id_": "79d667f6-b30a-465a-bdf1-eed6dfbed2c0", "embedding": null, "metadata": {"window": "During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n", "original_text": "As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71517e23-39d6-48ed-9c8d-95f8f216a5a1", "node_type": "1", "metadata": {"window": "The investments in our foundati onal distribution assets continue to support the growth of our business and the \nsuccess of our customers.  During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits. ", "original_text": "Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16fb59d7de1f401f696df1ecd22e01ba630716bc06aeb4b515475b4f117f3a04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7bb74e92-c57a-4669-8b83-c2811bcfa0e3", "node_type": "1", "metadata": {"window": "At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well. ", "original_text": "In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter. "}, "hash": "2a9cbfd895cefc8f2446873645f58713915d2d1dc566c664c7a3f65f0dd80a7b", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n", "start_char_idx": 2690, "end_char_idx": 2895, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7bb74e92-c57a-4669-8b83-c2811bcfa0e3": {"__data__": {"id_": "7bb74e92-c57a-4669-8b83-c2811bcfa0e3", "embedding": null, "metadata": {"window": "At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well. ", "original_text": "In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79d667f6-b30a-465a-bdf1-eed6dfbed2c0", "node_type": "1", "metadata": {"window": "During the third quarter, we saw solid volume increases across customer channels, \nwhich includes distribution to retail national accounts customers.  \n \n At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n", "original_text": "As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61f7b4f936325d9b9d2c5b8bb9079e0b0ef464ca6bab2d25a157a2a5654e3e5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "035982fd-75f2-4773-9c5b-0b3df67e580b", "node_type": "1", "metadata": {"window": "Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there. ", "original_text": "The improvement was partially driven by overall increase in \nprimary care visits. "}, "hash": "bfdef3ec36b269a8e78b536e82d1d54e8a47073f788cea1247a03cc4b475b8c6", "class_name": "RelatedNodeInfo"}}, "text": "In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter. ", "start_char_idx": 2895, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "035982fd-75f2-4773-9c5b-0b3df67e580b": {"__data__": {"id_": "035982fd-75f2-4773-9c5b-0b3df67e580b", "embedding": null, "metadata": {"window": "Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there. ", "original_text": "The improvement was partially driven by overall increase in \nprimary care visits. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7bb74e92-c57a-4669-8b83-c2811bcfa0e3", "node_type": "1", "metadata": {"window": "At the consolidated level, prescription volume growth remains stable.  Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well. ", "original_text": "In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58be8be9a4512a7f12b2c3da5ee49f1b0547f4c699de8b6d76be18b3236a9560", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a380c3b-2f8b-431c-ab21-81e73c03c35f", "node_type": "1", "metadata": {"window": "As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n"}, "hash": "52bcb918c51e7b56eb27f11688fd484aa99c3969c29b16e90e01b483dd3cc34e", "class_name": "RelatedNodeInfo"}}, "text": "The improvement was partially driven by overall increase in \nprimary care visits. ", "start_char_idx": 3058, "end_char_idx": 3140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a380c3b-2f8b-431c-ab21-81e73c03c35f": {"__data__": {"id_": "1a380c3b-2f8b-431c-ab21-81e73c03c35f", "embedding": null, "metadata": {"window": "As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "035982fd-75f2-4773-9c5b-0b3df67e580b", "node_type": "1", "metadata": {"window": "Certain product categories, including \nspecialty pharmaceuticals and GLP -1 medications continue to grow at a faster pace and contribute as a tailwind \nto our revenue growth.  \n \n As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there. ", "original_text": "The improvement was partially driven by overall increase in \nprimary care visits. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5056695cfa44503b0ea0c3b228f81a44706a417da70f234515b1e69fb65ef18c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34b75e51-506b-4bfa-a477-e602afdeb684", "node_type": "1", "metadata": {"window": "In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "In the International segment, our Canadian business continues to perform well. "}, "hash": "6a26a2472006b81b8044201c699714e15b026fb532f0d80ea4ca70ab2e6eba71", "class_name": "RelatedNodeInfo"}}, "text": "However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n", "start_char_idx": 3140, "end_char_idx": 3282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34b75e51-506b-4bfa-a477-e602afdeb684": {"__data__": {"id_": "34b75e51-506b-4bfa-a477-e602afdeb684", "embedding": null, "metadata": {"window": "In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "In the International segment, our Canadian business continues to perform well. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a380c3b-2f8b-431c-ab21-81e73c03c35f", "node_type": "1", "metadata": {"window": "As a reminder , we anticipate the growth from GLP -1 medications to slow in our fiscal fourth quarter, reflecting the \ninflection in volumes for these medications in the fourth quarter of fiscal 2023.  \n \n In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55af3fdea5d713016e7f5107370e5c37ca69337621ec81c386ab9429aeceba6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e86f015f-7ca3-4947-ba23-f4bc9b913aa7", "node_type": "1", "metadata": {"window": "The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there. "}, "hash": "1fa3e19c654d39ede95dfd215f99908dac092f53e2e0c951496b467aca9eb634", "class_name": "RelatedNodeInfo"}}, "text": "In the International segment, our Canadian business continues to perform well. ", "start_char_idx": 3282, "end_char_idx": 3361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e86f015f-7ca3-4947-ba23-f4bc9b913aa7": {"__data__": {"id_": "e86f015f-7ca3-4947-ba23-f4bc9b913aa7", "embedding": null, "metadata": {"window": "The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34b75e51-506b-4bfa-a477-e602afdeb684", "node_type": "1", "metadata": {"window": "In the Medical Surgical segment, primary care visits showed modest imp rovement on a sequential basis, after we \nobserved general market moderations last quarter.  The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "In the International segment, our Canadian business continues to perform well. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "273a232b70d8cc0a5f449d7dab8c6f2467fae7405940bd7db3e434de21e4da36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f628593-991d-4694-837e-7906cb5ed7d4", "node_type": "1", "metadata": {"window": "However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n "}, "hash": "db9f2f7ca41086a94e1d0d4d6714768f3dc453643ed355b317ef4f4c506488ab", "class_name": "RelatedNodeInfo"}}, "text": "It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there. ", "start_char_idx": 3361, "end_char_idx": 3539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f628593-991d-4694-837e-7906cb5ed7d4": {"__data__": {"id_": "0f628593-991d-4694-837e-7906cb5ed7d4", "embedding": null, "metadata": {"window": "However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ca576e0a488be660e101f3d8c6deffe0b5ae76aa00bad97b16abc2cc08f34d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e86f015f-7ca3-4947-ba23-f4bc9b913aa7", "node_type": "1", "metadata": {"window": "The improvement was partially driven by overall increase in \nprimary care visits.  However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there. ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a62b9806dd9927bccdf0c80b1847303767b453293adb05f3da6ddc1b8463605d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffae2788-5f15-4c1c-9393-79530a5fe133", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee. ", "original_text": "McKesson Corp.  "}, "hash": "cdfd1a35d5fe70da9b7df4bf3e6c4994e59ddd6340fcbc64a4abad2ddfa87f45", "class_name": "RelatedNodeInfo"}}, "text": "And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "start_char_idx": 3539, "end_char_idx": 3740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffae2788-5f15-4c1c-9393-79530a5fe133": {"__data__": {"id_": "ffae2788-5f15-4c1c-9393-79530a5fe133", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f628593-991d-4694-837e-7906cb5ed7d4", "node_type": "1", "metadata": {"window": "However, when compared to the prior year, patient visit volumes in the Medical segme nt \nremain a headwind to this quarter's performance.  \n \n In the International segment, our Canadian business continues to perform well.  It has a valuable portfolio of \nassets, including pharmaceutical distribution, retail pharmacies, digital offerings, we're co mmitted to strengthen \nand grow the business there.  And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "original_text": "And as a part of that commitment, we're executing on a multiyear initiative that will \nmodernize the distribution centers across Canada and deliver significant value to our employees and customers.  \n ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adcca880e90a99dd99050290b0a07e9a840b2e15ad1b4cd66ed833c92f07b7c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99436a68-631e-4a04-95aa-9fbe5f9a973d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms. "}, "hash": "ee1d3bf1e9fa8d3f827d0a3b8e5aacf734855d11e88ac0cc86f87dbc31abe0a7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99436a68-631e-4a04-95aa-9fbe5f9a973d": {"__data__": {"id_": "99436a68-631e-4a04-95aa-9fbe5f9a973d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffae2788-5f15-4c1c-9393-79530a5fe133", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8090e8f12d65c4f2a9b802e62cbead59a924862699e47494bb3b6c3e04ef3c90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e554f7c3-6e17-4ea5-9700-278a65600992", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states. ", "original_text": "We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n"}, "hash": "f5dbb8074afca06b1b1e9d1c4635efaf0f56673dc1f6282e756fb49105188a41", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms. ", "start_char_idx": 16, "end_char_idx": 255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e554f7c3-6e17-4ea5-9700-278a65600992": {"__data__": {"id_": "e554f7c3-6e17-4ea5-9700-278a65600992", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states. ", "original_text": "We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99436a68-631e-4a04-95aa-9fbe5f9a973d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2625ab88cc6d912d88154ca4001a34aec4a85b73ae3ecd428c1c68f0d020e63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a197862-7b05-4924-9a6f-a354414e33ee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n", "original_text": "Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee. "}, "hash": "a3d968f510d6205e9a6584ea110a400db550b02fa9df7d44c4617a2a11c4442d", "class_name": "RelatedNodeInfo"}}, "text": "We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n", "start_char_idx": 255, "end_char_idx": 437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a197862-7b05-4924-9a6f-a354414e33ee": {"__data__": {"id_": "2a197862-7b05-4924-9a6f-a354414e33ee", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n", "original_text": "Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e554f7c3-6e17-4ea5-9700-278a65600992", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states. ", "original_text": "We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a38f211b2cee6ca12f930f8352cef0b3cb04b468cd21f67ed74cd74238e77a4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3167d7df-c3d8-471a-8e38-e1ec89444ea9", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n", "original_text": "Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n"}, "hash": "904e3be2dc05ff07ce275adf08855b788d5365215e6a7899de1d6afed171b26a", "class_name": "RelatedNodeInfo"}}, "text": "Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee. ", "start_char_idx": 437, "end_char_idx": 551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3167d7df-c3d8-471a-8e38-e1ec89444ea9": {"__data__": {"id_": "3167d7df-c3d8-471a-8e38-e1ec89444ea9", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n", "original_text": "Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a197862-7b05-4924-9a6f-a354414e33ee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n", "original_text": "Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "049a2c9d50532b037f5c905b0f23fc98677ef5a0665de1c6425e8bae7f192c04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "222cd9bb-5c56-41e8-b057-2f30e442aa9f", "node_type": "1", "metadata": {"window": "We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions. ", "original_text": "Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states. "}, "hash": "8a7a51e2614929a306bb9b5ae98db5131515f947922349d83971e7c103b8e6a6", "class_name": "RelatedNodeInfo"}}, "text": "Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n", "start_char_idx": 551, "end_char_idx": 683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "222cd9bb-5c56-41e8-b057-2f30e442aa9f": {"__data__": {"id_": "222cd9bb-5c56-41e8-b057-2f30e442aa9f", "embedding": null, "metadata": {"window": "We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions. ", "original_text": "Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3167d7df-c3d8-471a-8e38-e1ec89444ea9", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n", "original_text": "Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e298e44e05055855be3ea8477326641ea76998b03f9191ed8bd36f584b64d6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34e3a96c-d0c3-4e8a-8930-470dc5744e75", "node_type": "1", "metadata": {"window": "Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n", "original_text": "The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n"}, "hash": "04ce46a836e40d634022a8e9aa653049c5280a9729cb7e10da64565da7aa584d", "class_name": "RelatedNodeInfo"}}, "text": "Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states. ", "start_char_idx": 683, "end_char_idx": 872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34e3a96c-d0c3-4e8a-8930-470dc5744e75": {"__data__": {"id_": "34e3a96c-d0c3-4e8a-8930-470dc5744e75", "embedding": null, "metadata": {"window": "Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n", "original_text": "The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "222cd9bb-5c56-41e8-b057-2f30e442aa9f", "node_type": "1", "metadata": {"window": "We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions. ", "original_text": "Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ad8f1adf9d91b0706f768d364c8b274942de35151b753d6f107501355c4245d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d11503ea-f48d-4a2d-8bee-22f85680f970", "node_type": "1", "metadata": {"window": "Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications. ", "original_text": "Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n"}, "hash": "1bca2d6143ce4f49a11b1c2b327c845d6cc23b398000eec2899d159552be9c18", "class_name": "RelatedNodeInfo"}}, "text": "The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n", "start_char_idx": 872, "end_char_idx": 1047, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d11503ea-f48d-4a2d-8bee-22f85680f970": {"__data__": {"id_": "d11503ea-f48d-4a2d-8bee-22f85680f970", "embedding": null, "metadata": {"window": "Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications. ", "original_text": "Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34e3a96c-d0c3-4e8a-8930-470dc5744e75", "node_type": "1", "metadata": {"window": "Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee.  Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n", "original_text": "The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c75c732204010e8d15d79fb838fac4b4daee2a6c02635246527802aedb95bf12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de0c0902-e9ee-46cb-82aa-71b79cef44a2", "node_type": "1", "metadata": {"window": "Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n", "original_text": "In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions. "}, "hash": "d9e66daddc483e0c02906774e960f665a4b607159c9c19ad1370e7c1ef97552e", "class_name": "RelatedNodeInfo"}}, "text": "Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n", "start_char_idx": 1047, "end_char_idx": 1243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de0c0902-e9ee-46cb-82aa-71b79cef44a2": {"__data__": {"id_": "de0c0902-e9ee-46cb-82aa-71b79cef44a2", "embedding": null, "metadata": {"window": "Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n", "original_text": "In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d11503ea-f48d-4a2d-8bee-22f85680f970", "node_type": "1", "metadata": {"window": "Over the past quarter, we welcomed two new practices, Nashville Oncology Associates and SCRI \nOncology Partners to the network.  \n \n Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications. ", "original_text": "Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0f33d1d30ea4af9c944ac3b6867f33a7f2e6f63f158ead1fd211c25b4754b91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75600b61-72cc-4079-89bf-2497daac509a", "node_type": "1", "metadata": {"window": "The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market. ", "original_text": "With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n"}, "hash": "81022be4a5a759547c43015dbd48066757967b2921afea53b0239817a939c63d", "class_name": "RelatedNodeInfo"}}, "text": "In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions. ", "start_char_idx": 1243, "end_char_idx": 1432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75600b61-72cc-4079-89bf-2497daac509a": {"__data__": {"id_": "75600b61-72cc-4079-89bf-2497daac509a", "embedding": null, "metadata": {"window": "The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market. ", "original_text": "With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de0c0902-e9ee-46cb-82aa-71b79cef44a2", "node_type": "1", "metadata": {"window": "Through the combination of  onboarding new practices and organic growth, The US Oncology Network has grown \nits provider base to over 2,500, spreading across nearly 600 sites in 30 states.  The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n", "original_text": "In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be89a7ca581eb5035c9913b91c9619fa9f6b7f8e56b922df5d22305ac6c62777", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dadac7c-e0ed-46aa-b65c-a90064e885a2", "node_type": "1", "metadata": {"window": "Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing. ", "original_text": "Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications. "}, "hash": "a241ab5fee9c2cb9aaa6552184d01ad88e47a7baec2d060f432ae91622997568", "class_name": "RelatedNodeInfo"}}, "text": "With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n", "start_char_idx": 1432, "end_char_idx": 1667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dadac7c-e0ed-46aa-b65c-a90064e885a2": {"__data__": {"id_": "6dadac7c-e0ed-46aa-b65c-a90064e885a2", "embedding": null, "metadata": {"window": "Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing. ", "original_text": "Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75600b61-72cc-4079-89bf-2497daac509a", "node_type": "1", "metadata": {"window": "The expansion of the network \nstrengthened our unique market position in community -based oncolog y practices and demonstrates our strong \nvalue proposition to providers.  \n \n Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market. ", "original_text": "With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21cfa3726f8190ddc357e57c0d52f6cf963009ab8a48f42f480a62f2f4677db5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8fe9881-545d-4160-a14d-542be1f18abf", "node_type": "1", "metadata": {"window": "In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n", "original_text": "In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n"}, "hash": "8e762deae822794a6b736ef596670ffd06602597b133d8197ebffbe1b1c87e29", "class_name": "RelatedNodeInfo"}}, "text": "Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications. ", "start_char_idx": 1667, "end_char_idx": 1852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8fe9881-545d-4160-a14d-542be1f18abf": {"__data__": {"id_": "c8fe9881-545d-4160-a14d-542be1f18abf", "embedding": null, "metadata": {"window": "In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n", "original_text": "In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dadac7c-e0ed-46aa-b65c-a90064e885a2", "node_type": "1", "metadata": {"window": "Through The US Oncology Network, we provide a range of comprehensive solutions to ease the administrative \nand operational burden, and to help enable the success of these community practices.  \n \n In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing. ", "original_text": "Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2efa74cc9e697b135cf7c6caed1d469407923d67b57c97f6417167a3b217a51a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d29241ac-6b04-40cb-b0a5-38ff62295847", "node_type": "1", "metadata": {"window": "With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide. ", "original_text": "Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market. "}, "hash": "b082d1738ba71ddbfa30b9e4ec945841e9c851efc2a53c8df6a665e5bd8bf54b", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n", "start_char_idx": 1852, "end_char_idx": 2138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d29241ac-6b04-40cb-b0a5-38ff62295847": {"__data__": {"id_": "d29241ac-6b04-40cb-b0a5-38ff62295847", "embedding": null, "metadata": {"window": "With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide. ", "original_text": "Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8fe9881-545d-4160-a14d-542be1f18abf", "node_type": "1", "metadata": {"window": "In the past quarter, we started integrating new artificial intelligence capabilities into the network, assisting \nproviders with revenue cycle management and evaluating clinical solutions.  With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n", "original_text": "In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbb38e90e7f3761c1ca7c92a40ca66373163438d5d0f128a7b2f73fb272f700d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17d1e7af-1823-490c-bbd4-88cb0d76b2dd", "node_type": "1", "metadata": {"window": "Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey. ", "original_text": "Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing. "}, "hash": "7ee0c5375263fcb10dd37ba94c3d194e8e97c3168ec1d2f5767633760b3659e5", "class_name": "RelatedNodeInfo"}}, "text": "Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market. ", "start_char_idx": 2138, "end_char_idx": 2248, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17d1e7af-1823-490c-bbd4-88cb0d76b2dd": {"__data__": {"id_": "17d1e7af-1823-490c-bbd4-88cb0d76b2dd", "embedding": null, "metadata": {"window": "Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey. ", "original_text": "Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d29241ac-6b04-40cb-b0a5-38ff62295847", "node_type": "1", "metadata": {"window": "With the help of AI and machine \nlearning technologies, p ractices will be able to navigate complex insurance coverage and reimbursement \nprocesses more efficiently, allowing providers to spend more time focused on their patients.  \n \n Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide. ", "original_text": "Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d7e3658702b0aef39a48c6a6642cb4045ed193aabf66e7ef8eb3b8a3d7c6eec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfc2d861-c65c-4d38-afb1-4fb81553a9fd", "node_type": "1", "metadata": {"window": "In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders. ", "original_text": "The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n"}, "hash": "5a8c4eeab18fa6d299e611a048a317f51d772af19b30d88d3839376a717205a6", "class_name": "RelatedNodeInfo"}}, "text": "Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing. ", "start_char_idx": 2248, "end_char_idx": 2395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfc2d861-c65c-4d38-afb1-4fb81553a9fd": {"__data__": {"id_": "dfc2d861-c65c-4d38-afb1-4fb81553a9fd", "embedding": null, "metadata": {"window": "In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders. ", "original_text": "The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17d1e7af-1823-490c-bbd4-88cb0d76b2dd", "node_type": "1", "metadata": {"window": "Within the Biopharma Services business, we continue to see strong market demand for  our differentiated \nsolutions that help improve access, affordability and adherence to medications.  In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey. ", "original_text": "Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c9c2e550c38b6f6b05cb8113c2286334905a69a8b450878c2d997186ec9d4059", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55475d1d-3be2-483f-bb51-8d9959e6f79f", "node_type": "1", "metadata": {"window": "Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n", "original_text": "The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide. "}, "hash": "4809487e616bb30cc74af2eb0b04374d0c919786140653e335d26b2c8e28d44a", "class_name": "RelatedNodeInfo"}}, "text": "The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n", "start_char_idx": 2395, "end_char_idx": 2594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55475d1d-3be2-483f-bb51-8d9959e6f79f": {"__data__": {"id_": "55475d1d-3be2-483f-bb51-8d9959e6f79f", "embedding": null, "metadata": {"window": "Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n", "original_text": "The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfc2d861-c65c-4d38-afb1-4fb81553a9fd", "node_type": "1", "metadata": {"window": "In the third quarter \u2013 or this fiscal \nthird quarter, the Prescription Technology Solutions segment delivered strong performance, primarily driven by \nthe gro wth at access solutions, including prior authorization solutions for branded pharmaceuticals, such as GLP -\n1 medications.  \n \n Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders. ", "original_text": "The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ccda1602884f1489b2386b07f335e612356ddd2491a18faf56898568aeaf174b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6f8960c-913d-4480-9abb-b237738e4a82", "node_type": "1", "metadata": {"window": "Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point. ", "original_text": "We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey. "}, "hash": "f053a843e6a15049b412eb2adee1e7657579b53131e7b7310d555a1cfee2628e", "class_name": "RelatedNodeInfo"}}, "text": "The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide. ", "start_char_idx": 2594, "end_char_idx": 2750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6f8960c-913d-4480-9abb-b237738e4a82": {"__data__": {"id_": "b6f8960c-913d-4480-9abb-b237738e4a82", "embedding": null, "metadata": {"window": "Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point. ", "original_text": "We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55475d1d-3be2-483f-bb51-8d9959e6f79f", "node_type": "1", "metadata": {"window": "Today, we provide prior authorization services for the vast majority of the GLP -1 medications in the market.  Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n", "original_text": "The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1eb6d1f2f416e4119bdb9c7b12482d61fc207fe3f508987b15a687a8be2e600", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a241c94f-c686-409f-8c52-22a361eeb50b", "node_type": "1", "metadata": {"window": "The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n", "original_text": "We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders. "}, "hash": "063be259b26340f3c788278ccf8baaf4120c878d419e789c9aa333673d1b58ec", "class_name": "RelatedNodeInfo"}}, "text": "We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey. ", "start_char_idx": 2750, "end_char_idx": 2870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a241c94f-c686-409f-8c52-22a361eeb50b": {"__data__": {"id_": "a241c94f-c686-409f-8c52-22a361eeb50b", "embedding": null, "metadata": {"window": "The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n", "original_text": "We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6f8960c-913d-4480-9abb-b237738e4a82", "node_type": "1", "metadata": {"window": "Our \nintegrated technology  streamlines the prior authorization process and helps overcome medication access \nchallenges that patients are facing.  The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point. ", "original_text": "We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ff0f45fb03095d2e5d620a233ceaeea5da81f63ffb7ada1375d85bd73a93904", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f49bd3c-0eae-4c88-ab0e-80f98bdc7308", "node_type": "1", "metadata": {"window": "The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season. ", "original_text": "The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n"}, "hash": "3e1c6376d1be292fe10ce143b931ef4dbb5e46aee84e768bacf549b6e68d4ade", "class_name": "RelatedNodeInfo"}}, "text": "We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders. ", "start_char_idx": 2870, "end_char_idx": 2950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f49bd3c-0eae-4c88-ab0e-80f98bdc7308": {"__data__": {"id_": "0f49bd3c-0eae-4c88-ab0e-80f98bdc7308", "embedding": null, "metadata": {"window": "The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season. ", "original_text": "The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a241c94f-c686-409f-8c52-22a361eeb50b", "node_type": "1", "metadata": {"window": "The main customers we serve are biopharma companies and through our \nscaled network connection, we can electronically process requests, bo th at the pharmacy counter and the \nprovider's offices.  \n \n The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n", "original_text": "We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0b8538c350349900a0c981d4b7d9239139d76ed8a5c140de58eaff306f69271", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6842de3b-de2a-478e-81d3-1d0c6f0bd5a8", "node_type": "1", "metadata": {"window": "We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities. ", "original_text": "The integrated solutions we offer can often be accessed through a single digital entry point. "}, "hash": "74177a7ab88e799e82391863288ffa104c91d323b84ff9fc17768e22c992017f", "class_name": "RelatedNodeInfo"}}, "text": "The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n", "start_char_idx": 2950, "end_char_idx": 3080, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6842de3b-de2a-478e-81d3-1d0c6f0bd5a8": {"__data__": {"id_": "6842de3b-de2a-478e-81d3-1d0c6f0bd5a8", "embedding": null, "metadata": {"window": "We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities. ", "original_text": "The integrated solutions we offer can often be accessed through a single digital entry point. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f49bd3c-0eae-4c88-ab0e-80f98bdc7308", "node_type": "1", "metadata": {"window": "The prior authorization solution is an example of the power of our capabilities and as part of a broader portfolio of \npatient support services we provide.  We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season. ", "original_text": "The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff5bd6fd244f2c5cb53d34051f13e5eae2de3c7a1f7637c4812c7e354603dae6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2427022c-7c88-45d9-adc0-6aa2b66b7e3f", "node_type": "1", "metadata": {"window": "We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs. ", "original_text": "For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n"}, "hash": "f9b0e7d28fffcd2b3ca18945af7715a3c8c2904ed4ab55bcc54dbaa21228464c", "class_name": "RelatedNodeInfo"}}, "text": "The integrated solutions we offer can often be accessed through a single digital entry point. ", "start_char_idx": 3080, "end_char_idx": 3174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2427022c-7c88-45d9-adc0-6aa2b66b7e3f": {"__data__": {"id_": "2427022c-7c88-45d9-adc0-6aa2b66b7e3f", "embedding": null, "metadata": {"window": "We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs. ", "original_text": "For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6842de3b-de2a-478e-81d3-1d0c6f0bd5a8", "node_type": "1", "metadata": {"window": "We believe our solutions are highly different iated and provide value to all \nstakeholders through a patient's journey.  We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities. ", "original_text": "The integrated solutions we offer can often be accessed through a single digital entry point. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b6cfd916c451e9ccce181f952879d5633f659bbf37b7c3502b9698ce798bc6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35f67f53-581c-4b92-bf5f-044f98408cf5", "node_type": "1", "metadata": {"window": "The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season. "}, "hash": "a39ea960cfbba9fd0ae7e69e6d54fbe46c1148430fd53413b41386133c044db1", "class_name": "RelatedNodeInfo"}}, "text": "For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n", "start_char_idx": 3174, "end_char_idx": 3311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35f67f53-581c-4b92-bf5f-044f98408cf5": {"__data__": {"id_": "35f67f53-581c-4b92-bf5f-044f98408cf5", "embedding": null, "metadata": {"window": "The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2427022c-7c88-45d9-adc0-6aa2b66b7e3f", "node_type": "1", "metadata": {"window": "We're connected to over 50,000 pharmacies and approximately 900,000 \nproviders.  The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs. ", "original_text": "For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3fca3962aaabdd5ef88680c38503a6e41bb4b389fa73c90c2c651eb5280072ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b1723d4-d76e-4811-b8d5-393f439a02ef", "node_type": "1", "metadata": {"window": "The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities. "}, "hash": "19e5d608e6a503cb638d430032d25a669378b8add1b121af680ffeb8aaa2adfe", "class_name": "RelatedNodeInfo"}}, "text": "In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season. ", "start_char_idx": 3311, "end_char_idx": 3419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b1723d4-d76e-4811-b8d5-393f439a02ef": {"__data__": {"id_": "9b1723d4-d76e-4811-b8d5-393f439a02ef", "embedding": null, "metadata": {"window": "The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35f67f53-581c-4b92-bf5f-044f98408cf5", "node_type": "1", "metadata": {"window": "The scale of our network provides a strong foundation that enables us to reach key stakeholders \neffectiv ely and seamlessly.  \n \n The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8709d03ae76c2318c9bcdaaa69c5719346a71e472d046762bc8ceb381673e579", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "204be92c-2131-490b-befe-383d4fda4b4f", "node_type": "1", "metadata": {"window": "For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs. "}, "hash": "14641963c1062069ce249a332741c49271ff14fe57c9badcc920555268f323ad", "class_name": "RelatedNodeInfo"}}, "text": "For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities. ", "start_char_idx": 3419, "end_char_idx": 3588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "204be92c-2131-490b-befe-383d4fda4b4f": {"__data__": {"id_": "204be92c-2131-490b-befe-383d4fda4b4f", "embedding": null, "metadata": {"window": "For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b1723d4-d76e-4811-b8d5-393f439a02ef", "node_type": "1", "metadata": {"window": "The integrated solutions we offer can often be accessed through a single digital entry point.  For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec0b8750acd2707b261655b4107dfe31661a3338dccc9e1557c79e5c4d3cf100", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30ba71fb-2fad-42ca-a503-a4ab95311b54", "node_type": "1", "metadata": {"window": "In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  "}, "hash": "d4ec203095806192890a32c8b682085acf3d1d719ce2885ae77f7a3ce7468ede", "class_name": "RelatedNodeInfo"}}, "text": "The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs. ", "start_char_idx": 3588, "end_char_idx": 3706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30ba71fb-2fad-42ca-a503-a4ab95311b54": {"__data__": {"id_": "30ba71fb-2fad-42ca-a503-a4ab95311b54", "embedding": null, "metadata": {"window": "In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5e649478-3ea1-4c36-8443-a80019444b0a", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e60a4a24e8e6b3747b61baf9d111b8ba750617c45cbb471b25a6dc62055f94a4", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "204be92c-2131-490b-befe-383d4fda4b4f", "node_type": "1", "metadata": {"window": "For our biopharma \ncustomers, the integration helps streamline workflows and increase transparency into how programs work \ntogether.  \n \n In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs. ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96f98b463faf96ed9bdcce1a86e8e7b946dc94198c75b8e22183be07c03db324", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3173be91-082f-4587-bb2f-4b77bd9dbfc2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise. ", "original_text": "McKesson Corp.  "}, "hash": "e25b0cba91f821a438d6d52402dc585190d332c08b3ef1e0eb9f71366a86542a", "class_name": "RelatedNodeInfo"}}, "text": "Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "start_char_idx": 3706, "end_char_idx": 3806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3173be91-082f-4587-bb2f-4b77bd9dbfc2": {"__data__": {"id_": "3173be91-082f-4587-bb2f-4b77bd9dbfc2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30ba71fb-2fad-42ca-a503-a4ab95311b54", "node_type": "1", "metadata": {"window": "In the pa st quarter, our team has been working diligently to prepare for what we call the blizzard season.  For the \nPrescription Technology Solutions segment, our fiscal fourth quarter is usually the busiest time of the year, due to \ncustomer annual verification acti vities.  The annual reset of insurance policies typically drives a large influx of \nseasonal volumes for many of our programs.  Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "original_text": "Each year, our teams come together to tackle the challenge of these \nsignificant volume increases.  ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a2bd165049139c997ee5228de58541257e244d22885db7e382bfcdaa374b154", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b13ca194-4fb8-4105-a3bc-544e7056904f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations. "}, "hash": "89a230cfba2509087e62d65e9e0a2fa67928b7457a8c31dd054b1fd39a397de8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b13ca194-4fb8-4105-a3bc-544e7056904f": {"__data__": {"id_": "b13ca194-4fb8-4105-a3bc-544e7056904f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3173be91-082f-4587-bb2f-4b77bd9dbfc2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "571fd0d598587dc33629e43e6fb669577ab41954af80fbb669782b3165a346f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "491b8f6f-2aec-43bd-99fe-6fda1c632595", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together. ", "original_text": "Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses. "}, "hash": "046f93e20dba32cde5b6b094adbd6ae0cbe46b4fa60615a572cf1e40709eb713", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations. ", "start_char_idx": 16, "end_char_idx": 311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "491b8f6f-2aec-43bd-99fe-6fda1c632595": {"__data__": {"id_": "491b8f6f-2aec-43bd-99fe-6fda1c632595", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together. ", "original_text": "Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b13ca194-4fb8-4105-a3bc-544e7056904f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5047e881567cd626568ab8009c54a15d0226f58c620aba3f5b522da090f66e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06c05d55-8657-4a3b-b2a0-486ae50bfe35", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share. ", "original_text": "We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise. "}, "hash": "f2e2fbcaa7032c06a13897b881b800d06213333838e9a8ae70d8cf2cee3e035e", "class_name": "RelatedNodeInfo"}}, "text": "Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses. ", "start_char_idx": 311, "end_char_idx": 482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06c05d55-8657-4a3b-b2a0-486ae50bfe35": {"__data__": {"id_": "06c05d55-8657-4a3b-b2a0-486ae50bfe35", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share. ", "original_text": "We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "491b8f6f-2aec-43bd-99fe-6fda1c632595", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together. ", "original_text": "Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ab86727a1b5b254ab9b65997dff88cb4663987d189bbc25714e8b9a2264ad8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23705095-5507-4f1a-8ef0-f9d552f59e63", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n", "original_text": "We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n"}, "hash": "d3ad7605245a9a377fa0e60daaebc72dbf017fbcab96529f83514b5b4609d77f", "class_name": "RelatedNodeInfo"}}, "text": "We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise. ", "start_char_idx": 482, "end_char_idx": 615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23705095-5507-4f1a-8ef0-f9d552f59e63": {"__data__": {"id_": "23705095-5507-4f1a-8ef0-f9d552f59e63", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n", "original_text": "We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06c05d55-8657-4a3b-b2a0-486ae50bfe35", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share. ", "original_text": "We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3af44261a758e53d3c135a7e4db903bf7fdde8182c701be0cdef4f27c8a61cf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da0ff8f5-5b5a-4d0d-921c-901f50cd98c4", "node_type": "1", "metadata": {"window": "Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market. ", "original_text": "So let m e pull it all together. "}, "hash": "48841f05a47c01a53a5f815cc0cbb91962238ce58c68d8d93ecf5752fc4618c8", "class_name": "RelatedNodeInfo"}}, "text": "We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n", "start_char_idx": 615, "end_char_idx": 727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da0ff8f5-5b5a-4d0d-921c-901f50cd98c4": {"__data__": {"id_": "da0ff8f5-5b5a-4d0d-921c-901f50cd98c4", "embedding": null, "metadata": {"window": "Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market. ", "original_text": "So let m e pull it all together. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23705095-5507-4f1a-8ef0-f9d552f59e63", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n", "original_text": "We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c0a4d2904ce2289aba366ddf99409420531630d6cf17a69ada958069e3e2979d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b64e846-1dba-41b3-84c6-9a9863e08a31", "node_type": "1", "metadata": {"window": "We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients. ", "original_text": "McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share. "}, "hash": "f4c00b462fd726d810d834523c7d731cffd878e435b66ae1ed18188033aaadd6", "class_name": "RelatedNodeInfo"}}, "text": "So let m e pull it all together. ", "start_char_idx": 727, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b64e846-1dba-41b3-84c6-9a9863e08a31": {"__data__": {"id_": "0b64e846-1dba-41b3-84c6-9a9863e08a31", "embedding": null, "metadata": {"window": "We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients. ", "original_text": "McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da0ff8f5-5b5a-4d0d-921c-901f50cd98c4", "node_type": "1", "metadata": {"window": "Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market. ", "original_text": "So let m e pull it all together. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15f69015450d7eaf66ec689d4a1ad6d09195750993f5398072aaf6e198adbb2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc173576-f139-4566-b7dc-eba168a55a0f", "node_type": "1", "metadata": {"window": "We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n", "original_text": "We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n"}, "hash": "1adee9b17a863ab827f487f60de270753a76ab8e34f868bc116646c5f7caa67c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share. ", "start_char_idx": 760, "end_char_idx": 918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc173576-f139-4566-b7dc-eba168a55a0f": {"__data__": {"id_": "fc173576-f139-4566-b7dc-eba168a55a0f", "embedding": null, "metadata": {"window": "We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n", "original_text": "We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b64e846-1dba-41b3-84c6-9a9863e08a31", "node_type": "1", "metadata": {"window": "We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise.  We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients. ", "original_text": "McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2de0b6d988ba58b87c4fcd5af2647903acbf69a1e0f16708abef12b2ddb7c4c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c67c9e3a-5521-4aa7-b4e9-c9039463bc87", "node_type": "1", "metadata": {"window": "So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n ", "original_text": "Healthcare is an ever -evolving market. "}, "hash": "680e6950b2374f90108cc2bacffe0430c5707cb50b52cfbd0e29d4dd87c9377d", "class_name": "RelatedNodeInfo"}}, "text": "We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n", "start_char_idx": 918, "end_char_idx": 1097, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c67c9e3a-5521-4aa7-b4e9-c9039463bc87": {"__data__": {"id_": "c67c9e3a-5521-4aa7-b4e9-c9039463bc87", "embedding": null, "metadata": {"window": "So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n ", "original_text": "Healthcare is an ever -evolving market. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc173576-f139-4566-b7dc-eba168a55a0f", "node_type": "1", "metadata": {"window": "We will \ncontinue to invest and innovate to support the evolving needs of our customers and their patients.  \n \n So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n", "original_text": "We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6fb13f1639c1e3e2409505f20ae6a50d91cdde1d36f68feb862df83bc7088b02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1792d35b-94ea-4daf-aedd-ef201cf97cae", "node_type": "1", "metadata": {"window": "McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients. "}, "hash": "3586527ed005819b32aa7d9a24480fddc31596309036f54f1d75e98374f0e54e", "class_name": "RelatedNodeInfo"}}, "text": "Healthcare is an ever -evolving market. ", "start_char_idx": 1097, "end_char_idx": 1137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1792d35b-94ea-4daf-aedd-ef201cf97cae": {"__data__": {"id_": "1792d35b-94ea-4daf-aedd-ef201cf97cae", "embedding": null, "metadata": {"window": "McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c67c9e3a-5521-4aa7-b4e9-c9039463bc87", "node_type": "1", "metadata": {"window": "So let m e pull it all together.  McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n ", "original_text": "Healthcare is an ever -evolving market. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b545711492556c7deabafe73bdc1f6f20a2c8799ba94c5066c9f47bca47c472c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5b58d9f-ece3-4bb6-9694-19945f4ade5c", "node_type": "1", "metadata": {"window": "We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon. ", "original_text": "I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n"}, "hash": "2049563d370ecd96540cbd45eec076d1360de8190aa43c79bf216a5f4efd1371", "class_name": "RelatedNodeInfo"}}, "text": "But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients. ", "start_char_idx": 1137, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5b58d9f-ece3-4bb6-9694-19945f4ade5c": {"__data__": {"id_": "a5b58d9f-ece3-4bb6-9694-19945f4ade5c", "embedding": null, "metadata": {"window": "We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon. ", "original_text": "I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1792d35b-94ea-4daf-aedd-ef201cf97cae", "node_type": "1", "metadata": {"window": "McKesson reported another solid quarter in fiscal 2024, that allowed us to raise and \nnarrow our full -year guidance for adjusted earnings per diluted share.  We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n", "original_text": "But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e95ec10cdf93851fa4633b66f0c7c9d899ca0a670f8426d7ddcda0da5d89a7cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a5a28d9-cbdb-4977-aaef-9c709e892c42", "node_type": "1", "metadata": {"window": "Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses. ", "original_text": "And with that, I'll hand it over to Britt for some additional insight and comments.  \n "}, "hash": "c5a57054551b16544e598e4c70590d56f0c31d9769ec56fd31b98882e5033f2b", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n", "start_char_idx": 1296, "end_char_idx": 1407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a5a28d9-cbdb-4977-aaef-9c709e892c42": {"__data__": {"id_": "9a5a28d9-cbdb-4977-aaef-9c709e892c42", "embedding": null, "metadata": {"window": "Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses. ", "original_text": "And with that, I'll hand it over to Britt for some additional insight and comments.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5b58d9f-ece3-4bb6-9694-19945f4ade5c", "node_type": "1", "metadata": {"window": "We're committed to our shareholders to \ndelivering long -term sustainable grow th, and this quarter's results reflect the continued progress in delivering on \nour commitment.  \n \n Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon. ", "original_text": "I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "682aef4c1b0ae4d51bbe34ccb5ac7c4af36e93831f1631021ed2efd6c3aa3ffb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70b43e66-4fcf-4d63-8ca6-91b9bdc7fa16", "node_type": "1", "metadata": {"window": "But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n"}, "hash": "11e1f958987200c039e4c605ab97d9caa565f0bc02d17fbeece4f5d7b5e4d67e", "class_name": "RelatedNodeInfo"}}, "text": "And with that, I'll hand it over to Britt for some additional insight and comments.  \n ", "start_char_idx": 1407, "end_char_idx": 1494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70b43e66-4fcf-4d63-8ca6-91b9bdc7fa16": {"__data__": {"id_": "70b43e66-4fcf-4d63-8ca6-91b9bdc7fa16", "embedding": null, "metadata": {"window": "But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a5a28d9-cbdb-4977-aaef-9c709e892c42", "node_type": "1", "metadata": {"window": "Healthcare is an ever -evolving market.  But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses. ", "original_text": "And with that, I'll hand it over to Britt for some additional insight and comments.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45a065a12a8f984595119e16ecbba0de9e09a9292ba69a58962884363e2e6ef9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2f7f456-25b6-4572-8c37-e50b7ea8906d", "node_type": "1", "metadata": {"window": "I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults. ", "original_text": "Thank you, Brian, and good afternoon. "}, "hash": "6b58fdce1a43d56e79701fe99b4b989738b6bcab62888140ec1bde980c8c1ac6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n", "start_char_idx": 1494, "end_char_idx": 1856, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2f7f456-25b6-4572-8c37-e50b7ea8906d": {"__data__": {"id_": "f2f7f456-25b6-4572-8c37-e50b7ea8906d", "embedding": null, "metadata": {"window": "I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults. ", "original_text": "Thank you, Brian, and good afternoon. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70b43e66-4fcf-4d63-8ca6-91b9bdc7fa16", "node_type": "1", "metadata": {"window": "But thanks to the hard work and dedication of our employees, we never \nstopped finding new ways to drive positive impacts on our customers and their patients.  I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3c020bde3cb605b25a2e01013fa1d93f84cfa6d8706e832baab2e3ebdebfebe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf393b88-dee1-447b-8dbf-cfa053d97aa5", "node_type": "1", "metadata": {"window": "And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment. ", "original_text": "We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses. "}, "hash": "b09e1886e0e968bf3749e5aca814ce9db898e1587c7489577ec66c466be4d81a", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Brian, and good afternoon. ", "start_char_idx": 1856, "end_char_idx": 1894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf393b88-dee1-447b-8dbf-cfa053d97aa5": {"__data__": {"id_": "cf393b88-dee1-447b-8dbf-cfa053d97aa5", "embedding": null, "metadata": {"window": "And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment. ", "original_text": "We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2f7f456-25b6-4572-8c37-e50b7ea8906d", "node_type": "1", "metadata": {"window": "I want to thank the over \n50,000 McKesson employees, who are working so tirelessly to advance our mission.  \n \n And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults. ", "original_text": "Thank you, Brian, and good afternoon. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82ff9ee9f965443e3284c4b27e0853fbeec2a4135c5b79d6f1f3fb76589be6c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcf35293-3157-429b-9751-1143b6c0fd73", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n", "original_text": "Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n"}, "hash": "727f5c839883445c7e10690d42de1b8a451dfd5b8818a09cdfac8cc294de7074", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses. ", "start_char_idx": 1894, "end_char_idx": 2051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcf35293-3157-429b-9751-1143b6c0fd73": {"__data__": {"id_": "fcf35293-3157-429b-9751-1143b6c0fd73", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n", "original_text": "Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf393b88-dee1-447b-8dbf-cfa053d97aa5", "node_type": "1", "metadata": {"window": "And with that, I'll hand it over to Britt for some additional insight and comments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment. ", "original_text": "We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c58564c6e933560539ec993be2119130ffbbd9a1b5d8b4da3906a7ed96eef04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "665cf7e8-89fb-4868-b9be-7d0c2cf9301f", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars. ", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults. "}, "hash": "067880f299ea29c91cc79ae4ac960b6c24638708675225ae4b1ba0fd068c885d", "class_name": "RelatedNodeInfo"}}, "text": "Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n", "start_char_idx": 2051, "end_char_idx": 2231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "665cf7e8-89fb-4868-b9be-7d0c2cf9301f": {"__data__": {"id_": "665cf7e8-89fb-4868-b9be-7d0c2cf9301f", "embedding": null, "metadata": {"window": "Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars. ", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcf35293-3157-429b-9751-1143b6c0fd73", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Fi nancial Officer & Executive Vice President, McKesson Corp.  \n Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n", "original_text": "Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "986afa3ecc0ecae9e990043131065a39b34be4e7e289b70d9069af87a9bb144b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eac99e62-aec4-42e7-8c57-bc5d35f8b0e7", "node_type": "1", "metadata": {"window": "We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments. ", "original_text": "We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment. "}, "hash": "cb0572f05b9d7e939f71f6fc3d6fdda2bf7233d428a73f1ca3f26fb1df459a9d", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults. ", "start_char_idx": 2231, "end_char_idx": 2357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eac99e62-aec4-42e7-8c57-bc5d35f8b0e7": {"__data__": {"id_": "eac99e62-aec4-42e7-8c57-bc5d35f8b0e7", "embedding": null, "metadata": {"window": "We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments. ", "original_text": "We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "665cf7e8-89fb-4868-b9be-7d0c2cf9301f", "node_type": "1", "metadata": {"window": "Thank you, Brian, and good afternoon.  We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars. ", "original_text": "Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "535aeb0469c315143eb879ff6ee50912f69ca814050e28b4d352f784a1aa946a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1120bd9d-15b0-403a-bd27-e8c7b04cac0e", "node_type": "1", "metadata": {"window": "Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n", "original_text": "This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n"}, "hash": "470e1350f18526f49eadcca8dd85027fa65217613ead3469222b920f09d9b97b", "class_name": "RelatedNodeInfo"}}, "text": "We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment. ", "start_char_idx": 2357, "end_char_idx": 2502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1120bd9d-15b0-403a-bd27-e8c7b04cac0e": {"__data__": {"id_": "1120bd9d-15b0-403a-bd27-e8c7b04cac0e", "embedding": null, "metadata": {"window": "Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n", "original_text": "This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eac99e62-aec4-42e7-8c57-bc5d35f8b0e7", "node_type": "1", "metadata": {"window": "We're pleased with our fiscal third quarter 2024 results, which reflect \nanother quarter of solid momentum with growth across our North American businesses.  Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments. ", "original_text": "We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff7555ef6a9afd533998003a461f2bac31b59cdd9d8011153923b1aec7d7c8f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0de351d-2951-4591-b91d-c98034620de2", "node_type": "1", "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results. ", "original_text": "We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars. "}, "hash": "86926863fc4ddbc3d637ca58f50a65ff37272f67a0504ecf1a9c311f9c09c6cc", "class_name": "RelatedNodeInfo"}}, "text": "This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n", "start_char_idx": 2502, "end_char_idx": 2652, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0de351d-2951-4591-b91d-c98034620de2": {"__data__": {"id_": "d0de351d-2951-4591-b91d-c98034620de2", "embedding": null, "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results. ", "original_text": "We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1120bd9d-15b0-403a-bd27-e8c7b04cac0e", "node_type": "1", "metadata": {"window": "Our results exceeded \nexpectations, demonstrating our ability to consistently execute against company priorities and create long -term \nsustainable value for our shareholders.  \n \n Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n", "original_text": "This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "caab6d60443f31310974dddfd59c5e475c75d19d90556e22bd8a669cfe7c9165", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74a1bf7e-b0e8-49f5-b8a1-cb1d4b68f263", "node_type": "1", "metadata": {"window": "We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter. ", "original_text": "We're closely monitoring \ndevelopments. "}, "hash": "168abb159e1970bedeb5c834059f5fd8330ecf946e3310d9fa28da4b33e42688", "class_name": "RelatedNodeInfo"}}, "text": "We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars. ", "start_char_idx": 2652, "end_char_idx": 2842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74a1bf7e-b0e8-49f5-b8a1-cb1d4b68f263": {"__data__": {"id_": "74a1bf7e-b0e8-49f5-b8a1-cb1d4b68f263", "embedding": null, "metadata": {"window": "We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter. ", "original_text": "We're closely monitoring \ndevelopments. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0de351d-2951-4591-b91d-c98034620de2", "node_type": "1", "metadata": {"window": "Before I turn to our consolidated results, I want to highlight one item that impac ted our third quarter GAAP -only \nresults.  We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results. ", "original_text": "We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36d58d353dd7bc7b8625454f9758e0690c43fbdfe6059732d7d3c9e0b47bab2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b502dc2-3c60-47eb-97e7-e640e95b2d64", "node_type": "1", "metadata": {"window": "This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "original_text": "Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n"}, "hash": "ec7ceb6c77c62ae09cb16ed9338dc611c550b2d2a32f58fa825efdf6790c1045", "class_name": "RelatedNodeInfo"}}, "text": "We're closely monitoring \ndevelopments. ", "start_char_idx": 2842, "end_char_idx": 2882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b502dc2-3c60-47eb-97e7-e640e95b2d64": {"__data__": {"id_": "4b502dc2-3c60-47eb-97e7-e640e95b2d64", "embedding": null, "metadata": {"window": "This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "original_text": "Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74a1bf7e-b0e8-49f5-b8a1-cb1d4b68f263", "node_type": "1", "metadata": {"window": "We recorded an additional pre -tax GAAP provision for bad debts of $515 million or $381 million after tax \nwithin the US Pharmaceutical segment.  This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter. ", "original_text": "We're closely monitoring \ndevelopments. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64ec4f56bde4700a1ab95059fd3e54156c62155a5475ad27bd5233cb92e9472b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d6430768-3ed5-465d-847a-e7dead00e6d8", "node_type": "1", "metadata": {"window": "We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services. ", "original_text": "The remainder of my comments will refer to our fiscal 2024 adjusted results. "}, "hash": "9f700ae7cd7b743af6a52f7f1bb488f507b73217d0fd18ee3f39fbab04959af4", "class_name": "RelatedNodeInfo"}}, "text": "Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n", "start_char_idx": 2882, "end_char_idx": 3004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d6430768-3ed5-465d-847a-e7dead00e6d8": {"__data__": {"id_": "d6430768-3ed5-465d-847a-e7dead00e6d8", "embedding": null, "metadata": {"window": "We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services. ", "original_text": "The remainder of my comments will refer to our fiscal 2024 adjusted results. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b502dc2-3c60-47eb-97e7-e640e95b2d64", "node_type": "1", "metadata": {"window": "This provision is for uncollected trade accounts receivable from sales t o \nRite Aid in October of 2023, prior to its bankruptcy petition filing.  \n \n We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "original_text": "Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75017e421f9d6080bddb2a7aab4facd653d9af4a7a5de9b73615a0d9f4cae930", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e3effdc9-1dfc-4d98-8c7f-8c8309bf1a74", "node_type": "1", "metadata": {"window": "We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n", "original_text": "Let me start with  a review of the \nfiscal third quarter. "}, "hash": "cde35736661108048a6ed7661122b6dccd0c7c1f947c8dd93ed0307f5a4dd6a1", "class_name": "RelatedNodeInfo"}}, "text": "The remainder of my comments will refer to our fiscal 2024 adjusted results. ", "start_char_idx": 3004, "end_char_idx": 3081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e3effdc9-1dfc-4d98-8c7f-8c8309bf1a74": {"__data__": {"id_": "e3effdc9-1dfc-4d98-8c7f-8c8309bf1a74", "embedding": null, "metadata": {"window": "We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n", "original_text": "Let me start with  a review of the \nfiscal third quarter. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d6430768-3ed5-465d-847a-e7dead00e6d8", "node_type": "1", "metadata": {"window": "We continue to provide distribution services to Rite Aid through an interim distribution agreement, providing the \nsame efficiency and operational excellence, as we have for over 20 ye ars.  We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services. ", "original_text": "The remainder of my comments will refer to our fiscal 2024 adjusted results. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84b77f670c6b00a9632125fdf3872f2aee112c09fa384a58e460719320ae1809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7689e6a0-8112-4703-9a2e-575ffef46302", "node_type": "1", "metadata": {"window": "Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results. ", "original_text": "McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n"}, "hash": "c8e85806c9a4c630efee74033420fe1790f6415b572bd34d07500a45a3aa98bb", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with  a review of the \nfiscal third quarter. ", "start_char_idx": 3081, "end_char_idx": 3139, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7689e6a0-8112-4703-9a2e-575ffef46302": {"__data__": {"id_": "7689e6a0-8112-4703-9a2e-575ffef46302", "embedding": null, "metadata": {"window": "Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results. ", "original_text": "McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e3effdc9-1dfc-4d98-8c7f-8c8309bf1a74", "node_type": "1", "metadata": {"window": "We're closely monitoring \ndevelopments.  Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n", "original_text": "Let me start with  a review of the \nfiscal third quarter. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8fd89b1023c76ec5a176eeba45b361ff57e13983ae2b11863a3956abfe2b162e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "513653a4-ea15-4399-94b3-af80946b37c9", "node_type": "1", "metadata": {"window": "The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services. "}, "hash": "5a7ea0f5c7d447d58bf73af1378aff8cdf4315565d91e3ab2cd377bbe36fc64a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "start_char_idx": 3139, "end_char_idx": 3307, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "513653a4-ea15-4399-94b3-af80946b37c9": {"__data__": {"id_": "513653a4-ea15-4399-94b3-af80946b37c9", "embedding": null, "metadata": {"window": "The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7689e6a0-8112-4703-9a2e-575ffef46302", "node_type": "1", "metadata": {"window": "Rite Aids bankruptcy will not have a material impact on our fiscal 2024 adjusted earnings per \ndiluted share results.  \n \n The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results. ", "original_text": "McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd1eae3cd448265d4acd429ffe449309974f19f52a92a8a7d7e564831fb818cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4429f84-8804-4148-81e7-4359c918f24d", "node_type": "1", "metadata": {"window": "Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n"}, "hash": "14b54f187cf21c0535d243ff6fac77ab901165adff58b1056d29503266c35692", "class_name": "RelatedNodeInfo"}}, "text": "This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services. ", "start_char_idx": 3307, "end_char_idx": 3480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4429f84-8804-4148-81e7-4359c918f24d": {"__data__": {"id_": "c4429f84-8804-4148-81e7-4359c918f24d", "embedding": null, "metadata": {"window": "Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "513653a4-ea15-4399-94b3-af80946b37c9", "node_type": "1", "metadata": {"window": "The remainder of my comments will refer to our fiscal 2024 adjusted results.  Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "354d71876a2c167fcbe4e5058585b662073be256c47e4393c1f49e5b5fb63f04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62271bad-f2c2-417d-b0b7-05414d3da30e", "node_type": "1", "metadata": {"window": "McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "Let me move to our consolidated results. "}, "hash": "4e671dcf417b8833807add892ed0c76bc5388953a9f035558e950b31f9bec090", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n", "start_char_idx": 3480, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62271bad-f2c2-417d-b0b7-05414d3da30e": {"__data__": {"id_": "62271bad-f2c2-417d-b0b7-05414d3da30e", "embedding": null, "metadata": {"window": "McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "Let me move to our consolidated results. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4429f84-8804-4148-81e7-4359c918f24d", "node_type": "1", "metadata": {"window": "Let me start with  a review of the \nfiscal third quarter.  McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "739feb358602e86a5e91da88639f1109233028d3cc7ce507083a7b0351d1eef9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19a94e8a-ef3e-45fc-8d6e-96c3a86311a2", "node_type": "1", "metadata": {"window": "This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  "}, "hash": "aca99d3fbc90e3e677ab6988ddde707535013237566227d4f2fba8960774e0cc", "class_name": "RelatedNodeInfo"}}, "text": "Let me move to our consolidated results. ", "start_char_idx": 3721, "end_char_idx": 3762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19a94e8a-ef3e-45fc-8d6e-96c3a86311a2": {"__data__": {"id_": "19a94e8a-ef3e-45fc-8d6e-96c3a86311a2", "embedding": null, "metadata": {"window": "This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe4faebefdb52e237c70dd684071825749100770e7202a1c0e1cec26e0b6d7d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62271bad-f2c2-417d-b0b7-05414d3da30e", "node_type": "1", "metadata": {"window": "McKesson delivered solid growth in the third quarter, led by sustained strong performance in \nthe US Pharmaceutical and Prescription Technology Solutions segments.  \n \n This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "Let me move to our consolidated results. ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33374aa8d123d8ffd397386691f978a3246070eb359752b5a8e72ffb2ef10771", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20a396ed-3bf7-44f7-98ed-694dbef7d5a9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "03254e4ba82aa5f03f638ea2fda513a9e87451d127cbd20803d37de5db0c3590", "class_name": "RelatedNodeInfo"}}, "text": "Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "start_char_idx": 3762, "end_char_idx": 4143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20a396ed-3bf7-44f7-98ed-694dbef7d5a9": {"__data__": {"id_": "20a396ed-3bf7-44f7-98ed-694dbef7d5a9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19a94e8a-ef3e-45fc-8d6e-96c3a86311a2", "node_type": "1", "metadata": {"window": "This year -over-year growth underscores operating exec ution across our diversified and differentiated portfolio, \nincluding investments in oncology and biopharma services.  As a result of the third quarter operating performance \nand our confidence in the business, we're increasing and narrowing our full -year out look for fiscal 2024 adjusted \nearnings per diluted share, to a new range of $27.25 to $27.65.  \n \n Let me move to our consolidated results.  Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "original_text": "Revenues increased 15% to $80.9 billion, led by continued strong \nutilization trends, growth in the US Pharmaceutical seg ment, including higher volumes from specialty products, \nretail national account customers and GLP -1 medications, partially offset by lower revenues in the International \nsegment, resulting from fiscal 2023 divestitures within McKesson's European business.  ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "628072debe41fea75460bce4c23bff63f1d9a01c758f5a1aa76bd546f218986c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b983867c-e5ba-4bc0-9278-9110bce50b91", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%. "}, "hash": "0bdcf78511c65f0e4df907be2e79a158444a6fe90690c7b6213e80b496b15b22", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b983867c-e5ba-4bc0-9278-9110bce50b91": {"__data__": {"id_": "b983867c-e5ba-4bc0-9278-9110bce50b91", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20a396ed-3bf7-44f7-98ed-694dbef7d5a9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20d97d2b555c6daa5c005510f2474f81777083622fdcabdddd1b434bad27c9bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e42c2a6-3701-49a8-b5ab-d05ceba2a3fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n", "original_text": "Gross profit was $3.1 billion for the quarter, an increase of 3%. "}, "hash": "d085d219578d1ad94834605df259eccfebe70f3db76bdd79af385ed4bc8f1330", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%. ", "start_char_idx": 16, "end_char_idx": 299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e42c2a6-3701-49a8-b5ab-d05ceba2a3fb": {"__data__": {"id_": "3e42c2a6-3701-49a8-b5ab-d05ceba2a3fb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n", "original_text": "Gross profit was $3.1 billion for the quarter, an increase of 3%. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b983867c-e5ba-4bc0-9278-9110bce50b91", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5701c1df2284ef1a8d4907993d301aae81a54873510df0bf507f63b16cd20513", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71ccbcc8-bf4e-42a5-84e1-bee34cf7c969", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion. ", "original_text": "When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n"}, "hash": "de6a4502400f90a96b50d03fd0ff2ef0c7e56d842dc6061b2b73243a549212b6", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was $3.1 billion for the quarter, an increase of 3%. ", "start_char_idx": 299, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71ccbcc8-bf4e-42a5-84e1-bee34cf7c969": {"__data__": {"id_": "71ccbcc8-bf4e-42a5-84e1-bee34cf7c969", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion. ", "original_text": "When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e42c2a6-3701-49a8-b5ab-d05ceba2a3fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n", "original_text": "Gross profit was $3.1 billion for the quarter, an increase of 3%. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9cc2dd043bad98754acd8f391ac52e5051e5ec05c425d31a787b7103a9f2100", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbf75c40-582c-4ba2-941a-a89504968425", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n", "original_text": "Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments. "}, "hash": "2a0cf638d690f7d071c1389e8a9c2124708ac60ce19e1c45b647758b07f4c9bf", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n", "start_char_idx": 365, "end_char_idx": 569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbf75c40-582c-4ba2-941a-a89504968425": {"__data__": {"id_": "cbf75c40-582c-4ba2-941a-a89504968425", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n", "original_text": "Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71ccbcc8-bf4e-42a5-84e1-bee34cf7c969", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion. ", "original_text": "When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc082fac0337996241153b17876b7955ea089ec804772ad46202c4b0f509e737", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "899baf8b-fd8c-4e87-a7d7-d557e0eaa216", "node_type": "1", "metadata": {"window": "Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n", "original_text": "When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n"}, "hash": "d04a98df2d288eaec17a1b79a1267ec72f9d812139023beadd5735349fe80250", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments. ", "start_char_idx": 569, "end_char_idx": 730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "899baf8b-fd8c-4e87-a7d7-d557e0eaa216": {"__data__": {"id_": "899baf8b-fd8c-4e87-a7d7-d557e0eaa216", "embedding": null, "metadata": {"window": "Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n", "original_text": "When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbf75c40-582c-4ba2-941a-a89504968425", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n", "original_text": "Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e1abc5e682864632963778dab3e42b70cdaddcba23c75746f1b6b7c3ab41b18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c6a0561-88a1-4cfc-b4ad-2e9eba58672b", "node_type": "1", "metadata": {"window": "When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment. ", "original_text": "Third quarter operating profit decreased 9% to $1.3 billion. "}, "hash": "42972ed4441eb146f04d3f1742326186110d7d00a25cb15d0114f65f36b29da7", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n", "start_char_idx": 730, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c6a0561-88a1-4cfc-b4ad-2e9eba58672b": {"__data__": {"id_": "2c6a0561-88a1-4cfc-b4ad-2e9eba58672b", "embedding": null, "metadata": {"window": "When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment. ", "original_text": "Third quarter operating profit decreased 9% to $1.3 billion. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "899baf8b-fd8c-4e87-a7d7-d557e0eaa216", "node_type": "1", "metadata": {"window": "Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n", "original_text": "When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1341eed534c5e18d07b0fdf0711b2732c044df616afb69ce1bf38303598184e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "751e737b-725b-4bbe-9a2f-16383b276d67", "node_type": "1", "metadata": {"window": "Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n", "original_text": "Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n"}, "hash": "4fba79b87149393bdafffcdb07bbac3c1a5258c255722f6358055dd25ad75183", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter operating profit decreased 9% to $1.3 billion. ", "start_char_idx": 885, "end_char_idx": 946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "751e737b-725b-4bbe-9a2f-16383b276d67": {"__data__": {"id_": "751e737b-725b-4bbe-9a2f-16383b276d67", "embedding": null, "metadata": {"window": "Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n", "original_text": "Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c6a0561-88a1-4cfc-b4ad-2e9eba58672b", "node_type": "1", "metadata": {"window": "When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment. ", "original_text": "Third quarter operating profit decreased 9% to $1.3 billion. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5d7fe56884410d2e1e25a421d8ac155f60d4d5ac8ab11553ecd5526305d5048", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "491d8362-a3d9-4c13-9b06-df38b594fd11", "node_type": "1", "metadata": {"window": "When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio. ", "original_text": "Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n"}, "hash": "991e2a3f06025b53da029da4cea54349ca11d40742aeeb92ae43323693debdd5", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n", "start_char_idx": 946, "end_char_idx": 1115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "491d8362-a3d9-4c13-9b06-df38b594fd11": {"__data__": {"id_": "491d8362-a3d9-4c13-9b06-df38b594fd11", "embedding": null, "metadata": {"window": "When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio. ", "original_text": "Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "751e737b-725b-4bbe-9a2f-16383b276d67", "node_type": "1", "metadata": {"window": "Operating expenses increased 4% in the quarter, due to higher costs to support growth in the US Pharmaceutical \nand Prescription Techn ology Solutions segments.  When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n", "original_text": "Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86018f73dfa82f835c818f05cdf48c63dc060e11c7482298fd70b8bfb9db399c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da0c3082-2360-4434-aa58-5217bb6ccff8", "node_type": "1", "metadata": {"window": "Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n", "original_text": "These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment. "}, "hash": "efc0b8d4c2872cb3e8f1e0edec7ac6c2ccfe859e96c0692fdf89cf490303de91", "class_name": "RelatedNodeInfo"}}, "text": "Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n", "start_char_idx": 1115, "end_char_idx": 1393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da0c3082-2360-4434-aa58-5217bb6ccff8": {"__data__": {"id_": "da0c3082-2360-4434-aa58-5217bb6ccff8", "embedding": null, "metadata": {"window": "Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n", "original_text": "These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "491d8362-a3d9-4c13-9b06-df38b594fd11", "node_type": "1", "metadata": {"window": "When excluding the impact of our European business \noperations, including the completed divestitures, operating expenses increased 6% year -over-year.  \n \n Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio. ", "original_text": "Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f1da8db2d664c548913288ba641e6434c250396978455f6ecdef60a755758cb0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2b8930a-0ef4-4245-bb55-8892496c03ff", "node_type": "1", "metadata": {"window": "Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items. ", "original_text": "When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n"}, "hash": "a0ede001efa85b36845e2e12979b12550f2039151bb695f80827ae69ec672578", "class_name": "RelatedNodeInfo"}}, "text": "These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment. ", "start_char_idx": 1393, "end_char_idx": 1510, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2b8930a-0ef4-4245-bb55-8892496c03ff": {"__data__": {"id_": "b2b8930a-0ef4-4245-bb55-8892496c03ff", "embedding": null, "metadata": {"window": "Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items. ", "original_text": "When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da0c3082-2360-4434-aa58-5217bb6ccff8", "node_type": "1", "metadata": {"window": "Third quarter operating profit decreased 9% to $1.3 billion.  Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n", "original_text": "These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a61e767e2fbbd7b404d88e5bdbb2ed07b9730705d4251a8945d9b074fc7401c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d840a1eb-dde2-44ec-bd0e-bbb65b114dfc", "node_type": "1", "metadata": {"window": "Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n", "original_text": "Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio. "}, "hash": "93de0570726606b8ec4b9a9ebcc55c48cacf137ba9024d157e36953f714aaf17", "class_name": "RelatedNodeInfo"}}, "text": "When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n", "start_char_idx": 1510, "end_char_idx": 1787, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d840a1eb-dde2-44ec-bd0e-bbb65b114dfc": {"__data__": {"id_": "d840a1eb-dde2-44ec-bd0e-bbb65b114dfc", "embedding": null, "metadata": {"window": "Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n", "original_text": "Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2b8930a-0ef4-4245-bb55-8892496c03ff", "node_type": "1", "metadata": {"window": "Fiscal 2023 results  included a pre -tax benefit of $126 \nmillion, related to the early termination of the tax receivable agreement, or TRA, with Change Healthcare.  \n \n Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items. ", "original_text": "When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7e9482cdf0d97d11a1a5f1cf99c06beaa600af2441df73c959e403d484d4351", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b92a787c-8ed7-4df3-b1ab-d11caec0f402", "node_type": "1", "metadata": {"window": "These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year. ", "original_text": "The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n"}, "hash": "4069aaeccea61c041451c782a404e4d9d3597d90cf5ac6838a6f1b486d898244", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio. ", "start_char_idx": 1787, "end_char_idx": 1934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b92a787c-8ed7-4df3-b1ab-d11caec0f402": {"__data__": {"id_": "b92a787c-8ed7-4df3-b1ab-d11caec0f402", "embedding": null, "metadata": {"window": "These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year. ", "original_text": "The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d840a1eb-dde2-44ec-bd0e-bbb65b114dfc", "node_type": "1", "metadata": {"window": "Year -over-year results were also impacted by anticipated lower contributions from the US government COVID -19 \nprograms, which were mitigated by contributions from commercial COVID -19 distribution and a non -recurring $30 \nmillion charge in our US Pharmaceutical segment.  \n \n These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n", "original_text": "Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12f1e92db8ee388e2a00ece073d9e43f874a34b33b02d921bf9bfc8631f24e12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "843966ca-8c19-4692-94c8-40a7eed7fd2b", "node_type": "1", "metadata": {"window": "When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n", "original_text": "As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items. "}, "hash": "5b762c7f1daa86de481596c1c7638cbd25d4ada7ae101953612a88cb547e6f51", "class_name": "RelatedNodeInfo"}}, "text": "The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n", "start_char_idx": 1934, "end_char_idx": 2061, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "843966ca-8c19-4692-94c8-40a7eed7fd2b": {"__data__": {"id_": "843966ca-8c19-4692-94c8-40a7eed7fd2b", "embedding": null, "metadata": {"window": "When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n", "original_text": "As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b92a787c-8ed7-4df3-b1ab-d11caec0f402", "node_type": "1", "metadata": {"window": "These items were partially offset by growth in the US Pharmaceutical and Prescription Technology Solutions \nsegment.  When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year. ", "original_text": "The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb96035ab3810b66d572ffdae2269c72e8c5d080569403d510a1e40cb269eb03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4293517-36f2-4a55-b237-54c1b02f0644", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n", "original_text": "Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n"}, "hash": "2e63f2ddf4a3dcd10722e658f9b9df980adcef97805d2aa0e13729988dc00796", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items. ", "start_char_idx": 2061, "end_char_idx": 2196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4293517-36f2-4a55-b237-54c1b02f0644": {"__data__": {"id_": "a4293517-36f2-4a55-b237-54c1b02f0644", "embedding": null, "metadata": {"window": "Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n", "original_text": "Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "843966ca-8c19-4692-94c8-40a7eed7fd2b", "node_type": "1", "metadata": {"window": "When adjusting for these items, including $126 million or $0.65 benefit from the early termination of the \nTRA in fiscal 2023 and gains and losses associated with McKesson Ventures equity investments in fiscal 2023 \nand 2024, operating pro fit increased 7% in the quarter.  \n \n Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n", "original_text": "As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a7b54299a7d1042eb0801f1a0fe98a374ab9074c75a1e1f0bba7c3fcaa3d4bad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dacf767-f9d5-4623-b104-7f1525f50024", "node_type": "1", "metadata": {"window": "The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n", "original_text": "Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year. "}, "hash": "d56aa3a62687030fe0d3a21b2fe357c2249b979e50e3d8b90b7d6ca270d284e1", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n", "start_char_idx": 2196, "end_char_idx": 2313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dacf767-f9d5-4623-b104-7f1525f50024": {"__data__": {"id_": "5dacf767-f9d5-4623-b104-7f1525f50024", "embedding": null, "metadata": {"window": "The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n", "original_text": "Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4293517-36f2-4a55-b237-54c1b02f0644", "node_type": "1", "metadata": {"window": "Moving below the line, interest expense was $58 million, a decrease of 16% year -over-year, driven by effective \nmanagement of our loan portfolio.  The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n", "original_text": "Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba8298207e3228532506177d6bc01b06b8ab6a8351d688c0a0edaabfde822b29", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "062fbe2d-a744-46fc-b1dd-f09347836106", "node_type": "1", "metadata": {"window": "As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n", "original_text": "This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n"}, "hash": "17f4e020e5900760a217276a7ecaf9ee10d3ef8e87209392f86f4f6ec1d5dcb5", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year. ", "start_char_idx": 2313, "end_char_idx": 2437, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "062fbe2d-a744-46fc-b1dd-f09347836106": {"__data__": {"id_": "062fbe2d-a744-46fc-b1dd-f09347836106", "embedding": null, "metadata": {"window": "As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n", "original_text": "This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dacf767-f9d5-4623-b104-7f1525f50024", "node_type": "1", "metadata": {"window": "The effective tax rate for the quarter was 10.6%, resulting from the recognit ion \nof discrete tax benefit in the quarter.  \n \n As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n", "original_text": "Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbf1a4ce021427673e37e3f7c5f934ab219110292a257dddec85b2d97644454d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52fa35e9-20e7-4103-9da2-82a9cbb8ce0f", "node_type": "1", "metadata": {"window": "Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023. ", "original_text": "Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n"}, "hash": "0df8742b0a426df7f90bf6a7385f4700a4dcd7cbc6585477f79cc9acf586955d", "class_name": "RelatedNodeInfo"}}, "text": "This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n", "start_char_idx": 2437, "end_char_idx": 2750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52fa35e9-20e7-4103-9da2-82a9cbb8ce0f": {"__data__": {"id_": "52fa35e9-20e7-4103-9da2-82a9cbb8ce0f", "embedding": null, "metadata": {"window": "Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023. ", "original_text": "Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "062fbe2d-a744-46fc-b1dd-f09347836106", "node_type": "1", "metadata": {"window": "As a reminder, our effective tax rate can vary quarter -to-quarter, driven by our mix of income and the timing of \ndiscrete tax items.  Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n", "original_text": "This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e4f0cdf1127effb1bc2004f36a31f973848fd7c4778f0b23c7232849e6de988", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "242fa5c8-78e9-4606-80d8-2a75712314d7", "node_type": "1", "metadata": {"window": "Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n"}, "hash": "1a1ceef59c90ba4e6ccbfa6cb9c9ff030920eebbf9585c7f734829ce030da58b", "class_name": "RelatedNodeInfo"}}, "text": "Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n", "start_char_idx": 2750, "end_char_idx": 2987, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "242fa5c8-78e9-4606-80d8-2a75712314d7": {"__data__": {"id_": "242fa5c8-78e9-4606-80d8-2a75712314d7", "embedding": null, "metadata": {"window": "Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52fa35e9-20e7-4103-9da2-82a9cbb8ce0f", "node_type": "1", "metadata": {"window": "Third quarter diluted weighted average shares outstanding was $133.3 million, a decrease of \n5% year -over-year.  \n \n Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023. ", "original_text": "Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5bcf5810b07d7ccd372fd90d9c2227ddb29a0f545e93e491abd0e3c3fe7f205d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9628cfe-7fda-4b53-abf9-9b9cc8f8c5c1", "node_type": "1", "metadata": {"window": "This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n"}, "hash": "ba4e2592d442504ee04b3169b6a5168a8fc85c0cd0c2e687a6c1165be04dad8b", "class_name": "RelatedNodeInfo"}}, "text": "Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n", "start_char_idx": 2987, "end_char_idx": 3100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9628cfe-7fda-4b53-abf9-9b9cc8f8c5c1": {"__data__": {"id_": "f9628cfe-7fda-4b53-abf9-9b9cc8f8c5c1", "embedding": null, "metadata": {"window": "This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "242fa5c8-78e9-4606-80d8-2a75712314d7", "node_type": "1", "metadata": {"window": "Consolidated third quarter earnings per diluted share, was $7.74, which represents an increase of 12% over the \nprior year.  This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a2a70d8d5cc5530b58953945817169152c42fb23c2b886864243082ecf0cad34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a446bab5-b994-4395-a6a0-eb31d679c11a", "node_type": "1", "metadata": {"window": "Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023. "}, "hash": "2a47113f49e2323ec539494370b1cba9693d6588232a6445cae262b7942f80f8", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n", "start_char_idx": 3100, "end_char_idx": 3333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a446bab5-b994-4395-a6a0-eb31d679c11a": {"__data__": {"id_": "a446bab5-b994-4395-a6a0-eb31d679c11a", "embedding": null, "metadata": {"window": "Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9628cfe-7fda-4b53-abf9-9b9cc8f8c5c1", "node_type": "1", "metadata": {"window": "This increase includes the impacts of approximately $0.63 related to the US government COVID -19 \nprogram and the $0.65 benefit from the termination of the TRA in fiscal 2023 and increased commercial COVID -\n19 vaccine distribution and a non -recurring charge in our US Pharmaceutical segment in fiscal 2024.  \n \n Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e62694a8741e74e0ccfa085fd8b1347b77d87a41dfc407d158ea42c7f08a07a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d852d842-69f7-45d1-b22c-289ce7de4053", "node_type": "1", "metadata": {"window": "Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n "}, "hash": "2ee1793734caf30ff9fd884b9b43041f68180a2e8d3c07ef47b7649332cbeb9e", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023. ", "start_char_idx": 3333, "end_char_idx": 3460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d852d842-69f7-45d1-b22c-289ce7de4053": {"__data__": {"id_": "d852d842-69f7-45d1-b22c-289ce7de4053", "embedding": null, "metadata": {"window": "Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0e4ccb757329db95738507a74c0ae2fa053f4cee1e6c9c6583698aef31f1cb6", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a446bab5-b994-4395-a6a0-eb31d679c11a", "node_type": "1", "metadata": {"window": "Turning to our third quarter segment results, whic h can be found on slide 7 through 11, and starting with US \nPharmaceutical, during the quarter, we experienced volume increases across all product categories and customer \nchannels.  \n \n Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023. ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41ea9d5d62d342f38a3a98947d5fec2501e7cd69839631e953679a5cdbc06e18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a52f991c-01b2-4948-8b45-a0d302cd090f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems. ", "original_text": "McKesson Corp.  "}, "hash": "84e519ac02f29c29be1407c343b005a54d33a10cae427dc80d1b63ab577647cf", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "start_char_idx": 3460, "end_char_idx": 3570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a52f991c-01b2-4948-8b45-a0d302cd090f": {"__data__": {"id_": "a52f991c-01b2-4948-8b45-a0d302cd090f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d852d842-69f7-45d1-b22c-289ce7de4053", "node_type": "1", "metadata": {"window": "Specialty pharmaceuticals and GLP -1 medications continue to grow at a faste r pace compared to the prior year. \n Third quarter revenues were $73 billion, an increase of 18% year -over-year, driven by increased prescription \nvolumes, including higher volumes from specialty products, retail national account customers and GLP -1 \nmedicatio ns. \n \n In the quarter, GLP -1 revenues were $7.5 billion, an increase of approximately $2.8 billion or 60%, compared to \nfiscal 2023.  During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "original_text": "During the quarter, we also noted increased contributions from commercial COVID -19 vaccine \ndistribution.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d5430de75440bcef464d4b8bbec147dd4e67b2cff4879b146ff00e3272dbd0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a789fbbc-2669-46ca-b260-dc14fe93d201", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December. "}, "hash": "5ceb6f8dd6f88602134830e73354ca32f315f47de4d04ea8d70e2409c22c3b0e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a789fbbc-2669-46ca-b260-dc14fe93d201": {"__data__": {"id_": "a789fbbc-2669-46ca-b260-dc14fe93d201", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a52f991c-01b2-4948-8b45-a0d302cd090f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "475d07aed05386493a9d11b8aa9ce39b8c125b007cda57399b75bc765f5b7f17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30cfd861-e470-4efe-9e42-421f197dd48a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services. ", "original_text": "We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n"}, "hash": "0e07550b4c64f7c1b1438b3ee1846b46f228e7d6418ad0b3fadcafa544a811c7", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December. ", "start_char_idx": 16, "end_char_idx": 324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30cfd861-e470-4efe-9e42-421f197dd48a": {"__data__": {"id_": "30cfd861-e470-4efe-9e42-421f197dd48a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services. ", "original_text": "We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a789fbbc-2669-46ca-b260-dc14fe93d201", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e940584b80c17ee50720c51a4de0300c2a115f59bdef395d369fda7d86684c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71230ef2-6263-4b8a-9e65-7370e154d3f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n", "original_text": "For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems. "}, "hash": "0207b56a5025d5bd5b6156c75ebaea9a70bb85c8a5622fcff840037607484496", "class_name": "RelatedNodeInfo"}}, "text": "We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n", "start_char_idx": 324, "end_char_idx": 450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71230ef2-6263-4b8a-9e65-7370e154d3f2": {"__data__": {"id_": "71230ef2-6263-4b8a-9e65-7370e154d3f2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n", "original_text": "For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30cfd861-e470-4efe-9e42-421f197dd48a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services. ", "original_text": "We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ae73689811c6dae399270f167a26eaffe807a0a33123a1851ce8aefb84c8400", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa92cede-2a2f-4a36-91da-8733190de3f4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n", "original_text": "Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n"}, "hash": "71186ff320d0b576a855e2a247b3c0809d4799e238b1aaaf6817d1e269b52076", "class_name": "RelatedNodeInfo"}}, "text": "For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems. ", "start_char_idx": 450, "end_char_idx": 614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa92cede-2a2f-4a36-91da-8733190de3f4": {"__data__": {"id_": "fa92cede-2a2f-4a36-91da-8733190de3f4", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n", "original_text": "Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71230ef2-6263-4b8a-9e65-7370e154d3f2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n", "original_text": "For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ee7c22418f1533ea599c899e01a8261060c0457a4095c258b1e6ae6f267649db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecf45a40-31cd-4d81-9215-0fbdcd56e572", "node_type": "1", "metadata": {"window": "We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n", "original_text": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services. "}, "hash": "69822d9d2212d8b1730364e97ef5a01f81d23ebe49bc98c4f6b054b9f0cefec1", "class_name": "RelatedNodeInfo"}}, "text": "Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n", "start_char_idx": 614, "end_char_idx": 896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecf45a40-31cd-4d81-9215-0fbdcd56e572": {"__data__": {"id_": "ecf45a40-31cd-4d81-9215-0fbdcd56e572", "embedding": null, "metadata": {"window": "We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n", "original_text": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa92cede-2a2f-4a36-91da-8733190de3f4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n", "original_text": "Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b50fd3ab19c6b5ab2717d434531f1a46daee2ce2e87c7f3df823bc3de26ec9c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1cbc38d9-a9e8-4094-ad35-2d39ff81f323", "node_type": "1", "metadata": {"window": "For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n", "original_text": "For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n"}, "hash": "e59973d29ee5c843ba09b143012e3d146bf258bb889f3c8367b8a840de855f9a", "class_name": "RelatedNodeInfo"}}, "text": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services. ", "start_char_idx": 896, "end_char_idx": 1091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1cbc38d9-a9e8-4094-ad35-2d39ff81f323": {"__data__": {"id_": "1cbc38d9-a9e8-4094-ad35-2d39ff81f323", "embedding": null, "metadata": {"window": "For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n", "original_text": "For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecf45a40-31cd-4d81-9215-0fbdcd56e572", "node_type": "1", "metadata": {"window": "We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n", "original_text": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dd60327c889cd749eb427399ec63d969869585c14dcc034ff8a062e643d4a5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b2b4d0d-cb8f-49a6-b5a8-c40fe5572343", "node_type": "1", "metadata": {"window": "Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis. ", "original_text": "Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n"}, "hash": "66bde1fb5f2d08e0888994ce45286faccc9f4d29e4cee0bc9f5010fd903d822b", "class_name": "RelatedNodeInfo"}}, "text": "For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n", "start_char_idx": 1091, "end_char_idx": 1226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b2b4d0d-cb8f-49a6-b5a8-c40fe5572343": {"__data__": {"id_": "4b2b4d0d-cb8f-49a6-b5a8-c40fe5572343", "embedding": null, "metadata": {"window": "Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis. ", "original_text": "Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1cbc38d9-a9e8-4094-ad35-2d39ff81f323", "node_type": "1", "metadata": {"window": "For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems.  Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n", "original_text": "For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93b77a91b6c65e91cd30da0a4050e6c219c68f4e6f0d626e5f848636409b8a1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f08013b-e61d-4c5f-bd6e-fa502a9f033d", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n", "original_text": "In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n"}, "hash": "a232cdc9c493ddb5e576ee260a01453687742deb2d8482ccdbc99ee016722488", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n", "start_char_idx": 1226, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f08013b-e61d-4c5f-bd6e-fa502a9f033d": {"__data__": {"id_": "6f08013b-e61d-4c5f-bd6e-fa502a9f033d", "embedding": null, "metadata": {"window": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n", "original_text": "In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b2b4d0d-cb8f-49a6-b5a8-c40fe5572343", "node_type": "1", "metadata": {"window": "Adjusting for the impact of the US government COVID -19 vaccine \ndistribution in fiscal 2023, commercial COVI D-19 distribution in fiscal 2024, and the $30 million non -recurring \ncharge in the US Pharmaceutical segment, delivered operating profit growth of 8% year -over-year.  \n \n In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis. ", "original_text": "Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ce5afba42c1c25d63ed56add621c4e07318b38bdb68409cde93975a4e50f0d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c767b56-7b62-42d9-b1e9-7ffc281264c1", "node_type": "1", "metadata": {"window": "For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year. ", "original_text": "Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n"}, "hash": "6d8d8155fd3e0eb356154d5dc718d2ff411a2f9abdd88b6b8bff6d13c8bd0db0", "class_name": "RelatedNodeInfo"}}, "text": "In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n", "start_char_idx": 1450, "end_char_idx": 1654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c767b56-7b62-42d9-b1e9-7ffc281264c1": {"__data__": {"id_": "2c767b56-7b62-42d9-b1e9-7ffc281264c1", "embedding": null, "metadata": {"window": "For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year. ", "original_text": "Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f08013b-e61d-4c5f-bd6e-fa502a9f033d", "node_type": "1", "metadata": {"window": "In our Prescription Technology Solutions segment, the growth of GLP -1 medications and new brand launches led \nto increased demand for our access solutions, such as prior authorization services.  For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n", "original_text": "In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db406c845e84603e8dc63570ae44a3a0277f98ba1d8cf2ad8829135b439ef8fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efc30014-e630-4ff2-875f-8948ccc89a4b", "node_type": "1", "metadata": {"window": "Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n", "original_text": "In the third quarter, primary care patient visits moderately increased on a sequential basis. "}, "hash": "80e306a4fc2ff2440400983303ce6dabaa01abbfb0a27b28d07375bfadf7c01a", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n", "start_char_idx": 1654, "end_char_idx": 2031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efc30014-e630-4ff2-875f-8948ccc89a4b": {"__data__": {"id_": "efc30014-e630-4ff2-875f-8948ccc89a4b", "embedding": null, "metadata": {"window": "Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n", "original_text": "In the third quarter, primary care patient visits moderately increased on a sequential basis. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c767b56-7b62-42d9-b1e9-7ffc281264c1", "node_type": "1", "metadata": {"window": "For the third quarter, \nrevenues increased 7% year -over-year to $1.2 billion, and operating profit increased 25% to $193 million.  \n \n Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year. ", "original_text": "Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "574ca3eae815a4aff5d58532ebd05c8f2dd4755eb7a3b4f254b677db4d6bbef3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfa9ce56-6cc0-4844-8669-c17fc7079d42", "node_type": "1", "metadata": {"window": "In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023. ", "original_text": "Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n"}, "hash": "3386a4afcabcde6f65a90f9d7e6cd2f67183e876d7917cef3a251187618fb099", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter, primary care patient visits moderately increased on a sequential basis. ", "start_char_idx": 2031, "end_char_idx": 2125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfa9ce56-6cc0-4844-8669-c17fc7079d42": {"__data__": {"id_": "bfa9ce56-6cc0-4844-8669-c17fc7079d42", "embedding": null, "metadata": {"window": "In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023. ", "original_text": "Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efc30014-e630-4ff2-875f-8948ccc89a4b", "node_type": "1", "metadata": {"window": "Third quarter results r eflect increased prescription transaction volumes, which drove higher demand for our \naccess solutions, principally prior authorization services and growth in our third -party logistics business.  \n \n In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n", "original_text": "In the third quarter, primary care patient visits moderately increased on a sequential basis. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8908be9018e243cc72011c0400b64cb76bb91c2da074e78a5c3eea6237a7aa5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2f8c334-1a77-4776-bb48-7793f9a27b75", "node_type": "1", "metadata": {"window": "Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n", "original_text": "The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year. "}, "hash": "70fa1ca9d1b6514f1f8282c82705ac8cf010c4c10ce0ed1e800e7499d6913634", "class_name": "RelatedNodeInfo"}}, "text": "Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n", "start_char_idx": 2125, "end_char_idx": 2296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2f8c334-1a77-4776-bb48-7793f9a27b75": {"__data__": {"id_": "c2f8c334-1a77-4776-bb48-7793f9a27b75", "embedding": null, "metadata": {"window": "Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n", "original_text": "The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfa9ce56-6cc0-4844-8669-c17fc7079d42", "node_type": "1", "metadata": {"window": "In addition to the strength of prior authorization services, Year -over-year growth was also supported by increased \nsales to new customers and programs across our access and affordability solutions.  \n \n Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023. ", "original_text": "Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e78df20a99471c15019bc201806776b208fc22fe5bc816898980b414eb41067", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46b62b18-5282-4f87-bd78-77eed74198bc", "node_type": "1", "metadata": {"window": "In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results. ", "original_text": "As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n"}, "hash": "18c5ee47d1b33e17d3555f62f28d9483b1c94d00b4275a74528930106915d5cf", "class_name": "RelatedNodeInfo"}}, "text": "The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year. ", "start_char_idx": 2296, "end_char_idx": 2462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46b62b18-5282-4f87-bd78-77eed74198bc": {"__data__": {"id_": "46b62b18-5282-4f87-bd78-77eed74198bc", "embedding": null, "metadata": {"window": "In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results. ", "original_text": "As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2f8c334-1a77-4776-bb48-7793f9a27b75", "node_type": "1", "metadata": {"window": "Turning to Medical Surgical Solutions, revenues were $3 billion in the quarter, an increase of 2%, primarily driven \nby growth in the primary care and extended care businesses, partially offset by anticipated lower contributions in \nthe kitting, storage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program \ncompared to the prior year.  \n \n In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n", "original_text": "The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a20ea661833c308169304c81169c20b1a2918dabedc9e56fad021be6dd38d809", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b1ed457-e2bf-4c9d-b0ce-d7482faa50ef", "node_type": "1", "metadata": {"window": "Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada. ", "original_text": "Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023. "}, "hash": "d4817e1879509b7760322121f99c45d084d41de00a14227ae4c91182ad73b2b7", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n", "start_char_idx": 2462, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b1ed457-e2bf-4c9d-b0ce-d7482faa50ef": {"__data__": {"id_": "8b1ed457-e2bf-4c9d-b0ce-d7482faa50ef", "embedding": null, "metadata": {"window": "Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada. ", "original_text": "Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46b62b18-5282-4f87-bd78-77eed74198bc", "node_type": "1", "metadata": {"window": "In the third quarter, primary care patient visits moderately increased on a sequential basis.  Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results. ", "original_text": "As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4964d84074037746381f2e9c73a792b3c2515487ff1d6bb1f7adb91fe153111c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caf50c72-24dd-4370-ac48-63006587bb6a", "node_type": "1", "metadata": {"window": "The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n"}, "hash": "ce2bfe6818d938832362ab779111b0924189f48c4c14319e2e82948a463bed10", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023. ", "start_char_idx": 2612, "end_char_idx": 2883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caf50c72-24dd-4370-ac48-63006587bb6a": {"__data__": {"id_": "caf50c72-24dd-4370-ac48-63006587bb6a", "embedding": null, "metadata": {"window": "The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b1ed457-e2bf-4c9d-b0ce-d7482faa50ef", "node_type": "1", "metadata": {"window": "Demand for \ncommercialized COVID -19 vaccine distribution, across the alternate sites of care that we serve, was also \nmodestly higher compared to prior expectations.  \n \n The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada. ", "original_text": "Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4265f1bc998aea53e7d5b2ef9223d570ced1e5ce27e539f6f318038faa99cc39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7840c024-0340-4942-8c5f-24be3b80d2c8", "node_type": "1", "metadata": {"window": "As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review. ", "original_text": "Next, let me address our International results. "}, "hash": "f4d0ba360b8b461014c3033582bb1a9eb50c648a6271ea80bd2ef23ff19fa3cf", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n", "start_char_idx": 2883, "end_char_idx": 3102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7840c024-0340-4942-8c5f-24be3b80d2c8": {"__data__": {"id_": "7840c024-0340-4942-8c5f-24be3b80d2c8", "embedding": null, "metadata": {"window": "As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review. ", "original_text": "Next, let me address our International results. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caf50c72-24dd-4370-ac48-63006587bb6a", "node_type": "1", "metadata": {"window": "The overall illness season dynamics, including vaccinations and testing, continue to be an operating profit \nheadwind in the quarter when compared to the prior year.  As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e773be0ede0e7aaade698d033d584e327f8355aace04bf43a415d9329a068427", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c398b3f-7f8e-4e76-8cab-6ce339377e97", "node_type": "1", "metadata": {"window": "Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio. ", "original_text": "Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada. "}, "hash": "000dddca3e54eff27c7df2d4f8575b967afc240d4cf278f930fe13b3c347c034", "class_name": "RelatedNodeInfo"}}, "text": "Next, let me address our International results. ", "start_char_idx": 3102, "end_char_idx": 3150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c398b3f-7f8e-4e76-8cab-6ce339377e97": {"__data__": {"id_": "2c398b3f-7f8e-4e76-8cab-6ce339377e97", "embedding": null, "metadata": {"window": "Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio. ", "original_text": "Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7840c024-0340-4942-8c5f-24be3b80d2c8", "node_type": "1", "metadata": {"window": "As a reminder, each illness season is unique, \ndepending on the onset and severity of various  respiratory illnesses during that particular year.  \n \n Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review. ", "original_text": "Next, let me address our International results. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0bf435af6ec60247905a03be6907907f3f69eed89457ab009a8962553f9ffa66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37cdb352-03dd-4bb9-8a7b-94a3026a0f41", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "original_text": "Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n"}, "hash": "dbd0d58c811f58f26100e59e0eae7fb71811a522640d5762d3c561aad34f796b", "class_name": "RelatedNodeInfo"}}, "text": "Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada. ", "start_char_idx": 3150, "end_char_idx": 3368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37cdb352-03dd-4bb9-8a7b-94a3026a0f41": {"__data__": {"id_": "37cdb352-03dd-4bb9-8a7b-94a3026a0f41", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "original_text": "Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c398b3f-7f8e-4e76-8cab-6ce339377e97", "node_type": "1", "metadata": {"window": "Operating profit was $282 million, a decrease of 16%, driven by anticipated lower contributions from the kitting, \nstorage, and distribution of ancillary supplies for the US government's COVID -19 vaccine program, and a softer \nillness season as compared to fiscal 2023.  When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio. ", "original_text": "Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dce6ae6d16c967b087f5f4c926cb035e02fd95d6e26d980a78e17503451a8c0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c93a39f9-ac52-48fd-870a-d95afdba63b3", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "Wrapping up our segment review. "}, "hash": "4763a12dcbc16223573082a5c6c72784ce5c58d2e1f5f232eef62284b12e5799", "class_name": "RelatedNodeInfo"}}, "text": "Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n", "start_char_idx": 3368, "end_char_idx": 3491, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c93a39f9-ac52-48fd-870a-d95afdba63b3": {"__data__": {"id_": "c93a39f9-ac52-48fd-870a-d95afdba63b3", "embedding": null, "metadata": {"window": "Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "Wrapping up our segment review. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37cdb352-03dd-4bb9-8a7b-94a3026a0f41", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items from the third \nquarter of fiscal 2023, the segment delivered operating profit growth of 7%, driven by growth in the primary care \nand extend ed care businesses.  \n \n Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "original_text": "Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "391a1fcf42e4a7d4de9bb15b08db07b0a712209330c652196c1630164b8ecd93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6783836-80c9-4a36-ba1a-3aab6fa3cd21", "node_type": "1", "metadata": {"window": "Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio. "}, "hash": "57dffb4805f227edc254688f8fd43de929a4430a4fe960432ba4682870922230", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our segment review. ", "start_char_idx": 3491, "end_char_idx": 3523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6783836-80c9-4a36-ba1a-3aab6fa3cd21": {"__data__": {"id_": "f6783836-80c9-4a36-ba1a-3aab6fa3cd21", "embedding": null, "metadata": {"window": "Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c93a39f9-ac52-48fd-870a-d95afdba63b3", "node_type": "1", "metadata": {"window": "Next, let me address our International results.  Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "Wrapping up our segment review. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c067ea2bd050e0660a7b1f4284d885a3fc8a86b2b9a997495a4ed3641c826af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "159c8651-4363-4aa6-a544-2f805126ef57", "node_type": "1", "metadata": {"window": "Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. "}, "hash": "51efc5196a51d62bbdccc1710eab0b8dad8c1997b73a3b38b6e7a65690f7a615", "class_name": "RelatedNodeInfo"}}, "text": "Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio. ", "start_char_idx": 3523, "end_char_idx": 3704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "159c8651-4363-4aa6-a544-2f805126ef57": {"__data__": {"id_": "159c8651-4363-4aa6-a544-2f805126ef57", "embedding": null, "metadata": {"window": "Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6783836-80c9-4a36-ba1a-3aab6fa3cd21", "node_type": "1", "metadata": {"window": "Revenues in the third quarter were $3.6 billion, a decrease of 18% \nyear-over-year, driven by divestitures with McKesson's European business, partially offset by higher \npharmaceutical dist ribution volumes in Canada.  Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f978423296352a4756405fb780457a7c0f8521471518807341bdce841d690a11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1c1ae9f-9efc-4f43-8d59-c472ccfbaf62", "node_type": "1", "metadata": {"window": "Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude "}, "hash": "93df07515bbf52166f217121899434e25590763589b96cdf52f9df7787c7efeb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "start_char_idx": 3704, "end_char_idx": 3846, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1c1ae9f-9efc-4f43-8d59-c472ccfbaf62": {"__data__": {"id_": "c1c1ae9f-9efc-4f43-8d59-c472ccfbaf62", "embedding": null, "metadata": {"window": "Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aff545c93f0456ca7753b5d25ee339dc9e7cbff292b14f8921b741c6e47e96de", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "159c8651-4363-4aa6-a544-2f805126ef57", "node_type": "1", "metadata": {"window": "Operating profit was $105 million, a decrease of 27%, driven by \ndivestitures within the McKesson's European business.  \n \n Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter. ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "90906742222c5b7a188838f346fb88ee33d54040095e3b7892cac3bf53fb0e28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "883cae08-68c1-4732-ae80-597921526fa2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "a33daf20ee75610f3395df71ec647b273d3086336d06f25f76fdb95951dfb5c2", "class_name": "RelatedNodeInfo"}}, "text": "As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "start_char_idx": 3846, "end_char_idx": 3940, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "883cae08-68c1-4732-ae80-597921526fa2": {"__data__": {"id_": "883cae08-68c1-4732-ae80-597921526fa2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1c1ae9f-9efc-4f43-8d59-c472ccfbaf62", "node_type": "1", "metadata": {"window": "Wrapping up our segment review.  Corporate expenses were $147 million in the quarter, which included losses of  \n$8 million or $0.05 per share, related to equity investments within the McKesson Ventures portfolio.  McKesson \nVentures impact on consolidated financials can be influenced by the performance of each individual investment \nquarter -to-quarter.  As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "original_text": "As a result, Mc Kesson's investments may result in gains and losses, the timing and magnitude ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7e95a058565595355a1e69028d5dc406238cc3785b8e51a4fbd7efe24336772", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44a12b6f-f703-4b7f-b1d6-f4862864be5c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment. "}, "hash": "2bcbc4b998dea2997e1043c77f326d88776d1f7ddcd5e682647890b91a887081", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44a12b6f-f703-4b7f-b1d6-f4862864be5c": {"__data__": {"id_": "44a12b6f-f703-4b7f-b1d6-f4862864be5c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "883cae08-68c1-4732-ae80-597921526fa2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0d89d385286526bfe0ad274b1d0eb2f4a4a3ca2144ba1da988e60d9f6482952", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f087ab77-358d-4910-91f7-8b8e87a9c90e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents. ", "original_text": "We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n"}, "hash": "58c2ca0940faf6868473219e8df5039e60be1fa19a14954306a23fb3ecf00222", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment. ", "start_char_idx": 16, "end_char_idx": 216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f087ab77-358d-4910-91f7-8b8e87a9c90e": {"__data__": {"id_": "f087ab77-358d-4910-91f7-8b8e87a9c90e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents. ", "original_text": "We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44a12b6f-f703-4b7f-b1d6-f4862864be5c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a77beaa65a34a5de3a2ff0b74ef10c74e9475be179fcd7baf3676d65b76c614b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91c76271-702d-4985-a8cf-e718aa75f9b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months. ", "original_text": "Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n"}, "hash": "45d67a3a3425d8ed04864f7e3ef52af99ae9af8a20486b4444303e0d2f16ae52", "class_name": "RelatedNodeInfo"}}, "text": "We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n", "start_char_idx": 216, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91c76271-702d-4985-a8cf-e718aa75f9b7": {"__data__": {"id_": "91c76271-702d-4985-a8cf-e718aa75f9b7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months. ", "original_text": "Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f087ab77-358d-4910-91f7-8b8e87a9c90e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents. ", "original_text": "We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1168138da331da042d5bf91dc4eff9cce18dd7ce721bd16a8a20d154aa750a27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa76678e-9ddd-4d8f-9275-c8bb1a308d61", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n", "original_text": "Turning now to cash flows and capital deployment,  which can be found on slide 12. "}, "hash": "e06383bb0be742e18c10deb0d3f7ee11eaac1913dd12cc88cd1704d4fb3a481d", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n", "start_char_idx": 318, "end_char_idx": 576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa76678e-9ddd-4d8f-9275-c8bb1a308d61": {"__data__": {"id_": "fa76678e-9ddd-4d8f-9275-c8bb1a308d61", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n", "original_text": "Turning now to cash flows and capital deployment,  which can be found on slide 12. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91c76271-702d-4985-a8cf-e718aa75f9b7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months. ", "original_text": "Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55abd70dec9f1a4fafa76b2095cac9e1753416b07bcb48f6194be70e4346d1f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87621a06-e365-4a0a-a039-3fe5fa5c5cba", "node_type": "1", "metadata": {"window": "We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n", "original_text": "We ended the quarter with $2 \nbillion in cash and cash equivalents. "}, "hash": "605d093d30e7fa12ef873a965c9f5a1b02c6187759d85c961f1be96d3447b40f", "class_name": "RelatedNodeInfo"}}, "text": "Turning now to cash flows and capital deployment,  which can be found on slide 12. ", "start_char_idx": 576, "end_char_idx": 659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87621a06-e365-4a0a-a039-3fe5fa5c5cba": {"__data__": {"id_": "87621a06-e365-4a0a-a039-3fe5fa5c5cba", "embedding": null, "metadata": {"window": "We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n", "original_text": "We ended the quarter with $2 \nbillion in cash and cash equivalents. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa76678e-9ddd-4d8f-9275-c8bb1a308d61", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n", "original_text": "Turning now to cash flows and capital deployment,  which can be found on slide 12. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33d3ba26902b7187f547fe242694db0d61c12fac23246ea916ad773b1c9f3f0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "902055b9-356f-4c75-b761-f6861557801b", "node_type": "1", "metadata": {"window": "Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities. ", "original_text": "We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months. "}, "hash": "22bfd126f886c1108ef58e0b8f0da72957d3385d1d82f369569e8ccb999b62cd", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with $2 \nbillion in cash and cash equivalents. ", "start_char_idx": 659, "end_char_idx": 727, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "902055b9-356f-4c75-b761-f6861557801b": {"__data__": {"id_": "902055b9-356f-4c75-b761-f6861557801b", "embedding": null, "metadata": {"window": "Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities. ", "original_text": "We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87621a06-e365-4a0a-a039-3fe5fa5c5cba", "node_type": "1", "metadata": {"window": "We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n", "original_text": "We ended the quarter with $2 \nbillion in cash and cash equivalents. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c3dcb52c94bf8be29081a516483c9abbb681732099ccd3e840b144a08fcb16d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f054395b-caef-44a7-a4b5-44db910d6975", "node_type": "1", "metadata": {"window": "Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n", "original_text": "Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n"}, "hash": "82fbbd6aa3d74a428cf0dca707a88b26ac88a6db5876db5751db9be67399aea2", "class_name": "RelatedNodeInfo"}}, "text": "We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months. ", "start_char_idx": 727, "end_char_idx": 838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f054395b-caef-44a7-a4b5-44db910d6975": {"__data__": {"id_": "f054395b-caef-44a7-a4b5-44db910d6975", "embedding": null, "metadata": {"window": "Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n", "original_text": "Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "902055b9-356f-4c75-b761-f6861557801b", "node_type": "1", "metadata": {"window": "Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities. ", "original_text": "We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c769f8716ccd6b61cbd31b043d20ea637babeff58e21b03ccc42cf6cbd68a868", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8856f700-e7b2-475d-8925-f140aabc79bd", "node_type": "1", "metadata": {"window": "We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook. ", "original_text": "As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n"}, "hash": "f99397b0b786753cd3934ae9442970bcb811040516c7ca4bed5e145e6566deda", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n", "start_char_idx": 838, "end_char_idx": 981, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8856f700-e7b2-475d-8925-f140aabc79bd": {"__data__": {"id_": "8856f700-e7b2-475d-8925-f140aabc79bd", "embedding": null, "metadata": {"window": "We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook. ", "original_text": "As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f054395b-caef-44a7-a4b5-44db910d6975", "node_type": "1", "metadata": {"window": "Turning now to cash flows and capital deployment,  which can be found on slide 12.  We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n", "original_text": "Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95002735050b0811d1db869aaa833a4037e596e05d874db8e755482c5c67da3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21a3e320-87f0-44e5-8819-05c675908266", "node_type": "1", "metadata": {"window": "We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis. ", "original_text": "During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities. "}, "hash": "9ae15b2f08a7887f0570c9da8c17cb45a598cc264a5c468a8b54c863b153f227", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n", "start_char_idx": 981, "end_char_idx": 1211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21a3e320-87f0-44e5-8819-05c675908266": {"__data__": {"id_": "21a3e320-87f0-44e5-8819-05c675908266", "embedding": null, "metadata": {"window": "We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis. ", "original_text": "During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8856f700-e7b2-475d-8925-f140aabc79bd", "node_type": "1", "metadata": {"window": "We ended the quarter with $2 \nbillion in cash and cash equivalents.  We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook. ", "original_text": "As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ddf7132e10ce1715105713b8bc8182440fcdf6401951881988258ee820f205e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "559fbe56-ff77-49a9-a436-70700a6195ca", "node_type": "1", "metadata": {"window": "Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis. ", "original_text": "Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n"}, "hash": "9c05cbcf24dad12f58652d2255dc249ab264448438315d6d48de2b0ac635eb40", "class_name": "RelatedNodeInfo"}}, "text": "During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities. ", "start_char_idx": 1211, "end_char_idx": 1465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "559fbe56-ff77-49a9-a436-70700a6195ca": {"__data__": {"id_": "559fbe56-ff77-49a9-a436-70700a6195ca", "embedding": null, "metadata": {"window": "Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis. ", "original_text": "Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21a3e320-87f0-44e5-8819-05c675908266", "node_type": "1", "metadata": {"window": "We delivered free cash flow of $100 million in the third quarter and $2.9 \nbillion for the trailing 12 months.  Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis. ", "original_text": "During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9abddc9debe8d604c702866dc4a0329282346f5cfff4834f27c3288eeb99f2ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c415bbd-aacc-4fc8-b469-177f59ebff25", "node_type": "1", "metadata": {"window": "As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n", "original_text": "Now, let me turn to our updated fiscal 2024 outl ook. "}, "hash": "eb60cefaa24bf58339165bd2904d010220858237704c4d1b00959a1df7152193", "class_name": "RelatedNodeInfo"}}, "text": "Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n", "start_char_idx": 1465, "end_char_idx": 1623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c415bbd-aacc-4fc8-b469-177f59ebff25": {"__data__": {"id_": "7c415bbd-aacc-4fc8-b469-177f59ebff25", "embedding": null, "metadata": {"window": "As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n", "original_text": "Now, let me turn to our updated fiscal 2024 outl ook. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "559fbe56-ff77-49a9-a436-70700a6195ca", "node_type": "1", "metadata": {"window": "Third quarter free cash flow was impacted by t he Rite Aid bankruptcy in October \nand its associated $725 million provision for bad debts.  \n \n As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis. ", "original_text": "Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e35db5f1149ee3882614a7252d5b9635910f487ab98b4edbc5fdc6d5061c07e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6acf1b2-b3de-4ec8-b9e8-5e9bd51f18aa", "node_type": "1", "metadata": {"window": "During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments. ", "original_text": "As a reminder, we do not provide forward -looking guidance \non a GAAP basis. "}, "hash": "f95827b2c023ac5817c3aacaf82c9a002136471c07376ad41795ec6d979a7987", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me turn to our updated fiscal 2024 outl ook. ", "start_char_idx": 1623, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6acf1b2-b3de-4ec8-b9e8-5e9bd51f18aa": {"__data__": {"id_": "b6acf1b2-b3de-4ec8-b9e8-5e9bd51f18aa", "embedding": null, "metadata": {"window": "During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments. ", "original_text": "As a reminder, we do not provide forward -looking guidance \non a GAAP basis. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c415bbd-aacc-4fc8-b469-177f59ebff25", "node_type": "1", "metadata": {"window": "As a reminder, our cash position, working capital metrics and resulting cash flows can each be impacted by \ntiming, which includes the day of the week that a quarter  ends on and, therefore, can vary from quarter -to-quarter.  \n \n During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n", "original_text": "Now, let me turn to our updated fiscal 2024 outl ook. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e939a0b609ccfa66ff44c94e605202f80958daec85b5b1e6cd6ec092661f099d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89889bfe-39da-49c0-845f-c0192d44a1ca", "node_type": "1", "metadata": {"window": "Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year. ", "original_text": "The following metrics are provided on an adjusted non -GAAP basis. "}, "hash": "352fd41aea03aa4289e04a92d56114549579b70f7312a1941a52a6423bff6662", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, we do not provide forward -looking guidance \non a GAAP basis. ", "start_char_idx": 1677, "end_char_idx": 1754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89889bfe-39da-49c0-845f-c0192d44a1ca": {"__data__": {"id_": "89889bfe-39da-49c0-845f-c0192d44a1ca", "embedding": null, "metadata": {"window": "Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year. ", "original_text": "The following metrics are provided on an adjusted non -GAAP basis. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6acf1b2-b3de-4ec8-b9e8-5e9bd51f18aa", "node_type": "1", "metadata": {"window": "During the first nine months of the fiscal year, we made capital expenditure investments of $418 million, which \nincluded new and existing distribution centers, as well as investments in technology , data and analytics to support \nour growth priorities.  Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments. ", "original_text": "As a reminder, we do not provide forward -looking guidance \non a GAAP basis. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f8cc3b6ddeebb6777a22921088731138e4c3b0601e0c8eb81438cea30bb033b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e180b470-04c1-45ef-9ade-4b761f198a0b", "node_type": "1", "metadata": {"window": "Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%. ", "original_text": "A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n"}, "hash": "50282fe30dcef6cbc95134905277dd6730afd97f8a189e4d6f5b78adecb0fa29", "class_name": "RelatedNodeInfo"}}, "text": "The following metrics are provided on an adjusted non -GAAP basis. ", "start_char_idx": 1754, "end_char_idx": 1821, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e180b470-04c1-45ef-9ade-4b761f198a0b": {"__data__": {"id_": "e180b470-04c1-45ef-9ade-4b761f198a0b", "embedding": null, "metadata": {"window": "Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%. ", "original_text": "A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89889bfe-39da-49c0-845f-c0192d44a1ca", "node_type": "1", "metadata": {"window": "Year -to-date, we returned $2.6 billion of cash to shareholders, which included $2.3 billion of \nshare repurchases and $232 million in dividend payments.  \n \n Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year. ", "original_text": "The following metrics are provided on an adjusted non -GAAP basis. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "396a0846c0eb9f5312c224020841d552b6cc828c6785490580052544e271ae95", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "151f8fe2-bc20-4ccd-9e06-59cc73b12bc3", "node_type": "1", "metadata": {"window": "As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n", "original_text": "Let me start with the fiscal 2024 outlook for our segments. "}, "hash": "7677992e9443bf0a4eb82a7a447019c352d81f85f5203c3dc46bff4ea4aadd3f", "class_name": "RelatedNodeInfo"}}, "text": "A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n", "start_char_idx": 1821, "end_char_idx": 1934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "151f8fe2-bc20-4ccd-9e06-59cc73b12bc3": {"__data__": {"id_": "151f8fe2-bc20-4ccd-9e06-59cc73b12bc3", "embedding": null, "metadata": {"window": "As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n", "original_text": "Let me start with the fiscal 2024 outlook for our segments. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e180b470-04c1-45ef-9ade-4b761f198a0b", "node_type": "1", "metadata": {"window": "Now, let me turn to our updated fiscal 2024 outl ook.  As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%. ", "original_text": "A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "465f01deee30a657beab3493fae9c980b489050153c339af40cf7e4ea34431c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80e26d6b-25bd-433a-bb45-1bf0c642da72", "node_type": "1", "metadata": {"window": "The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends. ", "original_text": "For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year. "}, "hash": "4f5138b08948466adc51eb8f3b99dab6555097bf85c1ec4ff0768e41fe257976", "class_name": "RelatedNodeInfo"}}, "text": "Let me start with the fiscal 2024 outlook for our segments. ", "start_char_idx": 1934, "end_char_idx": 1994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80e26d6b-25bd-433a-bb45-1bf0c642da72": {"__data__": {"id_": "80e26d6b-25bd-433a-bb45-1bf0c642da72", "embedding": null, "metadata": {"window": "The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends. ", "original_text": "For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "151f8fe2-bc20-4ccd-9e06-59cc73b12bc3", "node_type": "1", "metadata": {"window": "As a reminder, we do not provide forward -looking guidance \non a GAAP basis.  The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n", "original_text": "Let me start with the fiscal 2024 outlook for our segments. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "47152b80c61e7c1a6a3c0ab758f6c8e225c66bba6308a92f27d96597379b09d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8ac13c4-7809-44e4-b07a-4434d45fc8d0", "node_type": "1", "metadata": {"window": "A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter. ", "original_text": "Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%. "}, "hash": "8bdb5828efffe6f9c5963b61c2f8e892bb99fec28ad0ea51d509676fc315baf3", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year. ", "start_char_idx": 1994, "end_char_idx": 2141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8ac13c4-7809-44e4-b07a-4434d45fc8d0": {"__data__": {"id_": "f8ac13c4-7809-44e4-b07a-4434d45fc8d0", "embedding": null, "metadata": {"window": "A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter. ", "original_text": "Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80e26d6b-25bd-433a-bb45-1bf0c642da72", "node_type": "1", "metadata": {"window": "The following metrics are provided on an adjusted non -GAAP basis.  A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends. ", "original_text": "For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "177981c803127329387e0260d640a0b4a7d526466e9a9682a9af7ee61332b7dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4024b3e0-8117-4081-9dac-e8f69dbac026", "node_type": "1", "metadata": {"window": "Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n", "original_text": "The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n"}, "hash": "b3d7584699b7fe3fd658131120617dec09f16e46fff7c55cd18d904e784bdf1b", "class_name": "RelatedNodeInfo"}}, "text": "Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%. ", "start_char_idx": 2141, "end_char_idx": 2292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4024b3e0-8117-4081-9dac-e8f69dbac026": {"__data__": {"id_": "4024b3e0-8117-4081-9dac-e8f69dbac026", "embedding": null, "metadata": {"window": "Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n", "original_text": "The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8ac13c4-7809-44e4-b07a-4434d45fc8d0", "node_type": "1", "metadata": {"window": "A full list of our \nassumptions can be found on slides 13 through 17 in our supplemental slide presentation.  \n \n Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter. ", "original_text": "Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "487f134729fbc8311937c2f6e06305c38537ebca9c30008467082c2cad86425a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc51e0eb-d5d0-406c-b1ce-26ec2403f5a5", "node_type": "1", "metadata": {"window": "For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability. ", "original_text": "The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends. "}, "hash": "ce841d200cdebe9bfab40a5ab22f9feaa1f838de067ac2b1c5bdf86a45620237", "class_name": "RelatedNodeInfo"}}, "text": "The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n", "start_char_idx": 2292, "end_char_idx": 2511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc51e0eb-d5d0-406c-b1ce-26ec2403f5a5": {"__data__": {"id_": "bc51e0eb-d5d0-406c-b1ce-26ec2403f5a5", "embedding": null, "metadata": {"window": "For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability. ", "original_text": "The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4024b3e0-8117-4081-9dac-e8f69dbac026", "node_type": "1", "metadata": {"window": "Let me start with the fiscal 2024 outlook for our segments.  For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n", "original_text": "The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b911761fb48441577142e12f1128e69079ea67cf24aa9c51b966bc6838dffce5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9faf157b-3eb2-4271-bfd0-2ef1755bdd7b", "node_type": "1", "metadata": {"window": "Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform. ", "original_text": "Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter. "}, "hash": "fe39e686e2e057838fd71b138d455b7e015d22e1e5cae9c5e266714ecee267d1", "class_name": "RelatedNodeInfo"}}, "text": "The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends. ", "start_char_idx": 2511, "end_char_idx": 2686, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9faf157b-3eb2-4271-bfd0-2ef1755bdd7b": {"__data__": {"id_": "9faf157b-3eb2-4271-bfd0-2ef1755bdd7b", "embedding": null, "metadata": {"window": "Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform. ", "original_text": "Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc51e0eb-d5d0-406c-b1ce-26ec2403f5a5", "node_type": "1", "metadata": {"window": "For the full year, we now anticipate US Pharmaceutical \nrevenues to increase 16% to 18% and operating profit to increase 6% to 8% year -over-year.  Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability. ", "original_text": "The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8f4dc8cc7678a01c7d5b358d797336df67f56c121ba9eb33dfddc8576001b1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b961700-7e0f-494a-8885-ddeb62a37605", "node_type": "1", "metadata": {"window": "The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices. ", "original_text": "These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n"}, "hash": "1f63060d9fa3f84d65aaf02cfe7e68b09a0e6513ae11eea5e3f24308a8e3a8c8", "class_name": "RelatedNodeInfo"}}, "text": "Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter. ", "start_char_idx": 2686, "end_char_idx": 2841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b961700-7e0f-494a-8885-ddeb62a37605": {"__data__": {"id_": "6b961700-7e0f-494a-8885-ddeb62a37605", "embedding": null, "metadata": {"window": "The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices. ", "original_text": "These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9faf157b-3eb2-4271-bfd0-2ef1755bdd7b", "node_type": "1", "metadata": {"window": "Excluding the impact \nof COVID -19 vaccine distributio n for the US government in fiscal 2023, we anticipate operating profit to increase \n11% to 14%.  The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform. ", "original_text": "Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08bd86bcb6c40329f830a05a03d0f492f62ef25b792ace4e97c0f3795702b440", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dce7fe1-8901-4f16-826f-b8c71db309c6", "node_type": "1", "metadata": {"window": "The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n", "original_text": "Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability. "}, "hash": "0dc930b7973f1d63bab4d49779bd3ffdcbbf395ed5ef16ad9fa14a1afef70537", "class_name": "RelatedNodeInfo"}}, "text": "These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n", "start_char_idx": 2841, "end_char_idx": 2951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dce7fe1-8901-4f16-826f-b8c71db309c6": {"__data__": {"id_": "6dce7fe1-8901-4f16-826f-b8c71db309c6", "embedding": null, "metadata": {"window": "The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n", "original_text": "Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b961700-7e0f-494a-8885-ddeb62a37605", "node_type": "1", "metadata": {"window": "The impact of elevated commercial COVID -19 distribution in the third quarter, net of the $30 million \nnon-recurring charge also in the third quarter of fiscal 202 4 accounts for approximately 2% of segment growth.  \n \n The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices. ", "original_text": "These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "534ae7696fb1071b48124d5e337b1b0c078b1e034bcf6bc760c7e88be15e9698", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "affea702-68ea-490d-975c-51735142810d", "node_type": "1", "metadata": {"window": "Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n", "original_text": "And we continue to be pleased with the strength of our scaled \nand broad oncology platform. "}, "hash": "b55baf89e5282882b15f88a9a684f00707dbcf25c4a4fb35bee4808d8b0599af", "class_name": "RelatedNodeInfo"}}, "text": "Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability. ", "start_char_idx": 2951, "end_char_idx": 3123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "affea702-68ea-490d-975c-51735142810d": {"__data__": {"id_": "affea702-68ea-490d-975c-51735142810d", "embedding": null, "metadata": {"window": "Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n", "original_text": "And we continue to be pleased with the strength of our scaled \nand broad oncology platform. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dce7fe1-8901-4f16-826f-b8c71db309c6", "node_type": "1", "metadata": {"window": "The updated segment revenue outlook incorporates the strong third quarter performance and continued growth in \nspecialty distribution, supported by stable utilization trends.  Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n", "original_text": "Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5e624efe27696ae6c5a6b57127c8cc0b949a61d17d30c96bab1a55b85d788e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f85fb169-1859-4b6d-a78b-6eb99d2c429b", "node_type": "1", "metadata": {"window": "These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices. "}, "hash": "42791e14a8b4cf2338b79a1abe12e5d798fad6f56b54ed10754d3a016fa4eba1", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to be pleased with the strength of our scaled \nand broad oncology platform. ", "start_char_idx": 3123, "end_char_idx": 3215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f85fb169-1859-4b6d-a78b-6eb99d2c429b": {"__data__": {"id_": "f85fb169-1859-4b6d-a78b-6eb99d2c429b", "embedding": null, "metadata": {"window": "These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "affea702-68ea-490d-975c-51735142810d", "node_type": "1", "metadata": {"window": "Revenue growth assumes that GL P-1 medication \nvolumes will continue to be robust, although the rate of growth will moderate in our fiscal fourth quarter.  These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n", "original_text": "And we continue to be pleased with the strength of our scaled \nand broad oncology platform. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d6475408ad3e6b0ee33751f0f0e8e946e1f7eaa1f1c8148cdadfeaeea5570f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30f3bdee-a598-4146-923d-1c2939c1d8ad", "node_type": "1", "metadata": {"window": "Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n"}, "hash": "64667b60f7f995d4a566c735db55c5d258e68ca01381a325eec3d92ce6a83c3b", "class_name": "RelatedNodeInfo"}}, "text": "This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices. ", "start_char_idx": 3215, "end_char_idx": 3314, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30f3bdee-a598-4146-923d-1c2939c1d8ad": {"__data__": {"id_": "30f3bdee-a598-4146-923d-1c2939c1d8ad", "embedding": null, "metadata": {"window": "Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f85fb169-1859-4b6d-a78b-6eb99d2c429b", "node_type": "1", "metadata": {"window": "These \nmedications are lower margins and represent a headwind to year -over-year operating profit growth.  \n \n Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices. ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0a80b132d9187139cbbabf353151e547a2ef3cdb7882ac3e49d8556c0b30e76", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "035ed148-4649-4545-902a-0200e7cf322d", "node_type": "1", "metadata": {"window": "And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n"}, "hash": "0547e5761dbf153ebc0a505e5b9cca182d8e7d176810c288c764e762a6628fab", "class_name": "RelatedNodeInfo"}}, "text": "With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n", "start_char_idx": 3314, "end_char_idx": 3400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "035ed148-4649-4545-902a-0200e7cf322d": {"__data__": {"id_": "035ed148-4649-4545-902a-0200e7cf322d", "embedding": null, "metadata": {"window": "And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30f3bdee-a598-4146-923d-1c2939c1d8ad", "node_type": "1", "metadata": {"window": "Our full -year operating prof it growth also reflects our leading generics program, which continues to deliver on the \ndual mandate of lower cost and product availability.  And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a049b49eec99e81240724eaa945375f62baf30ceea6df203537be0f77183798", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97e07316-73d0-49d8-9ba8-e5543cac8f4a", "node_type": "1", "metadata": {"window": "This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  "}, "hash": "81061f2009156c91013b0bde67deb7fa18ac7d60f54ca6fda0572b02f050c36f", "class_name": "RelatedNodeInfo"}}, "text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n", "start_char_idx": 3400, "end_char_idx": 3719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97e07316-73d0-49d8-9ba8-e5543cac8f4a": {"__data__": {"id_": "97e07316-73d0-49d8-9ba8-e5543cac8f4a", "embedding": null, "metadata": {"window": "This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "45ab0081-c570-402d-a250-5c0e531645b1", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29532385d73e9281d0e1d9e276a3cadcdef2c3a207a055013971b4956d1b43e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "035ed148-4649-4545-902a-0200e7cf322d", "node_type": "1", "metadata": {"window": "And we continue to be pleased with the strength of our scaled \nand broad oncology platform.  This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e9c8e97d7216f266c66e4c1b90333b1ded67c679fac9fbbdbaf0a5a97da44680", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce7aad31-f418-4ef5-a685-c83db287d598", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year. ", "original_text": "McKesson Corp.  "}, "hash": "3fd66a98f6ea3a9d4a7ec380db73c724292bf5998cbc7850375affb2b4fb3e59", "class_name": "RelatedNodeInfo"}}, "text": "The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "start_char_idx": 3719, "end_char_idx": 4084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce7aad31-f418-4ef5-a685-c83db287d598": {"__data__": {"id_": "ce7aad31-f418-4ef5-a685-c83db287d598", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97e07316-73d0-49d8-9ba8-e5543cac8f4a", "node_type": "1", "metadata": {"window": "This quarter, as Brian m entioned, we expanded into Tennessee with the addition of \ntwo practices.  With these additions and organic growth, US Oncology is now over 2,500 providers.  \n \n In the Prescription Technology Solutions segment, we anticipate revenue growth of 9% to 13%, and we' ve \nincreased our operating profit growth outlook to 24% to 28%, reflecting strong third quarter performance, \ncontinued organic growth and higher transaction volumes across the access and affordability solutions.  \n \n The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "original_text": "The quarter -to-quarter variability in this segment is driven by prescription and transaction volumes, the timing and \npace and trajectory of new product drug launches, the timing and size of investments to support and expand our \nproduct portfolio, and the annual verification programs that we provide  for our customers that occur in our fiscal \nfourth quarter.  ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14f2398793b885da211b2696236f0da1c5c87ab79340f7f4c6cbcef024304eb5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4de169e3-40fd-4668-b466-a926e4635f11", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care. "}, "hash": "b71edb98e859b93a2952283c8253de339a901b4a5df583fed3b179464895ab9d", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4de169e3-40fd-4668-b466-a926e4635f11": {"__data__": {"id_": "4de169e3-40fd-4668-b466-a926e4635f11", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce7aad31-f418-4ef5-a685-c83db287d598", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5411db9147c10f8c0721917ea385595b5ce65204da5a0f0b9effe09f017bc467", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad81d690-e61b-4db8-b9bf-962fc5755982", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%. ", "original_text": "We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n"}, "hash": "8479e53ece2220e3260e147619fe2f4826421f783b80dd57cf770d6ec268c245", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care. ", "start_char_idx": 16, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad81d690-e61b-4db8-b9bf-962fc5755982": {"__data__": {"id_": "ad81d690-e61b-4db8-b9bf-962fc5755982", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%. ", "original_text": "We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4de169e3-40fd-4668-b466-a926e4635f11", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c01f018a013add83c772a44d6c018ec0313b282722d0c41c554b17494277b0f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb9511ed-da59-42bc-ae1b-98952d5984f6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year. "}, "hash": "19b4dc36c3bccbd79da76271547e0abd6706369c8d50cd6122f88ee370bda9e7", "class_name": "RelatedNodeInfo"}}, "text": "We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n", "start_char_idx": 287, "end_char_idx": 399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb9511ed-da59-42bc-ae1b-98952d5984f6": {"__data__": {"id_": "eb9511ed-da59-42bc-ae1b-98952d5984f6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad81d690-e61b-4db8-b9bf-962fc5755982", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%. ", "original_text": "We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f6ce5f9b17fee9082e031922fa08bcfdfcef4f0ba8257df1f6cda835ab34457", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9801e93-7247-426d-a8a1-885d0ab2adce", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n", "original_text": "Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n"}, "hash": "857e7148e5fd97917cff4e0d812aafb887de4f15b515a268041dbb8e16e06436", "class_name": "RelatedNodeInfo"}}, "text": "When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year. ", "start_char_idx": 399, "end_char_idx": 548, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9801e93-7247-426d-a8a1-885d0ab2adce": {"__data__": {"id_": "f9801e93-7247-426d-a8a1-885d0ab2adce", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n", "original_text": "Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb9511ed-da59-42bc-ae1b-98952d5984f6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n", "original_text": "When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df23effac3cc8b9496544b8437d2a05f2dd9fd17d546325a24ba9a0a5ad4e64c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a928b9c-fb0e-4803-a349-cb3a904a10aa", "node_type": "1", "metadata": {"window": "We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million. ", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 29% to 33%. "}, "hash": "f5f41ad2b15f4c7b03b12dd12795887a015e894f5b5dc380c959cdb2bdc56a9d", "class_name": "RelatedNodeInfo"}}, "text": "Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n", "start_char_idx": 548, "end_char_idx": 709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a928b9c-fb0e-4803-a349-cb3a904a10aa": {"__data__": {"id_": "3a928b9c-fb0e-4803-a349-cb3a904a10aa", "embedding": null, "metadata": {"window": "We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million. ", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 29% to 33%. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9801e93-7247-426d-a8a1-885d0ab2adce", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n", "original_text": "Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a13095a524682bfee8b191b3ac7ea0d4b67b8dc59bd55907fab82f9790e83fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22882f66-3068-494b-ad2b-95276d733ffc", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%. ", "original_text": "And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n"}, "hash": "a2dfa837609a6f12233da5e28b958032354bfc8344fe6ff693ed6ab7f61f08f2", "class_name": "RelatedNodeInfo"}}, "text": "Finally, in the International segment, we anticipate revenues to decline by 29% to 33%. ", "start_char_idx": 709, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22882f66-3068-494b-ad2b-95276d733ffc": {"__data__": {"id_": "22882f66-3068-494b-ad2b-95276d733ffc", "embedding": null, "metadata": {"window": "When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%. ", "original_text": "And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a928b9c-fb0e-4803-a349-cb3a904a10aa", "node_type": "1", "metadata": {"window": "We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million. ", "original_text": "Finally, in the International segment, we anticipate revenues to decline by 29% to 33%. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2f5581b5c1ded7a5a85f21acc187f64aff92a31e352b73c10bf8ea06740bd1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1429b3f-4a23-4392-8b6f-03c60ef4f2f5", "node_type": "1", "metadata": {"window": "Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n"}, "hash": "2c920828a389735dbedf179ae71e38b60e2bf71c7386673102a7e00fafbf7215", "class_name": "RelatedNodeInfo"}}, "text": "And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n", "start_char_idx": 797, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1429b3f-4a23-4392-8b6f-03c60ef4f2f5": {"__data__": {"id_": "b1429b3f-4a23-4392-8b6f-03c60ef4f2f5", "embedding": null, "metadata": {"window": "Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22882f66-3068-494b-ad2b-95276d733ffc", "node_type": "1", "metadata": {"window": "When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year.  Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%. ", "original_text": "And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e183f3ee7bf3e4ec53542d8d033893b4a0df5d2ba74f343d3b151c268629fc7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f13dc18e-7dcb-47a8-81de-e29ffe57a362", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment. ", "original_text": "Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million. "}, "hash": "f4f22aa0e639a3d3a9847fb37f127ee61436da23d0f0685ba15a6585ff9a78c4", "class_name": "RelatedNodeInfo"}}, "text": "In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n", "start_char_idx": 943, "end_char_idx": 1241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f13dc18e-7dcb-47a8-81de-e29ffe57a362": {"__data__": {"id_": "f13dc18e-7dcb-47a8-81de-e29ffe57a362", "embedding": null, "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment. ", "original_text": "Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1429b3f-4a23-4392-8b6f-03c60ef4f2f5", "node_type": "1", "metadata": {"window": "Our updated outlook incorporates the third quarter results that I discussed \nearlier, which reflect a modest improvement in sequential primary care traffic.  \n \n Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n", "original_text": "In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "571b384ac2026013a3db007690ebef3484664ae3fa8412499d03e253bc99e8c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0fb3356-b5f9-4196-971c-2f733b9139f6", "node_type": "1", "metadata": {"window": "And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion. ", "original_text": "We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%. "}, "hash": "0f7f8ca89704745b7f6d092e07c3f833b3d6db15c99ddc9d902ddd5dcc5788d4", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million. ", "start_char_idx": 1241, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0fb3356-b5f9-4196-971c-2f733b9139f6": {"__data__": {"id_": "f0fb3356-b5f9-4196-971c-2f733b9139f6", "embedding": null, "metadata": {"window": "And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion. ", "original_text": "We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f13dc18e-7dcb-47a8-81de-e29ffe57a362", "node_type": "1", "metadata": {"window": "Finally, in the International segment, we anticipate revenues to decline by 29% to 33%.  And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment. ", "original_text": "Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "505c23f889fc2b3a16766391b0996ddc6692c53726b0e0fa58049503e6e8da44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed4b4a7b-5dfb-4666-92af-a932c0b4dd2e", "node_type": "1", "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter. ", "original_text": "The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n"}, "hash": "f4ff0ba4ccb176246694a136131a7c747e69d572dac4f93ea2d631f76f786cd4", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%. ", "start_char_idx": 1452, "end_char_idx": 1543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed4b4a7b-5dfb-4666-92af-a932c0b4dd2e": {"__data__": {"id_": "ed4b4a7b-5dfb-4666-92af-a932c0b4dd2e", "embedding": null, "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter. ", "original_text": "The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0fb3356-b5f9-4196-971c-2f733b9139f6", "node_type": "1", "metadata": {"window": "And operating profit to \ndecline by 21% to 26%, reflecting divestitures within McKesson's European busi ness that closed during fiscal \n2023.  \n \n In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion. ", "original_text": "We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b98e32bd029370e539962ce9affe51f3f19c29fb9005927da0afe9094b4a23bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad668f9e-ef13-49d0-8af4-f96ee2599d82", "node_type": "1", "metadata": {"window": "Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n", "original_text": "Turning to  cash flow and capital deployment. "}, "hash": "58b4aa76f5c95ca5b2382cee9488e4fad6ee058e2b215edb6b7938f89b053426", "class_name": "RelatedNodeInfo"}}, "text": "The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n", "start_char_idx": 1543, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad668f9e-ef13-49d0-8af4-f96ee2599d82": {"__data__": {"id_": "ad668f9e-ef13-49d0-8af4-f96ee2599d82", "embedding": null, "metadata": {"window": "Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n", "original_text": "Turning to  cash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed4b4a7b-5dfb-4666-92af-a932c0b4dd2e", "node_type": "1", "metadata": {"window": "In the Corporate segment, we anticipate expenses to be in the range of $615 million to $655 million, which \nincludes losses associated with McKesson Ventures equity investments, recorded in the first nine months of the \nyear and elevated technology spend to support the growth of our business.  \n \n Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter. ", "original_text": "The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57feeddd5b3971c29d3bdaa671556064c57a57eb38c1d7bce66919f9e0ebc2c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3373bff8-3bf0-4276-aa8c-965eb9d53f76", "node_type": "1", "metadata": {"window": "We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares. ", "original_text": "We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion. "}, "hash": "3564c969a6f2d846c08100ffe8b032132deeb7bfbef5d084e4816558d4aa44b8", "class_name": "RelatedNodeInfo"}}, "text": "Turning to  cash flow and capital deployment. ", "start_char_idx": 1677, "end_char_idx": 1723, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3373bff8-3bf0-4276-aa8c-965eb9d53f76": {"__data__": {"id_": "3373bff8-3bf0-4276-aa8c-965eb9d53f76", "embedding": null, "metadata": {"window": "We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares. ", "original_text": "We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad668f9e-ef13-49d0-8af4-f96ee2599d82", "node_type": "1", "metadata": {"window": "Moving below the line, we anticipate interest expense to be approximately $220 million to $230 million and \nincome attributable to non -controlling interests to be in the range of $15 5 million to $165 million.  We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n", "original_text": "Turning to  cash flow and capital deployment. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d8e294fb48fe5b41b8b59900a3539c5d676605ed89e7c19b77116aa052fe840", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b0d473c-d0cf-490f-9978-4037cbb53a7a", "node_type": "1", "metadata": {"window": "The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n", "original_text": "Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter. "}, "hash": "e647c4f5ddf5c4acf1f27470526f745b452f8d7c767fd90f28db5c0010d88932", "class_name": "RelatedNodeInfo"}}, "text": "We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion. ", "start_char_idx": 1723, "end_char_idx": 1804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b0d473c-d0cf-490f-9978-4037cbb53a7a": {"__data__": {"id_": "4b0d473c-d0cf-490f-9978-4037cbb53a7a", "embedding": null, "metadata": {"window": "The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n", "original_text": "Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3373bff8-3bf0-4276-aa8c-965eb9d53f76", "node_type": "1", "metadata": {"window": "We anticipate no \nchange to the full -year effective tax rate of approximately 18% to 19%.  The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares. ", "original_text": "We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fc85df75db619610c6460c9ceeffed227da720911ee19c333e00dab3f9436128", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1fb6397-75be-4bd3-ad46-6dbd42f657a7", "node_type": "1", "metadata": {"window": "Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance. ", "original_text": "Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n"}, "hash": "131503a0cd9b625a428e034de16c9799486cdcbfa82da2bf323119675a6000b0", "class_name": "RelatedNodeInfo"}}, "text": "Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter. ", "start_char_idx": 1804, "end_char_idx": 1986, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1fb6397-75be-4bd3-ad46-6dbd42f657a7": {"__data__": {"id_": "f1fb6397-75be-4bd3-ad46-6dbd42f657a7", "embedding": null, "metadata": {"window": "Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance. ", "original_text": "Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b0d473c-d0cf-490f-9978-4037cbb53a7a", "node_type": "1", "metadata": {"window": "The timing of discrete tax item is difficult to \npredict, and therefore, we do not provide quarterly effective tax rate guidance.  \n \n Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n", "original_text": "Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbbc66a181e36cc8a5cf94e90cd0ad3114be56c0f80f38d6a5840ecce0f4732a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9596ea0c-c036-4da6-805a-9c8c8cabb482", "node_type": "1", "metadata": {"window": "We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n", "original_text": "Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares. "}, "hash": "f096b17dec4657ca0acd68542d240f3a7f09815f6a3608ba42f4bbaead3e48c4", "class_name": "RelatedNodeInfo"}}, "text": "Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n", "start_char_idx": 1986, "end_char_idx": 2068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9596ea0c-c036-4da6-805a-9c8c8cabb482": {"__data__": {"id_": "9596ea0c-c036-4da6-805a-9c8c8cabb482", "embedding": null, "metadata": {"window": "We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n", "original_text": "Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1fb6397-75be-4bd3-ad46-6dbd42f657a7", "node_type": "1", "metadata": {"window": "Turning to  cash flow and capital deployment.  We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance. ", "original_text": "Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f5c14922194aa7df96c26faf783a6b215b28000755c188f547645dce61fad7ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eda07e90-b480-44ca-b0c3-a112cbd02056", "node_type": "1", "metadata": {"window": "Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n", "original_text": "As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n"}, "hash": "21387cec37286098783308585c12d6cb4182fc192f7548fe36df83fc078bb3e8", "class_name": "RelatedNodeInfo"}}, "text": "Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares. ", "start_char_idx": 2068, "end_char_idx": 2162, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eda07e90-b480-44ca-b0c3-a112cbd02056": {"__data__": {"id_": "eda07e90-b480-44ca-b0c3-a112cbd02056", "embedding": null, "metadata": {"window": "Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n", "original_text": "As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9596ea0c-c036-4da6-805a-9c8c8cabb482", "node_type": "1", "metadata": {"window": "We now anticipate free cash flow of approximately $3.2 billion to \n$3.6 billion.  Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n", "original_text": "Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddc8050a6dcdfb51cc0d577224c5e6eb84296ee92c28a9f1aad9b92d5fabe2fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37a1fe54-8b47-407d-9d6f-396aa3d75f65", "node_type": "1", "metadata": {"window": "Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments. ", "original_text": "Wrapping up fiscal 2024 guidance. "}, "hash": "f76686eae2c3e3865fe65134815714f73fd05b3bd3a8bf0e0fdbee94a267406b", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n", "start_char_idx": 2162, "end_char_idx": 2319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37a1fe54-8b47-407d-9d6f-396aa3d75f65": {"__data__": {"id_": "37a1fe54-8b47-407d-9d6f-396aa3d75f65", "embedding": null, "metadata": {"window": "Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments. ", "original_text": "Wrapping up fiscal 2024 guidance. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eda07e90-b480-44ca-b0c3-a112cbd02056", "node_type": "1", "metadata": {"window": "Our working capital metrics and resulting free cash flow will vary from quarter -to-quarter, impacted by \ntiming, including the day of the week  that marks the close of the quarter.  Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n", "original_text": "As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "231ead5b38bd2010cab1b47ed2cc4671cd4f45964571d3ad0c563cdf70c96508", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "621a75f7-86dd-4ccd-a9a0-8cbd60fe7dcd", "node_type": "1", "metadata": {"window": "Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024. ", "original_text": "As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n"}, "hash": "ca615833816849188b6bcb53ece6a63c16ae7268ca3769fd1bd03f2b637c06c2", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up fiscal 2024 guidance. ", "start_char_idx": 2319, "end_char_idx": 2353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "621a75f7-86dd-4ccd-a9a0-8cbd60fe7dcd": {"__data__": {"id_": "621a75f7-86dd-4ccd-a9a0-8cbd60fe7dcd", "embedding": null, "metadata": {"window": "Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024. ", "original_text": "As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37a1fe54-8b47-407d-9d6f-396aa3d75f65", "node_type": "1", "metadata": {"window": "Our outlook also incorporates the impact \nof the October Rite Aid bankruptcy.  \n \n Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments. ", "original_text": "Wrapping up fiscal 2024 guidance. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad88ddf6a8bd5edf40b1871e2cfb1c587d9ccd6787e059b7600429f10f3e5961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f27fe77d-1c8b-443b-9cee-f90088dfdf46", "node_type": "1", "metadata": {"window": "As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n", "original_text": "We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n"}, "hash": "e5bdaedb447c15dded8775e642b416b96171d24e3910d662fdbf0899f0e6c4df", "class_name": "RelatedNodeInfo"}}, "text": "As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n", "start_char_idx": 2353, "end_char_idx": 2612, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f27fe77d-1c8b-443b-9cee-f90088dfdf46": {"__data__": {"id_": "f27fe77d-1c8b-443b-9cee-f90088dfdf46", "embedding": null, "metadata": {"window": "As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n", "original_text": "We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "621a75f7-86dd-4ccd-a9a0-8cbd60fe7dcd", "node_type": "1", "metadata": {"window": "Our guidance reflects plans to repurchase approximately $3 billion to $3.5 billion of shares.  As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024. ", "original_text": "As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22389c6dc977c6242d92d2bcae80cd91d4d8dfc8bdd9ccb17ca90c463242ffcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31e0f06a-9722-4862-bc8b-ab20212c223e", "node_type": "1", "metadata": {"window": "Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025. ", "original_text": "As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments. "}, "hash": "10637f3df4346fb8287f95c90b9d2d0c1823ed6f5f23c4ac9e40c88709e1c58b", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n", "start_char_idx": 2612, "end_char_idx": 2859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31e0f06a-9722-4862-bc8b-ab20212c223e": {"__data__": {"id_": "31e0f06a-9722-4862-bc8b-ab20212c223e", "embedding": null, "metadata": {"window": "Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025. ", "original_text": "As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f27fe77d-1c8b-443b-9cee-f90088dfdf46", "node_type": "1", "metadata": {"window": "As a result of the \nshare repurchase activity, we estimate weighted average diluted shares outstanding to be in the range of \napproximately 134 million.  \n \n Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n", "original_text": "We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4d9ab18a473c8817795501d0ce2253b8c118f650cfb3fc15cdfbf161cfd8f85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab091e24-c383-4c5b-ae56-01749f37546a", "node_type": "1", "metadata": {"window": "As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025. ", "original_text": "A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024. "}, "hash": "3a167a99e1071317f338d4668da91c5ae23af12353a8d9fb263e6bd0c6ea2571", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments. ", "start_char_idx": 2859, "end_char_idx": 3051, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab091e24-c383-4c5b-ae56-01749f37546a": {"__data__": {"id_": "ab091e24-c383-4c5b-ae56-01749f37546a", "embedding": null, "metadata": {"window": "As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025. ", "original_text": "A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31e0f06a-9722-4862-bc8b-ab20212c223e", "node_type": "1", "metadata": {"window": "Wrapping up fiscal 2024 guidance.  As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025. ", "original_text": "As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7863f244d5a08cff8ccb81659beb85c6a1cd5d2b1e3aa8f6c0140922c3d8a04a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1bb7d1cc-ad05-4d93-b1dc-d29fdb048e53", "node_type": "1", "metadata": {"window": "We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n"}, "hash": "62eda7221cdab5d9b02f21e175b7cb4390260b336bc1c4b7d16f98ed590312e3", "class_name": "RelatedNodeInfo"}}, "text": "A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024. ", "start_char_idx": 3051, "end_char_idx": 3274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1bb7d1cc-ad05-4d93-b1dc-d29fdb048e53": {"__data__": {"id_": "1bb7d1cc-ad05-4d93-b1dc-d29fdb048e53", "embedding": null, "metadata": {"window": "We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab091e24-c383-4c5b-ae56-01749f37546a", "node_type": "1", "metadata": {"window": "As a result of solid performance in the third quarter of fiscal 2024, combined \nwith our momentum and confidence movi ng forward, we are increasing and narrowing our earnings per diluted \nshare outlook for fiscal 2024, to a new range of $27.25 to $27.65.  \n \n We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025. ", "original_text": "A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6c92cc793c6bc9c986e9b852e73ae87c25b5cdf8d85ebcc271f600294929350", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa9d0e97-8232-4ce9-bc64-8846b3af7499", "node_type": "1", "metadata": {"window": "As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "Before I close, I'd like to share some initial thoughts on fiscal 2025. "}, "hash": "59f33e1335ee702e259654bd7455e25a989a20c4f05a8cfd6271ffbf046268a6", "class_name": "RelatedNodeInfo"}}, "text": "The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n", "start_char_idx": 3274, "end_char_idx": 3416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa9d0e97-8232-4ce9-bc64-8846b3af7499": {"__data__": {"id_": "aa9d0e97-8232-4ce9-bc64-8846b3af7499", "embedding": null, "metadata": {"window": "As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "Before I close, I'd like to share some initial thoughts on fiscal 2025. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1bb7d1cc-ad05-4d93-b1dc-d29fdb048e53", "node_type": "1", "metadata": {"window": "We anticipate operating profit will be a 2% decline to 1% growth compared to the prior year, excluding certain \nitems, w e anticipate operating profit to increase by approximately 8% to 11% year -over-year, above the long -term \ntarget range.  \n \n As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f62094421e9960cb2b0e165ccdcd1dea3267f45b554bfb594fc6f705bdf4433f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "227c624f-c3f4-419d-a87f-ed1dc5969c6e", "node_type": "1", "metadata": {"window": "A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025. "}, "hash": "94505fd94c20e88133d8c976d67579e0acf395a9f1322a2c00242f42cde18f6c", "class_name": "RelatedNodeInfo"}}, "text": "Before I close, I'd like to share some initial thoughts on fiscal 2025. ", "start_char_idx": 3416, "end_char_idx": 3488, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "227c624f-c3f4-419d-a87f-ed1dc5969c6e": {"__data__": {"id_": "227c624f-c3f4-419d-a87f-ed1dc5969c6e", "embedding": null, "metadata": {"window": "A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa9d0e97-8232-4ce9-bc64-8846b3af7499", "node_type": "1", "metadata": {"window": "As a reminder, certain items include the following: $1.90 related to fiscal 2023, US government COVID -19 \nprogram and COVID -19 tests in o ur US Pharmaceutical and Medical Surgical segments.  A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "Before I close, I'd like to share some initial thoughts on fiscal 2025. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aed7149b44be413eeaa0ed90ca9f144b4db1788d8f997bd42d727de11e0d4d9c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe25319d-fa0d-4d28-9647-43632a39e877", "node_type": "1", "metadata": {"window": "The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've "}, "hash": "a1490be5533d5d8e1e751c7d182261ca8d7e8bd296e7328dd3e3ed6c746f14d4", "class_name": "RelatedNodeInfo"}}, "text": "The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025. ", "start_char_idx": 3488, "end_char_idx": 3601, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe25319d-fa0d-4d28-9647-43632a39e877": {"__data__": {"id_": "fe25319d-fa0d-4d28-9647-43632a39e877", "embedding": null, "metadata": {"window": "The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fcefb117410ddd0813f1155c75cddf1f6ffc09097cbb17ddaced2759fc45e12a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "227c624f-c3f4-419d-a87f-ed1dc5969c6e", "node_type": "1", "metadata": {"window": "A $0.65 benefit related \nto the early termination of the tax receivable agreement with Change Healthcare in fiscal 2023, and gains and \nlosses associated with McKesson Ventures' equity investments in fiscal  2023 and 2024.  The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025. ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "858ad7c611dbc22531b0e25e424169663c942d7a9e3d71a8eca4e720b08d54cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccd70c8b-793d-4b03-a76f-109337ae751f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "59def723805a15692c71826dc7beab5648df180d42a2fcaa7fc4bca10218199b", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "start_char_idx": 3601, "end_char_idx": 3751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccd70c8b-793d-4b03-a76f-109337ae751f": {"__data__": {"id_": "ccd70c8b-793d-4b03-a76f-109337ae751f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe25319d-fa0d-4d28-9647-43632a39e877", "node_type": "1", "metadata": {"window": "The increase to our \noutlook for adjusted earnings per diluted share indicates growth of 16% to 18%, when excluding these certain \nitems.  \n \n Before I close, I'd like to share some initial thoughts on fiscal 2025.  The momentum we've seen across our \nbusiness over the past several years is expected to continue in fiscal 2025.  We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "original_text": "We anticipate the US Pharmaceutical \nand Medical Surgical Solutions segments will be more closely aligned to the long -term growth targets that we've ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ddbcf382f1fa9ff7165d6b1cc9de673ad4d1a5eddae0ed33e3b18860a09e4998", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c845133-550c-46be-923c-fa953e1892b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n"}, "hash": "bcc1917d980b2a64949a7447ed0fe7fb3dcb59a054c2a8fc13913dfe473ea397", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c845133-550c-46be-923c-fa953e1892b1": {"__data__": {"id_": "7c845133-550c-46be-923c-fa953e1892b1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccd70c8b-793d-4b03-a76f-109337ae751f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e0b9adbf6473f28738016f3f538d41dcc0275790c8826585806cf1c170ed87c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b83e1263-40b9-4ba4-bb28-67f2cb2f2d0a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n", "original_text": "We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n"}, "hash": "dbe307c7ad9c0b0bff3a1541f06b5ebb39e7d667a1e1df2ed88192d4c7aca146", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n", "start_char_idx": 16, "end_char_idx": 304, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b83e1263-40b9-4ba4-bb28-67f2cb2f2d0a": {"__data__": {"id_": "b83e1263-40b9-4ba4-bb28-67f2cb2f2d0a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n", "original_text": "We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c845133-550c-46be-923c-fa953e1892b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf27f2d358af31523f6d2906eda37ae6af42deeb14f41f87d6e693a10dad7558", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa656960-4093-441a-8c79-2f8fa7c173fa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n", "original_text": "In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n"}, "hash": "98ffbf94179191ba4e6607a89e2f77979d084e72e14ed9a37ed93b99dd3a1195", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n", "start_char_idx": 304, "end_char_idx": 492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa656960-4093-441a-8c79-2f8fa7c173fa": {"__data__": {"id_": "fa656960-4093-441a-8c79-2f8fa7c173fa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n", "original_text": "In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b83e1263-40b9-4ba4-bb28-67f2cb2f2d0a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n", "original_text": "We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2548999e3c5dd90ee50a44957d3134618a96b5ae36a3b368b2653b582b9eb0ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d25592e0-d38f-48cb-bf0b-1c2c023db042", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations. ", "original_text": "As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings. "}, "hash": "120d82cbab3174d04f0f0b1537496f8d60dbad226cf1409f9de07a9d11805d0d", "class_name": "RelatedNodeInfo"}}, "text": "In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n", "start_char_idx": 492, "end_char_idx": 780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d25592e0-d38f-48cb-bf0b-1c2c023db042": {"__data__": {"id_": "d25592e0-d38f-48cb-bf0b-1c2c023db042", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations. ", "original_text": "As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa656960-4093-441a-8c79-2f8fa7c173fa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n", "original_text": "In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01f62ce5f169415bfdb22d06b2d27a188b9243291e52cf14f3fa53daf6ffc74f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e181255-88a3-47ef-a7ea-d292d8fb40ba", "node_type": "1", "metadata": {"window": "We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n", "original_text": "Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n"}, "hash": "6158116275b64f6f38a3e895b2a0240bdd31506437b5853628a8770bffc60fba", "class_name": "RelatedNodeInfo"}}, "text": "As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings. ", "start_char_idx": 780, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e181255-88a3-47ef-a7ea-d292d8fb40ba": {"__data__": {"id_": "5e181255-88a3-47ef-a7ea-d292d8fb40ba", "embedding": null, "metadata": {"window": "We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n", "original_text": "Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d25592e0-d38f-48cb-bf0b-1c2c023db042", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations. ", "original_text": "As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ccf46c20ac7879142391a4013c991995c37faf78bfef3db5bed657e8605a752", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2dccc5f-f2c4-4387-9dd6-c5c24217136b", "node_type": "1", "metadata": {"window": "In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell. ", "original_text": "We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n"}, "hash": "20454a6eb84a6284de4f71c26c9e9e0498e0d4c33340715a5274ed66f252b567", "class_name": "RelatedNodeInfo"}}, "text": "Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n", "start_char_idx": 961, "end_char_idx": 1141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2dccc5f-f2c4-4387-9dd6-c5c24217136b": {"__data__": {"id_": "f2dccc5f-f2c4-4387-9dd6-c5c24217136b", "embedding": null, "metadata": {"window": "In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell. ", "original_text": "We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e181255-88a3-47ef-a7ea-d292d8fb40ba", "node_type": "1", "metadata": {"window": "We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n", "original_text": "Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d7bd98a7896a08019730c5fbd8392078d000eaadf9ebc4fef92d3342bb2c3d5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdb83e0c-8694-440f-bff6-e882ea39ed24", "node_type": "1", "metadata": {"window": "As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n", "original_text": "For the International segment, we anticipate continued growth in our Canadian operations. "}, "hash": "34078f15bb33fce91028681fb944c31c451e8601f5c28b4ae995df4084da29d8", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n", "start_char_idx": 1141, "end_char_idx": 1371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdb83e0c-8694-440f-bff6-e882ea39ed24": {"__data__": {"id_": "cdb83e0c-8694-440f-bff6-e882ea39ed24", "embedding": null, "metadata": {"window": "As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n", "original_text": "For the International segment, we anticipate continued growth in our Canadian operations. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2dccc5f-f2c4-4387-9dd6-c5c24217136b", "node_type": "1", "metadata": {"window": "In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell. ", "original_text": "We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4deeca5dbd67aff434cedfaa19594910bb3386d30704a8d7b17d15cb2f21cbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c029b9da-ea56-4945-a6bf-59a8a8ba1e73", "node_type": "1", "metadata": {"window": "Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts. ", "original_text": "And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n"}, "hash": "5344cb06eaff79a708eab84298b1f604401cc48177c882005c1f30a8a073cb29", "class_name": "RelatedNodeInfo"}}, "text": "For the International segment, we anticipate continued growth in our Canadian operations. ", "start_char_idx": 1371, "end_char_idx": 1461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c029b9da-ea56-4945-a6bf-59a8a8ba1e73": {"__data__": {"id_": "c029b9da-ea56-4945-a6bf-59a8a8ba1e73", "embedding": null, "metadata": {"window": "Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts. ", "original_text": "And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdb83e0c-8694-440f-bff6-e882ea39ed24", "node_type": "1", "metadata": {"window": "As the leader in the alternate site market, we believe that the Medical Surgical Solutions segment is well \npositioned as care continues to move across the alternate site settings.  Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n", "original_text": "For the International segment, we anticipate continued growth in our Canadian operations. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a9cb4626ebd2bb83b90660124203f3d209451db04c971a0076689d65d0d1bdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5ad4acf-0bf5-4bb8-b357-af0102c2961c", "node_type": "1", "metadata": {"window": "We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms. ", "original_text": "As a reminder, Norway remains the only country that we have not entered into an agreement to sell. "}, "hash": "6f78b3bdf41bad829b916709ca1e46d4b9dc480381bd6f8d7efa4d244ddae210", "class_name": "RelatedNodeInfo"}}, "text": "And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n", "start_char_idx": 1461, "end_char_idx": 1602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5ad4acf-0bf5-4bb8-b357-af0102c2961c": {"__data__": {"id_": "d5ad4acf-0bf5-4bb8-b357-af0102c2961c", "embedding": null, "metadata": {"window": "We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms. ", "original_text": "As a reminder, Norway remains the only country that we have not entered into an agreement to sell. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c029b9da-ea56-4945-a6bf-59a8a8ba1e73", "node_type": "1", "metadata": {"window": "Our experience and our relations hips in \nevery channel and setting of the alternate site markets enable us to capture the [ph] growth (29:59) opportunity in \nthe years ahead.  \n \n We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts. ", "original_text": "And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e43896fe3c7f94de91da24624f501b3fcc04da464137934fde673b8dfabbe67", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddaf6b65-1b9f-41a0-bfd8-b1664115d9ef", "node_type": "1", "metadata": {"window": "For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n", "original_text": "And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n"}, "hash": "3d3a213ecf0fefd6290e3eda58e097edb13821c5f8d761f5bf404602afc489a3", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, Norway remains the only country that we have not entered into an agreement to sell. ", "start_char_idx": 1602, "end_char_idx": 1701, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddaf6b65-1b9f-41a0-bfd8-b1664115d9ef": {"__data__": {"id_": "ddaf6b65-1b9f-41a0-bfd8-b1664115d9ef", "embedding": null, "metadata": {"window": "For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n", "original_text": "And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5ad4acf-0bf5-4bb8-b357-af0102c2961c", "node_type": "1", "metadata": {"window": "We anticipate that the Prescription Technology Solutions segment may perform modestly above the long -term \ngrowth t arget of 11% to 12%, driven by organic growth, as we expand our higher -margin biopharma services \nplatform.  \n \n For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms. ", "original_text": "As a reminder, Norway remains the only country that we have not entered into an agreement to sell. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "076e506dd4580cc151b7e2a81c6d4de7399d309d876d66abda731b152cc6d1dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67c23161-ed9d-454f-b039-dc55772b546b", "node_type": "1", "metadata": {"window": "And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n", "original_text": "Finally, we will continue to materially invest in the business on multiple fronts. "}, "hash": "ca4cf002baf77206981da0aff9384594b294f43e38d5541817f21f3dabe305aa", "class_name": "RelatedNodeInfo"}}, "text": "And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n", "start_char_idx": 1701, "end_char_idx": 1784, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67c23161-ed9d-454f-b039-dc55772b546b": {"__data__": {"id_": "67c23161-ed9d-454f-b039-dc55772b546b", "embedding": null, "metadata": {"window": "And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n", "original_text": "Finally, we will continue to materially invest in the business on multiple fronts. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddaf6b65-1b9f-41a0-bfd8-b1664115d9ef", "node_type": "1", "metadata": {"window": "For the International segment, we anticipate continued growth in our Canadian operations.  And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n", "original_text": "And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43a2fc59177b73f2100ed764998ece33ad7545e312f37d04c37382d7527f3e7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "996991c6-87f3-4ba5-aff5-60da497e0e65", "node_type": "1", "metadata": {"window": "As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities. ", "original_text": "We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms. "}, "hash": "b4292e6b5ff32274a20241e68bcada1f8beb10f4309b5e90659696ab71222f62", "class_name": "RelatedNodeInfo"}}, "text": "Finally, we will continue to materially invest in the business on multiple fronts. ", "start_char_idx": 1784, "end_char_idx": 1867, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "996991c6-87f3-4ba5-aff5-60da497e0e65": {"__data__": {"id_": "996991c6-87f3-4ba5-aff5-60da497e0e65", "embedding": null, "metadata": {"window": "As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities. ", "original_text": "We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67c23161-ed9d-454f-b039-dc55772b546b", "node_type": "1", "metadata": {"window": "And throughout fiscal \n2023, we completed divestitures of t he business operations in 11 of the 12 countries that we operated in Europe.  \n \n As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n", "original_text": "Finally, we will continue to materially invest in the business on multiple fronts. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0965699dd316434c67d56a585103207aa1510775344e9d0758990a683ff2e03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26e08cb8-8916-4af0-a4cd-2c12594b3f88", "node_type": "1", "metadata": {"window": "And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n", "original_text": "These investments will furth er our differentiated capabilities and market -leading positions.  \n \n"}, "hash": "f63bd3ac52c92bef6c0088882e717440a45415cb0857166d1ea7ecaca00413bc", "class_name": "RelatedNodeInfo"}}, "text": "We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms. ", "start_char_idx": 1867, "end_char_idx": 2014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26e08cb8-8916-4af0-a4cd-2c12594b3f88": {"__data__": {"id_": "26e08cb8-8916-4af0-a4cd-2c12594b3f88", "embedding": null, "metadata": {"window": "And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n", "original_text": "These investments will furth er our differentiated capabilities and market -leading positions.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "996991c6-87f3-4ba5-aff5-60da497e0e65", "node_type": "1", "metadata": {"window": "As a reminder, Norway remains the only country that we have not entered into an agreement to sell.  And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities. ", "original_text": "We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac98b8dfa049f4a964947b95a2a23ecc09d6e7e48b6835c47a1153b048024ef1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "499e7553-45af-4020-8203-06251699cff3", "node_type": "1", "metadata": {"window": "Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n", "original_text": "We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n"}, "hash": "3c9aeb8bb8a8d51861c7ad4f4307af7b9a53dad65e6c763878e8cbf779420b42", "class_name": "RelatedNodeInfo"}}, "text": "These investments will furth er our differentiated capabilities and market -leading positions.  \n \n", "start_char_idx": 2014, "end_char_idx": 2113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "499e7553-45af-4020-8203-06251699cff3": {"__data__": {"id_": "499e7553-45af-4020-8203-06251699cff3", "embedding": null, "metadata": {"window": "Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n", "original_text": "We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26e08cb8-8916-4af0-a4cd-2c12594b3f88", "node_type": "1", "metadata": {"window": "And we \nintend to exit Norway, as part of the completion of our European exit.  \n \n Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n", "original_text": "These investments will furth er our differentiated capabilities and market -leading positions.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87b50ac4d8ddffd7d40674aab719fcbc0b1135fe8068dd3be35e3a39af028702", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c85f88a-87c9-4aa6-81c0-3e49abf7997d", "node_type": "1", "metadata": {"window": "We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection. ", "original_text": "These investments include increased capacity, automation, and regulatory excellence capabilities. "}, "hash": "557dcc53b006f90d44e93d35f5c2f7ac72825cac26ba228dc1ce6e278c8ea532", "class_name": "RelatedNodeInfo"}}, "text": "We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n", "start_char_idx": 2113, "end_char_idx": 2228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c85f88a-87c9-4aa6-81c0-3e49abf7997d": {"__data__": {"id_": "5c85f88a-87c9-4aa6-81c0-3e49abf7997d", "embedding": null, "metadata": {"window": "We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection. ", "original_text": "These investments include increased capacity, automation, and regulatory excellence capabilities. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "499e7553-45af-4020-8203-06251699cff3", "node_type": "1", "metadata": {"window": "Finally, we will continue to materially invest in the business on multiple fronts.  We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n", "original_text": "We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8579119b009c99752b2e12c8862718c381c791789f71d5135eb349490428f9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9d4e460-02c0-456e-8b86-de90ced3d0ee", "node_type": "1", "metadata": {"window": "These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n", "original_text": "And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n"}, "hash": "c447c907de73607c1806953783bec5508b5599e74bc0e9f5521a5fb3442ea0d9", "class_name": "RelatedNodeInfo"}}, "text": "These investments include increased capacity, automation, and regulatory excellence capabilities. ", "start_char_idx": 2228, "end_char_idx": 2326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9d4e460-02c0-456e-8b86-de90ced3d0ee": {"__data__": {"id_": "e9d4e460-02c0-456e-8b86-de90ced3d0ee", "embedding": null, "metadata": {"window": "These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n", "original_text": "And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c85f88a-87c9-4aa6-81c0-3e49abf7997d", "node_type": "1", "metadata": {"window": "We will sustain the pace and \ncadence of investment in product development and enhancements across our oncology and biopharma services \nplatforms.  These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection. ", "original_text": "These investments include increased capacity, automation, and regulatory excellence capabilities. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c324573e2c0ac1bacc3aea9b2412cbc54a21471b35209f2141948112e5901a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cdfb22f-93d2-4aca-9ba9-915771121140", "node_type": "1", "metadata": {"window": "We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business. ", "original_text": "We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n"}, "hash": "2cdfba47fefc57b775e93fe542ec7720731ec78f3a372df5b8a0cc2bd9d8f41d", "class_name": "RelatedNodeInfo"}}, "text": "And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n", "start_char_idx": 2326, "end_char_idx": 2460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cdfb22f-93d2-4aca-9ba9-915771121140": {"__data__": {"id_": "4cdfb22f-93d2-4aca-9ba9-915771121140", "embedding": null, "metadata": {"window": "We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business. ", "original_text": "We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9d4e460-02c0-456e-8b86-de90ced3d0ee", "node_type": "1", "metadata": {"window": "These investments will furth er our differentiated capabilities and market -leading positions.  \n \n We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n", "original_text": "And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26069c2ffd8c9b6fa2d445521d8a05ca434e5f99d58d68e2a876b1cfe14895a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49d5c784-db2c-4f95-abcb-5a407c1a1c3e", "node_type": "1", "metadata": {"window": "These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook. ", "original_text": "Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection. "}, "hash": "6210931a8d29c0c966506f5091f47cf2a73bb00cc82b1d04cd7bdc1f9e2c361f", "class_name": "RelatedNodeInfo"}}, "text": "We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n", "start_char_idx": 2460, "end_char_idx": 2552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49d5c784-db2c-4f95-abcb-5a407c1a1c3e": {"__data__": {"id_": "49d5c784-db2c-4f95-abcb-5a407c1a1c3e", "embedding": null, "metadata": {"window": "These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook. ", "original_text": "Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cdfb22f-93d2-4aca-9ba9-915771121140", "node_type": "1", "metadata": {"window": "We will also continue to invest in adding capacity and capabilities to our North American distribution footprint. \n These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business. ", "original_text": "We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "620705fe7273dd000f61b74d0c43d8f950f89e162fe6cdb84316bb294e91188d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a70dc208-477a-41f6-a2fa-9ac2ad0cc559", "node_type": "1", "metadata": {"window": "And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n", "original_text": "Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n"}, "hash": "50be551da63ffb8a8b0e56e39b0f74e0579d4f2467920444bf12f9a475948075", "class_name": "RelatedNodeInfo"}}, "text": "Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection. ", "start_char_idx": 2552, "end_char_idx": 2869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a70dc208-477a-41f6-a2fa-9ac2ad0cc559": {"__data__": {"id_": "a70dc208-477a-41f6-a2fa-9ac2ad0cc559", "embedding": null, "metadata": {"window": "And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n", "original_text": "Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49d5c784-db2c-4f95-abcb-5a407c1a1c3e", "node_type": "1", "metadata": {"window": "These investments include increased capacity, automation, and regulatory excellence capabilities.  And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook. ", "original_text": "Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19afcfcf0c24b7fd1fb3f423116601d340ba55d80b26c3acc2049e02469255da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abba9a6f-073b-41e6-b9d1-a20290507da1", "node_type": "1", "metadata": {"window": "We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "To sum up, we see strength and stability in the underlying fundamentals of the business. "}, "hash": "3fb55595a4aad391b0c4299a58bab9c2f5d980b831488bea8118bfadf701ca2b", "class_name": "RelatedNodeInfo"}}, "text": "Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n", "start_char_idx": 2869, "end_char_idx": 3088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abba9a6f-073b-41e6-b9d1-a20290507da1": {"__data__": {"id_": "abba9a6f-073b-41e6-b9d1-a20290507da1", "embedding": null, "metadata": {"window": "We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "To sum up, we see strength and stability in the underlying fundamentals of the business. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a70dc208-477a-41f6-a2fa-9ac2ad0cc559", "node_type": "1", "metadata": {"window": "And we will \ncontinue to invest in data and analytics, including the acceleration of several investments in artificial intelligence. \n We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n", "original_text": "Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "21c7d8406de83d7c0f6fa5d149549ae7e70d73485b664a3669979a0112a97ddf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ece9950d-f9ce-41d4-af4a-020007fa0402", "node_type": "1", "metadata": {"window": "Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook. "}, "hash": "2259b8b12121c6968a1a3252c159712788e3af25befd2363655ce56121422dbd", "class_name": "RelatedNodeInfo"}}, "text": "To sum up, we see strength and stability in the underlying fundamentals of the business. ", "start_char_idx": 3088, "end_char_idx": 3177, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ece9950d-f9ce-41d4-af4a-020007fa0402": {"__data__": {"id_": "ece9950d-f9ce-41d4-af4a-020007fa0402", "embedding": null, "metadata": {"window": "Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abba9a6f-073b-41e6-b9d1-a20290507da1", "node_type": "1", "metadata": {"window": "We see AI as unlocking the potential to deliver customer and foundational enhancements.  \n \n Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "To sum up, we see strength and stability in the underlying fundamentals of the business. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b38c9ec860bb0131d75dc12f54cfd62a66cdaf367030ebca615cd041837edbc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9af466ba-9b2c-4c0d-8426-09009585e65f", "node_type": "1", "metadata": {"window": "Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n"}, "hash": "affba72f0e46a39590294d4b74c268a4f0844dfc8284cf2b52db57935b704b4b", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook. ", "start_char_idx": 3177, "end_char_idx": 3277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9af466ba-9b2c-4c0d-8426-09009585e65f": {"__data__": {"id_": "9af466ba-9b2c-4c0d-8426-09009585e65f", "embedding": null, "metadata": {"window": "Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ece9950d-f9ce-41d4-af4a-020007fa0402", "node_type": "1", "metadata": {"window": "Although i n the early stages, we're using AI to improve patient intake and workflow, and improve productivity \nthroughout the system, including automatic clinical note generation and several supply -chain use cases, including \nsupply -chain disruption predictions, forec ast accuracy algorithms and fraud detection.  Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook. ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93156508c9bd0b797e102e8ade5222099238bfbe33ac400bd7e5bbf62be48841", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1068a5e6-977a-4f83-9ca2-7d4f4a603ae4", "node_type": "1", "metadata": {"window": "To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "And with that, let's move to our Q&A session.  \n  "}, "hash": "f7a4924eb2fae88f69509fc327043118437a68d66e0ce3c1063b497c00471b94", "class_name": "RelatedNodeInfo"}}, "text": "McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n", "start_char_idx": 3277, "end_char_idx": 3486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1068a5e6-977a-4f83-9ca2-7d4f4a603ae4": {"__data__": {"id_": "1068a5e6-977a-4f83-9ca2-7d4f4a603ae4", "embedding": null, "metadata": {"window": "To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "And with that, let's move to our Q&A session.  \n  ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab41e59fa375bf3083d727135e2a12fb233f4c90ed5581d394a618fc051a9cc3", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9af466ba-9b2c-4c0d-8426-09009585e65f", "node_type": "1", "metadata": {"window": "Although, we're in the early \nstages of our AI development and implementation, we're committed to increased investment to further extend our \nleadership positions and deliver value to our partners and stakeholders . \n \n To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93eed90c05462db8eea85ac1825238b3a3bc16248104d1396295e05d3159c302", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a9042cd-f73f-4124-9546-e7cf90364883", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n ", "original_text": "McKesson Corp.  "}, "hash": "78e0288d124443195aa499535f95e826d61be2475241166b107ec5618b6a061b", "class_name": "RelatedNodeInfo"}}, "text": "And with that, let's move to our Q&A session.  \n  ", "start_char_idx": 3486, "end_char_idx": 3536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a9042cd-f73f-4124-9546-e7cf90364883": {"__data__": {"id_": "4a9042cd-f73f-4124-9546-e7cf90364883", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1068a5e6-977a-4f83-9ca2-7d4f4a603ae4", "node_type": "1", "metadata": {"window": "To sum up, we see strength and stability in the underlying fundamentals of the business.  We're pleased with our \nstrong fiscal 2024 performance, and we remain optimistic about the outlook.  McKesson is well positioned to \ncontinue to deliver strong results , as we successfully executed against our strategic and financial framework to \ndrive long -term sustainable growth for all stakeholders.  \n \n And with that, let's move to our Q&A session.  \n  ", "original_text": "And with that, let's move to our Q&A session.  \n  ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d76e392ee3d3b8ae415fba27b53c6bc53c33cc7cf0ef0d05a1c3caf93c00bba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ce3b2b9-35d3-4f86-b3ad-0227fba243a8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "d6a4765272fbd87eaf1489835acf1ce68f9b7c34a0e0dd4609e3cefc50f5e58e", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ce3b2b9-35d3-4f86-b3ad-0227fba243a8": {"__data__": {"id_": "7ce3b2b9-35d3-4f86-b3ad-0227fba243a8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a9042cd-f73f-4124-9546-e7cf90364883", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "183c1b07f100a2c1809417c7f2533ed87fdc2d1f06dff1cc6297378940db2422", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebdc0639-70a4-47c5-bb06-2e364454de74", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "[Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen. "}, "hash": "8b70d34bb0a9390cc90b4e2956697efd1722f052cea38ac685f800b79b02a9a4", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 16, "end_char_idx": 238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebdc0639-70a4-47c5-bb06-2e364454de74": {"__data__": {"id_": "ebdc0639-70a4-47c5-bb06-2e364454de74", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "[Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ce3b2b9-35d3-4f86-b3ad-0227fba243a8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b5621f1bbfbe88685e87439d848a37d52087b10bad30e6684562567958d957e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5c6c919-0fd1-4d34-8347-a751c0c628a9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions. ", "original_text": "Please go ahead.  \n "}, "hash": "57ee8cfbe1c3fbf1c5605ebadb74f12c38240e3963d0585bf509c7c2c80c427d", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen. ", "start_char_idx": 238, "end_char_idx": 331, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c6c919-0fd1-4d34-8347-a751c0c628a9": {"__data__": {"id_": "c5c6c919-0fd1-4d34-8347-a751c0c628a9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebdc0639-70a4-47c5-bb06-2e364454de74", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "[Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d88216c368a9d1e5b4e8a9d8b03a22149a3ac3cdfc610ae98ed01df796b3bf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "485e67c5-b6ca-4f00-b282-ac3e2c6ec515", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "43cffd2cb2088e3f66df575fb98255f6317a96b6b40157dcbe5ecede736e58d4", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 331, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "485e67c5-b6ca-4f00-b282-ac3e2c6ec515": {"__data__": {"id_": "485e67c5-b6ca-4f00-b282-ac3e2c6ec515", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c6c919-0fd1-4d34-8347-a751c0c628a9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d7fe2bbcc59f147557073558c9d6b42db849f791516c5998c9e3355dade6651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02200d30-20c1-4f1e-8534-d7f10df6afe5", "node_type": "1", "metadata": {"window": "[Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n", "original_text": "LLC  Q \nYeah. "}, "hash": "72f4e91ea85a405721a537dd610f2315574dcedace1c5fe03f1f0c447e5b044e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 351, "end_char_idx": 660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02200d30-20c1-4f1e-8534-d7f10df6afe5": {"__data__": {"id_": "02200d30-20c1-4f1e-8534-d7f10df6afe5", "embedding": null, "metadata": {"window": "[Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n", "original_text": "LLC  Q \nYeah. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "485e67c5-b6ca-4f00-b282-ac3e2c6ec515", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa5d3570cb14024828a7afa9441a2e83b5e8f3a6808199ebdd756b9133db0f63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a68cbb3-3e91-4600-b70f-3598344f9938", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly. ", "original_text": "Thanks for taking the questions. "}, "hash": "ff530686f57392869de9801e102bb4a35d5f22fd2604c99c15689a6a7f9fd543", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 660, "end_char_idx": 674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a68cbb3-3e91-4600-b70f-3598344f9938": {"__data__": {"id_": "4a68cbb3-3e91-4600-b70f-3598344f9938", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly. ", "original_text": "Thanks for taking the questions. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02200d30-20c1-4f1e-8534-d7f10df6afe5", "node_type": "1", "metadata": {"window": "[Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n", "original_text": "LLC  Q \nYeah. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "834bd4da0670e6948057f4400c1ba1aadba5cd5d983ececafbea41d6fcaddbdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37bede98-5749-478f-9332-5115cda2eeae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths? ", "original_text": "Obviously, strong performance in RxTS, as implied in the guidance. \n"}, "hash": "f623dec47eb102f2021e46922251c995131004384c2d42c576f9b4272f617a8f", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the questions. ", "start_char_idx": 674, "end_char_idx": 707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37bede98-5749-478f-9332-5115cda2eeae": {"__data__": {"id_": "37bede98-5749-478f-9332-5115cda2eeae", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths? ", "original_text": "Obviously, strong performance in RxTS, as implied in the guidance. \n", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a68cbb3-3e91-4600-b70f-3598344f9938", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly. ", "original_text": "Thanks for taking the questions. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24f393282b2412d3bce4bfc184246bd66e25aaa9c282382f50382580dbad4199", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab47f78a-58f9-483f-a943-43dd3380158e", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like? ", "original_text": "Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n"}, "hash": "f07e9ce9473a5fdb2eedf1ec938b286f3e7483be72815a17a1be793a0c5ef93d", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, strong performance in RxTS, as implied in the guidance. \n", "start_char_idx": 707, "end_char_idx": 775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab47f78a-58f9-483f-a943-43dd3380158e": {"__data__": {"id_": "ab47f78a-58f9-483f-a943-43dd3380158e", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like? ", "original_text": "Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37bede98-5749-478f-9332-5115cda2eeae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths? ", "original_text": "Obviously, strong performance in RxTS, as implied in the guidance. \n", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "547e87628526b301aac8481beb6441f7add9aee4c3edf19d2b59c072027ac94d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ea75706-fd85-4516-a6b0-53e371627819", "node_type": "1", "metadata": {"window": "Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n ", "original_text": "And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly. "}, "hash": "178f26003392a44e4889641f4c6b2a9d06600fd297726abc2249a8a85bd2c435", "class_name": "RelatedNodeInfo"}}, "text": "Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n", "start_char_idx": 775, "end_char_idx": 889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ea75706-fd85-4516-a6b0-53e371627819": {"__data__": {"id_": "1ea75706-fd85-4516-a6b0-53e371627819", "embedding": null, "metadata": {"window": "Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n ", "original_text": "And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab47f78a-58f9-483f-a943-43dd3380158e", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like? ", "original_text": "Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cebb6a73ab4580da3d59ff7df05510827cfb503291f093c9aa019617009cbdac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fd05cd7-2336-465c-aad1-97955cfba4e1", "node_type": "1", "metadata": {"window": "Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Can you give us a sense of what the life cycle typically is for prior auths? "}, "hash": "9ab33e7571f030828c14ec64d9b984e76db55d53677ccf4febf86d666d7b4b36", "class_name": "RelatedNodeInfo"}}, "text": "And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly. ", "start_char_idx": 889, "end_char_idx": 1140, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fd05cd7-2336-465c-aad1-97955cfba4e1": {"__data__": {"id_": "4fd05cd7-2336-465c-aad1-97955cfba4e1", "embedding": null, "metadata": {"window": "Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Can you give us a sense of what the life cycle typically is for prior auths? ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ea75706-fd85-4516-a6b0-53e371627819", "node_type": "1", "metadata": {"window": "Thanks for taking the questions.  Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n ", "original_text": "And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1273ff3e68db4db835908c84cdcb3d67c02109d299f80290e6ba71c0aad2082f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "586549e8-ff46-47cb-8c87-3cf2dbb51506", "node_type": "1", "metadata": {"window": "Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles. ", "original_text": "Over time as products \nmature, what does that activity looks like? "}, "hash": "2d6fe0b91cfc5c739760d7852f8127c5f6ba97f9ebb42c7b3ef30a3aa8502d2d", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us a sense of what the life cycle typically is for prior auths? ", "start_char_idx": 1140, "end_char_idx": 1217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "586549e8-ff46-47cb-8c87-3cf2dbb51506": {"__data__": {"id_": "586549e8-ff46-47cb-8c87-3cf2dbb51506", "embedding": null, "metadata": {"window": "Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles. ", "original_text": "Over time as products \nmature, what does that activity looks like? ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fd05cd7-2336-465c-aad1-97955cfba4e1", "node_type": "1", "metadata": {"window": "Obviously, strong performance in RxTS, as implied in the guidance. \n Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Can you give us a sense of what the life cycle typically is for prior auths? ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "952e80b51d3a06dcb2234eabca0b84ea644af98c10b4a2d435f71923823d6768", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "877ef944-becc-477d-8ce9-401f844a0a36", "node_type": "1", "metadata": {"window": "And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on. ", "original_text": "And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n "}, "hash": "ed68f09f9d7ba24b8a1ac23b09a31777d0500ecfb45193332617796fd481b964", "class_name": "RelatedNodeInfo"}}, "text": "Over time as products \nmature, what does that activity looks like? ", "start_char_idx": 1217, "end_char_idx": 1284, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "877ef944-becc-477d-8ce9-401f844a0a36": {"__data__": {"id_": "877ef944-becc-477d-8ce9-401f844a0a36", "embedding": null, "metadata": {"window": "And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on. ", "original_text": "And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "586549e8-ff46-47cb-8c87-3cf2dbb51506", "node_type": "1", "metadata": {"window": "Maybe you can kind of give us a feel for the mix between reauthorizations versus new prior auths in that mix.  \n \n And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles. ", "original_text": "Over time as products \nmature, what does that activity looks like? ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbd2fe535d1542951c07096d41cc064a4daf9bc0ca53fd86bc8bad22b0916ad5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b30a1e8f-7f70-4c44-b25b-dccb908ab33e", "node_type": "1", "metadata": {"window": "Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "3c9917ad03a4bc167ba08b44e7412d8f266a0f61000ff5b6d4f7571c46bc25cf", "class_name": "RelatedNodeInfo"}}, "text": "And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n ", "start_char_idx": 1284, "end_char_idx": 1396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b30a1e8f-7f70-4c44-b25b-dccb908ab33e": {"__data__": {"id_": "b30a1e8f-7f70-4c44-b25b-dccb908ab33e", "embedding": null, "metadata": {"window": "Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "877ef944-becc-477d-8ce9-401f844a0a36", "node_type": "1", "metadata": {"window": "And as we think about through the course of the year as kind of new category, like this is sort of a category that's \nkind of grown significantly over the last year or so, particularly and if we think about the launch of Zepbound as \nwell from Lilly.  Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on. ", "original_text": "And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8652d8db41fe87737f19648d8f6445412a41f93e2da2f43e5363968d01b73832", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f9cf1e1-6852-4164-9dd9-210b0cfa2e42", "node_type": "1", "metadata": {"window": "Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers. ", "original_text": "A \nThanks, Charles. "}, "hash": "02e0977b54b487fc65c93378ab9bf6257d30d6cacc43e6bec5269124d0097862", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1396, "end_char_idx": 1740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f9cf1e1-6852-4164-9dd9-210b0cfa2e42": {"__data__": {"id_": "4f9cf1e1-6852-4164-9dd9-210b0cfa2e42", "embedding": null, "metadata": {"window": "Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers. ", "original_text": "A \nThanks, Charles. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b30a1e8f-7f70-4c44-b25b-dccb908ab33e", "node_type": "1", "metadata": {"window": "Can you give us a sense of what the life cycle typically is for prior auths?  Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "59b0f0fdcb610646fb9d081947c43336a5fbbef3b01ccbdee97c94a73c6060e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99c516bf-6494-4353-a6fa-4c412d415014", "node_type": "1", "metadata": {"window": "And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment. ", "original_text": "I'll start, and Britt, as always, feel free to add on. "}, "hash": "95c7e9761cd9b0ad5bf840e19c7670a2d7cf6e73ef110b022d0eb01229aaa2b9", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks, Charles. ", "start_char_idx": 1740, "end_char_idx": 1760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99c516bf-6494-4353-a6fa-4c412d415014": {"__data__": {"id_": "99c516bf-6494-4353-a6fa-4c412d415014", "embedding": null, "metadata": {"window": "And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment. ", "original_text": "I'll start, and Britt, as always, feel free to add on. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f9cf1e1-6852-4164-9dd9-210b0cfa2e42", "node_type": "1", "metadata": {"window": "Over time as products \nmature, what does that activity looks like?  And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers. ", "original_text": "A \nThanks, Charles. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2977f3070575ed71e75e3785307f0cc88b302cd6d4848ca5519da543dc3b7a18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ea82c4b-958a-4ddd-8941-681a5e4b158a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization. ", "original_text": "First off, we're very pleas ed with the solutions \nthat we have in this segment. "}, "hash": "36c146dcd145821f4ac02e384f3a759d4c1c7520af39a067e3859de6629111ad", "class_name": "RelatedNodeInfo"}}, "text": "I'll start, and Britt, as always, feel free to add on. ", "start_char_idx": 1760, "end_char_idx": 1815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ea82c4b-958a-4ddd-8941-681a5e4b158a": {"__data__": {"id_": "2ea82c4b-958a-4ddd-8941-681a5e4b158a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization. ", "original_text": "First off, we're very pleas ed with the solutions \nthat we have in this segment. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99c516bf-6494-4353-a6fa-4c412d415014", "node_type": "1", "metadata": {"window": "And maybe give us a sen se for what you kind of expect right now, \nparticularly in this the GLP -1 category?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment. ", "original_text": "I'll start, and Britt, as always, feel free to add on. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4fa771cbaecbd5dc1d7fc47dc1add8222e0a05bc084ae23919fb43e5cb095e5f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bae626ff-b13d-4d64-9808-c4bd9146d008", "node_type": "1", "metadata": {"window": "A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there. ", "original_text": "We think the growth over the last several quarters demonstrates the value that they \nbring to providers. "}, "hash": "fd80a57cc2782cbabe929c87eee3a2aa4c8ea2dc5e4e9bb80b89042822a98af8", "class_name": "RelatedNodeInfo"}}, "text": "First off, we're very pleas ed with the solutions \nthat we have in this segment. ", "start_char_idx": 1815, "end_char_idx": 1896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bae626ff-b13d-4d64-9808-c4bd9146d008": {"__data__": {"id_": "bae626ff-b13d-4d64-9808-c4bd9146d008", "embedding": null, "metadata": {"window": "A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there. ", "original_text": "We think the growth over the last several quarters demonstrates the value that they \nbring to providers. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ea82c4b-958a-4ddd-8941-681a5e4b158a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization. ", "original_text": "First off, we're very pleas ed with the solutions \nthat we have in this segment. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c90323886774566451689a35a1150b7e7fb62976d56f26ba25175e59496a6799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0ff796f-1e15-47fd-ab3b-2487a2ad0c23", "node_type": "1", "metadata": {"window": "I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business. ", "original_text": "Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment. "}, "hash": "feaca9f77b854725b862187715e9fe86718ce4451485bbedc40868e4eb8db02c", "class_name": "RelatedNodeInfo"}}, "text": "We think the growth over the last several quarters demonstrates the value that they \nbring to providers. ", "start_char_idx": 1896, "end_char_idx": 2001, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0ff796f-1e15-47fd-ab3b-2487a2ad0c23": {"__data__": {"id_": "f0ff796f-1e15-47fd-ab3b-2487a2ad0c23", "embedding": null, "metadata": {"window": "I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business. ", "original_text": "Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bae626ff-b13d-4d64-9808-c4bd9146d008", "node_type": "1", "metadata": {"window": "A \nThanks, Charles.  I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there. ", "original_text": "We think the growth over the last several quarters demonstrates the value that they \nbring to providers. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68f6682a9ce01d1cb3ffb646123fa316aff4a0eef776594626cddd74b03d3b81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b575f828-5395-4d6d-8650-4dff320822cd", "node_type": "1", "metadata": {"window": "First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n", "original_text": "They typically require prior authorization. "}, "hash": "7875de2f235d12e94a9f4781601d146aa19f996434b291648819ba1f5da24edd", "class_name": "RelatedNodeInfo"}}, "text": "Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment. ", "start_char_idx": 2001, "end_char_idx": 2117, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b575f828-5395-4d6d-8650-4dff320822cd": {"__data__": {"id_": "b575f828-5395-4d6d-8650-4dff320822cd", "embedding": null, "metadata": {"window": "First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n", "original_text": "They typically require prior authorization. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0ff796f-1e15-47fd-ab3b-2487a2ad0c23", "node_type": "1", "metadata": {"window": "I'll start, and Britt, as always, feel free to add on.  First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business. ", "original_text": "Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bedf4e109f5900b0f959b9f47887845ca52c9f3cc61b1482c4516cf12c180712", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ec0b957-575e-4964-a929-f273a0733868", "node_type": "1", "metadata": {"window": "We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us. ", "original_text": "We have automated solutions there. "}, "hash": "764f584d6ae507cf7e6a9430d26d2559830d31bda0cf36d56b551b67e132eb74", "class_name": "RelatedNodeInfo"}}, "text": "They typically require prior authorization. ", "start_char_idx": 2117, "end_char_idx": 2161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ec0b957-575e-4964-a929-f273a0733868": {"__data__": {"id_": "8ec0b957-575e-4964-a929-f273a0733868", "embedding": null, "metadata": {"window": "We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us. ", "original_text": "We have automated solutions there. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b575f828-5395-4d6d-8650-4dff320822cd", "node_type": "1", "metadata": {"window": "First off, we're very pleas ed with the solutions \nthat we have in this segment.  We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n", "original_text": "They typically require prior authorization. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7519d4203ff3e4ad138543c3b6b753efbffb8411ffe08add19b93f28c980e5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc2f6a6c-9dbb-4ca4-816a-7b5670db0fd6", "node_type": "1", "metadata": {"window": "Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n", "original_text": "So, as those \nvolumes grow, that's generally good for this business. "}, "hash": "f87d87bf54ef7872e1674c70bde053d630821ebcf9a4bb193b02ea2fde10f9ee", "class_name": "RelatedNodeInfo"}}, "text": "We have automated solutions there. ", "start_char_idx": 2161, "end_char_idx": 2196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc2f6a6c-9dbb-4ca4-816a-7b5670db0fd6": {"__data__": {"id_": "cc2f6a6c-9dbb-4ca4-816a-7b5670db0fd6", "embedding": null, "metadata": {"window": "Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n", "original_text": "So, as those \nvolumes grow, that's generally good for this business. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ec0b957-575e-4964-a929-f273a0733868", "node_type": "1", "metadata": {"window": "We think the growth over the last several quarters demonstrates the value that they \nbring to providers.  Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us. ", "original_text": "We have automated solutions there. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a4022f7d265da094d349393db33934327ee8762659ce86507d0b6d8e33f7ced", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "062011cf-a6cf-432a-8c96-b1284fddbbf6", "node_type": "1", "metadata": {"window": "They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to. ", "original_text": "The GLP -1s were a strong contributor in the current \nquarter.  \n \n"}, "hash": "fa91150073de8ffd84f6c2b0a93a1299020d2a2ab2b795c953632d0810b75e5d", "class_name": "RelatedNodeInfo"}}, "text": "So, as those \nvolumes grow, that's generally good for this business. ", "start_char_idx": 2196, "end_char_idx": 2265, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "062011cf-a6cf-432a-8c96-b1284fddbbf6": {"__data__": {"id_": "062011cf-a6cf-432a-8c96-b1284fddbbf6", "embedding": null, "metadata": {"window": "They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to. ", "original_text": "The GLP -1s were a strong contributor in the current \nquarter.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc2f6a6c-9dbb-4ca4-816a-7b5670db0fd6", "node_type": "1", "metadata": {"window": "Just as a reminder, this segment, new brand launches, particularly high -cost drugs, are drivers \nfor this segment.  They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n", "original_text": "So, as those \nvolumes grow, that's generally good for this business. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43160ca2f4e10efa6db3be2aadc1ef8404ccf33fe2dd2fc0a10c3079cb3b4877", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1630b878-5ef6-4df3-bae9-000ad74b14da", "node_type": "1", "metadata": {"window": "We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work. ", "original_text": "How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us. "}, "hash": "032ed8277c81f119abc413a9a40b23729ceae2cfb3e8a6579642ec2e3de97a2d", "class_name": "RelatedNodeInfo"}}, "text": "The GLP -1s were a strong contributor in the current \nquarter.  \n \n", "start_char_idx": 2265, "end_char_idx": 2332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1630b878-5ef6-4df3-bae9-000ad74b14da": {"__data__": {"id_": "1630b878-5ef6-4df3-bae9-000ad74b14da", "embedding": null, "metadata": {"window": "We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work. ", "original_text": "How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "062011cf-a6cf-432a-8c96-b1284fddbbf6", "node_type": "1", "metadata": {"window": "They typically require prior authorization.  We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to. ", "original_text": "The GLP -1s were a strong contributor in the current \nquarter.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "702dfc27129d8f385a48ce64e80af11b115dce5bb63eca31ba21bca4e294bdb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b5e665f-e391-4c56-b861-71fa0acf63db", "node_type": "1", "metadata": {"window": "So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work. ", "original_text": "And that's to the blizzard season. \n"}, "hash": "b86706928c0b1ef0560f530f37d5e1203266b222ee626fa9dd90aa3cd233d1eb", "class_name": "RelatedNodeInfo"}}, "text": "How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us. ", "start_char_idx": 2332, "end_char_idx": 2530, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b5e665f-e391-4c56-b861-71fa0acf63db": {"__data__": {"id_": "8b5e665f-e391-4c56-b861-71fa0acf63db", "embedding": null, "metadata": {"window": "So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work. ", "original_text": "And that's to the blizzard season. \n", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1630b878-5ef6-4df3-bae9-000ad74b14da", "node_type": "1", "metadata": {"window": "We have automated solutions there.  So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work. ", "original_text": "How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80b50a3e269a878303d9842f728c6215098df917550a105989ede47525495d5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f236f191-e810-4a83-941c-711143ef8219", "node_type": "1", "metadata": {"window": "The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n ", "original_text": "I'm pleased to say it played out in accordance to how we e xpected it to. "}, "hash": "6a14505b0eabacb0ebe97d6d0bbd3e75f484c30e5c4e6834a5d0998a78b42c65", "class_name": "RelatedNodeInfo"}}, "text": "And that's to the blizzard season. \n", "start_char_idx": 2530, "end_char_idx": 2566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f236f191-e810-4a83-941c-711143ef8219": {"__data__": {"id_": "f236f191-e810-4a83-941c-711143ef8219", "embedding": null, "metadata": {"window": "The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n ", "original_text": "I'm pleased to say it played out in accordance to how we e xpected it to. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b5e665f-e391-4c56-b861-71fa0acf63db", "node_type": "1", "metadata": {"window": "So, as those \nvolumes grow, that's generally good for this business.  The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work. ", "original_text": "And that's to the blizzard season. \n", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b0204aead998389bcfda94bc6b7b77e7d2932ad4c0aeda3f8c0c150a652f2456", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3615b977-0fea-42eb-8809-02ea24aba08f", "node_type": "1", "metadata": {"window": "How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's a lot of work. "}, "hash": "1e61cb1e272ba5c1cec52e62ec62f85900847c216c6379005c508b08d6c7fe54", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased to say it played out in accordance to how we e xpected it to. ", "start_char_idx": 2566, "end_char_idx": 2640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3615b977-0fea-42eb-8809-02ea24aba08f": {"__data__": {"id_": "3615b977-0fea-42eb-8809-02ea24aba08f", "embedding": null, "metadata": {"window": "How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's a lot of work. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f236f191-e810-4a83-941c-711143ef8219", "node_type": "1", "metadata": {"window": "The GLP -1s were a strong contributor in the current \nquarter.  \n \n How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n ", "original_text": "I'm pleased to say it played out in accordance to how we e xpected it to. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0c6c4fed80e9567bf7c9930917f407e985ef3ac4aad34500b4666119be743b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5408f33-ecf0-4eb9-8c48-1f2ba0db97be", "node_type": "1", "metadata": {"window": "And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "The team really put their \nhead down, had a good plan, and is pushing through that work. "}, "hash": "f95ebc19d9350340d861d491c3ea7998fed92a1d1ebd68c8bfd531c2b99de4be", "class_name": "RelatedNodeInfo"}}, "text": "It's a lot of work. ", "start_char_idx": 2640, "end_char_idx": 2660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5408f33-ecf0-4eb9-8c48-1f2ba0db97be": {"__data__": {"id_": "a5408f33-ecf0-4eb9-8c48-1f2ba0db97be", "embedding": null, "metadata": {"window": "And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "The team really put their \nhead down, had a good plan, and is pushing through that work. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3615b977-0fea-42eb-8809-02ea24aba08f", "node_type": "1", "metadata": {"window": "How the programs evolve will larg ely be dependent on payer decisions in terms of how frequently they require an \nauthorization or a reauthorization, but certainly it's been a good tailwind for us.  And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "It's a lot of work. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be00d47d4d7ebda901a9998e125c35ad778051cb185606eb6dd1e251c9b21b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ac6805d-7b66-4a95-99ef-5e22878970f6", "node_type": "1", "metadata": {"window": "I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n "}, "hash": "9ed7d9d201bbddc84c46ce75445ce6d387967f003cddd5a4b854f96d16ff1bf3", "class_name": "RelatedNodeInfo"}}, "text": "The team really put their \nhead down, had a good plan, and is pushing through that work. ", "start_char_idx": 2660, "end_char_idx": 2749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ac6805d-7b66-4a95-99ef-5e22878970f6": {"__data__": {"id_": "7ac6805d-7b66-4a95-99ef-5e22878970f6", "embedding": null, "metadata": {"window": "I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5408f33-ecf0-4eb9-8c48-1f2ba0db97be", "node_type": "1", "metadata": {"window": "And that's to the blizzard season. \n I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "The team really put their \nhead down, had a good plan, and is pushing through that work. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50b524faeeef9f43a85846c46722c5de6f90a93ae32512387281f83acf7e2b31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc2123af-2550-40b1-a499-61afc35984f0", "node_type": "1", "metadata": {"window": "It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "4bfced87484c06b2708597c9f2a68e15bc931c3475299ef783e0ab1e53965ded", "class_name": "RelatedNodeInfo"}}, "text": "And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n ", "start_char_idx": 2749, "end_char_idx": 2880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc2123af-2550-40b1-a499-61afc35984f0": {"__data__": {"id_": "bc2123af-2550-40b1-a499-61afc35984f0", "embedding": null, "metadata": {"window": "It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ac6805d-7b66-4a95-99ef-5e22878970f6", "node_type": "1", "metadata": {"window": "I'm pleased to say it played out in accordance to how we e xpected it to.  It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "original_text": "And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2255b56025606298bf99687f1b601f54aa4641a3b6bb9787193f14ec8549e3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b790c4f7-b807-4a74-a825-84742e25d789", "node_type": "1", "metadata": {"window": "The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please?  \n "}, "hash": "e79fcce38c440380cc0d6c0d25ff0b3bbdb471b5f0995a1a5cfeae03b074dda7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 2880, "end_char_idx": 3226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b790c4f7-b807-4a74-a825-84742e25d789": {"__data__": {"id_": "b790c4f7-b807-4a74-a825-84742e25d789", "embedding": null, "metadata": {"window": "The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please?  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc2123af-2550-40b1-a499-61afc35984f0", "node_type": "1", "metadata": {"window": "It's a lot of work.  The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2014b4632cd526dc7dacb32fbb463f5bbf8fc2f27daab45e6169dd3722a00d16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa020700-75cf-4093-8599-9d2adcd23417", "node_type": "1", "metadata": {"window": "And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. "}, "hash": "00e10f9bba2d017dc4f3b94c01d1a4ea979afaf0a5001d066976779ca10cdf99", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 3226, "end_char_idx": 3255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa020700-75cf-4093-8599-9d2adcd23417": {"__data__": {"id_": "fa020700-75cf-4093-8599-9d2adcd23417", "embedding": null, "metadata": {"window": "And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b790c4f7-b807-4a74-a825-84742e25d789", "node_type": "1", "metadata": {"window": "The team really put their \nhead down, had a good plan, and is pushing through that work.  And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "original_text": "A \nNext question, please?  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7dfdb72cdd7f4f0e0d3809ee9b270c18a5fa1c831f1f26790f6394302f5b197", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7f81ed3-1024-4f35-84a5-03ca20328168", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year. ", "original_text": "Please go ahead.  \n "}, "hash": "dd33e4504180ad10a114199253256268faab13782a8106f5ddd3617873ccef48", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "start_char_idx": 3255, "end_char_idx": 3593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7f81ed3-1024-4f35-84a5-03ca20328168": {"__data__": {"id_": "a7f81ed3-1024-4f35-84a5-03ca20328168", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa020700-75cf-4093-8599-9d2adcd23417", "node_type": "1", "metadata": {"window": "And we're very confident, we'll end this blizzard \nseason more or less in line with our expectations at the outset of the year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89a98076db54a26cf2012ec47a13f80083f50b28c6eb1af0a359b5d028092a18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a3fa3f4-1c9d-44d9-984c-689253acbe07", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "c0fec451dc0b9c72372c8beebc108678f2cda6eed6d6f7cd38f8ddb04bc00fe2", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 331, "end_char_idx": 351, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a3fa3f4-1c9d-44d9-984c-689253acbe07": {"__data__": {"id_": "7a3fa3f4-1c9d-44d9-984c-689253acbe07", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7f81ed3-1024-4f35-84a5-03ca20328168", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRach el Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year. ", "original_text": "Please go ahead.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "161870b37a5e0128a5980f9efa95a959a069f4a951bd960fc5f516f06ed666e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "384b9944-febf-4c10-9ae6-95db51117e04", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n ", "original_text": "I appreciate the 2025 initial commentary, and I wanted to focus in on specialty. "}, "hash": "ad50f6f291c3ef79c7f984ef6ef27fa2e9eaba0f8f4ec4a5630d77683d488899", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 3613, "end_char_idx": 3945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "384b9944-febf-4c10-9ae6-95db51117e04": {"__data__": {"id_": "384b9944-febf-4c10-9ae6-95db51117e04", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n ", "original_text": "I appreciate the 2025 initial commentary, and I wanted to focus in on specialty. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a3fa3f4-1c9d-44d9-984c-689253acbe07", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81f7fd401831245f0a763dc5cd3b4ce0d4f448f17e2bb70ffcf93da90f2c7a2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a6d00be-7887-4b8c-8cbb-d360b5668105", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year. "}, "hash": "076e5d152beb63a174df6a4b03976987856049837b1f43972c4b3d2a5389ede0", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate the 2025 initial commentary, and I wanted to focus in on specialty. ", "start_char_idx": 3945, "end_char_idx": 4026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a6d00be-7887-4b8c-8cbb-d360b5668105": {"__data__": {"id_": "1a6d00be-7887-4b8c-8cbb-d360b5668105", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "384b9944-febf-4c10-9ae6-95db51117e04", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Percher with Nephron Research.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n ", "original_text": "I appreciate the 2025 initial commentary, and I wanted to focus in on specialty. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0d885211da1c98438bd7bb669ab8a9564ec8939f320bb056c378fcab4dabe18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83d06875-b556-42b6-ba2f-07a083cc2554", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty? "}, "hash": "aef3bfb08c288b2c71042c12242c5332ecbfd1e2873f8e19ba340d6057aad047", "class_name": "RelatedNodeInfo"}}, "text": "I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year. ", "start_char_idx": 4026, "end_char_idx": 4136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83d06875-b556-42b6-ba2f-07a083cc2554": {"__data__": {"id_": "83d06875-b556-42b6-ba2f-07a083cc2554", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty? ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a6d00be-7887-4b8c-8cbb-d360b5668105", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year. ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "634fa8d8aef245a1013d997829767850bd06a52e78555f9266c6527cec350fac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0746af92-3685-4f8b-a8c0-b17538525f62", "node_type": "1", "metadata": {"window": "I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n "}, "hash": "88c234b9f389692e7f55e7567c3acc14d596b8408221b4b299bcded11fa4639d", "class_name": "RelatedNodeInfo"}}, "text": "And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty? ", "start_char_idx": 4136, "end_char_idx": 4288, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0746af92-3685-4f8b-a8c0-b17538525f62": {"__data__": {"id_": "0746af92-3685-4f8b-a8c0-b17538525f62", "embedding": null, "metadata": {"window": "I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83d06875-b556-42b6-ba2f-07a083cc2554", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty? ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "810cef486a94d95575f89341672e4bde3dc63875c4576092d2aaa7268dfad3b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45a0c71e-efe6-478a-97d4-93b6ac36eb86", "node_type": "1", "metadata": {"window": "I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "c642df67e40e5886b9ba9b1042c0515d1ca8087fb078c4e3bb6ae6f4e64594ce", "class_name": "RelatedNodeInfo"}}, "text": "And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n ", "start_char_idx": 4288, "end_char_idx": 4453, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45a0c71e-efe6-478a-97d4-93b6ac36eb86": {"__data__": {"id_": "45a0c71e-efe6-478a-97d4-93b6ac36eb86", "embedding": null, "metadata": {"window": "I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a4bb6263195cfd38cec431c37ef99734c52619c970e7dbc03889bc4b6d50998", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0746af92-3685-4f8b-a8c0-b17538525f62", "node_type": "1", "metadata": {"window": "I appreciate the 2025 initial commentary, and I wanted to focus in on specialty.  I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "558979e02747de122337521bfda7ea209af90cb91095b3b7ed1c79cc8727b9a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8fe945d-d14a-4c55-bb23-aa9d79d205f8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices. ", "original_text": "McKesson Corp.  "}, "hash": "512a94302476ed93b47cb309ece32e26b17d4f568b79c4350ade76979ca674dc", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 351, "end_char_idx": 622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8fe945d-d14a-4c55-bb23-aa9d79d205f8": {"__data__": {"id_": "f8fe945d-d14a-4c55-bb23-aa9d79d205f8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45a0c71e-efe6-478a-97d4-93b6ac36eb86", "node_type": "1", "metadata": {"window": "I thought coming out of \nthe pandemic, we saw elevated growth and you're calling out higher growth this year.  And I'd like to understand \nhow much of that is organic growth versus gaining of share an d beyond oncology, an increase of share in multi -\nspecialty?  And then finally, I'd ask for those practices you're acquiring now, I think you've known them for quite \nsome time, what is it that's driving them to join today?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "686243db1e0c08eb9c7917bef7376a072969076470d15da64893b1ae2c10da59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72848a64-73d5-4cd1-96d6-6143828378d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  "}, "hash": "3f7c29bd7f77744a587866fbc6f40836116e0c355a3c3a81d53bb989a20a7716", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72848a64-73d5-4cd1-96d6-6143828378d1": {"__data__": {"id_": "72848a64-73d5-4cd1-96d6-6143828378d1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8fe945d-d14a-4c55-bb23-aa9d79d205f8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c49b9fb026c06ed8d63b6b0c0913084c626435284d069d1aafcfe802c7b8f0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "686b4d3d-8845-466e-aae0-6a114365305b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have. ", "original_text": "A \nLet me start. "}, "hash": "00e84a69131eb5a9bb8eea1ebfe717a9f4d5bc928eaf6a4b9bda301c257efa84", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "686b4d3d-8845-466e-aae0-6a114365305b": {"__data__": {"id_": "686b4d3d-8845-466e-aae0-6a114365305b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have. ", "original_text": "A \nLet me start. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72848a64-73d5-4cd1-96d6-6143828378d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d0aea94f6dba5cf0a29cd4ed7f886d4a2e506bfc1760c3ba53b5ef4730074c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97374d8b-bcd0-4dc8-aaa8-01a164f4a184", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice. ", "original_text": "I guess I'll start where you ended with the practices. "}, "hash": "e6df009cdc2373462850a4e9e4ba4fc81242767bf2b671fadfaae45fc87eb1a1", "class_name": "RelatedNodeInfo"}}, "text": "A \nLet me start. ", "start_char_idx": 254, "end_char_idx": 271, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97374d8b-bcd0-4dc8-aaa8-01a164f4a184": {"__data__": {"id_": "97374d8b-bcd0-4dc8-aaa8-01a164f4a184", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice. ", "original_text": "I guess I'll start where you ended with the practices. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "686b4d3d-8845-466e-aae0-6a114365305b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have. ", "original_text": "A \nLet me start. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3eee0cc81cd837f6187fa08857fe9c10270067cef3f10c123b9c593a937d04e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "522b9300-5d5f-44fd-95ce-eeaa1401b0c7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices. ", "original_text": "First thing I think I would say is, we are very \npleased with the solid growth in our same store. "}, "hash": "464eb1b022ce1cfcd5fde8605d601b1c687f2ef55f7221961c6d446b1bface3e", "class_name": "RelatedNodeInfo"}}, "text": "I guess I'll start where you ended with the practices. ", "start_char_idx": 271, "end_char_idx": 326, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "522b9300-5d5f-44fd-95ce-eeaa1401b0c7": {"__data__": {"id_": "522b9300-5d5f-44fd-95ce-eeaa1401b0c7", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices. ", "original_text": "First thing I think I would say is, we are very \npleased with the solid growth in our same store. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97374d8b-bcd0-4dc8-aaa8-01a164f4a184", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice. ", "original_text": "I guess I'll start where you ended with the practices. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b18f2ce00b9f1ebc69953b16ac66c06e2c28bf4b0d7c81ed3d535d281353eb39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "69712870-cb52-4772-b146-1a5b8379cdd4", "node_type": "1", "metadata": {"window": "A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n", "original_text": "We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have. "}, "hash": "6ac7eb9d16f0ae0ae50056730d1c43fc4bc53cfb055bb88e291136c3e5659701", "class_name": "RelatedNodeInfo"}}, "text": "First thing I think I would say is, we are very \npleased with the solid growth in our same store. ", "start_char_idx": 326, "end_char_idx": 424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "69712870-cb52-4772-b146-1a5b8379cdd4": {"__data__": {"id_": "69712870-cb52-4772-b146-1a5b8379cdd4", "embedding": null, "metadata": {"window": "A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n", "original_text": "We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "522b9300-5d5f-44fd-95ce-eeaa1401b0c7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices. ", "original_text": "First thing I think I would say is, we are very \npleased with the solid growth in our same store. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d38e6d171172b717545306a5ec6de369124560bf96ffcf7a7cb9136f597ca03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c730e6f6-b620-46b0-a264-9260bd1cdd03", "node_type": "1", "metadata": {"window": "I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network. ", "original_text": "We could \ngreenfield the new practice. "}, "hash": "57f7cc3a20b4cf26d0e5871f143ab7a41bc3d16b8b2f87a0fec96ac3c45e9dbf", "class_name": "RelatedNodeInfo"}}, "text": "We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have. ", "start_char_idx": 424, "end_char_idx": 579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c730e6f6-b620-46b0-a264-9260bd1cdd03": {"__data__": {"id_": "c730e6f6-b620-46b0-a264-9260bd1cdd03", "embedding": null, "metadata": {"window": "I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network. ", "original_text": "We could \ngreenfield the new practice. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "69712870-cb52-4772-b146-1a5b8379cdd4", "node_type": "1", "metadata": {"window": "A \nLet me start.  I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n", "original_text": "We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4117e1c17f781bf7aa8d271f378ec8b3d99ff211b7ca7191522352054ded56fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6463a506-1846-4265-8955-367e2f23ddfa", "node_type": "1", "metadata": {"window": "First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years. ", "original_text": "We did onboard new practices. "}, "hash": "08747c2368bbfa110636df3b6b228579666da02ef45c090d79e853450ec5bea8", "class_name": "RelatedNodeInfo"}}, "text": "We could \ngreenfield the new practice. ", "start_char_idx": 579, "end_char_idx": 618, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6463a506-1846-4265-8955-367e2f23ddfa": {"__data__": {"id_": "6463a506-1846-4265-8955-367e2f23ddfa", "embedding": null, "metadata": {"window": "First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years. ", "original_text": "We did onboard new practices. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c730e6f6-b620-46b0-a264-9260bd1cdd03", "node_type": "1", "metadata": {"window": "I guess I'll start where you ended with the practices.  First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network. ", "original_text": "We could \ngreenfield the new practice. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c29022048a144533c50cf4e7a7a1d9513b91e0371b6254755d9edfc5d426ceaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08ea544f-71f6-4fa9-ae9e-8da4e524c8d0", "node_type": "1", "metadata": {"window": "We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n", "original_text": "And really, we've been benefiting over the last few \nyears from all three of those.  \n \n"}, "hash": "56e2e797ef872ce755362e128d92b3de2c8f7c2c0370f5d187e45ddd476829da", "class_name": "RelatedNodeInfo"}}, "text": "We did onboard new practices. ", "start_char_idx": 618, "end_char_idx": 648, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08ea544f-71f6-4fa9-ae9e-8da4e524c8d0": {"__data__": {"id_": "08ea544f-71f6-4fa9-ae9e-8da4e524c8d0", "embedding": null, "metadata": {"window": "We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n", "original_text": "And really, we've been benefiting over the last few \nyears from all three of those.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6463a506-1846-4265-8955-367e2f23ddfa", "node_type": "1", "metadata": {"window": "First thing I think I would say is, we are very \npleased with the solid growth in our same store.  We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years. ", "original_text": "We did onboard new practices. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd9eac19412db26c55a169a8d02dd34f26a6b4b63ef7801007c99a43d54e4ca7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1b48df6-2eac-4f46-a0be-0a6c6dfef4dc", "node_type": "1", "metadata": {"window": "We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that? ", "original_text": "We have been very pleased with our ability to attract new members to The US Oncology Network. "}, "hash": "2281d163df78bb1cbbeb6105bd966f4e57ae03f4f5f510cac027a7e7f8400e0f", "class_name": "RelatedNodeInfo"}}, "text": "And really, we've been benefiting over the last few \nyears from all three of those.  \n \n", "start_char_idx": 648, "end_char_idx": 736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1b48df6-2eac-4f46-a0be-0a6c6dfef4dc": {"__data__": {"id_": "e1b48df6-2eac-4f46-a0be-0a6c6dfef4dc", "embedding": null, "metadata": {"window": "We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that? ", "original_text": "We have been very pleased with our ability to attract new members to The US Oncology Network. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08ea544f-71f6-4fa9-ae9e-8da4e524c8d0", "node_type": "1", "metadata": {"window": "We can obviously grow our US Oncology Network in mu ltiple \nways, we can add \u2013 we could add oncologists or providers to an existing practice that we have.  We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n", "original_text": "And really, we've been benefiting over the last few \nyears from all three of those.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a246c2bc56da410c6e8b8306420aa44d78d1914eb0c0fb70ea6120da009f67d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b973d9b-9c36-4658-b67d-8c911a391d3a", "node_type": "1", "metadata": {"window": "We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management. ", "original_text": "We've added, I \ndon't know, 500 or 600 providers over the last couple of years. "}, "hash": "929e46b0f8ac05ccd2e6ce12e11df2be6381603975fcac924bb0309369a49ae8", "class_name": "RelatedNodeInfo"}}, "text": "We have been very pleased with our ability to attract new members to The US Oncology Network. ", "start_char_idx": 736, "end_char_idx": 830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b973d9b-9c36-4658-b67d-8c911a391d3a": {"__data__": {"id_": "6b973d9b-9c36-4658-b67d-8c911a391d3a", "embedding": null, "metadata": {"window": "We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management. ", "original_text": "We've added, I \ndon't know, 500 or 600 providers over the last couple of years. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1b48df6-2eac-4f46-a0be-0a6c6dfef4dc", "node_type": "1", "metadata": {"window": "We could \ngreenfield the new practice.  We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that? ", "original_text": "We have been very pleased with our ability to attract new members to The US Oncology Network. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0ea83323c444d0deaca049a23f3515d28383ecfaee15716247689f3152bd4e8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33738b0e-56a3-4db5-99e8-87c87c813f61", "node_type": "1", "metadata": {"window": "And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years. ", "original_text": "We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n"}, "hash": "ba8486a1911f6281d06043813c2034c845ae4bb1eb6fbe5591ff2a4bdf9f707f", "class_name": "RelatedNodeInfo"}}, "text": "We've added, I \ndon't know, 500 or 600 providers over the last couple of years. ", "start_char_idx": 830, "end_char_idx": 910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33738b0e-56a3-4db5-99e8-87c87c813f61": {"__data__": {"id_": "33738b0e-56a3-4db5-99e8-87c87c813f61", "embedding": null, "metadata": {"window": "And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years. ", "original_text": "We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b973d9b-9c36-4658-b67d-8c911a391d3a", "node_type": "1", "metadata": {"window": "We did onboard new practices.  And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management. ", "original_text": "We've added, I \ndon't know, 500 or 600 providers over the last couple of years. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b678e4412b6a5a25eb75f8dbb2fe6c88a5d0c3e9cb6f9c34ee400d23cdb7e6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d834054-eb51-4c51-afae-ec923ce2f9d1", "node_type": "1", "metadata": {"window": "We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR. ", "original_text": "Why are we able to do that? "}, "hash": "51dc837f7adbe2d6e71583d603d0a8608ef6a79936466124d87e588455d41388", "class_name": "RelatedNodeInfo"}}, "text": "We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n", "start_char_idx": 910, "end_char_idx": 1030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d834054-eb51-4c51-afae-ec923ce2f9d1": {"__data__": {"id_": "5d834054-eb51-4c51-afae-ec923ce2f9d1", "embedding": null, "metadata": {"window": "We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR. ", "original_text": "Why are we able to do that? ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33738b0e-56a3-4db5-99e8-87c87c813f61", "node_type": "1", "metadata": {"window": "And really, we've been benefiting over the last few \nyears from all three of those.  \n \n We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years. ", "original_text": "We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84483b54eb556e0e01b8451eae69813e1c542a93be77a13464ab4ae31c91543d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "caa529e5-0f2b-4cd7-85c0-06c108e659d1", "node_type": "1", "metadata": {"window": "We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies. ", "original_text": "We think it's not just great practice management. "}, "hash": "7f9c7212501d096f1e9d0b2d67125d8a8e026a36f8acf03843fda0063ef95af6", "class_name": "RelatedNodeInfo"}}, "text": "Why are we able to do that? ", "start_char_idx": 1030, "end_char_idx": 1058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "caa529e5-0f2b-4cd7-85c0-06c108e659d1": {"__data__": {"id_": "caa529e5-0f2b-4cd7-85c0-06c108e659d1", "embedding": null, "metadata": {"window": "We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies. ", "original_text": "We think it's not just great practice management. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d834054-eb51-4c51-afae-ec923ce2f9d1", "node_type": "1", "metadata": {"window": "We have been very pleased with our ability to attract new members to The US Oncology Network.  We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR. ", "original_text": "Why are we able to do that? ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dab714e76ebcbcdd903612d0188e5cd4924d060fbb3b6b5f8da5447800cc3c63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa9ca713-b549-42c7-873d-c525fceda67d", "node_type": "1", "metadata": {"window": "We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead. ", "original_text": "We've been at this for 15 years. "}, "hash": "b151482704b92c6369ed3c8d850e5846e016d67d513d099d426ac7d32c595e77", "class_name": "RelatedNodeInfo"}}, "text": "We think it's not just great practice management. ", "start_char_idx": 1058, "end_char_idx": 1108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa9ca713-b549-42c7-873d-c525fceda67d": {"__data__": {"id_": "aa9ca713-b549-42c7-873d-c525fceda67d", "embedding": null, "metadata": {"window": "We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead. ", "original_text": "We've been at this for 15 years. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "caa529e5-0f2b-4cd7-85c0-06c108e659d1", "node_type": "1", "metadata": {"window": "We've added, I \ndon't know, 500 or 600 providers over the last couple of years.  We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies. ", "original_text": "We think it's not just great practice management. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a32524048a3f0eacfec440af70516c941908621fe573659cf6a2626a5a20f24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dad46a9f-329f-4a97-84e3-92a01ea78c2d", "node_type": "1", "metadata": {"window": "Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers. ", "original_text": "So \nwe've got a leading EMR. "}, "hash": "9cd1391ba28b0df24afe5bb2eba0bfe9c40d6318fd26fa8c3dbe2ae9c3ab5119", "class_name": "RelatedNodeInfo"}}, "text": "We've been at this for 15 years. ", "start_char_idx": 1108, "end_char_idx": 1141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dad46a9f-329f-4a97-84e3-92a01ea78c2d": {"__data__": {"id_": "dad46a9f-329f-4a97-84e3-92a01ea78c2d", "embedding": null, "metadata": {"window": "Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers. ", "original_text": "So \nwe've got a leading EMR. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa9ca713-b549-42c7-873d-c525fceda67d", "node_type": "1", "metadata": {"window": "We've entered into six new \u2013 we added six new \npractices and eight new geographies ove r the calendar year of 2023.  \n \n Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead. ", "original_text": "We've been at this for 15 years. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68c72131284264d8defc60751e488ba89d58617463d1e937c19fef2498cf16b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbdbdf78-f0bc-4b1a-a962-169d8fb83f9a", "node_type": "1", "metadata": {"window": "We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities. ", "original_text": "We've got leading technologies. "}, "hash": "be859eb00a0c5a479c765170c529a0f96526936a2f6c76e26a47e244a51e2f0a", "class_name": "RelatedNodeInfo"}}, "text": "So \nwe've got a leading EMR. ", "start_char_idx": 1141, "end_char_idx": 1170, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbdbdf78-f0bc-4b1a-a962-169d8fb83f9a": {"__data__": {"id_": "bbdbdf78-f0bc-4b1a-a962-169d8fb83f9a", "embedding": null, "metadata": {"window": "We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities. ", "original_text": "We've got leading technologies. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dad46a9f-329f-4a97-84e3-92a01ea78c2d", "node_type": "1", "metadata": {"window": "Why are we able to do that?  We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers. ", "original_text": "So \nwe've got a leading EMR. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "faf0ff40c30099cb1bf25ac3e78a13af3c8dbced61108f322abf94a7f977f709", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54869ba2-2042-4284-a332-077be571a6c6", "node_type": "1", "metadata": {"window": "We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n ", "original_text": "Britt talked about investments we're making to extend \nthat lead. "}, "hash": "f4a165059a8d5f8a77f79c96412945d4617e684fcfb58fc7bd4529fbd9a82cf1", "class_name": "RelatedNodeInfo"}}, "text": "We've got leading technologies. ", "start_char_idx": 1170, "end_char_idx": 1202, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54869ba2-2042-4284-a332-077be571a6c6": {"__data__": {"id_": "54869ba2-2042-4284-a332-077be571a6c6", "embedding": null, "metadata": {"window": "We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n ", "original_text": "Britt talked about investments we're making to extend \nthat lead. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbdbdf78-f0bc-4b1a-a962-169d8fb83f9a", "node_type": "1", "metadata": {"window": "We think it's not just great practice management.  We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities. ", "original_text": "We've got leading technologies. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a340cfb7e77d3a9074a16d9d146eabed7da1f2391497dddcf8c48def3098866c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0989a747-b1a3-4d99-8945-0130dea84e27", "node_type": "1", "metadata": {"window": "So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers. "}, "hash": "c7817e343c9f834bf72b38fa1c7fe23f00811548a263e760fc4703fbe0a3f418", "class_name": "RelatedNodeInfo"}}, "text": "Britt talked about investments we're making to extend \nthat lead. ", "start_char_idx": 1202, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0989a747-b1a3-4d99-8945-0130dea84e27": {"__data__": {"id_": "0989a747-b1a3-4d99-8945-0130dea84e27", "embedding": null, "metadata": {"window": "So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54869ba2-2042-4284-a332-077be571a6c6", "node_type": "1", "metadata": {"window": "We've been at this for 15 years.  So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n ", "original_text": "Britt talked about investments we're making to extend \nthat lead. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c951493db31174b39fcf9ac1e36930dfa1c6fdf91f5efdd7538668d8b903c14d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a99188c1-a845-4d1f-982c-ebf516591e1c", "node_type": "1", "metadata": {"window": "We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems. ", "original_text": "It includes SCRI, which brings them clinical research and trial capabilities. "}, "hash": "3f823e221a5bf2797dae17ad6e0e6d89c599754800071c4031b49610968a2b17", "class_name": "RelatedNodeInfo"}}, "text": "But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers. ", "start_char_idx": 1268, "end_char_idx": 1388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a99188c1-a845-4d1f-982c-ebf516591e1c": {"__data__": {"id_": "a99188c1-a845-4d1f-982c-ebf516591e1c", "embedding": null, "metadata": {"window": "We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems. ", "original_text": "It includes SCRI, which brings them clinical research and trial capabilities. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0989a747-b1a3-4d99-8945-0130dea84e27", "node_type": "1", "metadata": {"window": "So \nwe've got a leading EMR.  We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7b2d4caddbde3fb97879461d4f704e9119c30496031d099591c3233d58490ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3eadd9e-5633-4efb-badc-478e1a8f8c46", "node_type": "1", "metadata": {"window": "Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n", "original_text": "And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n "}, "hash": "8d5739c925f9d0110a552324946d959a0afe7ea18c182562d8c047f0dd26e928", "class_name": "RelatedNodeInfo"}}, "text": "It includes SCRI, which brings them clinical research and trial capabilities. ", "start_char_idx": 1388, "end_char_idx": 1466, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3eadd9e-5633-4efb-badc-478e1a8f8c46": {"__data__": {"id_": "a3eadd9e-5633-4efb-badc-478e1a8f8c46", "embedding": null, "metadata": {"window": "Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n", "original_text": "And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a99188c1-a845-4d1f-982c-ebf516591e1c", "node_type": "1", "metadata": {"window": "We've got leading technologies.  Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems. ", "original_text": "It includes SCRI, which brings them clinical research and trial capabilities. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5d511cb371af7590a7ba4ee86a278a07e78c74f8268d5c73693ef8713aff378", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "781ed85b-d11e-4230-bef8-65e8a68f95b5", "node_type": "1", "metadata": {"window": "But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "5bd68d8dcea298bc3d3ec031c30d2166c7527882b11603aee23e62e093679ca7", "class_name": "RelatedNodeInfo"}}, "text": "And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n ", "start_char_idx": 1466, "end_char_idx": 1620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "781ed85b-d11e-4230-bef8-65e8a68f95b5": {"__data__": {"id_": "781ed85b-d11e-4230-bef8-65e8a68f95b5", "embedding": null, "metadata": {"window": "But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3eadd9e-5633-4efb-badc-478e1a8f8c46", "node_type": "1", "metadata": {"window": "Britt talked about investments we're making to extend \nthat lead.  But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n", "original_text": "And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d784cf11fef63b6a1f801aa1bd0fe973f25e703cfcb2fbde8c9a879912f4ccdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e570362-54b1-4ef2-8b83-2c40bff2a94b", "node_type": "1", "metadata": {"window": "It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n", "original_text": "A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems. "}, "hash": "d6e7c069ac2a259de366c3d89c0ee06008c5b78c5965978469261153503b73f7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1620, "end_char_idx": 1980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e570362-54b1-4ef2-8b83-2c40bff2a94b": {"__data__": {"id_": "4e570362-54b1-4ef2-8b83-2c40bff2a94b", "embedding": null, "metadata": {"window": "It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n", "original_text": "A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "781ed85b-d11e-4230-bef8-65e8a68f95b5", "node_type": "1", "metadata": {"window": "But I think, we also have this broad ecosystem that includes Ontada, which helps us provide insights to \nour providers.  It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9f9cc08249fef2d6300441074722eb113a7328090bbff3dc8b51f492bce20162", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af673cb7-8d91-4321-b6bb-98c9dc9ca6c7", "node_type": "1", "metadata": {"window": "And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication. ", "original_text": "And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n"}, "hash": "39e7791505d5083bd00832578e053709898b9a68d9bc366b199a5cd3b00237ca", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems. ", "start_char_idx": 1980, "end_char_idx": 2196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af673cb7-8d91-4321-b6bb-98c9dc9ca6c7": {"__data__": {"id_": "af673cb7-8d91-4321-b6bb-98c9dc9ca6c7", "embedding": null, "metadata": {"window": "And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication. ", "original_text": "And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e570362-54b1-4ef2-8b83-2c40bff2a94b", "node_type": "1", "metadata": {"window": "It includes SCRI, which brings them clinical research and trial capabilities.  And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n", "original_text": "A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0b6280f00d03cd50f2d19002ca825f58a2d3de5c4cc3c7e1a1a82f879273e48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7e5e841-9ee5-4da2-8271-0105321ecabf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business. ", "original_text": "So we're seeing growth in specialty products. "}, "hash": "95bbefd4cd77aa54491213ce412c7694b3e09509dfa54c3b8aecb1f59b804d31", "class_name": "RelatedNodeInfo"}}, "text": "And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n", "start_char_idx": 2196, "end_char_idx": 2347, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7e5e841-9ee5-4da2-8271-0105321ecabf": {"__data__": {"id_": "c7e5e841-9ee5-4da2-8271-0105321ecabf", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business. ", "original_text": "So we're seeing growth in specialty products. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af673cb7-8d91-4321-b6bb-98c9dc9ca6c7", "node_type": "1", "metadata": {"window": "And so we think it's that \nreally broad value prop osition, Eric, which allows us to compel the growth we're seeing in The US Oncology \nNetwork today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication. ", "original_text": "And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "95241738764dca95978deff455399f8cf68764e467639515d237da3327c6ee2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b73661e-01b5-4bc4-99df-eb6d7dd3cbe3", "node_type": "1", "metadata": {"window": "A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n ", "original_text": "We're seeing growth across the specialty providers that we service. \n"}, "hash": "ad50045a51ebe03bc6347d141535728879b5bc1fcfd22f731ab980732a74f987", "class_name": "RelatedNodeInfo"}}, "text": "So we're seeing growth in specialty products. ", "start_char_idx": 2347, "end_char_idx": 2393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b73661e-01b5-4bc4-99df-eb6d7dd3cbe3": {"__data__": {"id_": "3b73661e-01b5-4bc4-99df-eb6d7dd3cbe3", "embedding": null, "metadata": {"window": "A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n ", "original_text": "We're seeing growth across the specialty providers that we service. \n", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7e5e841-9ee5-4da2-8271-0105321ecabf", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business. ", "original_text": "So we're seeing growth in specialty products. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "677707b12ae8756acad1b23b551bdd419c0b82ccde528f6e540f311b78712d8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e290d57-eecd-471b-b8c3-916fca8e95e0", "node_type": "1", "metadata": {"window": "And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And as I mentioned, we're also seeing significant growth from GLP -1 medication. "}, "hash": "5db172e797ae3b1f57dd9b5e114e1549821df34984b5e7d5c4dff75917f685d0", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing growth across the specialty providers that we service. \n", "start_char_idx": 2393, "end_char_idx": 2462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e290d57-eecd-471b-b8c3-916fca8e95e0": {"__data__": {"id_": "3e290d57-eecd-471b-b8c3-916fca8e95e0", "embedding": null, "metadata": {"window": "And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And as I mentioned, we're also seeing significant growth from GLP -1 medication. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b73661e-01b5-4bc4-99df-eb6d7dd3cbe3", "node_type": "1", "metadata": {"window": "A \nAnd Eric, maybe I'll just add on, when we think about specialty pro duct growth, we're certainly seeing specialty \nproduct growth across not only our largest customers, but across, as I mentioned, health systems.  And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n ", "original_text": "We're seeing growth across the specialty providers that we service. \n", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14400d91adb09ad16e2931b0ca227c792cfcc8f520cfb2383ffa34cdc0a1ea69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "283c9132-e416-40f8-805a-f29f17478163", "node_type": "1", "metadata": {"window": "So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "So, we're really waiting acro ss \nthe entirety of our scaled business. "}, "hash": "8deed8efaa4ad7335c943e3d00d7c8e0c47e80931d204ec80ea2de2306d07cfd", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned, we're also seeing significant growth from GLP -1 medication. ", "start_char_idx": 2462, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "283c9132-e416-40f8-805a-f29f17478163": {"__data__": {"id_": "283c9132-e416-40f8-805a-f29f17478163", "embedding": null, "metadata": {"window": "So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "So, we're really waiting acro ss \nthe entirety of our scaled business. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e290d57-eecd-471b-b8c3-916fca8e95e0", "node_type": "1", "metadata": {"window": "And certainly, \nas we continue to grow The US Oncology Network and oncology in general, we're certainly seeing mo re growth in \nthat area as well.  \n \n So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And as I mentioned, we're also seeing significant growth from GLP -1 medication. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16d19807c2a6e030fb73f051ad728fd393dff33b22549000b0a7e78975fc1b3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d40bbd1-50a2-4ee6-bb80-16cbf4740d19", "node_type": "1", "metadata": {"window": "We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n "}, "hash": "6dfd328715793d349a7d98fd7cb4b7a0881fcf0a6b4fdd6ff8f80adeca6c6e6d", "class_name": "RelatedNodeInfo"}}, "text": "So, we're really waiting acro ss \nthe entirety of our scaled business. ", "start_char_idx": 2543, "end_char_idx": 2614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d40bbd1-50a2-4ee6-bb80-16cbf4740d19": {"__data__": {"id_": "8d40bbd1-50a2-4ee6-bb80-16cbf4740d19", "embedding": null, "metadata": {"window": "We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "283c9132-e416-40f8-805a-f29f17478163", "node_type": "1", "metadata": {"window": "So we're seeing growth in specialty products.  We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "So, we're really waiting acro ss \nthe entirety of our scaled business. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f30dbe8987aee9d4da2439a34736f1c4db7351c3d5eaa79e5785d7b697865d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27b8fb36-bde5-4864-812a-e1778230f32b", "node_type": "1", "metadata": {"window": "And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "4ee5ebfec126f48d97cb69c9024e0256665b07fd9dc2a97470433b2dd39d015e", "class_name": "RelatedNodeInfo"}}, "text": "And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n ", "start_char_idx": 2614, "end_char_idx": 2714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27b8fb36-bde5-4864-812a-e1778230f32b": {"__data__": {"id_": "27b8fb36-bde5-4864-812a-e1778230f32b", "embedding": null, "metadata": {"window": "And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d40bbd1-50a2-4ee6-bb80-16cbf4740d19", "node_type": "1", "metadata": {"window": "We're seeing growth across the specialty providers that we service. \n And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "original_text": "And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "852a7ce08ad7e4a964116c1c45c75eb9e73cb750e9880ed5eba822cdc77b8f7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bedd14e2-c917-4cfe-8371-588f41aa9713", "node_type": "1", "metadata": {"window": "So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "A \nNext question, please?  \n "}, "hash": "2ca286cc5478c9d33bb5325b14137bc2277b354b0a56a60a838a67b8dc6eccc3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 2714, "end_char_idx": 3059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bedd14e2-c917-4cfe-8371-588f41aa9713": {"__data__": {"id_": "bedd14e2-c917-4cfe-8371-588f41aa9713", "embedding": null, "metadata": {"window": "So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27b8fb36-bde5-4864-812a-e1778230f32b", "node_type": "1", "metadata": {"window": "And as I mentioned, we're also seeing significant growth from GLP -1 medication.  So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "acc7dff476c323a9dc5058be17d0c597976ac68b1698ee488f5735cf0633d663", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97a212c0-4946-45f3-bb11-1d747c6085a0", "node_type": "1", "metadata": {"window": "And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. "}, "hash": "169286655631a34bbe8a478aeb62e445ad9e18068d9f31a35f84e83db8771b67", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 3059, "end_char_idx": 3088, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97a212c0-4946-45f3-bb11-1d747c6085a0": {"__data__": {"id_": "97a212c0-4946-45f3-bb11-1d747c6085a0", "embedding": null, "metadata": {"window": "And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bedd14e2-c917-4cfe-8371-588f41aa9713", "node_type": "1", "metadata": {"window": "So, we're really waiting acro ss \nthe entirety of our scaled business.  And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "A \nNext question, please?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4970b679b82ba392bb6082461a55466caebd5c27e0ad533236573bb5ac271f37", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5633219-f734-4f06-adcb-aff02de0aa80", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall. ", "original_text": "Please go ahead.  \n "}, "hash": "259c10fb186367b38c532e9f509d370775b62151be2d7eebc523ff87e2ebf843", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "start_char_idx": 3088, "end_char_idx": 3415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5633219-f734-4f06-adcb-aff02de0aa80": {"__data__": {"id_": "a5633219-f734-4f06-adcb-aff02de0aa80", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall. ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97a212c0-4946-45f3-bb11-1d747c6085a0", "node_type": "1", "metadata": {"window": "And of course, as our customers continue to win, that's reflected in the volume \nincreases also.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b954c65534e836551f3f26eaa6e95edf455ec89ea8e0009fa849bcba5434620", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdec7572-094a-415e-bdf4-975299580e81", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. "}, "hash": "716ad2b5231c2391cf875e255b424648c5c336e5b40ee8f52dce3f3bbf605a97", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 3415, "end_char_idx": 3435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdec7572-094a-415e-bdf4-975299580e81": {"__data__": {"id_": "fdec7572-094a-415e-bdf4-975299580e81", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5633219-f734-4f06-adcb-aff02de0aa80", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall. ", "original_text": "Please go ahead.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5586fbb6c825fc1dec6e5e0df80f0bf8661b410840c5826db9632eb3a031026", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f583bc9b-f771-4bf0-bb73-5ce69576ab7b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks and good afternoon. "}, "hash": "71d3ae2364e085815e8f618442a3a8ad93fa3e6f88245e7e9f35e3dfc3f2aaad", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "start_char_idx": 3435, "end_char_idx": 3766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f583bc9b-f771-4bf0-bb73-5ce69576ab7b": {"__data__": {"id_": "f583bc9b-f771-4bf0-bb73-5ce69576ab7b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks and good afternoon. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdec7572-094a-415e-bdf4-975299580e81", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5612f8353ce1f6b7f0cf17511a2dc30ae989f4569ecc5a256f6724f5eea67726", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8897a0bf-bc6a-4fe7-a490-d3c7f8c04e4d", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall. "}, "hash": "24756dfb57173d723f80813dc7e7518f5fbb0d30d3d025d2c9d674d3efd3a26d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks and good afternoon. ", "start_char_idx": 3766, "end_char_idx": 3793, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8897a0bf-bc6a-4fe7-a490-d3c7f8c04e4d": {"__data__": {"id_": "8897a0bf-bc6a-4fe7-a490-d3c7f8c04e4d", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f583bc9b-f771-4bf0-bb73-5ce69576ab7b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Thanks and good afternoon. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2bf92330c8ada825647ae5bf1232931f93638a0afefcd8004d4449a1211e921", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aad1fea-7504-4da9-b590-0a4be0b0045f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n "}, "hash": "f380e7788a0fbc5a955d5c9016397aaf8e653926ca8bdd40002bd70a1ab0a4d9", "class_name": "RelatedNodeInfo"}}, "text": "I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall. ", "start_char_idx": 3793, "end_char_idx": 3956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aad1fea-7504-4da9-b590-0a4be0b0045f": {"__data__": {"id_": "0aad1fea-7504-4da9-b590-0a4be0b0045f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8897a0bf-bc6a-4fe7-a490-d3c7f8c04e4d", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall. ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "166dbcc65a81f4ee7e9a9ca071c7d8773dda2d4a4a511cbbe4d26fa2662d529c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98004126-7970-4e00-b09f-c6500bd40c39", "node_type": "1", "metadata": {"window": "Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "1bc578ae4057653bea5bd58dac051354f9b4d46c87cabdf5199f29820021f9ca", "class_name": "RelatedNodeInfo"}}, "text": "Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n ", "start_char_idx": 3956, "end_char_idx": 4040, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98004126-7970-4e00-b09f-c6500bd40c39": {"__data__": {"id_": "98004126-7970-4e00-b09f-c6500bd40c39", "embedding": null, "metadata": {"window": "Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aad1fea-7504-4da9-b590-0a4be0b0045f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d7ab23f834906faece944d9226f7a902ed0dde72ac7f2d28da6dc1ce5ec546b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "362671c4-ce73-4137-a97e-05a88828c1f7", "node_type": "1", "metadata": {"window": "I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A "}, "hash": "9b509761de2e9c1e6fc398a02ca3b25efd98350feeb39b7e9b2ffb07aa9d25b7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4040, "end_char_idx": 4384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "362671c4-ce73-4137-a97e-05a88828c1f7": {"__data__": {"id_": "362671c4-ce73-4137-a97e-05a88828c1f7", "embedding": null, "metadata": {"window": "I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d11dc646-7603-4427-901a-12238153d34f", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d416bd02195ea05959a689164261f8af685826248fbc525dc2bbc669042c4354", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98004126-7970-4e00-b09f-c6500bd40c39", "node_type": "1", "metadata": {"window": "Thanks and good afternoon.  I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ceebe20c4707958ef423f49c07fc1fb27de20dc39c2bb2b0f4637ca64d5b14f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c47e179-368c-4f03-b4ad-f51f4840b60f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there. ", "original_text": "McKesson Corp.  "}, "hash": "fe6cf2d68b0cea9def96576e9fa169dc124b63b80e6863699ad04f19d500ab44", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 254, "end_char_idx": 256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c47e179-368c-4f03-b4ad-f51f4840b60f": {"__data__": {"id_": "5c47e179-368c-4f03-b4ad-f51f4840b60f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "362671c4-ce73-4137-a97e-05a88828c1f7", "node_type": "1", "metadata": {"window": "I just want to go to your International business, and you talked about how \nstrong Canada is, but there's been some specul ation in the marketplace around Rexall.  Can you talk about the \nstrategy in Canada and specific to owning a drug retail?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c228f0a5ccade2378d1126dfa1bd950a18f2110478d6ecc35d3b386929d6c97", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72403bf4-2f52-4b68-8b60-cb0591f05d2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors. "}, "hash": "d4a5d097d09c5bfdbb733e732f900bdf30366487a5326cc7b4017c9e2e09b835", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72403bf4-2f52-4b68-8b60-cb0591f05d2a": {"__data__": {"id_": "72403bf4-2f52-4b68-8b60-cb0591f05d2a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c47e179-368c-4f03-b4ad-f51f4840b60f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d0679c4affcd2286b907b6034c0a1058d6106752f3cdc9444dd296e4a9ffb1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61661cc0-44cb-45e3-9a60-43f6b367f69a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies. ", "original_text": "Let me say this a bout Canada. "}, "hash": "b03d56eba18ba38ac4ab31b122e23f4a7085c1198d6b09b410707b7282d447b2", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors. ", "start_char_idx": 16, "end_char_idx": 226, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61661cc0-44cb-45e3-9a60-43f6b367f69a": {"__data__": {"id_": "61661cc0-44cb-45e3-9a60-43f6b367f69a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies. ", "original_text": "Let me say this a bout Canada. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72403bf4-2f52-4b68-8b60-cb0591f05d2a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8adb9878c26a782921d1f8ab3e9530ee5482d2deb0d7ccbd7ca277c7d76e7529", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23fb7e9d-89a0-47d1-a170-1304ebec53c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n", "original_text": "We have a very scaled, broad and \nimpactful healthcare services business there. "}, "hash": "6c543c2bbc19d876f22c021f757282b35f5b43b9a6bc3faeee568860cec42681", "class_name": "RelatedNodeInfo"}}, "text": "Let me say this a bout Canada. ", "start_char_idx": 226, "end_char_idx": 257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23fb7e9d-89a0-47d1-a170-1304ebec53c0": {"__data__": {"id_": "23fb7e9d-89a0-47d1-a170-1304ebec53c0", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n", "original_text": "We have a very scaled, broad and \nimpactful healthcare services business there. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61661cc0-44cb-45e3-9a60-43f6b367f69a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies. ", "original_text": "Let me say this a bout Canada. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edb99d7e650b5c2401f0ff1eb5b1dfa30a02a10e3bc9aaca74d04f0572bd9140", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01799d7c-2e60-4e0f-af4f-dd1e1a6cc5f7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general. ", "original_text": "It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities. "}, "hash": "fb428d9e8da728268308cf0bf7dd22550502fd596df85695b017a85039e0025a", "class_name": "RelatedNodeInfo"}}, "text": "We have a very scaled, broad and \nimpactful healthcare services business there. ", "start_char_idx": 257, "end_char_idx": 337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01799d7c-2e60-4e0f-af4f-dd1e1a6cc5f7": {"__data__": {"id_": "01799d7c-2e60-4e0f-af4f-dd1e1a6cc5f7", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general. ", "original_text": "It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23fb7e9d-89a0-47d1-a170-1304ebec53c0", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n", "original_text": "We have a very scaled, broad and \nimpactful healthcare services business there. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "378837212f68c483ef6d26991178e6b56b6e6509d3f4e580fdc678ed1190de0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b6f6e93-8d15-46b0-93f0-60997ad34357", "node_type": "1", "metadata": {"window": "Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business. ", "original_text": "It includes retail pharmacies. "}, "hash": "e9b092ec4dd262d56e723521c3b20d694f7d0721b355ae80ccf694d9bdaf929e", "class_name": "RelatedNodeInfo"}}, "text": "It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities. ", "start_char_idx": 337, "end_char_idx": 443, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b6f6e93-8d15-46b0-93f0-60997ad34357": {"__data__": {"id_": "8b6f6e93-8d15-46b0-93f0-60997ad34357", "embedding": null, "metadata": {"window": "Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business. ", "original_text": "It includes retail pharmacies. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01799d7c-2e60-4e0f-af4f-dd1e1a6cc5f7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general. ", "original_text": "It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ed668b0ae762c4fd75786bcb943b82d3e3c900db407372f4bf5e6b76b4fa686", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11677b7e-10ac-4b9b-b85f-5e5b63a32841", "node_type": "1", "metadata": {"window": "We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going. ", "original_text": "It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n"}, "hash": "cb7b58fe84d5d0d4a0975962f2c4f5377c7a6ecda1ea95c341bc282e51d79d16", "class_name": "RelatedNodeInfo"}}, "text": "It includes retail pharmacies. ", "start_char_idx": 443, "end_char_idx": 474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11677b7e-10ac-4b9b-b85f-5e5b63a32841": {"__data__": {"id_": "11677b7e-10ac-4b9b-b85f-5e5b63a32841", "embedding": null, "metadata": {"window": "We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going. ", "original_text": "It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b6f6e93-8d15-46b0-93f0-60997ad34357", "node_type": "1", "metadata": {"window": "Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business. ", "original_text": "It includes retail pharmacies. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea6169acb4020756788716cb6632f889d60c034113227bee532332df3d346395", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46014dcd-39a2-417f-b881-36a1d1afc5a1", "node_type": "1", "metadata": {"window": "It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n ", "original_text": "So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general. "}, "hash": "33a7e38750207fb1ea073f2bf73adf6a38cf6a6434d6a48c70942469bcd97062", "class_name": "RelatedNodeInfo"}}, "text": "It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n", "start_char_idx": 474, "end_char_idx": 628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46014dcd-39a2-417f-b881-36a1d1afc5a1": {"__data__": {"id_": "46014dcd-39a2-417f-b881-36a1d1afc5a1", "embedding": null, "metadata": {"window": "It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n ", "original_text": "So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11677b7e-10ac-4b9b-b85f-5e5b63a32841", "node_type": "1", "metadata": {"window": "We have a very scaled, broad and \nimpactful healthcare services business there.  It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going. ", "original_text": "It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d2d93be207bf6852ba8008c87ebe20262854f56090f86d77d92d33499991ab26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8522a4d3-15b7-44fc-beb2-11feae32c01a", "node_type": "1", "metadata": {"window": "It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "W e've been very pleased with the performance of the business. "}, "hash": "9b25fd36f5de45d28e5b2d377e27bf930d51a3e1b08ba09e6ee201097df062f5", "class_name": "RelatedNodeInfo"}}, "text": "So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general. ", "start_char_idx": 628, "end_char_idx": 762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8522a4d3-15b7-44fc-beb2-11feae32c01a": {"__data__": {"id_": "8522a4d3-15b7-44fc-beb2-11feae32c01a", "embedding": null, "metadata": {"window": "It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "W e've been very pleased with the performance of the business. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46014dcd-39a2-417f-b881-36a1d1afc5a1", "node_type": "1", "metadata": {"window": "It's obviously anchored in our distribution assets, but it includes \nspecialty distribution capabilities.  It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n ", "original_text": "So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99d2023ba9afecf5c8a9a474bafda5191a50a51d90c1c83651dc667e1b139fca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfd97ad7-8ec9-4acd-be2b-7d2eaa6978f1", "node_type": "1", "metadata": {"window": "It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from. ", "original_text": "Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going. "}, "hash": "6b0f6aa2404d207ffc574f1cc8a62c822fa72e6de5e191e07e329801d06323cb", "class_name": "RelatedNodeInfo"}}, "text": "W e've been very pleased with the performance of the business. ", "start_char_idx": 762, "end_char_idx": 825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfd97ad7-8ec9-4acd-be2b-7d2eaa6978f1": {"__data__": {"id_": "dfd97ad7-8ec9-4acd-be2b-7d2eaa6978f1", "embedding": null, "metadata": {"window": "It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from. ", "original_text": "Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8522a4d3-15b7-44fc-beb2-11feae32c01a", "node_type": "1", "metadata": {"window": "It includes retail pharmacies.  It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "W e've been very pleased with the performance of the business. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca46ac9d9f1f0abd2c22a29376037b469735f9a3eb9d04db1b4464dae2a0d76c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea576c0f-bb04-4f62-af37-e682f4f220f4", "node_type": "1", "metadata": {"window": "So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win. ", "original_text": "And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n "}, "hash": "3756c367c26678cb0e93770182bea0f886e7de33120a33906a6a81584bf06de3", "class_name": "RelatedNodeInfo"}}, "text": "Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going. ", "start_char_idx": 825, "end_char_idx": 945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea576c0f-bb04-4f62-af37-e682f4f220f4": {"__data__": {"id_": "ea576c0f-bb04-4f62-af37-e682f4f220f4", "embedding": null, "metadata": {"window": "So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win. ", "original_text": "And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfd97ad7-8ec9-4acd-be2b-7d2eaa6978f1", "node_type": "1", "metadata": {"window": "It includes one of the best online brands in Well.ca, \nincludes infusion clinics, and it includes a growing biopharma manufacturer services business.  \n \n So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from. ", "original_text": "Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a155c169868fea39c7cff535d9462fbb88b5a294619058b2749700cfc5861ca3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d4ca333-badd-40ed-b273-c58429f30a20", "node_type": "1", "metadata": {"window": "W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "a56c65500c7e8b9cbfac0a4a7731d03938b7f914f664da1b4d84419aed111835", "class_name": "RelatedNodeInfo"}}, "text": "And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n ", "start_char_idx": 945, "end_char_idx": 1056, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d4ca333-badd-40ed-b273-c58429f30a20": {"__data__": {"id_": "5d4ca333-badd-40ed-b273-c58429f30a20", "embedding": null, "metadata": {"window": "W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea576c0f-bb04-4f62-af37-e682f4f220f4", "node_type": "1", "metadata": {"window": "So we're very, very broad in our capabilities and really one of the leading players in the Canadian Healthcare \nlandscape in general.  W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win. ", "original_text": "And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87b436ceca1eb89e99918891839872fa8e51fa1a396f317b8da27c6c8a88c983", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2317e537-30cc-40e9-a16e-8854fcb95565", "node_type": "1", "metadata": {"window": "Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n ", "original_text": "A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from. "}, "hash": "562e1bf761e99cc2c51f9f0e53f8440a3c832c23a9d4d3b17b4a732598d5adb1", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1056, "end_char_idx": 1416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2317e537-30cc-40e9-a16e-8854fcb95565": {"__data__": {"id_": "2317e537-30cc-40e9-a16e-8854fcb95565", "embedding": null, "metadata": {"window": "Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n ", "original_text": "A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d4ca333-badd-40ed-b273-c58429f30a20", "node_type": "1", "metadata": {"window": "W e've been very pleased with the performance of the business.  Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f09e00a630be4abf021a102dd50bca840356deb014aa46e865e6c382544fa5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58d0f5de-f345-4cdf-85f1-99c67e6cd68c", "node_type": "1", "metadata": {"window": "And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.  ", "original_text": "And it's helping our customers win. "}, "hash": "56b155baec979e66fc5c8d0b6281d0177f501186a2b2a3855ad8d4a44fa91d49", "class_name": "RelatedNodeInfo"}}, "text": "A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from. ", "start_char_idx": 1416, "end_char_idx": 1584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58d0f5de-f345-4cdf-85f1-99c67e6cd68c": {"__data__": {"id_": "58d0f5de-f345-4cdf-85f1-99c67e6cd68c", "embedding": null, "metadata": {"window": "And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.  ", "original_text": "And it's helping our customers win. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2317e537-30cc-40e9-a16e-8854fcb95565", "node_type": "1", "metadata": {"window": "Britt talked about some of \nthe investments we continue to make into that business to keep our growth trajectory going.  And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n ", "original_text": "A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "003dca23f9367fcb234fe0c83baf547e8d77ba7e2eaa5aa673863b0dd55bde46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba2744fa-c130-4589-a332-467a3df8cf30", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And helping us drive \nincreased distribution volume. "}, "hash": "0dd3c0f368bb1a522f5fcc997fe59c00b4f3ca44c88e45c0bdb1c4f628b4e9cc", "class_name": "RelatedNodeInfo"}}, "text": "And it's helping our customers win. ", "start_char_idx": 1584, "end_char_idx": 1620, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba2744fa-c130-4589-a332-467a3df8cf30": {"__data__": {"id_": "ba2744fa-c130-4589-a332-467a3df8cf30", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And helping us drive \nincreased distribution volume. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58d0f5de-f345-4cdf-85f1-99c67e6cd68c", "node_type": "1", "metadata": {"window": "And I'd say we just \u2013 \nwe're very pleased with the performance and very commi tted to the current strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.  ", "original_text": "And it's helping our customers win. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca3394d8cbb14d3f27e2af6d9210f5857aa520ef15798393509a3a85037b1e0c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed98c0ff-4c36-45c6-973b-72963b0adefc", "node_type": "1", "metadata": {"window": "A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n "}, "hash": "b587f75943ad2e24b7eb5fa76e39e82abd8164908e7e8475e5b19d03c348150a", "class_name": "RelatedNodeInfo"}}, "text": "And helping us drive \nincreased distribution volume. ", "start_char_idx": 1620, "end_char_idx": 1673, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed98c0ff-4c36-45c6-973b-72963b0adefc": {"__data__": {"id_": "ed98c0ff-4c36-45c6-973b-72963b0adefc", "embedding": null, "metadata": {"window": "A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba2744fa-c130-4589-a332-467a3df8cf30", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And helping us drive \nincreased distribution volume. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81f5a39ea0f300ddf8c9497739528e42a33235aeb7e83f105e34591b59487903", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19d94678-b7ae-444b-8e5f-7afdf1f2a295", "node_type": "1", "metadata": {"window": "And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.  "}, "hash": "a122a6a2650d3b03777ee1b377b28a7c2d367f7ed3dc1de3e06781020fd711c9", "class_name": "RelatedNodeInfo"}}, "text": "So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n ", "start_char_idx": 1673, "end_char_idx": 1792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19d94678-b7ae-444b-8e5f-7afdf1f2a295": {"__data__": {"id_": "19d94678-b7ae-444b-8e5f-7afdf1f2a295", "embedding": null, "metadata": {"window": "And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed98c0ff-4c36-45c6-973b-72963b0adefc", "node_type": "1", "metadata": {"window": "A \nThe only thing I would add is similar to our US business, in Canada, we have very strong strategic sourcing \ncapabilities as well, which our customers benefit from.  And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "original_text": "So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cc185d71bfe67a665e11409b34bfcd92c6d3c6b765564adf794462630a4cfd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a00b9e8-a625-49a1-bb1d-feab29f47269", "node_type": "1", "metadata": {"window": "And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please?  \n "}, "hash": "b4baf0f217987eb35622962aee87905ef206079b38c6e4e0bbc6c54bc8de846f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.  ", "start_char_idx": 1792, "end_char_idx": 2138, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a00b9e8-a625-49a1-bb1d-feab29f47269": {"__data__": {"id_": "1a00b9e8-a625-49a1-bb1d-feab29f47269", "embedding": null, "metadata": {"window": "And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19d94678-b7ae-444b-8e5f-7afdf1f2a295", "node_type": "1", "metadata": {"window": "And it's helping our customers win.  And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "200731d762e334c85fc07aefd312b9232acb812f070caab702f883c5e408c389", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27fc6ce0-4344-43ff-9a7d-ca476e9bbec4", "node_type": "1", "metadata": {"window": "So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. "}, "hash": "7feda569058ae78cb7e6a779671ccb497a39776266c2d7be1493ba9659ec6844", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 2138, "end_char_idx": 2167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27fc6ce0-4344-43ff-9a7d-ca476e9bbec4": {"__data__": {"id_": "27fc6ce0-4344-43ff-9a7d-ca476e9bbec4", "embedding": null, "metadata": {"window": "So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a00b9e8-a625-49a1-bb1d-feab29f47269", "node_type": "1", "metadata": {"window": "And helping us drive \nincreased distribution volume.  So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83a716929de11515a990347c5602a2e830f97225e4941c0771f7eeadce3c3152", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "915be9cd-dfb6-4516-8d17-37b4ab268819", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question. ", "original_text": "Please go ahead.  \n "}, "hash": "8eb55690e01f732f6483e743bae530a2e5bf8f148a64b9e385923c3e3c18e586", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "start_char_idx": 2167, "end_char_idx": 2502, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "915be9cd-dfb6-4516-8d17-37b4ab268819": {"__data__": {"id_": "915be9cd-dfb6-4516-8d17-37b4ab268819", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27fc6ce0-4344-43ff-9a7d-ca476e9bbec4", "node_type": "1", "metadata": {"window": "So very similar to the US, we utilize our strong scaled strategic sourcing \ncapabilities to help our customers win.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "916b0935b2f79d151521b81b8d045743ec7f60b426dfd68ae7bde03eb940a3ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5a8e7c6a-428c-42b7-85d2-f079fe64c881", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  "}, "hash": "bba4760568fd8a9f26cdff4de563010ab05e621db14ebfe218e3668f11a67af3", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2502, "end_char_idx": 2522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5a8e7c6a-428c-42b7-85d2-f079fe64c881": {"__data__": {"id_": "5a8e7c6a-428c-42b7-85d2-f079fe64c881", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "915be9cd-dfb6-4516-8d17-37b4ab268819", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice P resident of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question. ", "original_text": "Please go ahead.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "08e50c5142832e15e2b1da2020ea89a14b2b4598513e026dc6ebcad02cabfac4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf4c9882-2c58-4bf3-bb3a-2f71b9d15bc3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here? ", "original_text": "Q \nGood afternoon. "}, "hash": "a38851a9a1b80cc962785c34e0191a453ccb4e21aab738a38f262dc0936ea061", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 2522, "end_char_idx": 2839, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf4c9882-2c58-4bf3-bb3a-2f71b9d15bc3": {"__data__": {"id_": "cf4c9882-2c58-4bf3-bb3a-2f71b9d15bc3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here? ", "original_text": "Q \nGood afternoon. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5a8e7c6a-428c-42b7-85d2-f079fe64c881", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a15b1d149731a07e289ef1bc7ed4987f52120862158b39ca3c23e4c79366a8cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dc7d4e8-23a8-4fd7-a924-6d40039f1d70", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%? ", "original_text": "And thanks for taking the question. "}, "hash": "4310ae0f2c867e110bc9a340bd34e55435584c132613f0390f3f17ee32b99ca2", "class_name": "RelatedNodeInfo"}}, "text": "Q \nGood afternoon. ", "start_char_idx": 2839, "end_char_idx": 2858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dc7d4e8-23a8-4fd7-a924-6d40039f1d70": {"__data__": {"id_": "5dc7d4e8-23a8-4fd7-a924-6d40039f1d70", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%? ", "original_text": "And thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf4c9882-2c58-4bf3-bb3a-2f71b9d15bc3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Allen Lutz with Bank of America.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here? ", "original_text": "Q \nGood afternoon. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e6c05827e5257938df93032c595d4202498d6553ac96c48d704f2cbf8138421", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84253701-3332-40cd-a241-5f0738ae4efb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n ", "original_text": "Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures. "}, "hash": "0c8b70f1d29dd6adabeff2cd0923a4c626fc5aa42b598fb986e9757e7dcec68c", "class_name": "RelatedNodeInfo"}}, "text": "And thanks for taking the question. ", "start_char_idx": 2858, "end_char_idx": 2894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84253701-3332-40cd-a241-5f0738ae4efb": {"__data__": {"id_": "84253701-3332-40cd-a241-5f0738ae4efb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n ", "original_text": "Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dc7d4e8-23a8-4fd7-a924-6d40039f1d70", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%? ", "original_text": "And thanks for taking the question. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d88fa8d5980a057e698a20ac3990f5ce0e1e773946788c0131a6370f3bfaf7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fc568ac-6092-485f-8b99-27b69b3c4fbc", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here? "}, "hash": "9a4b9382cc2bc639bd47ca520b3dfe4cbcafa3340655368b268225417d3698ae", "class_name": "RelatedNodeInfo"}}, "text": "Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures. ", "start_char_idx": 2894, "end_char_idx": 2984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fc568ac-6092-485f-8b99-27b69b3c4fbc": {"__data__": {"id_": "4fc568ac-6092-485f-8b99-27b69b3c4fbc", "embedding": null, "metadata": {"window": "Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here? ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84253701-3332-40cd-a241-5f0738ae4efb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nAllen Lutz  \nAnalyst, BofA Securities, Inc.   Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n ", "original_text": "Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5096cdec34bb3732a6962f6a6b3ecae2bd2389a672297ee37eac7abc0ec47204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d764a1a0-6f8d-4701-a8c7-3fdb686c46d9", "node_type": "1", "metadata": {"window": "And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen. ", "original_text": "And then  is there any reason \nwhy that would tick higher or lower versus that 6%? "}, "hash": "d047e927fa4736c4d0dcc16fc448dd2a14aa2911e6a9104bb4db6fc81374959a", "class_name": "RelatedNodeInfo"}}, "text": "As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here? ", "start_char_idx": 2984, "end_char_idx": 3144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d764a1a0-6f8d-4701-a8c7-3fdb686c46d9": {"__data__": {"id_": "d764a1a0-6f8d-4701-a8c7-3fdb686c46d9", "embedding": null, "metadata": {"window": "And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen. ", "original_text": "And then  is there any reason \nwhy that would tick higher or lower versus that 6%? ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fc568ac-6092-485f-8b99-27b69b3c4fbc", "node_type": "1", "metadata": {"window": "Q \nGood afternoon.  And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here? ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57428ad20e14d0ed623c58b571879f3c1a61349c498901dd6f939aaf128e73e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9e85856-3499-44f2-b0bf-1ebac908c0ed", "node_type": "1", "metadata": {"window": "Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit. ", "original_text": "Thanks.  \n "}, "hash": "85df423c75f870c01bb127705ef1727716773158090959f7c52b1cabd41186d8", "class_name": "RelatedNodeInfo"}}, "text": "And then  is there any reason \nwhy that would tick higher or lower versus that 6%? ", "start_char_idx": 3144, "end_char_idx": 3227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9e85856-3499-44f2-b0bf-1ebac908c0ed": {"__data__": {"id_": "b9e85856-3499-44f2-b0bf-1ebac908c0ed", "embedding": null, "metadata": {"window": "Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit. ", "original_text": "Thanks.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d764a1a0-6f8d-4701-a8c7-3fdb686c46d9", "node_type": "1", "metadata": {"window": "And thanks for taking the question.  Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen. ", "original_text": "And then  is there any reason \nwhy that would tick higher or lower versus that 6%? ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3aecf6efc4538e94718e2b96e678d48bb963cc76a0db3bb26a300b4a5093fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c90186b-3801-4a6e-b8cb-d4c7639dd822", "node_type": "1", "metadata": {"window": "As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "57ea9cd817bd214b09d948f3acc7b781ba1d9c9e54e10e086146a903b00b9c04", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 3227, "end_char_idx": 3238, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c90186b-3801-4a6e-b8cb-d4c7639dd822": {"__data__": {"id_": "4c90186b-3801-4a6e-b8cb-d4c7639dd822", "embedding": null, "metadata": {"window": "As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9e85856-3499-44f2-b0bf-1ebac908c0ed", "node_type": "1", "metadata": {"window": "Britt, you mentioned core operating expense growth was \nabout 6%, excluding divestitures.  As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit. ", "original_text": "Thanks.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05bca1bd7f83bb6ce5da133b8ed5ee6db14d8cc1f707b2dae547ef54885264f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb187781-252b-4aa9-b67a-141f0f96be14", "node_type": "1", "metadata": {"window": "And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business. ", "original_text": "A \nThanks for the question, Allen. "}, "hash": "95e73c5618360904d7e7fb93938df422b9c9ac94ee64e98964e094397adc0f97", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1056, "end_char_idx": 1416, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb187781-252b-4aa9-b67a-141f0f96be14": {"__data__": {"id_": "fb187781-252b-4aa9-b67a-141f0f96be14", "embedding": null, "metadata": {"window": "And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business. ", "original_text": "A \nThanks for the question, Allen. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c90186b-3801-4a6e-b8cb-d4c7639dd822", "node_type": "1", "metadata": {"window": "As we think about the current growth across your different businesses, is that \n6% growth rate the right way to think about operating expense growth from here?  And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0fe52e302507818802f775a04c2065c2235af2bcda0e3dba13e9a30698d25735", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff64538e-d8f3-415d-897a-f2e8ef6d4de9", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that. ", "original_text": "I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit. "}, "hash": "9d9b48fc10f72eb14c4c37319abf68a0732816227e155a3e1fce0fa109b3f9e7", "class_name": "RelatedNodeInfo"}}, "text": "A \nThanks for the question, Allen. ", "start_char_idx": 3598, "end_char_idx": 3633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff64538e-d8f3-415d-897a-f2e8ef6d4de9": {"__data__": {"id_": "ff64538e-d8f3-415d-897a-f2e8ef6d4de9", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that. ", "original_text": "I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb187781-252b-4aa9-b67a-141f0f96be14", "node_type": "1", "metadata": {"window": "And then  is there any reason \nwhy that would tick higher or lower versus that 6%?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business. ", "original_text": "A \nThanks for the question, Allen. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9fdd15bb4b5ab00587cefc19c3ec0a88e38c1874fee9af998c04372060a5d8f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e155c06-d60e-4f85-80b7-217f88637133", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n ", "original_text": "And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n"}, "hash": "6043287036ef84e621923080a9b8fcf3a698488a4bc58aac31fde1c2c5ef2430", "class_name": "RelatedNodeInfo"}}, "text": "I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit. ", "start_char_idx": 3633, "end_char_idx": 3801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e155c06-d60e-4f85-80b7-217f88637133": {"__data__": {"id_": "7e155c06-d60e-4f85-80b7-217f88637133", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n ", "original_text": "And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff64538e-d8f3-415d-897a-f2e8ef6d4de9", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that. ", "original_text": "I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "15f61200e04d1d0e0bdabd5af02cca1e6335e1ab5133fc9023fa82bd3d5e59d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9bc4a21a-4a14-4d67-accc-514ba13bd665", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "Now we 've been investing back in the business. "}, "hash": "3165ac16c943c06836053cbb6a01920f8d7371e720addc4f10c48fcc2ad00063", "class_name": "RelatedNodeInfo"}}, "text": "And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n", "start_char_idx": 3801, "end_char_idx": 3942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9bc4a21a-4a14-4d67-accc-514ba13bd665": {"__data__": {"id_": "9bc4a21a-4a14-4d67-accc-514ba13bd665", "embedding": null, "metadata": {"window": "A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "Now we 've been investing back in the business. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e155c06-d60e-4f85-80b7-217f88637133", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n ", "original_text": "And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dd14dcca37203201ef665cd4cb0b91856f39adfe5282cfcff4fda336e82f505", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4fbc6cf-8f30-44b8-9b28-2d64e9f66fe4", "node_type": "1", "metadata": {"window": "I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that. "}, "hash": "84930cea272737b1fd5c2922b25bee8cefdc2fef4d6d2ecdb6857de494a59a04", "class_name": "RelatedNodeInfo"}}, "text": "Now we 've been investing back in the business. ", "start_char_idx": 3942, "end_char_idx": 3990, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4fbc6cf-8f30-44b8-9b28-2d64e9f66fe4": {"__data__": {"id_": "d4fbc6cf-8f30-44b8-9b28-2d64e9f66fe4", "embedding": null, "metadata": {"window": "I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9bc4a21a-4a14-4d67-accc-514ba13bd665", "node_type": "1", "metadata": {"window": "A \nThanks for the question, Allen.  I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "Now we 've been investing back in the business. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb9e3c301a1642f6ba39b3ff42c0b6f408ee0502d2c012d7e2e59acbf4e94008", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94bce131-e003-4150-8e13-3fb10876599d", "node_type": "1", "metadata": {"window": "And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "original_text": "But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n "}, "hash": "e9508592ca20bf06d55e45e9206edc2c2cec76153456d0cac22e873a209eac48", "class_name": "RelatedNodeInfo"}}, "text": "And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that. ", "start_char_idx": 3990, "end_char_idx": 4227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94bce131-e003-4150-8e13-3fb10876599d": {"__data__": {"id_": "94bce131-e003-4150-8e13-3fb10876599d", "embedding": null, "metadata": {"window": "And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "original_text": "But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4fbc6cf-8f30-44b8-9b28-2d64e9f66fe4", "node_type": "1", "metadata": {"window": "I think when you look at our operating expenses, what  we tried to do, and what \nwe've been able to do over a long period of time is gain leverage on our gross profit.  And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e2181221e6919f5802a2ca9120f454483009fc7292add6c900916a7a4bac3b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cad26a4d-9a6e-4211-a7bf-7db4da31d213", "node_type": "1", "metadata": {"window": "Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "eda025c401080babcdc1d05068f439946d25f24c48e34248a650db08e13b82cd", "class_name": "RelatedNodeInfo"}}, "text": "But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n ", "start_char_idx": 4227, "end_char_idx": 4320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cad26a4d-9a6e-4211-a7bf-7db4da31d213": {"__data__": {"id_": "cad26a4d-9a6e-4211-a7bf-7db4da31d213", "embedding": null, "metadata": {"window": "Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94bce131-e003-4150-8e13-3fb10876599d", "node_type": "1", "metadata": {"window": "And so what we strive to do \nand we've demonstrated that, our operating expenses typically will grow at a slower pace than gross profit.  \n \n Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "original_text": "But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbcb377080d6b14fc015ffa070300f644b18cca1e097d374e22e4d59e05254d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ecc9347-a8bf-40a8-b623-4dc1dd73fbf0", "node_type": "1", "metadata": {"window": "And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "A \nNext question, please?  \n "}, "hash": "eea7601cfa0ad46b6a79578c740462c5fab3ee5f0db5fd69680b56dd1d5124cd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 4320, "end_char_idx": 4665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ecc9347-a8bf-40a8-b623-4dc1dd73fbf0": {"__data__": {"id_": "4ecc9347-a8bf-40a8-b623-4dc1dd73fbf0", "embedding": null, "metadata": {"window": "And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cad26a4d-9a6e-4211-a7bf-7db4da31d213", "node_type": "1", "metadata": {"window": "Now we 've been investing back in the business.  And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20670637bad633b1fb8c1fbdbaa84631d8e32c98cc5c3b99a3aa21a6bddfaee2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fcf486cc-f360-431d-a408-bacc5c1887c6", "node_type": "1", "metadata": {"window": "But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. "}, "hash": "fe1fba1dbbd59da7e9c9d407c714df223783468476139a8d40ca876dee1c2f56", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 2138, "end_char_idx": 2167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fcf486cc-f360-431d-a408-bacc5c1887c6": {"__data__": {"id_": "fcf486cc-f360-431d-a408-bacc5c1887c6", "embedding": null, "metadata": {"window": "But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ecc9347-a8bf-40a8-b623-4dc1dd73fbf0", "node_type": "1", "metadata": {"window": "And so as we've been investing not only in distribution \ncapabilities, data and analytics and now an accelerated investment in artificial intelligence, quarterly variability in \nthat operating expense number, you can expect to see that.  But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "A \nNext question, please?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8994ed0ab6024a6512af752e0335126fc76da44d268e5cb4cdb222bac60fd6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1953738-709b-4686-a6e2-39823c62894d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "Please go ahead.  "}, "hash": "02b6b036d192356d35d6de88004e33d4d06c64a48b3c3b061d562ea3b70ad565", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "start_char_idx": 4694, "end_char_idx": 5028, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1953738-709b-4686-a6e2-39823c62894d": {"__data__": {"id_": "b1953738-709b-4686-a6e2-39823c62894d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "Please go ahead.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2a331aed375af53d36a112c5fba4acd766303b28862617651f4e930b3336897", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fcf486cc-f360-431d-a408-bacc5c1887c6", "node_type": "1", "metadata": {"window": "But generally speaking, you will see us generate \noperating leverage on our gross margin.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies. ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "961138c943a8ea05dad97b269e632c27472760eca5cefd2b89f88deb889cb4b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77c4fd4b-1c66-489e-afcf-ace7571a503f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front? ", "original_text": "McKesson Corp.  "}, "hash": "c9dcbf014ce19816b1a6d2672674b293c60baaf4e0737d331d7befd633d9fb74", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  ", "start_char_idx": 2502, "end_char_idx": 2520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77c4fd4b-1c66-489e-afcf-ace7571a503f": {"__data__": {"id_": "77c4fd4b-1c66-489e-afcf-ace7571a503f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front? ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1953738-709b-4686-a6e2-39823c62894d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  Please go ahead.  ", "original_text": "Please go ahead.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "316135e71b9c468c1ee2edbe55d42f3f2c9a54372d27055c7516432dddb3c212", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65239a86-1c5f-49bd-986f-4e7cd4bfec05", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. "}, "hash": "aea8b355fd60f357674a7a61fff30c2d76df486f954eee697fa70608d44d31b2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65239a86-1c5f-49bd-986f-4e7cd4bfec05": {"__data__": {"id_": "65239a86-1c5f-49bd-986f-4e7cd4bfec05", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77c4fd4b-1c66-489e-afcf-ace7571a503f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front? ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8cf88b6dc854100e84beb81865106d9fbdb6c410096e3db10d2a6d2daec8c3b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ba6322c-a72e-46a9-80bd-2448de523907", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Good afternoon, guys. "}, "hash": "02875a6b3706da9ad97463e480a4493d3d6acfa2204f843484582f3d3482980a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "start_char_idx": 16, "end_char_idx": 231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ba6322c-a72e-46a9-80bd-2448de523907": {"__data__": {"id_": "6ba6322c-a72e-46a9-80bd-2448de523907", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Good afternoon, guys. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65239a86-1c5f-49bd-986f-4e7cd4bfec05", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8678f0e4a15512401d2a8ead5c63db7f8d9abad9c722eef528eb3bd065329de3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37d01b00-c7b9-41a9-9a08-06301c6bbcb1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes. ", "original_text": "Maybe, Britt, just curious what you're seeing on the generic pricing front? "}, "hash": "8d157d074f78853c220138958f9b338ce4c0444b85b361715a1cb89a7b7b11f6", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys. ", "start_char_idx": 231, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37d01b00-c7b9-41a9-9a08-06301c6bbcb1": {"__data__": {"id_": "37d01b00-c7b9-41a9-9a08-06301c6bbcb1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes. ", "original_text": "Maybe, Britt, just curious what you're seeing on the generic pricing front? ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ba6322c-a72e-46a9-80bd-2448de523907", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Good afternoon, guys. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd03cd9e6088ff6e7a08bb60c724d521001d909dd2b180b626407e9a32ae3f02", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d19b3dc-fc9c-492f-a5b2-7e1b815daf98", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian. ", "original_text": "And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n "}, "hash": "ae2a1a9394332f2d98fad83e0e856e5230ca7cc7f2c4932f482920e889516269", "class_name": "RelatedNodeInfo"}}, "text": "Maybe, Britt, just curious what you're seeing on the generic pricing front? ", "start_char_idx": 253, "end_char_idx": 329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d19b3dc-fc9c-492f-a5b2-7e1b815daf98": {"__data__": {"id_": "2d19b3dc-fc9c-492f-a5b2-7e1b815daf98", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian. ", "original_text": "And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37d01b00-c7b9-41a9-9a08-06301c6bbcb1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes. ", "original_text": "Maybe, Britt, just curious what you're seeing on the generic pricing front? ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcc37c606f995fad2f585599eb60dba066b1cff9849ef08610fc3599827a94fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e59eb3b-2de0-4b0e-a1b6-f3fac0a0236c", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "4b362f9a63bf175c2439974bb1acf0beb86f1f16dc2b93509263860edebe3c26", "class_name": "RelatedNodeInfo"}}, "text": "And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n ", "start_char_idx": 329, "end_char_idx": 481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e59eb3b-2de0-4b0e-a1b6-f3fac0a0236c": {"__data__": {"id_": "6e59eb3b-2de0-4b0e-a1b6-f3fac0a0236c", "embedding": null, "metadata": {"window": "Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d19b3dc-fc9c-492f-a5b2-7e1b815daf98", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian. ", "original_text": "And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8dd814c324adf8502e7958854e5884ec529e8853c1881bb72be91ba03d8d83e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ce3ceb8-3b9c-4b1b-9dcb-2de927d9f061", "node_type": "1", "metadata": {"window": "Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits. ", "original_text": "A \nYes. "}, "hash": "f1299eb2c727f45eb92909e9ce0fbc513f354515e4741830f793e2ffdca5d0cd", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 481, "end_char_idx": 841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ce3ceb8-3b9c-4b1b-9dcb-2de927d9f061": {"__data__": {"id_": "6ce3ceb8-3b9c-4b1b-9dcb-2de927d9f061", "embedding": null, "metadata": {"window": "Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits. ", "original_text": "A \nYes. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e59eb3b-2de0-4b0e-a1b6-f3fac0a0236c", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5ea50749e3f8ee65f978b09f8a4bf2530c27bd0d614c91ec51e70f6445345d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77b8b06a-6575-4058-b578-661e76b490c0", "node_type": "1", "metadata": {"window": "And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers. ", "original_text": "Thanks for the question, Brian. "}, "hash": "712822510f4012c824d02fc47a76cf53e46a79ff156fd115d158260eca79ce26", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 841, "end_char_idx": 849, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77b8b06a-6575-4058-b578-661e76b490c0": {"__data__": {"id_": "77b8b06a-6575-4058-b578-661e76b490c0", "embedding": null, "metadata": {"window": "And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers. ", "original_text": "Thanks for the question, Brian. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ce3ceb8-3b9c-4b1b-9dcb-2de927d9f061", "node_type": "1", "metadata": {"window": "Maybe, Britt, just curious what you're seeing on the generic pricing front?  And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits. ", "original_text": "A \nYes. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7c9569fe5e053a1974d7b2c34bedfc64b71f7f0ffdeee7df355787a8cb9f1e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a927da81-849f-4158-b599-a373e492d179", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply. ", "original_text": "In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE. "}, "hash": "d2c018030e3fcde1bcfa915adcb22c2af5e14519b4d79f5f6cbd00d445c83836", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question, Brian. ", "start_char_idx": 849, "end_char_idx": 881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a927da81-849f-4158-b599-a373e492d179": {"__data__": {"id_": "a927da81-849f-4158-b599-a373e492d179", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply. ", "original_text": "In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77b8b06a-6575-4058-b578-661e76b490c0", "node_type": "1", "metadata": {"window": "And what \nopportunities we should be thinking about, as we think about combinat ion of drug shortages and just broader \ninflation trends in generic?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers. ", "original_text": "Thanks for the question, Brian. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c8fe586b03259d568475cb8871cc33a4bf3ca546b44784e6c96da1f1bbc90ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "015a2e4a-955b-4eab-8498-a2d1698c650a", "node_type": "1", "metadata": {"window": "A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n", "original_text": "ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits. "}, "hash": "cddaf3fba20a8d7f550c29a43213bc15050ff5d0458a817ac597082fbc0dd1f3", "class_name": "RelatedNodeInfo"}}, "text": "In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE. ", "start_char_idx": 881, "end_char_idx": 963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "015a2e4a-955b-4eab-8498-a2d1698c650a": {"__data__": {"id_": "015a2e4a-955b-4eab-8498-a2d1698c650a", "embedding": null, "metadata": {"window": "A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n", "original_text": "ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a927da81-849f-4158-b599-a373e492d179", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply. ", "original_text": "In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6093f4361d24b337b473249cf484131a34485a60ed95ef5425fd9745cf69d577", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11c5f84e-c869-4779-9497-84afacb015cb", "node_type": "1", "metadata": {"window": "Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow. ", "original_text": "I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers. "}, "hash": "8578c6cd5e43a2f1146be4bca6f5f65bbca497ddb3a0a83f80fef2b1927f5f50", "class_name": "RelatedNodeInfo"}}, "text": "ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits. ", "start_char_idx": 963, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11c5f84e-c869-4779-9497-84afacb015cb": {"__data__": {"id_": "11c5f84e-c869-4779-9497-84afacb015cb", "embedding": null, "metadata": {"window": "Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow. ", "original_text": "I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "015a2e4a-955b-4eab-8498-a2d1698c650a", "node_type": "1", "metadata": {"window": "A \nYes.  Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n", "original_text": "ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e76fafa64b7234922b4418587a60ffb5d46d0a214d742801f0bcc9e4d18b714d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f0f683c-43b9-4688-a97d-41f323f7edfe", "node_type": "1", "metadata": {"window": "In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities. ", "original_text": "At the same time, it's driving the highest availability of supply. "}, "hash": "f1d8c63898e15fef769ee3fb0af4df336741b551884234b484f95516ea711347", "class_name": "RelatedNodeInfo"}}, "text": "I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers. ", "start_char_idx": 1079, "end_char_idx": 1211, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f0f683c-43b9-4688-a97d-41f323f7edfe": {"__data__": {"id_": "0f0f683c-43b9-4688-a97d-41f323f7edfe", "embedding": null, "metadata": {"window": "In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities. ", "original_text": "At the same time, it's driving the highest availability of supply. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11c5f84e-c869-4779-9497-84afacb015cb", "node_type": "1", "metadata": {"window": "Thanks for the question, Brian.  In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow. ", "original_text": "I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50ae0ae9dce54d4645c33b985267de3a12d395bbc9d30b48ee4aa340e7f0ad9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "002da6de-5467-4556-a3ec-ed7fe83e2369", "node_type": "1", "metadata": {"window": "ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n", "original_text": "We've been able \nto do that over a long period of time.  \n \n"}, "hash": "4d600ffdd9affebc18bdc02300553ab5b353eadbe2b495b28e7e7bf79573a21a", "class_name": "RelatedNodeInfo"}}, "text": "At the same time, it's driving the highest availability of supply. ", "start_char_idx": 1211, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "002da6de-5467-4556-a3ec-ed7fe83e2369": {"__data__": {"id_": "002da6de-5467-4556-a3ec-ed7fe83e2369", "embedding": null, "metadata": {"window": "ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n", "original_text": "We've been able \nto do that over a long period of time.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f0f683c-43b9-4688-a97d-41f323f7edfe", "node_type": "1", "metadata": {"window": "In generics, we continue to have a very scaled sourcing opera tion in \nClarusONE.  ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities. ", "original_text": "At the same time, it's driving the highest availability of supply. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ce4dbf84a7365bc391cb32f93597529a02d247fab174fd76329b759b5421b8b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3096dfd-c280-446e-a05f-c0f0785c6f4e", "node_type": "1", "metadata": {"window": "I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n ", "original_text": "Our generics business continues to grow. "}, "hash": "ab8a9fbe41a7ca6cfd0dfba72e0e5c0cb5cbb3b4b1a4bd3d33ba37f7ff33d18c", "class_name": "RelatedNodeInfo"}}, "text": "We've been able \nto do that over a long period of time.  \n \n", "start_char_idx": 1278, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3096dfd-c280-446e-a05f-c0f0785c6f4e": {"__data__": {"id_": "d3096dfd-c280-446e-a05f-c0f0785c6f4e", "embedding": null, "metadata": {"window": "I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n ", "original_text": "Our generics business continues to grow. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "002da6de-5467-4556-a3ec-ed7fe83e2369", "node_type": "1", "metadata": {"window": "ClarusONE continues to partner very closely with our broad set of customers, is generating good \nsourcing benefits.  I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n", "original_text": "We've been able \nto do that over a long period of time.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1def52e2de301d2b81c91ed8ccdf141cb379324f80d261e39cb5d5d1370ad758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40c65c05-88ad-47c4-9051-cdcb75e99529", "node_type": "1", "metadata": {"window": "At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.  ", "original_text": "And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities. "}, "hash": "17af6fe2d0f5529a95cdcde01b31b4b88d8a86391869c09bc5b934f576fc7ce1", "class_name": "RelatedNodeInfo"}}, "text": "Our generics business continues to grow. ", "start_char_idx": 1338, "end_char_idx": 1379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40c65c05-88ad-47c4-9051-cdcb75e99529": {"__data__": {"id_": "40c65c05-88ad-47c4-9051-cdcb75e99529", "embedding": null, "metadata": {"window": "At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.  ", "original_text": "And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3096dfd-c280-446e-a05f-c0f0785c6f4e", "node_type": "1", "metadata": {"window": "I talked about the dual mandate that we focus on, which is driving low -cost capabilities \u2013 low-\ncost positions for our cust omers.  At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n ", "original_text": "Our generics business continues to grow. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2224a505dc1d405577efb55387cd762f2e2146df3e4f51a134631fb93b9ed7d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8347c81-a453-49a7-9462-693e9a89efea", "node_type": "1", "metadata": {"window": "We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n"}, "hash": "f38704bd7f47690d3dc529ff1924215e2ae8ae708f2a95759354a7c063a6a58a", "class_name": "RelatedNodeInfo"}}, "text": "And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities. ", "start_char_idx": 1379, "end_char_idx": 1500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8347c81-a453-49a7-9462-693e9a89efea": {"__data__": {"id_": "f8347c81-a453-49a7-9462-693e9a89efea", "embedding": null, "metadata": {"window": "We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40c65c05-88ad-47c4-9051-cdcb75e99529", "node_type": "1", "metadata": {"window": "At the same time, it's driving the highest availability of supply.  We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.  ", "original_text": "And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "322b17a8b1b3c5657559328efdb60510768fe9932ddfd3116f641ce2e65d3649", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "420c75e0-7e5a-423d-b803-8bd024909bed", "node_type": "1", "metadata": {"window": "Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n "}, "hash": "2004cbbeb006c45de18a58dbd01edef1022a72d757c060f43c75075610c9707e", "class_name": "RelatedNodeInfo"}}, "text": "And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n", "start_char_idx": 1500, "end_char_idx": 1602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "420c75e0-7e5a-423d-b803-8bd024909bed": {"__data__": {"id_": "420c75e0-7e5a-423d-b803-8bd024909bed", "embedding": null, "metadata": {"window": "Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8347c81-a453-49a7-9462-693e9a89efea", "node_type": "1", "metadata": {"window": "We've been able \nto do that over a long period of time.  \n \n Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "709ec3492db6d49b8fc9638293a5594a257754b83ca2eea7c4b569728681633c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5a81f01-79de-47ab-afef-7a3a4a2404b0", "node_type": "1", "metadata": {"window": "And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.  "}, "hash": "13bd3513e63416a5f5aac566c03c374b88c8be1463446c933a715f4f56e2c9b6", "class_name": "RelatedNodeInfo"}}, "text": "So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n ", "start_char_idx": 1602, "end_char_idx": 1931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5a81f01-79de-47ab-afef-7a3a4a2404b0": {"__data__": {"id_": "b5a81f01-79de-47ab-afef-7a3a4a2404b0", "embedding": null, "metadata": {"window": "And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "420c75e0-7e5a-423d-b803-8bd024909bed", "node_type": "1", "metadata": {"window": "Our generics business continues to grow.  And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "original_text": "So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "78ed15fd05a3b91ec02744d30158aab57d07e98a3a406c0ea9ecc32d3dd75229", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fbe90bc3-5131-4eb4-a8d0-9ea2e6448f74", "node_type": "1", "metadata": {"window": "And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "original_text": "A \nNext question, please?  \n "}, "hash": "d6557babfe6ac55f4e5616eb0eca74268ddfa587c3c701686bad5fe7e6051e64", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.  ", "start_char_idx": 1931, "end_char_idx": 2277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fbe90bc3-5131-4eb4-a8d0-9ea2e6448f74": {"__data__": {"id_": "fbe90bc3-5131-4eb4-a8d0-9ea2e6448f74", "embedding": null, "metadata": {"window": "And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "original_text": "A \nNext question, please?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5a81f01-79de-47ab-afef-7a3a4a2404b0", "node_type": "1", "metadata": {"window": "And we're quite pleased with the sourcing spread that we're able to \ngenerate from our  sourcing buy -side capabilities.  And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c89791928b647fdc296c6c412910a079729ad1bedae32960d6d97b4f1399d645", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9005e904-c3c2-40e4-bbce-6c20842c9354", "node_type": "1", "metadata": {"window": "So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. "}, "hash": "69cbb28b651b38a878bc99202cf3e9bc4bb747a5fcba3a3049b97183d75cf836", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 2277, "end_char_idx": 2306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9005e904-c3c2-40e4-bbce-6c20842c9354": {"__data__": {"id_": "9005e904-c3c2-40e4-bbce-6c20842c9354", "embedding": null, "metadata": {"window": "So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fbe90bc3-5131-4eb4-a8d0-9ea2e6448f74", "node_type": "1", "metadata": {"window": "And we think that our customers are benefiting as well, and we \nsee that in high compliance rate.  \n \n So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "original_text": "A \nNext question, please?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "75a4dbefc8958986693e66d9969ae7ef9b35cc6fbb40a0fe609323bcc068044c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7d5b4b9-9869-4431-ae66-b593604f1e88", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact. ", "original_text": "Please go ahead.  \n "}, "hash": "3bed3f59fad6bd98d4c811560019ce8c29b26add4bd973eb10dbb3a8a3e159a0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "start_char_idx": 2306, "end_char_idx": 2633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7d5b4b9-9869-4431-ae66-b593604f1e88": {"__data__": {"id_": "a7d5b4b9-9869-4431-ae66-b593604f1e88", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9005e904-c3c2-40e4-bbce-6c20842c9354", "node_type": "1", "metadata": {"window": "So it's been a competitive but stable marketplace in the Generic space, but the capabilities that we have on \nsourcing, the ability for us to drive lower cost and high availability of product, and generate spread for our \ncustomers in a disciplined way, that has proven to be a good formula for us over a long period of time.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aca2fe4ff3543ab5604f6d4523c4b2984a08f079052275e2794b917ad5a38804", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "72b405d0-0d3c-4b02-924f-69c609f1e4b2", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. "}, "hash": "0123dcceeadd4155839fdd2497a195e79aa1e312c57eccc446960ac99da88cb0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2633, "end_char_idx": 2653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "72b405d0-0d3c-4b02-924f-69c609f1e4b2": {"__data__": {"id_": "72b405d0-0d3c-4b02-924f-69c609f1e4b2", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7d5b4b9-9869-4431-ae66-b593604f1e88", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations , McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact. ", "original_text": "Please go ahead.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "160272ca45a658b07cf0bb6a173e16062378808d44d9e2ce87dce26b5fc0da01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4c070621-89b2-4911-a3ec-c8d9bf440688", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here? ", "original_text": "Thanks for taking my question. "}, "hash": "d113f2b31874626a5779d6f54c0198c5ce8dd1cfc087da49fb24e152480c8a60", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "start_char_idx": 2653, "end_char_idx": 2982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4c070621-89b2-4911-a3ec-c8d9bf440688": {"__data__": {"id_": "4c070621-89b2-4911-a3ec-c8d9bf440688", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here? ", "original_text": "Thanks for taking my question. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "72b405d0-0d3c-4b02-924f-69c609f1e4b2", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1de1fd0c08c5689c5f5dc6214a93c36d65f5cfc37dcc0789f1fc441f55da81ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "024f5141-db0b-455b-9ca2-1f54ae63b85b", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n ", "original_text": "I appreciate the color on the Rite Aid impact. "}, "hash": "0761217d45f65d75c71d97fc407ec27a34f58d61e29e93ee6f09520649c98e66", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 2982, "end_char_idx": 3013, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "024f5141-db0b-455b-9ca2-1f54ae63b85b": {"__data__": {"id_": "024f5141-db0b-455b-9ca2-1f54ae63b85b", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n ", "original_text": "I appreciate the color on the Rite Aid impact. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4c070621-89b2-4911-a3ec-c8d9bf440688", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Kevin Caliendo with UBS.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here? ", "original_text": "Thanks for taking my question. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c2c3ce2222586691eb93d1463eda3f239051344940c34a9bb2b9bc5156a373d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab26f6d4-2297-4ead-86aa-8651d875bf64", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n"}, "hash": "cd983506970ee07b9f3c86690684ba99c32ab0e024e7143775ce3fea5460116b", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate the color on the Rite Aid impact. ", "start_char_idx": 3013, "end_char_idx": 3060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab26f6d4-2297-4ead-86aa-8651d875bf64": {"__data__": {"id_": "ab26f6d4-2297-4ead-86aa-8651d875bf64", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "024f5141-db0b-455b-9ca2-1f54ae63b85b", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n ", "original_text": "I appreciate the color on the Rite Aid impact. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0272e8c404dc28388245f4356c79c08cf9d2bba2bd4ced60b4946bb6dcec219e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "138ceca5-2ff8-4746-9ca5-41c5e831ba6d", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question. ", "original_text": "But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here? "}, "hash": "d376617cb9dae146fd1340688623d8c9e2c2289d6786eb6e26ba4097ab0d5b9e", "class_name": "RelatedNodeInfo"}}, "text": "I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n", "start_char_idx": 3060, "end_char_idx": 3205, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "138ceca5-2ff8-4746-9ca5-41c5e831ba6d": {"__data__": {"id_": "138ceca5-2ff8-4746-9ca5-41c5e831ba6d", "embedding": null, "metadata": {"window": "Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question. ", "original_text": "But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here? ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab26f6d4-2297-4ead-86aa-8651d875bf64", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nKevin Caliendo  \nAnalyst, UBS Securities LLC  Q \nThanks.  Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4cb001a7c536b5014088d94fe28240f3fc923dff2714be98daeaec0becc1fa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e027ad18-6def-47b9-b2b1-044e7bddcdef", "node_type": "1", "metadata": {"window": "I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid. ", "original_text": "Like is it built in, in your comments and how meaningful can it be?  \n "}, "hash": "e789652d87d6944a991ac407b1cc94a900c5b38b2e20dba6844f11a0b3a98dea", "class_name": "RelatedNodeInfo"}}, "text": "But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here? ", "start_char_idx": 3205, "end_char_idx": 3335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e027ad18-6def-47b9-b2b1-044e7bddcdef": {"__data__": {"id_": "e027ad18-6def-47b9-b2b1-044e7bddcdef", "embedding": null, "metadata": {"window": "I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid. ", "original_text": "Like is it built in, in your comments and how meaningful can it be?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "138ceca5-2ff8-4746-9ca5-41c5e831ba6d", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question. ", "original_text": "But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here? ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0861c5b6be0582d1b5476c2ad6c65e9d47bb6763d08eb9c7b0d09ad240ad380a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ce3bd24-a664-4157-961a-c0c2ac6caeba", "node_type": "1", "metadata": {"window": "I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "9d8714bfe050ce6b442f069a04b0a74d57ab6017f912ede8362700658de219b8", "class_name": "RelatedNodeInfo"}}, "text": "Like is it built in, in your comments and how meaningful can it be?  \n ", "start_char_idx": 3335, "end_char_idx": 3406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ce3bd24-a664-4157-961a-c0c2ac6caeba": {"__data__": {"id_": "9ce3bd24-a664-4157-961a-c0c2ac6caeba", "embedding": null, "metadata": {"window": "I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e027ad18-6def-47b9-b2b1-044e7bddcdef", "node_type": "1", "metadata": {"window": "I appreciate the color on the Rite Aid impact.  I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid. ", "original_text": "Like is it built in, in your comments and how meaningful can it be?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6748aaf93e7b40274fe9be4f5d063f12f248a7e6ced75a8a59a10a66a7b31f92", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98e1ef3c-8940-42cb-a06d-749c7efe68ca", "node_type": "1", "metadata": {"window": "But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults. ", "original_text": "A \nI appreciate the question. "}, "hash": "052593ace38de4004e263c4315b4298f2006d9557998a9d9894dca6b97ac4539", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 481, "end_char_idx": 841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98e1ef3c-8940-42cb-a06d-749c7efe68ca": {"__data__": {"id_": "98e1ef3c-8940-42cb-a06d-749c7efe68ca", "embedding": null, "metadata": {"window": "But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults. ", "original_text": "A \nI appreciate the question. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ce3bd24-a664-4157-961a-c0c2ac6caeba", "node_type": "1", "metadata": {"window": "I'm gue ssing my question is, \nI know we don't know exactly what's going to happen with the rest of Rite Aid, we should hopefully know soon.  \n \n But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19fbfc9b46c6a69690efabeae61704f69e8cbf2a16d62e70be225b7ea4b66231", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b42c6c7a-a7b3-4398-9e5e-4ed10c44b5d8", "node_type": "1", "metadata": {"window": "Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that. ", "original_text": "I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid. "}, "hash": "50f6b29ab0e32a81d8bb61a18fde4c92bed011f7c3049d4b45c7fb122802c91d", "class_name": "RelatedNodeInfo"}}, "text": "A \nI appreciate the question. ", "start_char_idx": 3766, "end_char_idx": 3796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b42c6c7a-a7b3-4398-9e5e-4ed10c44b5d8": {"__data__": {"id_": "b42c6c7a-a7b3-4398-9e5e-4ed10c44b5d8", "embedding": null, "metadata": {"window": "Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that. ", "original_text": "I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98e1ef3c-8940-42cb-a06d-749c7efe68ca", "node_type": "1", "metadata": {"window": "But what are the assumptions built in for fiscal 2025 around the potential impact from whatever happens with Rite \nAid from here?  Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults. ", "original_text": "A \nI appreciate the question. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88004ed935ca0957fab4fbb27da019a1419d520e467839f203a38cf471e640b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e388a5e6-980d-4539-8cf5-57142a953437", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months. ", "original_text": "What I can tell you \nis what we've talked about for fiscal 2024. "}, "hash": "113bc07253e0bd854e8fdf8acd887539d024eb5000763c5e6eaa7190514a1f86", "class_name": "RelatedNodeInfo"}}, "text": "I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid. ", "start_char_idx": 3796, "end_char_idx": 3868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e388a5e6-980d-4539-8cf5-57142a953437": {"__data__": {"id_": "e388a5e6-980d-4539-8cf5-57142a953437", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months. ", "original_text": "What I can tell you \nis what we've talked about for fiscal 2024. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b42c6c7a-a7b3-4398-9e5e-4ed10c44b5d8", "node_type": "1", "metadata": {"window": "Like is it built in, in your comments and how meaningful can it be?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that. ", "original_text": "I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f37ab60ea409879eb62e0dbd7d0439432ffb43f3ecf49ed04af16a089f27ce4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab6cbccd-d312-4811-b769-3d4a0684edd8", "node_type": "1", "metadata": {"window": "A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions. ", "original_text": "And Rite Aid is not going to have a material impact on our financial \nresults. "}, "hash": "aa75ab2c4c7515646fab84b16af3b6ff9910ef72227a09eda5ff89d29f4eec55", "class_name": "RelatedNodeInfo"}}, "text": "What I can tell you \nis what we've talked about for fiscal 2024. ", "start_char_idx": 3868, "end_char_idx": 3933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab6cbccd-d312-4811-b769-3d4a0684edd8": {"__data__": {"id_": "ab6cbccd-d312-4811-b769-3d4a0684edd8", "embedding": null, "metadata": {"window": "A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions. ", "original_text": "And Rite Aid is not going to have a material impact on our financial \nresults. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e388a5e6-980d-4539-8cf5-57142a953437", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months. ", "original_text": "What I can tell you \nis what we've talked about for fiscal 2024. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0eab3226afd186946bc35265920598da13bdefdc1f20d3535810018208eca283", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa84a815-50b7-4fc8-a006-1484166eba52", "node_type": "1", "metadata": {"window": "I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n ", "original_text": "So I would leave it at that. "}, "hash": "5b3b50b54d0ae4ade60c120c0c5b79984c1153534ff203c92791a7fad94af1f2", "class_name": "RelatedNodeInfo"}}, "text": "And Rite Aid is not going to have a material impact on our financial \nresults. ", "start_char_idx": 3933, "end_char_idx": 4012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa84a815-50b7-4fc8-a006-1484166eba52": {"__data__": {"id_": "aa84a815-50b7-4fc8-a006-1484166eba52", "embedding": null, "metadata": {"window": "I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n ", "original_text": "So I would leave it at that. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab6cbccd-d312-4811-b769-3d4a0684edd8", "node_type": "1", "metadata": {"window": "A \nI appreciate the question.  I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions. ", "original_text": "And Rite Aid is not going to have a material impact on our financial \nresults. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35d6f950fa27aae9deb71b418f665cd8bbfad30c82c8fba05c0116f745cd37b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16d4b767-b9c9-471e-8808-4972cf43a8ea", "node_type": "1", "metadata": {"window": "What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "In terms of 2025, we'll learn more over the next few months. "}, "hash": "e3337e83a3453012356145eff9dc19855c75b5eaf666ae794ddf9aa2cca06482", "class_name": "RelatedNodeInfo"}}, "text": "So I would leave it at that. ", "start_char_idx": 4012, "end_char_idx": 4041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16d4b767-b9c9-471e-8808-4972cf43a8ea": {"__data__": {"id_": "16d4b767-b9c9-471e-8808-4972cf43a8ea", "embedding": null, "metadata": {"window": "What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "In terms of 2025, we'll learn more over the next few months. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa84a815-50b7-4fc8-a006-1484166eba52", "node_type": "1", "metadata": {"window": "I obviously can't \u2013 am not in a position to comment a lot on Rite  Aid.  What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n ", "original_text": "So I would leave it at that. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ba7d89302f70f8ae105b192ac897daa85a5f87e952b6dd557ce22b7265482f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52d0be2b-5828-4d19-95a4-55970cc58fd0", "node_type": "1", "metadata": {"window": "And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions. "}, "hash": "6550b50b07b533a23c18509e98ce5ae526f1635f9e14ce197faf9bd813d7f9d0", "class_name": "RelatedNodeInfo"}}, "text": "In terms of 2025, we'll learn more over the next few months. ", "start_char_idx": 4041, "end_char_idx": 4102, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52d0be2b-5828-4d19-95a4-55970cc58fd0": {"__data__": {"id_": "52d0be2b-5828-4d19-95a4-55970cc58fd0", "embedding": null, "metadata": {"window": "And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16d4b767-b9c9-471e-8808-4972cf43a8ea", "node_type": "1", "metadata": {"window": "What I can tell you \nis what we've talked about for fiscal 2024.  And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "In terms of 2025, we'll learn more over the next few months. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6b384041f08aa8945bc3d4c5c7bbbb31308fac84f7880215db4ae04ee7c40cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a9873f8-0a7f-4430-b704-db97a19a8bde", "node_type": "1", "metadata": {"window": "So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n "}, "hash": "545cb8c3708e1ca344538b4beca279e56a5dbb7e70fe14b0accc9c425f37d0ef", "class_name": "RelatedNodeInfo"}}, "text": "We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions. ", "start_char_idx": 4102, "end_char_idx": 4209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a9873f8-0a7f-4430-b704-db97a19a8bde": {"__data__": {"id_": "8a9873f8-0a7f-4430-b704-db97a19a8bde", "embedding": null, "metadata": {"window": "So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52d0be2b-5828-4d19-95a4-55970cc58fd0", "node_type": "1", "metadata": {"window": "And Rite Aid is not going to have a material impact on our financial \nresults.  So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions. ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5f5ac8750529a5491eb72563b21cb9e26af673157834c86193135da28c2496c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1172e5a-abc9-463e-9e8f-dae34f2fe017", "node_type": "1", "metadata": {"window": "In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "5919fc73d0f2866deff556b678e657155c449d0abec0b66f99c40360534415ff", "class_name": "RelatedNodeInfo"}}, "text": "But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n ", "start_char_idx": 4209, "end_char_idx": 4283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1172e5a-abc9-463e-9e8f-dae34f2fe017": {"__data__": {"id_": "e1172e5a-abc9-463e-9e8f-dae34f2fe017", "embedding": null, "metadata": {"window": "In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a9873f8-0a7f-4430-b704-db97a19a8bde", "node_type": "1", "metadata": {"window": "So I would leave it at that.  In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "576276325f669491ad2b37b855a5fb3fb73e44f161a1d859842ee190a6a2a360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e41a6e1-fa3a-4585-ab5f-8ddd80e3572f", "node_type": "1", "metadata": {"window": "We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "A "}, "hash": "ab74fc056c30e20d8dd04511882594a2c2e44a1590f3ddd602d0cffb6bdbed43", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 4283, "end_char_idx": 4628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e41a6e1-fa3a-4585-ab5f-8ddd80e3572f": {"__data__": {"id_": "7e41a6e1-fa3a-4585-ab5f-8ddd80e3572f", "embedding": null, "metadata": {"window": "We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "A ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e7b43a772b9886e2ede3f789bdca3540557d5b794e4f7ddfe2f382d50ed04971", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1172e5a-abc9-463e-9e8f-dae34f2fe017", "node_type": "1", "metadata": {"window": "In terms of 2025, we'll learn more over the next few months.  We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc9ed26767b5827d04122262547f7b02371eb4fe57648d389cc3c77ee7316bf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed11d05d-6e96-4908-84ef-ee7131e318be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "McKesson Corp.  "}, "hash": "5bf3363daf0933c4f8e5078d6dfc74f8eba5a8db5fdbad0a2f6b675b76719ea6", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 841, "end_char_idx": 843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed11d05d-6e96-4908-84ef-ee7131e318be": {"__data__": {"id_": "ed11d05d-6e96-4908-84ef-ee7131e318be", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e41a6e1-fa3a-4585-ab5f-8ddd80e3572f", "node_type": "1", "metadata": {"window": "We'll give you \nmore information as we give you further information on all of our fiscal 2025 assumptions.  But Rite Aid is not \nmaterial to our financial results in fiscal 2024.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A ", "original_text": "A ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb7c967c98fe472124c95d1ee083c8ed96bcee62fcb159e4d876d3fa458bd0ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98a27a5d-70ea-459c-a76f-c5b0dda93fde", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n "}, "hash": "a06e1a6ffcac171deafe0a69ed6171154c0021af1bf273221b04970ca75e50f7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98a27a5d-70ea-459c-a76f-c5b0dda93fde": {"__data__": {"id_": "98a27a5d-70ea-459c-a76f-c5b0dda93fde", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed11d05d-6e96-4908-84ef-ee7131e318be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07957077b792915a09716742e4ce28b18e1ea226e324af462410a2d514fda8da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b36545ab-e208-43bf-83ed-824c9a1a69c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. "}, "hash": "c326964cf6319a82ee247f119976de2959317aabec191dfb0078bbdd56a4f50f", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n ", "start_char_idx": 16, "end_char_idx": 207, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b36545ab-e208-43bf-83ed-824c9a1a69c3": {"__data__": {"id_": "b36545ab-e208-43bf-83ed-824c9a1a69c3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98a27a5d-70ea-459c-a76f-c5b0dda93fde", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b74f793fa6336414340e65c41f365dd80448a37d6e81fcf2540c33a177e69b6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3220052-24a2-4ca0-8d2c-0455ea769c0e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon. ", "original_text": "Please go ahead.  \n "}, "hash": "653085eecad5eb2012a1e996061a6ab4b71a0a0dfaf8999018948e7673389b2b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "start_char_idx": 207, "end_char_idx": 535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3220052-24a2-4ca0-8d2c-0455ea769c0e": {"__data__": {"id_": "c3220052-24a2-4ca0-8d2c-0455ea769c0e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon. ", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b36545ab-e208-43bf-83ed-824c9a1a69c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "577b970cc5707274aaacc0213f2e59d6c464dee3a28a6c118ad1d3680c0c58c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b8fcea1-2114-47c8-bb54-033b4d0ef87a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "1815a0321dd1be07684dae46bcede8a9b7f0f7dc49cb4310b9fddab65749a716", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 535, "end_char_idx": 555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b8fcea1-2114-47c8-bb54-033b4d0ef87a": {"__data__": {"id_": "0b8fcea1-2114-47c8-bb54-033b4d0ef87a", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3220052-24a2-4ca0-8d2c-0455ea769c0e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon. ", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "579a307c8801a09d2f37a07820989797fafc7d2d3191feeb73f942735c25815c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b2e4087-281d-4d38-aaf3-90c92e13e5a3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact? ", "original_text": "Q \nThank you. "}, "hash": "0006cb2963df68251ff4f3057877cce6d998ab9f669841463cdc3d2e95e222bf", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 555, "end_char_idx": 887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b2e4087-281d-4d38-aaf3-90c92e13e5a3": {"__data__": {"id_": "5b2e4087-281d-4d38-aaf3-90c92e13e5a3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact? ", "original_text": "Q \nThank you. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b8fcea1-2114-47c8-bb54-033b4d0ef87a", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc79fc1634485a754581fc819508f487c1f53e009cfb0475c341cb5e83a590c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a3b1ec4-0df0-4491-a456-61129bbbf9cd", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n", "original_text": "Good afternoon. "}, "hash": "c4f1caad978e5078f7b0beffec19a6080fa9f5a5cb3c2d779ba53d2ec73f0493", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThank you. ", "start_char_idx": 887, "end_char_idx": 901, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a3b1ec4-0df0-4491-a456-61129bbbf9cd": {"__data__": {"id_": "8a3b1ec4-0df0-4491-a456-61129bbbf9cd", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n", "original_text": "Good afternoon. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b2e4087-281d-4d38-aaf3-90c92e13e5a3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact? ", "original_text": "Q \nThank you. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "79dd6dd09c5394e960c87d60d4fc5ac485ae73d8fe6e2dd0fa79c254fa1b5720", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6db7766d-49e6-4117-8a03-3cc2d95081bc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n", "original_text": "This one, I think, is fairly obvious and fairly simple, but I just want to make sure. "}, "hash": "80d7ddcffd5fe8b71a224cc2de543595971d3e44334aa8faad6c25fc00c8945f", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon. ", "start_char_idx": 901, "end_char_idx": 917, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6db7766d-49e6-4117-8a03-3cc2d95081bc": {"__data__": {"id_": "6db7766d-49e6-4117-8a03-3cc2d95081bc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n", "original_text": "This one, I think, is fairly obvious and fairly simple, but I just want to make sure. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a3b1ec4-0df0-4491-a456-61129bbbf9cd", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n", "original_text": "Good afternoon. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a60d14e65672f7f2c28af559346626ac2775c3427a1802533f0742140860b59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac922c23-7e0c-45f3-991f-2b60bd136a7a", "node_type": "1", "metadata": {"window": "Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic? ", "original_text": "The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact? "}, "hash": "bc18df33f227af95ee9ded936b0b9d0f6ad1c4fca63e6a9265df119c331efea5", "class_name": "RelatedNodeInfo"}}, "text": "This one, I think, is fairly obvious and fairly simple, but I just want to make sure. ", "start_char_idx": 917, "end_char_idx": 1003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac922c23-7e0c-45f3-991f-2b60bd136a7a": {"__data__": {"id_": "ac922c23-7e0c-45f3-991f-2b60bd136a7a", "embedding": null, "metadata": {"window": "Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic? ", "original_text": "The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact? ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6db7766d-49e6-4117-8a03-3cc2d95081bc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n", "original_text": "This one, I think, is fairly obvious and fairly simple, but I just want to make sure. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1280db7319dab10e1788f6876e6982eaa76f04fafd6e8cb70584aa3a7b6a8c3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5c4ff7e-7325-459a-b9fc-5d4a6b5d3784", "node_type": "1", "metadata": {"window": "Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo. ", "original_text": "And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n"}, "hash": "7de8bb0688c18257ec653e27ff745835578aebdade2c3a5d0db8ba5c3472d99c", "class_name": "RelatedNodeInfo"}}, "text": "The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact? ", "start_char_idx": 1003, "end_char_idx": 1111, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c4ff7e-7325-459a-b9fc-5d4a6b5d3784": {"__data__": {"id_": "c5c4ff7e-7325-459a-b9fc-5d4a6b5d3784", "embedding": null, "metadata": {"window": "Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo. ", "original_text": "And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac922c23-7e0c-45f3-991f-2b60bd136a7a", "node_type": "1", "metadata": {"window": "Q \nThank you.  Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic? ", "original_text": "The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact? ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9600169ccb2a2726c3a6c7470e98aa31b5f4b1eb56f9b8415e9f584489b7ea1d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f597381-71ea-4374-96dc-f9b3177c9afd", "node_type": "1", "metadata": {"window": "This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n ", "original_text": "And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n"}, "hash": "a25fd5ef19f54d1a1d660545973174fdbbb81fce62dc664b0d3c9997dcf20d19", "class_name": "RelatedNodeInfo"}}, "text": "And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n", "start_char_idx": 1111, "end_char_idx": 1324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f597381-71ea-4374-96dc-f9b3177c9afd": {"__data__": {"id_": "6f597381-71ea-4374-96dc-f9b3177c9afd", "embedding": null, "metadata": {"window": "This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n ", "original_text": "And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c4ff7e-7325-459a-b9fc-5d4a6b5d3784", "node_type": "1", "metadata": {"window": "Good afternoon.  This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo. ", "original_text": "And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d709f60163e00d6551f7b322cc485ba66e77bb270467271608d186e3da25360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa94e81a-9e61-4809-8917-44678930c507", "node_type": "1", "metadata": {"window": "The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic? "}, "hash": "bdfc099d091281ba66bc787e2f8dbf8ac6ddaea68f2e579680846947d1eb9d0d", "class_name": "RelatedNodeInfo"}}, "text": "And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n", "start_char_idx": 1324, "end_char_idx": 1447, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa94e81a-9e61-4809-8917-44678930c507": {"__data__": {"id_": "fa94e81a-9e61-4809-8917-44678930c507", "embedding": null, "metadata": {"window": "The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic? ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f597381-71ea-4374-96dc-f9b3177c9afd", "node_type": "1", "metadata": {"window": "This one, I think, is fairly obvious and fairly simple, but I just want to make sure.  The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n ", "original_text": "And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc83a71f62c2c2b0b161f2792b11822a28dbff4d84fcfe8351a7af8af071bb25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "032c2696-74b9-4c7b-99e4-a38265e5f349", "node_type": "1", "metadata": {"window": "And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Those are my only \ntwo. "}, "hash": "46559b23a96d7dccab6ed5291895b02f7e837b2063a5c127442ab2d3a67619d1", "class_name": "RelatedNodeInfo"}}, "text": "Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic? ", "start_char_idx": 1447, "end_char_idx": 1544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "032c2696-74b9-4c7b-99e4-a38265e5f349": {"__data__": {"id_": "032c2696-74b9-4c7b-99e4-a38265e5f349", "embedding": null, "metadata": {"window": "And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Those are my only \ntwo. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa94e81a-9e61-4809-8917-44678930c507", "node_type": "1", "metadata": {"window": "The \nfree cash flow reduction versus prior guide, is that specifically and only due to the Rite Aid impact?  And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic? ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "728b3ea574ad8841ab5cabb71dce8cd7258d0843f003459b0dc5329cc393b3c6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3989eac8-ea2d-451f-9109-afe340df7d6e", "node_type": "1", "metadata": {"window": "And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric. ", "original_text": "Thank you very much.  \n "}, "hash": "7e99aa30e3638a2c92065f7bf8dc6340ecc15edd7c927e443954dd98bd74df78", "class_name": "RelatedNodeInfo"}}, "text": "Those are my only \ntwo. ", "start_char_idx": 1544, "end_char_idx": 1568, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3989eac8-ea2d-451f-9109-afe340df7d6e": {"__data__": {"id_": "3989eac8-ea2d-451f-9109-afe340df7d6e", "embedding": null, "metadata": {"window": "And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric. ", "original_text": "Thank you very much.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "032c2696-74b9-4c7b-99e4-a38265e5f349", "node_type": "1", "metadata": {"window": "And if so, I \nguess the question is why you didn't take that last quarter, perhaps when \u2013 I guess maybe that's not a fair \nquestion given the timing, but I jus t want to make sure that's the only topic there.  \n \n And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah. ", "original_text": "Those are my only \ntwo. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46cabb9a9a5a5d3dc0841cf6f86002b3cba2e7447b28c55e26cb2646a7d512e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "031a4fcb-ae94-4637-95f8-0230d6da4921", "node_type": "1", "metadata": {"window": "Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "b010a7a8e4fcb2905825c3bf8ecf716e5ac936164ae2c9f24dee7de88298ae9c", "class_name": "RelatedNodeInfo"}}, "text": "Thank you very much.  \n ", "start_char_idx": 1568, "end_char_idx": 1592, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "031a4fcb-ae94-4637-95f8-0230d6da4921": {"__data__": {"id_": "031a4fcb-ae94-4637-95f8-0230d6da4921", "embedding": null, "metadata": {"window": "Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3989eac8-ea2d-451f-9109-afe340df7d6e", "node_type": "1", "metadata": {"window": "And then on the repo activity as well, slightly lower outlook here, $3 billion to $3.5 billion versus prior $3.5 billion. \n Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric. ", "original_text": "Thank you very much.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a0d98656aa7ae8f8eb0bc28e99a199687d28f81f71d6d06c301662b7181c1ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fbd1228-b8a3-4c5c-b1d6-3451cd6f19e2", "node_type": "1", "metadata": {"window": "Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that. ", "original_text": "A \nYeah. "}, "hash": "c73857a5e82f0e2167087e055261a65bc60586d087a4989fe7d60817ffdd49b7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 1592, "end_char_idx": 1952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fbd1228-b8a3-4c5c-b1d6-3451cd6f19e2": {"__data__": {"id_": "5fbd1228-b8a3-4c5c-b1d6-3451cd6f19e2", "embedding": null, "metadata": {"window": "Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "031a4fcb-ae94-4637-95f8-0230d6da4921", "node_type": "1", "metadata": {"window": "Is that also the Rite Aid impact or perhaps due to valuation in the market or some o ther topic?  Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9ab2b9cc93030f84ae74c855ea17cef1ba20a4b6bc944d4c4f8f3033552edeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6382bd9-385f-4e8d-b837-65d14d717550", "node_type": "1", "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n", "original_text": "Appreciate the question, Eric. "}, "hash": "960262eacafa4002762fd2bfd7e75a79ba2dedc5f4abe789726ccba70190e331", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1952, "end_char_idx": 1961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6382bd9-385f-4e8d-b837-65d14d717550": {"__data__": {"id_": "c6382bd9-385f-4e8d-b837-65d14d717550", "embedding": null, "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n", "original_text": "Appreciate the question, Eric. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fbd1228-b8a3-4c5c-b1d6-3451cd6f19e2", "node_type": "1", "metadata": {"window": "Those are my only \ntwo.  Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "24571b17ce8e0db8e954bf9653bb59a1be436ee8789229e05599ca1ec5ac3799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "afc7339f-e7e8-4803-bab2-f5631c8e8843", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that. ", "original_text": "And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n"}, "hash": "c2d42fe743f5c6d181bf9c050cefbb8fd48a96438428e4d03ec498a4c0033957", "class_name": "RelatedNodeInfo"}}, "text": "Appreciate the question, Eric. ", "start_char_idx": 1961, "end_char_idx": 1992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "afc7339f-e7e8-4803-bab2-f5631c8e8843": {"__data__": {"id_": "afc7339f-e7e8-4803-bab2-f5631c8e8843", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that. ", "original_text": "And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6382bd9-385f-4e8d-b837-65d14d717550", "node_type": "1", "metadata": {"window": "Thank you very much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n", "original_text": "Appreciate the question, Eric. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4dd946cb5b63decd8e69286ff232c37aeda9bcf6b4ed3dcbcbab7714085696e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f64404fb-007e-420d-9beb-fef94b63d1fe", "node_type": "1", "metadata": {"window": "A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide. ", "original_text": "So it is a key driver to that. "}, "hash": "870ec4d8fb87c521b52ca0e2a7fe54291c3c7d88c6ce55624b6379c024a56185", "class_name": "RelatedNodeInfo"}}, "text": "And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n", "start_char_idx": 1992, "end_char_idx": 2190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f64404fb-007e-420d-9beb-fef94b63d1fe": {"__data__": {"id_": "f64404fb-007e-420d-9beb-fef94b63d1fe", "embedding": null, "metadata": {"window": "A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide. ", "original_text": "So it is a key driver to that. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "afc7339f-e7e8-4803-bab2-f5631c8e8843", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that. ", "original_text": "And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9b4b6bda01293eeb095eb31c6f3c00cfd6cb061b2fbd69a4398f0050c7fcceb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f65034ad-b1a7-406e-93b7-0914f880dd8f", "node_type": "1", "metadata": {"window": "Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n", "original_text": "So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n"}, "hash": "b3f067e1233c9c1f00e654c9c6beda0a844c40eb3774667c941bfc87d94f8d22", "class_name": "RelatedNodeInfo"}}, "text": "So it is a key driver to that. ", "start_char_idx": 2190, "end_char_idx": 2221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f65034ad-b1a7-406e-93b7-0914f880dd8f": {"__data__": {"id_": "f65034ad-b1a7-406e-93b7-0914f880dd8f", "embedding": null, "metadata": {"window": "Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n", "original_text": "So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f64404fb-007e-420d-9beb-fef94b63d1fe", "node_type": "1", "metadata": {"window": "A \nYeah.  Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide. ", "original_text": "So it is a key driver to that. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ae72f3c08039d6d03ebda786592d91a9e9d5fcf3f1f322d31fced2045b8d3b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad0d0614-d184-4e55-a467-e9952e98a15b", "node_type": "1", "metadata": {"window": "And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock. ", "original_text": "In terms of share repo, I'd say that there's two things that are driving that. "}, "hash": "b4b11fe82447c43936504d1e66ef75c50169ec80d7d4b602fdd358ff50b0f075", "class_name": "RelatedNodeInfo"}}, "text": "So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n", "start_char_idx": 2221, "end_char_idx": 2338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad0d0614-d184-4e55-a467-e9952e98a15b": {"__data__": {"id_": "ad0d0614-d184-4e55-a467-e9952e98a15b", "embedding": null, "metadata": {"window": "And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock. ", "original_text": "In terms of share repo, I'd say that there's two things that are driving that. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f65034ad-b1a7-406e-93b7-0914f880dd8f", "node_type": "1", "metadata": {"window": "Appreciate the question, Eric.  And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n", "original_text": "So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33a779b33e58bc1d72e67f5bd34529febe426ff9f9e1aefa2ca3d4ad9e5bd09a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d09eea6-9749-4fa9-a010-57a20de7e9b6", "node_type": "1", "metadata": {"window": "So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us. ", "original_text": "Clearly, we are taking a look at our free \ncash flow guide. "}, "hash": "df8044f386b8741af3ff31312da146da8dc1bdb1ae5582738b3efe0df7303ec4", "class_name": "RelatedNodeInfo"}}, "text": "In terms of share repo, I'd say that there's two things that are driving that. ", "start_char_idx": 2338, "end_char_idx": 2417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d09eea6-9749-4fa9-a010-57a20de7e9b6": {"__data__": {"id_": "1d09eea6-9749-4fa9-a010-57a20de7e9b6", "embedding": null, "metadata": {"window": "So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us. ", "original_text": "Clearly, we are taking a look at our free \ncash flow guide. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad0d0614-d184-4e55-a467-e9952e98a15b", "node_type": "1", "metadata": {"window": "And you'll note that in our free cash flow guide for the rest of the year , the \nreduction versus the prior guidance that we gave you is not the full impact of the Rite Aid provision for bad debt. \n So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock. ", "original_text": "In terms of share repo, I'd say that there's two things that are driving that. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d346a5b53b2b6e07992e00fc3258fb47ca333951b0e231f2c1c2b708347f9c1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4d1bcdf-8ded-4c2d-a28c-417c586c8bdf", "node_type": "1", "metadata": {"window": "So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined. ", "original_text": "But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n"}, "hash": "3178d03a4db515ed9d1d4b741847204ef8a62ddac2ae46b100692caf84adecf1", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, we are taking a look at our free \ncash flow guide. ", "start_char_idx": 2417, "end_char_idx": 2477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4d1bcdf-8ded-4c2d-a28c-417c586c8bdf": {"__data__": {"id_": "b4d1bcdf-8ded-4c2d-a28c-417c586c8bdf", "embedding": null, "metadata": {"window": "So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined. ", "original_text": "But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d09eea6-9749-4fa9-a010-57a20de7e9b6", "node_type": "1", "metadata": {"window": "So it is a key driver to that.  So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us. ", "original_text": "Clearly, we are taking a look at our free \ncash flow guide. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89bc1149d9c4e11796137facfffbfc4ec16649b309bbb6073a0715e761d2f201", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "153214a0-b38e-478e-95b3-495089b4ba76", "node_type": "1", "metadata": {"window": "In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n ", "original_text": "And secondly, we're going to be looking at the intrinsic value of the stock. "}, "hash": "715801efab2d659b5b562641f2fee3d7c93873b5debdaef927b93df76575e317", "class_name": "RelatedNodeInfo"}}, "text": "But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n", "start_char_idx": 2477, "end_char_idx": 2695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "153214a0-b38e-478e-95b3-495089b4ba76": {"__data__": {"id_": "153214a0-b38e-478e-95b3-495089b4ba76", "embedding": null, "metadata": {"window": "In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n ", "original_text": "And secondly, we're going to be looking at the intrinsic value of the stock. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4d1bcdf-8ded-4c2d-a28c-417c586c8bdf", "node_type": "1", "metadata": {"window": "So to answer your question very simply as Rite Aid and the bankruptcy is a driver on \nfree cash flow red uction.  \n \n In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined. ", "original_text": "But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c06daf7b799aa823935bfa31e58b64a664e66a77d594fc5d900057efbc1cb8b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efbd0f9e-76ad-4418-9432-779929b7f4e0", "node_type": "1", "metadata": {"window": "Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.  ", "original_text": "We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us. "}, "hash": "068390972739b6fdae48b473a0d3d44b9745bd4ad10dfca73b316fcee010a185", "class_name": "RelatedNodeInfo"}}, "text": "And secondly, we're going to be looking at the intrinsic value of the stock. ", "start_char_idx": 2695, "end_char_idx": 2772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efbd0f9e-76ad-4418-9432-779929b7f4e0": {"__data__": {"id_": "efbd0f9e-76ad-4418-9432-779929b7f4e0", "embedding": null, "metadata": {"window": "Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.  ", "original_text": "We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "153214a0-b38e-478e-95b3-495089b4ba76", "node_type": "1", "metadata": {"window": "In terms of share repo, I'd say that there's two things that are driving that.  Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n ", "original_text": "And secondly, we're going to be looking at the intrinsic value of the stock. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff7c3115ca5fca7a15ee689db6d44c9debcbfe685eba2c26e7c16fb781d08b20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b5f948b-5a87-494b-91a6-561cf055bb5c", "node_type": "1", "metadata": {"window": "But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And so we're going to continue to be disciplined. "}, "hash": "410ef7c8379cd8052f3c5b31aee5cf1d13ca34d30e08d34a977f5a51fd1343c5", "class_name": "RelatedNodeInfo"}}, "text": "We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us. ", "start_char_idx": 2772, "end_char_idx": 2935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b5f948b-5a87-494b-91a6-561cf055bb5c": {"__data__": {"id_": "3b5f948b-5a87-494b-91a6-561cf055bb5c", "embedding": null, "metadata": {"window": "But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And so we're going to continue to be disciplined. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efbd0f9e-76ad-4418-9432-779929b7f4e0", "node_type": "1", "metadata": {"window": "Clearly, we are taking a look at our free \ncash flow guide.  But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.  ", "original_text": "We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e179db7376f09cc31b017ebd344aa56d3a76e6954587100bbd8b04ea777bdeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06976a04-633c-4d35-93b0-5dacaf70fa7f", "node_type": "1", "metadata": {"window": "And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "original_text": "And so a portion of that is reflected in the lower \nshare buyback.  \n "}, "hash": "0315a0f0892aa41fb95894e3ba804bf8b14d6affb752cc6b02b9bb7bd4fadb69", "class_name": "RelatedNodeInfo"}}, "text": "And so we're going to continue to be disciplined. ", "start_char_idx": 2935, "end_char_idx": 2985, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06976a04-633c-4d35-93b0-5dacaf70fa7f": {"__data__": {"id_": "06976a04-633c-4d35-93b0-5dacaf70fa7f", "embedding": null, "metadata": {"window": "And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "original_text": "And so a portion of that is reflected in the lower \nshare buyback.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b5f948b-5a87-494b-91a6-561cf055bb5c", "node_type": "1", "metadata": {"window": "But going back to our principles of how we deploy capital, one of the things that we've talked \nabout is, a, w e will buy back shares when cash \u2013 there's excess cash on hand that we can deploy in a growth \nformat.  \n \n And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And so we're going to continue to be disciplined. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6198c5693883df31acac05e79d4c20448f9b61ab08daad641bf263984a90033", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d9bad1a-7570-441f-9d21-31b370dbffbd", "node_type": "1", "metadata": {"window": "We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.  "}, "hash": "ba38ba17bded3c84fab718ed03575b52d99710b503f2bff53e28af890622cd3b", "class_name": "RelatedNodeInfo"}}, "text": "And so a portion of that is reflected in the lower \nshare buyback.  \n ", "start_char_idx": 2985, "end_char_idx": 3055, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d9bad1a-7570-441f-9d21-31b370dbffbd": {"__data__": {"id_": "5d9bad1a-7570-441f-9d21-31b370dbffbd", "embedding": null, "metadata": {"window": "We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06976a04-633c-4d35-93b0-5dacaf70fa7f", "node_type": "1", "metadata": {"window": "And secondly, we're going to be looking at the intrinsic value of the stock.  We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "original_text": "And so a portion of that is reflected in the lower \nshare buyback.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d04413618d520e93a113a2548d4f73d829ec313483a1d94012076b5f79aa4bac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7c38b92-2266-4456-8fe0-4bcb551c107f", "node_type": "1", "metadata": {"window": "And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys. ", "original_text": "A \nNext question, please?  \n "}, "hash": "ae0210b9349f186f44f12824eae6a759824bb0d49881e1fa4a5000b7fee8e352", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.  ", "start_char_idx": 3055, "end_char_idx": 3401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7c38b92-2266-4456-8fe0-4bcb551c107f": {"__data__": {"id_": "c7c38b92-2266-4456-8fe0-4bcb551c107f", "embedding": null, "metadata": {"window": "And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys. ", "original_text": "A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d9bad1a-7570-441f-9d21-31b370dbffbd", "node_type": "1", "metadata": {"window": "We want to be in the market, and we \nwant to return capital to our shareholders through share repurchases, but those two factors are going to be \nimportant to us.  And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7cc42ba7f6d4950bc458de151418858cc1a7babea501ea0b7a0ce46925f4fac7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ac961fe-5511-4cbd-afa7-0329edfae3b7", "node_type": "1", "metadata": {"window": "And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. "}, "hash": "dc9082432f6c9d5b1fcc4dcb6404c74187bf01606d7f1ec41aff8fb5ec961f93", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 3401, "end_char_idx": 3430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ac961fe-5511-4cbd-afa7-0329edfae3b7": {"__data__": {"id_": "1ac961fe-5511-4cbd-afa7-0329edfae3b7", "embedding": null, "metadata": {"window": "And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7c38b92-2266-4456-8fe0-4bcb551c107f", "node_type": "1", "metadata": {"window": "And so we're going to continue to be disciplined.  And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys. ", "original_text": "A \nNext question, please?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "519156f15b2ca457a63456b7a44c62c081aa83efe977586f1e75372766413fce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4155f242-875a-4f14-8f54-cedfc6f1f47b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that? ", "original_text": "Please go ahead.  \n "}, "hash": "6224541e893aaa4640ec94073a7782a7c6873b9a0a6bc881289bd621e3a4dcc7", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "start_char_idx": 3430, "end_char_idx": 3763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4155f242-875a-4f14-8f54-cedfc6f1f47b": {"__data__": {"id_": "4155f242-875a-4f14-8f54-cedfc6f1f47b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that? ", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ac961fe-5511-4cbd-afa7-0329edfae3b7", "node_type": "1", "metadata": {"window": "And so a portion of that is reflected in the lower \nshare buyback.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8689067dbf09ee2728b09cd2c1cec07ae543c18af379ee52106dbfe296a3a3c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "100e0463-c2c8-426b-a695-59a86af7c4d5", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys. "}, "hash": "1f1f9f6745c52deb99da969fcc933aac6fe7c7a61636b89c724a6f28efa7e662", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 535, "end_char_idx": 555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "100e0463-c2c8-426b-a695-59a86af7c4d5": {"__data__": {"id_": "100e0463-c2c8-426b-a695-59a86af7c4d5", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4155f242-875a-4f14-8f54-cedfc6f1f47b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor  Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that? ", "original_text": "Please go ahead.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a073d9f3ec5121fe0533dc690d9f88bcdd559733626b34d2ce1dfe2e1695838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89aafaae-d0c1-43a5-80ee-437b4117b780", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n ", "original_text": "Thanks for taking my question. "}, "hash": "b9ee402146fcddb0ebfd4072f100296b3c05f28d873c6c46ff35f10f6d5f3f71", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys. ", "start_char_idx": 3783, "end_char_idx": 4114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89aafaae-d0c1-43a5-80ee-437b4117b780": {"__data__": {"id_": "89aafaae-d0c1-43a5-80ee-437b4117b780", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n ", "original_text": "Thanks for taking my question. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "100e0463-c2c8-426b-a695-59a86af7c4d5", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83f67bc40361db1123b64f3a61cb4ef645d33fe23d2d8ed1f29642800986cc2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d039f5bd-6156-4802-9a84-c035c14ae3ed", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that? "}, "hash": "495bba2086ef40241e9474db03e77225f4af375057de6eb7fddcb4f7dbf373dd", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking my question. ", "start_char_idx": 4114, "end_char_idx": 4145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d039f5bd-6156-4802-9a84-c035c14ae3ed": {"__data__": {"id_": "d039f5bd-6156-4802-9a84-c035c14ae3ed", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that? ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89aafaae-d0c1-43a5-80ee-437b4117b780", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephanie Davis with Barclays.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n ", "original_text": "Thanks for taking my question. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "133869b0df97decbd64737832bf6f14c541d84e823be8bfd2547aba49bc82a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64eebb6c-8326-46d4-8cc4-679ba81495fc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw. "}, "hash": "d5a8c58b1e20fa07363fb2a1349cb3a8459ca3384c638576ab05d7bad36b6993", "class_name": "RelatedNodeInfo"}}, "text": "I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that? ", "start_char_idx": 4145, "end_char_idx": 4408, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64eebb6c-8326-46d4-8cc4-679ba81495fc": {"__data__": {"id_": "64eebb6c-8326-46d4-8cc4-679ba81495fc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d039f5bd-6156-4802-9a84-c035c14ae3ed", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that? ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fd97e1d39db2072136eb103238d97715b067fef312da3f1041c90d1bf659a9a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14dd76d6-5e2d-4608-83bc-f5583d14564a", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Could you \nclarify kind of any impact that would have on the margin flow through?  \n "}, "hash": "b606200d4cf775b4dd5d434cd228da0f504351fdb32d647bb349c1d3b787c4f6", "class_name": "RelatedNodeInfo"}}, "text": "And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw. ", "start_char_idx": 4408, "end_char_idx": 4534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14dd76d6-5e2d-4608-83bc-f5583d14564a": {"__data__": {"id_": "14dd76d6-5e2d-4608-83bc-f5583d14564a", "embedding": null, "metadata": {"window": "Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Could you \nclarify kind of any impact that would have on the margin flow through?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64eebb6c-8326-46d4-8cc4-679ba81495fc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephanie July Davis  \nAnalyst, Barclays PLC  Q \nHi, guys.  Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw. ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8c077bab06a37a3f21d0d49826dfff901fdbaaa6af1356e31be6f982b72142ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66042b9d-6a12-4e96-86ce-6de33bca0e68", "node_type": "1", "metadata": {"window": "I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "424c6bc7c3be991a97b72c3331b101fe060e2403101119dd8412bfd09bb01b85", "class_name": "RelatedNodeInfo"}}, "text": "Could you \nclarify kind of any impact that would have on the margin flow through?  \n ", "start_char_idx": 4534, "end_char_idx": 4619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66042b9d-6a12-4e96-86ce-6de33bca0e68": {"__data__": {"id_": "66042b9d-6a12-4e96-86ce-6de33bca0e68", "embedding": null, "metadata": {"window": "I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97f79dfc0b803d33534eca2e77d8d9745e1653a931c79711acf5753ff5a89229", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14dd76d6-5e2d-4608-83bc-f5583d14564a", "node_type": "1", "metadata": {"window": "Thanks for taking my question.  I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Could you \nclarify kind of any impact that would have on the margin flow through?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb104b73dbe594a0da2dbda5f7ed5f3a48e82a5f03a304d484a87cb2b7f2819d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7c36d6d-699d-46e0-af60-243a0ee5491b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things. ", "original_text": "McKesson Corp.  "}, "hash": "1b5ec9e76005928917bd892af138c0c6d58f3944e0d2a3767335a2907f4c5018", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 207, "end_char_idx": 478, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7c36d6d-699d-46e0-af60-243a0ee5491b": {"__data__": {"id_": "d7c36d6d-699d-46e0-af60-243a0ee5491b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66042b9d-6a12-4e96-86ce-6de33bca0e68", "node_type": "1", "metadata": {"window": "I was \u2013 I know you've given a lot of  great color on this, but I was hoping \nwe could dig a little bit more into the strong US Pharmaceutical growth and how to think about the lighter flow \nthrough the margin, is there anything beyond GLP -1s kind of doing that?  And you made a comment on \ncommerc ial COVID net of $30 million non -recurring accounting for some of the growth that we saw.  Could you \nclarify kind of any impact that would have on the margin flow through?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbacf92f912439d72dfb5e3f8e8423189bb2c18e683c5a61d3f7500cea330ca7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17ab0b63-1f1e-4d03-9c4c-61a02ee4a570", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "57b7823fa210207c62d601e8bb1179595a926cafda378735f7b449b23e830ef7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17ab0b63-1f1e-4d03-9c4c-61a02ee4a570": {"__data__": {"id_": "17ab0b63-1f1e-4d03-9c4c-61a02ee4a570", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7c36d6d-699d-46e0-af60-243a0ee5491b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e81de4dd67eb74ce18ea861bb2f5ba20c87edb3dbca287f700798ef670ea0dba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39400718-d18c-4896-8b1f-2337ab4e06aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter. ", "original_text": "A \nYes. "}, "hash": "388a2c741cb99e31eea4d0fa8e7ca9075f728e330950d76342f0ca6b93b3c6c9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39400718-d18c-4896-8b1f-2337ab4e06aa": {"__data__": {"id_": "39400718-d18c-4896-8b1f-2337ab4e06aa", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter. ", "original_text": "A \nYes. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17ab0b63-1f1e-4d03-9c4c-61a02ee4a570", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1539e914e6ddae914f421bff72725e66c194f9f6f8eacc6e88f1a1544a8a83b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2eee060e-fd74-428a-ae44-77de237a4bb9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year. ", "original_text": "So let me comment on a couple of things. "}, "hash": "5f5113e186a8158512ac07f21575fdfed6612e6230f459abb23674af22410277", "class_name": "RelatedNodeInfo"}}, "text": "A \nYes. ", "start_char_idx": 269, "end_char_idx": 277, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2eee060e-fd74-428a-ae44-77de237a4bb9": {"__data__": {"id_": "2eee060e-fd74-428a-ae44-77de237a4bb9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year. ", "original_text": "So let me comment on a couple of things. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39400718-d18c-4896-8b1f-2337ab4e06aa", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter. ", "original_text": "A \nYes. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f5214d2306102eeb99cc1918da83f52037249f280edb204a96569b3726ce398", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4d40e250-a51d-4809-b4f6-4a710f5f36df", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off. ", "original_text": "We're really pleased with our US Pharmaceutical results. "}, "hash": "021b2847bac41f05c03b8ab5150bf5c257afe06a5503a31ab8207112f5197dbe", "class_name": "RelatedNodeInfo"}}, "text": "So let me comment on a couple of things. ", "start_char_idx": 277, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4d40e250-a51d-4809-b4f6-4a710f5f36df": {"__data__": {"id_": "4d40e250-a51d-4809-b4f6-4a710f5f36df", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off. ", "original_text": "We're really pleased with our US Pharmaceutical results. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2eee060e-fd74-428a-ae44-77de237a4bb9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year. ", "original_text": "So let me comment on a couple of things. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7400a185702783e82eb00d88a51d86c85184dde75fe32fff72ca2cb882912276", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d61203e5-3b90-4769-abed-3e66001e6e7d", "node_type": "1", "metadata": {"window": "A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter. ", "original_text": "They \ndelivered another strong quarter. "}, "hash": "f0e4a996562d7f91177d0089cd438109ab9cf55592df6db19364e66734083f54", "class_name": "RelatedNodeInfo"}}, "text": "We're really pleased with our US Pharmaceutical results. ", "start_char_idx": 318, "end_char_idx": 375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d61203e5-3b90-4769-abed-3e66001e6e7d": {"__data__": {"id_": "d61203e5-3b90-4769-abed-3e66001e6e7d", "embedding": null, "metadata": {"window": "A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter. ", "original_text": "They \ndelivered another strong quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4d40e250-a51d-4809-b4f6-4a710f5f36df", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off. ", "original_text": "We're really pleased with our US Pharmaceutical results. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3fe304ceb3433cdf02622920758a1d887a1fc946bdb3173bb2e45c0f5000a75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a12e48b4-2532-4d59-8316-c1443c4b187a", "node_type": "1", "metadata": {"window": "So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n", "original_text": "Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year. "}, "hash": "e1ea948c7112df56b712fad827200ee1f87f6d721ac8dbb71bffc2d9c9ab2d4b", "class_name": "RelatedNodeInfo"}}, "text": "They \ndelivered another strong quarter. ", "start_char_idx": 375, "end_char_idx": 415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a12e48b4-2532-4d59-8316-c1443c4b187a": {"__data__": {"id_": "a12e48b4-2532-4d59-8316-c1443c4b187a", "embedding": null, "metadata": {"window": "So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n", "original_text": "Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d61203e5-3b90-4769-abed-3e66001e6e7d", "node_type": "1", "metadata": {"window": "A \nYes.  So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter. ", "original_text": "They \ndelivered another strong quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cde412faaa54cee937c484e9bbcb876664b6f93c05e258f8cc6a2a39f0ed8d8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15a15b28-b917-4587-a2a6-f2be1afeed05", "node_type": "1", "metadata": {"window": "We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels. ", "original_text": "T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off. "}, "hash": "456dd1965879d5b197b546e1e3e0caea4ecc9c7c665a68812535de42f81d3145", "class_name": "RelatedNodeInfo"}}, "text": "Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year. ", "start_char_idx": 415, "end_char_idx": 520, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15a15b28-b917-4587-a2a6-f2be1afeed05": {"__data__": {"id_": "15a15b28-b917-4587-a2a6-f2be1afeed05", "embedding": null, "metadata": {"window": "We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels. ", "original_text": "T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a12e48b4-2532-4d59-8316-c1443c4b187a", "node_type": "1", "metadata": {"window": "So let me comment on a couple of things.  We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n", "original_text": "Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed292c66fae830206c4b3569884cec41b185156c370b210a16349bee7fad60b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f95b5d0-ad9f-4cb8-b802-83dfa772dcfc", "node_type": "1", "metadata": {"window": "They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n", "original_text": "We did have a one -time non -recurring charge in the quarter. "}, "hash": "429ba14d5561d2263ee00954c27036fff1462aba9c4c21c2da0cab60205f52b1", "class_name": "RelatedNodeInfo"}}, "text": "T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off. ", "start_char_idx": 520, "end_char_idx": 623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f95b5d0-ad9f-4cb8-b802-83dfa772dcfc": {"__data__": {"id_": "4f95b5d0-ad9f-4cb8-b802-83dfa772dcfc", "embedding": null, "metadata": {"window": "They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n", "original_text": "We did have a one -time non -recurring charge in the quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15a15b28-b917-4587-a2a6-f2be1afeed05", "node_type": "1", "metadata": {"window": "We're really pleased with our US Pharmaceutical results.  They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels. ", "original_text": "T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5ee3c30ca3ef11375094b76e776a924cd428e7884e07dc044a08fe8f76648a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8048eb50-340f-4db8-b3d5-424cb7539fe6", "node_type": "1", "metadata": {"window": "Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n ", "original_text": "When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n"}, "hash": "ec6760f656c0b97282501f39df145de133b6a90c6cc2ed353e7c5f577e07f3c3", "class_name": "RelatedNodeInfo"}}, "text": "We did have a one -time non -recurring charge in the quarter. ", "start_char_idx": 623, "end_char_idx": 685, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8048eb50-340f-4db8-b3d5-424cb7539fe6": {"__data__": {"id_": "8048eb50-340f-4db8-b3d5-424cb7539fe6", "embedding": null, "metadata": {"window": "Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n ", "original_text": "When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f95b5d0-ad9f-4cb8-b802-83dfa772dcfc", "node_type": "1", "metadata": {"window": "They \ndelivered another strong quarter.  Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n", "original_text": "We did have a one -time non -recurring charge in the quarter. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5484fc8a0b782625d44f88c8489567963a5e68390ec520f64bb2b61ded50ee52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbea23fa-273a-464a-aaa8-9716b3b65eec", "node_type": "1", "metadata": {"window": "T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels. "}, "hash": "55cf981b929e7c70fd7c704d4a86879cbfd0ed014205a99c816c24adc803b552", "class_name": "RelatedNodeInfo"}}, "text": "When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n", "start_char_idx": 685, "end_char_idx": 833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbea23fa-273a-464a-aaa8-9716b3b65eec": {"__data__": {"id_": "cbea23fa-273a-464a-aaa8-9716b3b65eec", "embedding": null, "metadata": {"window": "T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8048eb50-340f-4db8-b3d5-424cb7539fe6", "node_type": "1", "metadata": {"window": "Included in that, obviously, we are lapping the effects of the government \nprogram, the COVID last year.  T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n ", "original_text": "When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "addf42fa1cf23721224d4cbda44513547f24dd1ae47d13c171118bb95ebfd69b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fefe3f2d-4ce0-436f-b027-559a21934059", "node_type": "1", "metadata": {"window": "We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n"}, "hash": "7311ed458e2b908f92ac47a9719413cefc33028d42e876fb99662e47ef292433", "class_name": "RelatedNodeInfo"}}, "text": "So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels. ", "start_char_idx": 833, "end_char_idx": 1022, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fefe3f2d-4ce0-436f-b027-559a21934059": {"__data__": {"id_": "fefe3f2d-4ce0-436f-b027-559a21934059", "embedding": null, "metadata": {"window": "We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbea23fa-273a-464a-aaa8-9716b3b65eec", "node_type": "1", "metadata": {"window": "T his year, we do have commercial COVID vaccines, that peaked in October and \nthen it really fell off.  We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "277e8566444dbad99066a0ad7469e8e6755ef323c564bd3aeda8c076898033bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94d664dd-133c-4229-a1eb-a4a268af6518", "node_type": "1", "metadata": {"window": "When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n "}, "hash": "f9b619d26baa5261ede4c733511559f59b23adb99a70a1f2e77fa5ed71ada652", "class_name": "RelatedNodeInfo"}}, "text": "And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n", "start_char_idx": 1022, "end_char_idx": 1249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94d664dd-133c-4229-a1eb-a4a268af6518": {"__data__": {"id_": "94d664dd-133c-4229-a1eb-a4a268af6518", "embedding": null, "metadata": {"window": "When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fefe3f2d-4ce0-436f-b027-559a21934059", "node_type": "1", "metadata": {"window": "We did have a one -time non -recurring charge in the quarter.  When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n ", "original_text": "And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e9b52c0d4ccf338629da159d99c0ec69a0fd07c8f047245f8d7f31b40a409f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e71ba35-0955-48a5-bda4-a62c4badb7a9", "node_type": "1", "metadata": {"window": "So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "63562f0482ac4434a017a920061565532d8de29f051f17d3c869caf6c41e0809", "class_name": "RelatedNodeInfo"}}, "text": "So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n ", "start_char_idx": 1249, "end_char_idx": 1451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e71ba35-0955-48a5-bda4-a62c4badb7a9": {"__data__": {"id_": "6e71ba35-0955-48a5-bda4-a62c4badb7a9", "embedding": null, "metadata": {"window": "So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94d664dd-133c-4229-a1eb-a4a268af6518", "node_type": "1", "metadata": {"window": "When you net the commercial \nCOVID vaccine contribution in that charge, it roughly offsets the go vernment program contribution from last year.  \n \n So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "original_text": "So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65dae1c68f224cf394339f023445986fd059244882bbba90a9197ae88c1cd3f7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b32e05a9-2f8e-4285-a5cd-df25e99983f0", "node_type": "1", "metadata": {"window": "And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question, please?  \n "}, "hash": "c61e33ae49291f2acf1eb0dd5f6bd076197ea1b5c42da4059a5b981f89a5811b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 1451, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b32e05a9-2f8e-4285-a5cd-df25e99983f0": {"__data__": {"id_": "b32e05a9-2f8e-4285-a5cd-df25e99983f0", "embedding": null, "metadata": {"window": "And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question, please?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e71ba35-0955-48a5-bda4-a62c4badb7a9", "node_type": "1", "metadata": {"window": "So the performance within this segment is just strong continued utilization that we're seeing in the marketplace, \ncontinued strong growth of specialty across all of our customer channels.  And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "553c09a11c39625fe6278a3498f4b14314db4760f635a633672b6ba0147d6866", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aedcb9c-07d8-47ed-b1b1-87c21f9effee", "node_type": "1", "metadata": {"window": "So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. "}, "hash": "1b505e47da5db46cfb4e1b5290af57cbebb13cc487318320cbb0bf492bbbbb5a", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  \n ", "start_char_idx": 1796, "end_char_idx": 1825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aedcb9c-07d8-47ed-b1b1-87c21f9effee": {"__data__": {"id_": "6aedcb9c-07d8-47ed-b1b1-87c21f9effee", "embedding": null, "metadata": {"window": "So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b32e05a9-2f8e-4285-a5cd-df25e99983f0", "node_type": "1", "metadata": {"window": "And the continued gro wth in our \noncology business, as well as, as I mentioned, I provided a number on the revenue impact from GLP -1s, which \nagain come at a lower margin rate and have been a headwind to year -over-year.  \n \n So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "original_text": "A \nNext question, please?  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56b665a6d0645312121da45ca9695fa32762c32551732484822ce0218c452b69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29683966-0ecb-48c3-b636-056250b058dc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks. ", "original_text": "Please go ahead.  \n "}, "hash": "00b505328f075227cbd81a8cfca19a7c910d9a1517c2e8430f45cdd6a7a8b6e9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "start_char_idx": 1825, "end_char_idx": 2160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29683966-0ecb-48c3-b636-056250b058dc": {"__data__": {"id_": "29683966-0ecb-48c3-b636-056250b058dc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks. ", "original_text": "Please go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aedcb9c-07d8-47ed-b1b1-87c21f9effee", "node_type": "1", "metadata": {"window": "So just sort of sum up, it's just continued strong utiliza tion in the marketplace in general, continued good growth of \nour customers and channels and continued growth within our oncology business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30818a451649d16b888dd3c8062d6585c31dfd3ce942a3abff41811256453c78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "923f2ae9-b844-49a2-8915-a668219b0a80", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. "}, "hash": "cefcc3bc7dff0fe8a2021af76737905757632db851dcd28963ea1b888aa512fe", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2160, "end_char_idx": 2180, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "923f2ae9-b844-49a2-8915-a668219b0a80": {"__data__": {"id_": "923f2ae9-b844-49a2-8915-a668219b0a80", "embedding": null, "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29683966-0ecb-48c3-b636-056250b058dc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks. ", "original_text": "Please go ahead.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f911cbcd2ac900f7809b661f32287ab954ef6ff06da9789cdb433a66db0fa66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c07b7018-0b3b-4b1f-b56a-373886187c71", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer? ", "original_text": "LLC  Q \nHi. "}, "hash": "1d0995016f3df97f337e16d238970fc634e9d5eca049394e7435c731e931b876", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 2180, "end_char_idx": 2503, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c07b7018-0b3b-4b1f-b56a-373886187c71": {"__data__": {"id_": "c07b7018-0b3b-4b1f-b56a-373886187c71", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer? ", "original_text": "LLC  Q \nHi. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "923f2ae9-b844-49a2-8915-a668219b0a80", "node_type": "1", "metadata": {"window": "A \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16cf58bcebfd8ca59ac435d6b1f84b56527473857a970f831e961629bdc75e5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bfa669a6-29b9-4bba-a5f5-36572025dfc5", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025? ", "original_text": "Thanks. "}, "hash": "bf2150e5bb6ed7a477ed908a5dbb4c75cb1f332023b22f484cd3e7855c1b0442", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nHi. ", "start_char_idx": 2503, "end_char_idx": 2515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bfa669a6-29b9-4bba-a5f5-36572025dfc5": {"__data__": {"id_": "bfa669a6-29b9-4bba-a5f5-36572025dfc5", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025? ", "original_text": "Thanks. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c07b7018-0b3b-4b1f-b56a-373886187c71", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Erin Wright with Morgan Stanley.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer? ", "original_text": "LLC  Q \nHi. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "601049c6ba873bd857347f8f20b53992939f06224a230434b8a7a1636d9d5e28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "762088ac-ca57-4429-900f-c4352de364dc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n ", "original_text": "So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment? "}, "hash": "f30e6d25339f78c786fdee8aa2ce8e6fa3dbe37a70de4e6b3a0feefe825c13d2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 2515, "end_char_idx": 2523, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "762088ac-ca57-4429-900f-c4352de364dc": {"__data__": {"id_": "762088ac-ca57-4429-900f-c4352de364dc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n ", "original_text": "So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment? ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bfa669a6-29b9-4bba-a5f5-36572025dfc5", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025? ", "original_text": "Thanks. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54337bc8d21d30d11b667598a1be37a634d0b2c614b1b236fb022e02c2dc4297", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b74b0705-bc89-41d8-bda7-73275c8632f7", "node_type": "1", "metadata": {"window": "LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And just do you think kind of the \nlong-term growth has inflected higher at this point for longer? "}, "hash": "eeaaa7b3ae65f49b8e250d2c5d356b6ca28b84710bcd4993c17e803d75af4867", "class_name": "RelatedNodeInfo"}}, "text": "So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment? ", "start_char_idx": 2523, "end_char_idx": 2705, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b74b0705-bc89-41d8-bda7-73275c8632f7": {"__data__": {"id_": "b74b0705-bc89-41d8-bda7-73275c8632f7", "embedding": null, "metadata": {"window": "LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And just do you think kind of the \nlong-term growth has inflected higher at this point for longer? ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "762088ac-ca57-4429-900f-c4352de364dc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nErin Wilson Wright  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n ", "original_text": "So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment? ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "76bbcf10d60a4df35bef721b3038c7f31cc3624d1c1dcd5e23a028a319d80e4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1f5d671-653e-4238-a81c-c4640f7d0bcb", "node_type": "1", "metadata": {"window": "Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question. ", "original_text": "Or what are some of those offsets that we should be \nthinking about in 2025? "}, "hash": "92ab50f4921f78e90e9a2d53035eec9200c2baabc2c0f0b8bd6c3a08cbb4e93d", "class_name": "RelatedNodeInfo"}}, "text": "And just do you think kind of the \nlong-term growth has inflected higher at this point for longer? ", "start_char_idx": 2705, "end_char_idx": 2804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1f5d671-653e-4238-a81c-c4640f7d0bcb": {"__data__": {"id_": "b1f5d671-653e-4238-a81c-c4640f7d0bcb", "embedding": null, "metadata": {"window": "Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question. ", "original_text": "Or what are some of those offsets that we should be \nthinking about in 2025? ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b74b0705-bc89-41d8-bda7-73275c8632f7", "node_type": "1", "metadata": {"window": "LLC  Q \nHi.  Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "And just do you think kind of the \nlong-term growth has inflected higher at this point for longer? ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5750148ca47d48bce5c6c459c286e4e1f23880da4dd0c6cc46f30c13d8efda38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeda4c70-ec4e-4ad5-b5cb-d36230339de1", "node_type": "1", "metadata": {"window": "So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n", "original_text": "Thanks.  \n "}, "hash": "358aa558be3f05c9833dceeb3e2d6df717899b3cf94b1321006ed663db6ee41c", "class_name": "RelatedNodeInfo"}}, "text": "Or what are some of those offsets that we should be \nthinking about in 2025? ", "start_char_idx": 2804, "end_char_idx": 2881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeda4c70-ec4e-4ad5-b5cb-d36230339de1": {"__data__": {"id_": "aeda4c70-ec4e-4ad5-b5cb-d36230339de1", "embedding": null, "metadata": {"window": "So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1f5d671-653e-4238-a81c-c4640f7d0bcb", "node_type": "1", "metadata": {"window": "Thanks.  So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question. ", "original_text": "Or what are some of those offsets that we should be \nthinking about in 2025? ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9749356c5fcd7f4333723879670acbf64ba654c3e2c56afbeeb806acc6892b6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f8a9505-745f-4d8e-8c02-08c941c84e30", "node_type": "1", "metadata": {"window": "And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "4c31be1f2aa5df368a6e2b45d3b17ec6d07a7065aa9fbc35200a03e9ff0ffe6e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 2881, "end_char_idx": 2892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f8a9505-745f-4d8e-8c02-08c941c84e30": {"__data__": {"id_": "0f8a9505-745f-4d8e-8c02-08c941c84e30", "embedding": null, "metadata": {"window": "And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeda4c70-ec4e-4ad5-b5cb-d36230339de1", "node_type": "1", "metadata": {"window": "So if I think about 2025, why is 5% to 7% still the right growth target for US Pharma, just given the \nspecialty contributio ns and growth there, and favorable generics environment?  And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n", "original_text": "Thanks.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a301a9c60e89fce4f75fe15bfac03f4156ebff7342125283b3e9689d0c42a3ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8373dd6-2097-4ab5-9949-866335a5431a", "node_type": "1", "metadata": {"window": "Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that. ", "original_text": "A \nAppreciate the question. "}, "hash": "60a566de255385c6d2460faa1d431a5620c146f87c8f8b213f4bcf051f52ec1d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 2892, "end_char_idx": 3252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8373dd6-2097-4ab5-9949-866335a5431a": {"__data__": {"id_": "d8373dd6-2097-4ab5-9949-866335a5431a", "embedding": null, "metadata": {"window": "Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that. ", "original_text": "A \nAppreciate the question. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f8a9505-745f-4d8e-8c02-08c941c84e30", "node_type": "1", "metadata": {"window": "And just do you think kind of the \nlong-term growth has inflected higher at this point for longer?  Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a1735b71bf085fb1449bd4b69b7f1f232b1e0d6fc9b855a75ab8535f615c95b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "657e2b4d-ca5d-4e21-9d3a-a3ce0a679709", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n ", "original_text": "Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n"}, "hash": "e03d597fd1515976cf1ac4faa57cb5811600c03506bb18f40caaa058dd451d7d", "class_name": "RelatedNodeInfo"}}, "text": "A \nAppreciate the question. ", "start_char_idx": 3252, "end_char_idx": 3280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "657e2b4d-ca5d-4e21-9d3a-a3ce0a679709": {"__data__": {"id_": "657e2b4d-ca5d-4e21-9d3a-a3ce0a679709", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n ", "original_text": "Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8373dd6-2097-4ab5-9949-866335a5431a", "node_type": "1", "metadata": {"window": "Or what are some of those offsets that we should be \nthinking about in 2025?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that. ", "original_text": "A \nAppreciate the question. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dadea45ed7d22bfccea473128d3143bf6bb2cadc14ce20e938e70d260be24a5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bfd5a2e-a1c8-43b0-9e40-b54d6baf617a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n"}, "hash": "474397999247872f6b747ae984271bf67ea95db74817c0b48fc6efdddf019fed", "class_name": "RelatedNodeInfo"}}, "text": "Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n", "start_char_idx": 3280, "end_char_idx": 3541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bfd5a2e-a1c8-43b0-9e40-b54d6baf617a": {"__data__": {"id_": "6bfd5a2e-a1c8-43b0-9e40-b54d6baf617a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "657e2b4d-ca5d-4e21-9d3a-a3ce0a679709", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n ", "original_text": "Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "523874a89a05baabf4d4514eaa33e07a0031f483c28bccf64dd5391ec9fbf5e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7052506-73dd-4125-9548-8d1ad9d917dd", "node_type": "1", "metadata": {"window": "A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that. "}, "hash": "596bc00c4abaf64ca99856c6f317a2512f88bb12e219dcfa55b37bef7e60a71e", "class_name": "RelatedNodeInfo"}}, "text": "What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n", "start_char_idx": 3541, "end_char_idx": 3833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7052506-73dd-4125-9548-8d1ad9d917dd": {"__data__": {"id_": "b7052506-73dd-4125-9548-8d1ad9d917dd", "embedding": null, "metadata": {"window": "A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bfd5a2e-a1c8-43b0-9e40-b54d6baf617a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalo ne \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bfcb43ffdab836ec982af6b791195b6e375acff1404aee543790e71ced334f2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8843aba-fa42-4789-87f3-fee55d4e2289", "node_type": "1", "metadata": {"window": "Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n "}, "hash": "f1d2bd28b2466f82cf2870a87d6d99487fe40395ca257eb5fb4359d522d4ab0e", "class_name": "RelatedNodeInfo"}}, "text": "Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that. ", "start_char_idx": 3833, "end_char_idx": 3977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8843aba-fa42-4789-87f3-fee55d4e2289": {"__data__": {"id_": "f8843aba-fa42-4789-87f3-fee55d4e2289", "embedding": null, "metadata": {"window": "Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7052506-73dd-4125-9548-8d1ad9d917dd", "node_type": "1", "metadata": {"window": "A \nAppreciate the question.  Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that. ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a4fe07fbb14de4799f9faaf94386c1f75802a0b7a2c5a8e03b825bdb5564226b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61147e0a-a7ce-45c0-a71b-e75f00773209", "node_type": "1", "metadata": {"window": "What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "d0183f02c4f9fab6e78fb0ab6c0697b35d06a07a4d36f1156faf634f34ec1f22", "class_name": "RelatedNodeInfo"}}, "text": "But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n ", "start_char_idx": 3977, "end_char_idx": 4175, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61147e0a-a7ce-45c0-a71b-e75f00773209": {"__data__": {"id_": "61147e0a-a7ce-45c0-a71b-e75f00773209", "embedding": null, "metadata": {"window": "What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8843aba-fa42-4789-87f3-fee55d4e2289", "node_type": "1", "metadata": {"window": "Let me just start by stating at the beginning of the year, when we gave guidance, the \nlong-term growth rate for the segment was 4% to 6%, given the performanc e that we've seen this year, we \nincreased that target, that long -term target rate to 5% to 7%.  \n \n What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1149b120548b3e6a152a4743e60cb6e806b9950d5165a8be815c71a087b7dfeb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30600360-0a5c-4717-a856-87782073dde5", "node_type": "1", "metadata": {"window": "Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "A \nNext question, please?  "}, "hash": "2c8c5323fcffdee79f15d04ef5fcd10d5d928910893d567b9a3c034ecc55e2a8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 1451, "end_char_idx": 1796, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30600360-0a5c-4717-a856-87782073dde5": {"__data__": {"id_": "30600360-0a5c-4717-a856-87782073dde5", "embedding": null, "metadata": {"window": "Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "A \nNext question, please?  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5f1837fe34c9778ff4db099bfe5e515c17e5db109a74eeff0b7023de2dff66e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61147e0a-a7ce-45c0-a71b-e75f00773209", "node_type": "1", "metadata": {"window": "What I'm trying to provide you now is an early view into some of the qualitative factors that we're looking at and \nsome of the momentum that we see going forwar d and indicating that, that long -term range that we increased this \nyear, we still see that as being the right number today.  \n \n Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a7b21c3a373214165d3b3ff4687285a0ab2bce69939cd345d12d143dfef9293", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6802474-0d9d-4c3a-a101-f3364f7cd7b3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "McKesson Corp.  "}, "hash": "9785f9b4a982fe477d54a494e442d286e0de81fd299b748e02775faa180a424b", "class_name": "RelatedNodeInfo"}}, "text": "A \nNext question, please?  ", "start_char_idx": 1796, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6802474-0d9d-4c3a-a101-f3364f7cd7b3": {"__data__": {"id_": "a6802474-0d9d-4c3a-a101-f3364f7cd7b3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30600360-0a5c-4717-a856-87782073dde5", "node_type": "1", "metadata": {"window": "Now, we'll continue to do some analysis and work, and we come forward with our full -year assumptions, we'll give \nyou more insight i nto that.  But just as a reminder, we have already increased the long -term target range this year \nfrom 4% to 6% to 5% to 7% and we're certainly pleased with the momentum that we're seeing in the segment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nNext question, please?  ", "original_text": "A \nNext question, please?  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35269b81fed5eea59669d1462bd9b630ae49b5418f528a3e9b1436739de77894", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a879c777-f7fb-4959-af1b-4972d6fc5778", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi. "}, "hash": "8d372ff087f3e8faddabd3cad841d7f2a2eae2304708ab204ac0425b43c26334", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a879c777-f7fb-4959-af1b-4972d6fc5778": {"__data__": {"id_": "a879c777-f7fb-4959-af1b-4972d6fc5778", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6802474-0d9d-4c3a-a101-f3364f7cd7b3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f105b1d43d5b79efb2bb9b77a33bb28dd266438cc16e599ef519b79bbe0594dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28c9736b-373d-40c5-9ad2-6e47e4f57134", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain. ", "original_text": "Please go ahead.  \n "}, "hash": "fccf10c021dc429029aa433216e60c0aa3e38b1b3e1bcf5223632767050bc45a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi. ", "start_char_idx": 16, "end_char_idx": 240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28c9736b-373d-40c5-9ad2-6e47e4f57134": {"__data__": {"id_": "28c9736b-373d-40c5-9ad2-6e47e4f57134", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain. ", "original_text": "Please go ahead.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a879c777-f7fb-4959-af1b-4972d6fc5778", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e6af3dfa5359fa552f923be51cd7f99b43ca5fc4f232be4d28cda618db35ab4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28006901-5005-4903-840c-bb4f18b6e5fe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  "}, "hash": "97e7633361b12271352c7fc4336b3036cb112cf3352e1479a82682922ba28c25", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 240, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28006901-5005-4903-840c-bb4f18b6e5fe": {"__data__": {"id_": "28006901-5005-4903-840c-bb4f18b6e5fe", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28c9736b-373d-40c5-9ad2-6e47e4f57134", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain. ", "original_text": "Please go ahead.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3804f19281c65cbc3ef892d3c4f947a8cc5fb78728bfd4faf59f0dd4cc69c79e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c0a5064-6239-42b6-b0cd-f22c642038d0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Q \nThanks for taking the question. "}, "hash": "db0641d43b6e33865efed15a54e73b3c0eb2c640c89f95bebc9b61948ee5b9c6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "start_char_idx": 260, "end_char_idx": 593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c0a5064-6239-42b6-b0cd-f22c642038d0": {"__data__": {"id_": "7c0a5064-6239-42b6-b0cd-f22c642038d0", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Q \nThanks for taking the question. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28006901-5005-4903-840c-bb4f18b6e5fe", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7014286c8c1ce865731231b59aa7eb7422554e54bb3b78ad37b917e0e9fa1669", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77ac81a3-de6c-4b3b-bb4c-2003d08388f6", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide. ", "original_text": "One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain. "}, "hash": "c938690c63fa5837ce0312209b74d78b97e7cba70b431f55dec200f4092509d9", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks for taking the question. ", "start_char_idx": 593, "end_char_idx": 628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77ac81a3-de6c-4b3b-bb4c-2003d08388f6": {"__data__": {"id_": "77ac81a3-de6c-4b3b-bb4c-2003d08388f6", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide. ", "original_text": "One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c0a5064-6239-42b6-b0cd-f22c642038d0", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Q \nThanks for taking the question. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ca41c86963d0f078afa8fad5a5638da6e34ca856671a8a9fa918574c29f2a49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19dbb4fe-0a7c-4414-8bb0-1926a8285e44", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products. ", "original_text": "I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n "}, "hash": "e0f09943199031e7b4ad1bd8de5d613b5b9580b5c305857061644226b1310538", "class_name": "RelatedNodeInfo"}}, "text": "One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain. ", "start_char_idx": 628, "end_char_idx": 809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19dbb4fe-0a7c-4414-8bb0-1926a8285e44": {"__data__": {"id_": "19dbb4fe-0a7c-4414-8bb0-1926a8285e44", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products. ", "original_text": "I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77ac81a3-de6c-4b3b-bb4c-2003d08388f6", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide. ", "original_text": "One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55a3af231fa2beacc9d6573d917115e4ac6d6ce9a58cbb8b85472dc1b6b0da99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ab44665-5995-4972-9439-1869897df317", "node_type": "1", "metadata": {"window": "Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "9b5b71f17436c844d5fafe19ddb2a487377504ab266cea2043bc7fcae9d1cf62", "class_name": "RelatedNodeInfo"}}, "text": "I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n ", "start_char_idx": 809, "end_char_idx": 1002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ab44665-5995-4972-9439-1869897df317": {"__data__": {"id_": "8ab44665-5995-4972-9439-1869897df317", "embedding": null, "metadata": {"window": "Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19dbb4fe-0a7c-4414-8bb0-1926a8285e44", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.   Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products. ", "original_text": "I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9a9cc24b39bf394566ece2dfbc1fa67c652f8fc8401af172bca787fb9f6dceaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "840cec52-ceb2-476b-bc5a-2d4fc3a25675", "node_type": "1", "metadata": {"window": "One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses. ", "original_text": "A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide. "}, "hash": "b385b34cc355b82a5886985385ebe52c944b660f4494b3f9cf2efc3dc5242039", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1002, "end_char_idx": 1346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "840cec52-ceb2-476b-bc5a-2d4fc3a25675": {"__data__": {"id_": "840cec52-ceb2-476b-bc5a-2d4fc3a25675", "embedding": null, "metadata": {"window": "One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses. ", "original_text": "A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ab44665-5995-4972-9439-1869897df317", "node_type": "1", "metadata": {"window": "Q \nThanks for taking the question.  One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d9f1600d90783b98c698a4daa7334eae6efd2e1b8c24d4c669c05cb6bc1f2d98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1baf33de-50f2-454e-aefb-f7e9150689d9", "node_type": "1", "metadata": {"window": "I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n ", "original_text": "And then obviously, we want to provide as many \nservices as we can in support of those products. "}, "hash": "292979c05fc9096072aa30907940ac3f9dd7b2364f50f426575329359fbd28d5", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide. ", "start_char_idx": 1346, "end_char_idx": 1536, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1baf33de-50f2-454e-aefb-f7e9150689d9": {"__data__": {"id_": "1baf33de-50f2-454e-aefb-f7e9150689d9", "embedding": null, "metadata": {"window": "I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n ", "original_text": "And then obviously, we want to provide as many \nservices as we can in support of those products. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "840cec52-ceb2-476b-bc5a-2d4fc3a25675", "node_type": "1", "metadata": {"window": "One of your competitors mentioned that there may be an ability to renegotiate \nGLP-1 contracts as they come due, to potentially extract a bit more margin for the drug supply chain.  I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses. ", "original_text": "A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a71026172129bf5bf1fd1fa64e153c057bb3b5680d33e864b3d10c767fe265c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64868c4e-9cdb-4a77-921f-c2c741156ad8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n"}, "hash": "d0809c868d4f3a1bde114d788c8feef836532901ab5c56499c6a49915d17d01e", "class_name": "RelatedNodeInfo"}}, "text": "And then obviously, we want to provide as many \nservices as we can in support of those products. ", "start_char_idx": 1536, "end_char_idx": 1633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64868c4e-9cdb-4a77-921f-c2c741156ad8": {"__data__": {"id_": "64868c4e-9cdb-4a77-921f-c2c741156ad8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1baf33de-50f2-454e-aefb-f7e9150689d9", "node_type": "1", "metadata": {"window": "I was \nwondering if you could comment on your views of contract negotiations as those contracts renew, and if t here \nmay be an ability to boost the margin profile of GLP -1s going forward?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n ", "original_text": "And then obviously, we want to provide as many \nservices as we can in support of those products. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e5689548d5964b584a357d48932048df61ed94afba0a75a99395038f289d98e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca1a504e-1c08-496e-b3c9-5f9f33bcc6c2", "node_type": "1", "metadata": {"window": "A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay. ", "original_text": "So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses. "}, "hash": "c63467e985a3fd8d824162d566e576161e0552680c4ae7d29a25b0bdb583e1f7", "class_name": "RelatedNodeInfo"}}, "text": "And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n", "start_char_idx": 1633, "end_char_idx": 1760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca1a504e-1c08-496e-b3c9-5f9f33bcc6c2": {"__data__": {"id_": "ca1a504e-1c08-496e-b3c9-5f9f33bcc6c2", "embedding": null, "metadata": {"window": "A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay. ", "original_text": "So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64868c4e-9cdb-4a77-921f-c2c741156ad8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2454b6c6b675bbbe29264c71eb8791812d70dd6ffaee929679c0bb6f3e7baf1b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b20bb00-4033-4669-b145-dceeae56c5cf", "node_type": "1", "metadata": {"window": "And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n ", "original_text": "And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n "}, "hash": "d6ece2f117599a87680f7e1c64d64646db77568a5ef3135c3815630afd23b46b", "class_name": "RelatedNodeInfo"}}, "text": "So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses. ", "start_char_idx": 1760, "end_char_idx": 2060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b20bb00-4033-4669-b145-dceeae56c5cf": {"__data__": {"id_": "8b20bb00-4033-4669-b145-dceeae56c5cf", "embedding": null, "metadata": {"window": "And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n ", "original_text": "And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca1a504e-1c08-496e-b3c9-5f9f33bcc6c2", "node_type": "1", "metadata": {"window": "A \nWell, I would say this, I think we've talked many times on these calls that the first most important thing  for us to do \nis make sure we get fair value for the services that we provide.  And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay. ", "original_text": "So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07fe4c9e21d91eec7d003ca5d1f41aedd06b36850c3d7e7dd371ae04fc368056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0714e56e-4fda-4287-8f2e-785e88ae9555", "node_type": "1", "metadata": {"window": "And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "e4664aa3b1596ddc608cea4b43adc4a8f7d607b9fbef660e3b3d56819cc5fd1c", "class_name": "RelatedNodeInfo"}}, "text": "And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n ", "start_char_idx": 2060, "end_char_idx": 2200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0714e56e-4fda-4287-8f2e-785e88ae9555": {"__data__": {"id_": "0714e56e-4fda-4287-8f2e-785e88ae9555", "embedding": null, "metadata": {"window": "And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b20bb00-4033-4669-b145-dceeae56c5cf", "node_type": "1", "metadata": {"window": "And then obviously, we want to provide as many \nservices as we can in support of those products.  And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n ", "original_text": "And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1690eb2aa2ad05555e6022d3b1f61d0e4a22e616a1717cfbde694d52dcab0617", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95d275ec-bf2e-4e55-bcc0-9115cf6c8eff", "node_type": "1", "metadata": {"window": "So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "A \nOkay. "}, "hash": "595c327bfdc086f6d9389db1f669c19a293ea9b0be734147d7f533f420808173", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 2200, "end_char_idx": 2545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95d275ec-bf2e-4e55-bcc0-9115cf6c8eff": {"__data__": {"id_": "95d275ec-bf2e-4e55-bcc0-9115cf6c8eff", "embedding": null, "metadata": {"window": "So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "A \nOkay. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0714e56e-4fda-4287-8f2e-785e88ae9555", "node_type": "1", "metadata": {"window": "And that philosophy is no different for the GLP -1 class than it is, \nfrankly, for all of the products that we distribute.  \n \n So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aac695593f91cb58fe5f1406468cd7dfffc3860b05c8504565fbe90cff82c6e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d86da0f-d520-45f4-939d-a24176ddbc9e", "node_type": "1", "metadata": {"window": "And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "Next question, please?  \n "}, "hash": "c5f3f11e58d2c9511d053929e7da548bebda56b593eb7a933b4c85c3825487cc", "class_name": "RelatedNodeInfo"}}, "text": "A \nOkay. ", "start_char_idx": 2545, "end_char_idx": 2554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d86da0f-d520-45f4-939d-a24176ddbc9e": {"__data__": {"id_": "1d86da0f-d520-45f4-939d-a24176ddbc9e", "embedding": null, "metadata": {"window": "And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "Next question, please?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95d275ec-bf2e-4e55-bcc0-9115cf6c8eff", "node_type": "1", "metadata": {"window": "So, we are always in close contact and communication with our biopharma partners to talk about the value that \nwe deliver, to talk about maybe the ancillary services that we could offer in support of those programs, and to find \nways that we can both support the growth of our respective businesses.  And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n ", "original_text": "A \nOkay. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d17a88671f430bc277d8e10de96f6bd9b031915094eb2c293d19e12b6e0eb5ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66531c36-360b-4440-a3eb-2b4ed7b4a2fd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. "}, "hash": "88269a27ca33c98f9f9c0e1993dcadb4c85808cf34872adb25563ac9b5696c04", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please?  \n ", "start_char_idx": 2554, "end_char_idx": 2580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66531c36-360b-4440-a3eb-2b4ed7b4a2fd": {"__data__": {"id_": "66531c36-360b-4440-a3eb-2b4ed7b4a2fd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d86da0f-d520-45f4-939d-a24176ddbc9e", "node_type": "1", "metadata": {"window": "And that's exactly the lens we'll bring to \nthis product class and it's really no different than the way we run the business day -to-day. \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "original_text": "Next question, please?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df63847744dd73342c8d8bdedd18dae889df41afd28272e4961f7348179adda6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6e2d79d-81ca-4db1-92f9-7251ac6dca1f", "node_type": "1", "metadata": {"window": "A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera. ", "original_text": "Please go ahead.  \n "}, "hash": "45fa37ef6bcb42e5bc6b62ed1de1e507859556eb74d80ff3c35ab27fb94160f5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "start_char_idx": 2580, "end_char_idx": 2920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6e2d79d-81ca-4db1-92f9-7251ac6dca1f": {"__data__": {"id_": "a6e2d79d-81ca-4db1-92f9-7251ac6dca1f", "embedding": null, "metadata": {"window": "A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera. ", "original_text": "Please go ahead.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66531c36-360b-4440-a3eb-2b4ed7b4a2fd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83ac9b28620ce32dfbcfde20e2350bc776940dbcf12921cd8b99f051fee8f37c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5084f07c-a65a-4d83-a92d-4d45b7548e47", "node_type": "1", "metadata": {"window": "Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. "}, "hash": "96b13ef139a1c0344e58654475bf6e3b72ca62eb808ef6c538a7c1dde474a6fe", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 240, "end_char_idx": 260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5084f07c-a65a-4d83-a92d-4d45b7548e47": {"__data__": {"id_": "5084f07c-a65a-4d83-a92d-4d45b7548e47", "embedding": null, "metadata": {"window": "Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6e2d79d-81ca-4db1-92f9-7251ac6dca1f", "node_type": "1", "metadata": {"window": "A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera. ", "original_text": "Please go ahead.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20e615f5032e0a0025c13954af7933956b356e7020872876ccfe49a0b29edea8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fbc4205-307b-4a73-bd15-e03be0e9eafb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n ", "original_text": "Thanks so much for the question. "}, "hash": "daeffde459ebab84d0efad23a9eb55fc7990cc694459fb9f839124de26bb2047", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "start_char_idx": 2940, "end_char_idx": 3269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fbc4205-307b-4a73-bd15-e03be0e9eafb": {"__data__": {"id_": "2fbc4205-307b-4a73-bd15-e03be0e9eafb", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n ", "original_text": "Thanks so much for the question. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5084f07c-a65a-4d83-a92d-4d45b7548e47", "node_type": "1", "metadata": {"window": "Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcd1048ce6aaf4536a2b108aa8c7bb7815e91e902b76c3ecf35405ba0f2dfb85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98a05cd2-8be3-4d0e-866b-d99aaa0e83d5", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera. "}, "hash": "3e2acfee14bb91aad69d317c0b30788931713c769c2436ec3ed1c2e289dfbca4", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 3269, "end_char_idx": 3302, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98a05cd2-8be3-4d0e-866b-d99aaa0e83d5": {"__data__": {"id_": "98a05cd2-8be3-4d0e-866b-d99aaa0e83d5", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fbc4205-307b-4a73-bd15-e03be0e9eafb", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore ISI.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n ", "original_text": "Thanks so much for the question. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3e37ecf3faabda56ea6eed4dbf153584b629dc786be65584cbb9c9c3019da4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f88a1af-763c-4227-ac13-76de9e0c9a9a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on. ", "original_text": "I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have? "}, "hash": "0e801811c0c12d717e73140dbabe7739b55e22da2741e894ddb419c2e2bec885", "class_name": "RelatedNodeInfo"}}, "text": "You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera. ", "start_char_idx": 3302, "end_char_idx": 3457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f88a1af-763c-4227-ac13-76de9e0c9a9a": {"__data__": {"id_": "4f88a1af-763c-4227-ac13-76de9e0c9a9a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on. ", "original_text": "I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have? ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98a05cd2-8be3-4d0e-866b-d99aaa0e83d5", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aae29a8614a2b83b275793e53e4e2488a9803bf0aeb1e3ac0ac41331d1c17bc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5f7921f-8548-414f-8ee6-531f636eedd2", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness. ", "original_text": "Thanks.  \n "}, "hash": "ea705032fbbc6a43e6d11ddc4cb93989e5435ff75ae722f0153d17dc7652f366", "class_name": "RelatedNodeInfo"}}, "text": "I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have? ", "start_char_idx": 3457, "end_char_idx": 3644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5f7921f-8548-414f-8ee6-531f636eedd2": {"__data__": {"id_": "c5f7921f-8548-414f-8ee6-531f636eedd2", "embedding": null, "metadata": {"window": "Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f88a1af-763c-4227-ac13-76de9e0c9a9a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore ISI  Q \nHi, guys.  Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on. ", "original_text": "I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have? ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e38ff7c82bdd672d7ee8e187f1f33d96e52d16720ea9ea419cb2ade5304dcb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b52b05d4-f28d-4768-83fd-9f8a1d4621e0", "node_type": "1", "metadata": {"window": "You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "c3343581c4e7755beb64de1716333a4ca1cb7cc2bca1b27ee781e664dc0a847e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 3644, "end_char_idx": 3655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b52b05d4-f28d-4768-83fd-9f8a1d4621e0": {"__data__": {"id_": "b52b05d4-f28d-4768-83fd-9f8a1d4621e0", "embedding": null, "metadata": {"window": "You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5f7921f-8548-414f-8ee6-531f636eedd2", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness. ", "original_text": "Thanks.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56424c763e778648940ec6f1d4ebfc1416ebb75fccc53d172083aa9ed6221da3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80155aba-3543-4412-abf4-54e91ce284cd", "node_type": "1", "metadata": {"window": "I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n", "original_text": "A \nSure, I'll start, and Britt can tack on. "}, "hash": "a9473b69bed0bdf243a7d4aeb58c9a96ac78c8d5f3a446694a11cf9d2304087a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1002, "end_char_idx": 1346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80155aba-3543-4412-abf4-54e91ce284cd": {"__data__": {"id_": "80155aba-3543-4412-abf4-54e91ce284cd", "embedding": null, "metadata": {"window": "I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n", "original_text": "A \nSure, I'll start, and Britt can tack on. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b52b05d4-f28d-4768-83fd-9f8a1d4621e0", "node_type": "1", "metadata": {"window": "You guys talked  about continuing to invest in some of the longer -term \ndrivers of the Pharma growth in terms of oncology, biopharma services, et cetera.  I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc318c5a5a1ba25141e940c7049b1dcf0b09f5180ccc5124c890f778d6d149c5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "48f53da9-bc9b-4aae-8ccf-c7b3a5cb5cea", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition. ", "original_text": "First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness. "}, "hash": "87fce4dbdab1bd41abc753b676a581d9a3cfc5d436f05b773e840d8e541a62fd", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure, I'll start, and Britt can tack on. ", "start_char_idx": 3999, "end_char_idx": 4043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "48f53da9-bc9b-4aae-8ccf-c7b3a5cb5cea": {"__data__": {"id_": "48f53da9-bc9b-4aae-8ccf-c7b3a5cb5cea", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition. ", "original_text": "First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80155aba-3543-4412-abf4-54e91ce284cd", "node_type": "1", "metadata": {"window": "I was hoping you could unpack \nthat a little bit more and sort of talk a bit more about where you sort of see the most a ttractive opportunities versus \nthe assets that you already have?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n", "original_text": "A \nSure, I'll start, and Britt can tack on. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d98a0789484f1f6f249e1e8aee1fc496b80018cceda32fe8dbe798560faab009", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdef0dca-05ba-4b80-a246-b6d0423d210c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology. ", "original_text": "And we view that as part of good portfolio management. "}, "hash": "9507759057ed96724fab13c4dc154f60698bfe6744f5cf35cf433c16e6a49027", "class_name": "RelatedNodeInfo"}}, "text": "First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness. ", "start_char_idx": 4043, "end_char_idx": 4239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdef0dca-05ba-4b80-a246-b6d0423d210c": {"__data__": {"id_": "cdef0dca-05ba-4b80-a246-b6d0423d210c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology. ", "original_text": "And we view that as part of good portfolio management. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "48f53da9-bc9b-4aae-8ccf-c7b3a5cb5cea", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition. ", "original_text": "First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff6592c234d6221a144f6b547eeabd57fdfa407058f792c7e97ead7243a567c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "943e96df-bb67-4d56-8fb0-5d3c991f1834", "node_type": "1", "metadata": {"window": "A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business. ", "original_text": "I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n"}, "hash": "57efd04bf622d4760b5a17b6db317318a820921c1a7ae898108689184b167960", "class_name": "RelatedNodeInfo"}}, "text": "And we view that as part of good portfolio management. ", "start_char_idx": 4239, "end_char_idx": 4294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "943e96df-bb67-4d56-8fb0-5d3c991f1834": {"__data__": {"id_": "943e96df-bb67-4d56-8fb0-5d3c991f1834", "embedding": null, "metadata": {"window": "A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business. ", "original_text": "I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdef0dca-05ba-4b80-a246-b6d0423d210c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology. ", "original_text": "And we view that as part of good portfolio management. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2ca2a313f9a61e84978ef2e0191cbc02fdfdd4f5554ef22f89d1a2e68890ea7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "772e284a-cf40-4877-92b8-7e38dc0e6e04", "node_type": "1", "metadata": {"window": "First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition. "}, "hash": "17b123f7fcf8489f71cf798857d4e973eade5a52a4b64ea22dc5f915aa664f94", "class_name": "RelatedNodeInfo"}}, "text": "I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n", "start_char_idx": 4294, "end_char_idx": 4440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "772e284a-cf40-4877-92b8-7e38dc0e6e04": {"__data__": {"id_": "772e284a-cf40-4877-92b8-7e38dc0e6e04", "embedding": null, "metadata": {"window": "First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "943e96df-bb67-4d56-8fb0-5d3c991f1834", "node_type": "1", "metadata": {"window": "A \nSure, I'll start, and Britt can tack on.  First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business. ", "original_text": "I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a92af805c9925a3a8f90f006249570065085ef84fa33bf30b9a5adb76ea81aed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0af590c-5992-4fcd-acd9-93267ef4ec8d", "node_type": "1", "metadata": {"window": "And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "But a lo t will go into, we call our growth \npillars, and that would be oncology. "}, "hash": "8e873db18bb62d538688111cdfa42c11e84bcc0b99f9f3bccee05d0224ac66c4", "class_name": "RelatedNodeInfo"}}, "text": "So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition. ", "start_char_idx": 4440, "end_char_idx": 4624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0af590c-5992-4fcd-acd9-93267ef4ec8d": {"__data__": {"id_": "d0af590c-5992-4fcd-acd9-93267ef4ec8d", "embedding": null, "metadata": {"window": "And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "But a lo t will go into, we call our growth \npillars, and that would be oncology. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "772e284a-cf40-4877-92b8-7e38dc0e6e04", "node_type": "1", "metadata": {"window": "First thing I would say is, I'm really pleased over the last several  years, we \nhave been very disciplined in making sure that we made organic investment or reinvestment back into the \nbusiness.  And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d15758630e33b5652a063409f63e2acedb2e1146fb689f986af278172db9c232", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5e5fe7d-a9ab-4901-85a8-2ce015295a71", "node_type": "1", "metadata": {"window": "I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business. "}, "hash": "4587cccb1d8071f22229d3a9632d4e83e160e65ed45a89bb1b647e5011e59aee", "class_name": "RelatedNodeInfo"}}, "text": "But a lo t will go into, we call our growth \npillars, and that would be oncology. ", "start_char_idx": 4624, "end_char_idx": 4706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5e5fe7d-a9ab-4901-85a8-2ce015295a71": {"__data__": {"id_": "d5e5fe7d-a9ab-4901-85a8-2ce015295a71", "embedding": null, "metadata": {"window": "I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0af590c-5992-4fcd-acd9-93267ef4ec8d", "node_type": "1", "metadata": {"window": "And we view that as part of good portfolio management.  I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "But a lo t will go into, we call our growth \npillars, and that would be oncology. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb0c45c17e3159dba8857891c9f07df4726d77bd3986f58a3d5a268eadcd2c1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2551b75-c7eb-4733-8487-521ac3475e15", "node_type": "1", "metadata": {"window": "So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  "}, "hash": "f40a45aa294befe6d64bba2965273a794836a7dde6d11f7aa8f53617fd6d0c9d", "class_name": "RelatedNodeInfo"}}, "text": "So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business. ", "start_char_idx": 4706, "end_char_idx": 4825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2551b75-c7eb-4733-8487-521ac3475e15": {"__data__": {"id_": "c2551b75-c7eb-4733-8487-521ac3475e15", "embedding": null, "metadata": {"window": "So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fc80c155314f7a38566d4b8b27743b3aaec3438b694b13bdbeed80370a3b562", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5e5fe7d-a9ab-4901-85a8-2ce015295a71", "node_type": "1", "metadata": {"window": "I mean, our goal is to continue to extend the \ngrowth that we see in our mark ets and to innovate \u2013 innovating new solutions as part of that.  \n \n So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business. ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ef21b2b30a42fb40637419242c90a9d36b1ac7c24bbf47dadc3ed870fc746a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7321ac7b-0ba1-4727-a497-a11fb189bb72", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast. ", "original_text": "McKesson Corp.  "}, "hash": "544379dc914fe1e919538afc841690799c880ad5279805c9a80635ebda4fb346", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "start_char_idx": 4825, "end_char_idx": 4918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7321ac7b-0ba1-4727-a497-a11fb189bb72": {"__data__": {"id_": "7321ac7b-0ba1-4727-a497-a11fb189bb72", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2551b75-c7eb-4733-8487-521ac3475e15", "node_type": "1", "metadata": {"window": "So, across now when we allocate that investment capital, certainly, some goes into the core, where we think we \ncan get efficiency, better services, extend our base value proposition.  But a lo t will go into, we call our growth \npillars, and that would be oncology.  So in one instance, we've talked a lot is about greenfielding our Ontada \nbusiness or our data and analytics business.  Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "original_text": "Obviously, we've gone inorganic with SCRI and extended into \nclinic al trials and research.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "834593029ab0f30b1ed30fbab63126cf434c606f1594963714b79ccdcd4086de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c63f137-08d3-4f77-888b-35d9403c830d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions. "}, "hash": "b5287e22b5214793b6d64810a6e4b155614e3eb9109b8cc70a03e78f19072e94", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c63f137-08d3-4f77-888b-35d9403c830d": {"__data__": {"id_": "3c63f137-08d3-4f77-888b-35d9403c830d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7321ac7b-0ba1-4727-a497-a11fb189bb72", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "031acca95da200f646fb547c09ef1b2bd393170d80f158c975865d39c30c0e52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e22a3cc0-0749-4537-859e-d622a273e69f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business. ", "original_text": "So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n"}, "hash": "fbf5b58243d0b0a28715f2bec3067e081aaac5d7e6d04207ca992d0da5743be8", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions. ", "start_char_idx": 16, "end_char_idx": 374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e22a3cc0-0749-4537-859e-d622a273e69f": {"__data__": {"id_": "e22a3cc0-0749-4537-859e-d622a273e69f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business. ", "original_text": "So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c63f137-08d3-4f77-888b-35d9403c830d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8fe592c7880b7858120b72fc21e6dfa9d26ebd4f4e41e55fb2d001161455c35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf7755b7-4064-4e7b-9291-bc26fd269000", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n ", "original_text": "I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast. "}, "hash": "9098638f9552a92b63186e02dbc212ffaa5161aa5c2e30dc1ae2eb6c87b95935", "class_name": "RelatedNodeInfo"}}, "text": "So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n", "start_char_idx": 374, "end_char_idx": 526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf7755b7-4064-4e7b-9291-bc26fd269000": {"__data__": {"id_": "cf7755b7-4064-4e7b-9291-bc26fd269000", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n ", "original_text": "I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e22a3cc0-0749-4537-859e-d622a273e69f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business. ", "original_text": "So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a14fa0c261a3acfc8c761a5c90466829d69ed3310400b1cc26c04a6c346f27b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c352993a-4906-457f-9f67-6fc25e78c459", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n"}, "hash": "76caea384b6e918a9a3eeed8dac82a6ce94c8233eb4f42c6041edb1ff381b0b6", "class_name": "RelatedNodeInfo"}}, "text": "I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast. ", "start_char_idx": 526, "end_char_idx": 756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c352993a-4906-457f-9f67-6fc25e78c459": {"__data__": {"id_": "c352993a-4906-457f-9f67-6fc25e78c459", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf7755b7-4064-4e7b-9291-bc26fd269000", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n ", "original_text": "I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "712a754355043be1630c5d573e104ad6b1de1ff9de884cb73a3aab438c3d7ea6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88611dc9-2a77-4850-a8b6-c15fe0f9dc85", "node_type": "1", "metadata": {"window": "So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay. ", "original_text": "And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business. "}, "hash": "4840f93cbd32b928c875308d39043cc5a5f5e6a7262c65ebbae5c9d5868ae4c4", "class_name": "RelatedNodeInfo"}}, "text": "And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n", "start_char_idx": 756, "end_char_idx": 890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88611dc9-2a77-4850-a8b6-c15fe0f9dc85": {"__data__": {"id_": "88611dc9-2a77-4850-a8b6-c15fe0f9dc85", "embedding": null, "metadata": {"window": "So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay. ", "original_text": "And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c352993a-4906-457f-9f67-6fc25e78c459", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c756f8f67ea9c13ad0fd0e606dd3216d46f35d555d2cf09f93f6688c7e44a91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "041eed41-3963-4ecf-8120-f77e8e163be9", "node_type": "1", "metadata": {"window": "I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n ", "original_text": "So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n "}, "hash": "1bbb3951b9f7ac0635fec52e55b1355736ecbcd5c2c6bf1b38b26d6d5eb1bc92", "class_name": "RelatedNodeInfo"}}, "text": "And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business. ", "start_char_idx": 890, "end_char_idx": 1157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "041eed41-3963-4ecf-8120-f77e8e163be9": {"__data__": {"id_": "041eed41-3963-4ecf-8120-f77e8e163be9", "embedding": null, "metadata": {"window": "I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n ", "original_text": "So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88611dc9-2a77-4850-a8b6-c15fe0f9dc85", "node_type": "1", "metadata": {"window": "So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay. ", "original_text": "And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f2b63ce7d10b6414fa225eab41ba7b000fafb7aefabb6c70aa439255857300c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c30aeba-44e8-4f34-a5ef-a82aa4adbd97", "node_type": "1", "metadata": {"window": "And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "96309b3c33313ae28dfbcc47abc64b3358927182d6084099a79a6e32b56acab0", "class_name": "RelatedNodeInfo"}}, "text": "So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n ", "start_char_idx": 1157, "end_char_idx": 1292, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c30aeba-44e8-4f34-a5ef-a82aa4adbd97": {"__data__": {"id_": "6c30aeba-44e8-4f34-a5ef-a82aa4adbd97", "embedding": null, "metadata": {"window": "And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "041eed41-3963-4ecf-8120-f77e8e163be9", "node_type": "1", "metadata": {"window": "I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast.  And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n ", "original_text": "So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dd04b2b9cc1a7416f5df6380c23365edade7ac1f89dd1bc6e16c8e2772b9e064", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca776b91-6f0b-4ad6-be7e-6a861f34a227", "node_type": "1", "metadata": {"window": "And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "A \nOkay. "}, "hash": "06e033fd87e2d679093ededb8a765d564e421a2f9f588419474a6faedb085094", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 1292, "end_char_idx": 1637, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca776b91-6f0b-4ad6-be7e-6a861f34a227": {"__data__": {"id_": "ca776b91-6f0b-4ad6-be7e-6a861f34a227", "embedding": null, "metadata": {"window": "And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "A \nOkay. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c30aeba-44e8-4f34-a5ef-a82aa4adbd97", "node_type": "1", "metadata": {"window": "And when you think about a business that operates at our kind of scale, we're very excited about the \nopportunities we see there.  \n \n And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b813cc3234e1505b2b42ad39d0253618ca0314c36916e8bc22348ed7a9807ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "060fec8e-4535-4e5d-967f-b1e43947b241", "node_type": "1", "metadata": {"window": "So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "Next question, please?  \n "}, "hash": "0a34e2df70c0ff0b088ef8918c9e31ddc845f8fdd0d1f3e881b82a428662e8c6", "class_name": "RelatedNodeInfo"}}, "text": "A \nOkay. ", "start_char_idx": 1637, "end_char_idx": 1646, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "060fec8e-4535-4e5d-967f-b1e43947b241": {"__data__": {"id_": "060fec8e-4535-4e5d-967f-b1e43947b241", "embedding": null, "metadata": {"window": "So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "Next question, please?  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca776b91-6f0b-4ad6-be7e-6a861f34a227", "node_type": "1", "metadata": {"window": "And when you think about like the US Oncology, Bri tt highlighted several places where we think we can use this \nkind of technology to make a better patient experience, make our provider experience better and to continue to \ndrive efficiencies through that business.  So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n ", "original_text": "A \nOkay. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a0ac420464fe5385c95bcd3e71db6708832d26ebecff20af3f892705f8d24632", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84ef6f33-c9d0-47d0-ae79-224d9339f77d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank. "}, "hash": "295cc2f980324c9e93331a7f8a94df1fcd5dbd8e5be796095f1be0f1e4a4049d", "class_name": "RelatedNodeInfo"}}, "text": "Next question, please?  \n ", "start_char_idx": 1646, "end_char_idx": 1672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84ef6f33-c9d0-47d0-ae79-224d9339f77d": {"__data__": {"id_": "84ef6f33-c9d0-47d0-ae79-224d9339f77d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "060fec8e-4535-4e5d-967f-b1e43947b241", "node_type": "1", "metadata": {"window": "So, we will continue to be committed to in vesting back in the business, \nwhere we see good financial returns tied to our strategy.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "original_text": "Next question, please?  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "417b9fefa1bb2095c41c16050dbbfafafbb71e64f1feba596ad18f046ce44ee6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3031bd59-0ec5-4ef1-87f8-68330016e642", "node_type": "1", "metadata": {"window": "A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys. ", "original_text": "Please go ahead.  \n "}, "hash": "2f31fa1a46b462830867c6778703cd126380c1575e97f586b347af0ea969d34a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank. ", "start_char_idx": 1672, "end_char_idx": 2006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3031bd59-0ec5-4ef1-87f8-68330016e642": {"__data__": {"id_": "3031bd59-0ec5-4ef1-87f8-68330016e642", "embedding": null, "metadata": {"window": "A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys. ", "original_text": "Please go ahead.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84ef6f33-c9d0-47d0-ae79-224d9339f77d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "145c97feca6cf1136dd9c6ccbdc290ca2ac67fe597630741d69e13f7f0dca085", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d683b71-93cf-431d-a4a7-735b762ad821", "node_type": "1", "metadata": {"window": "Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  "}, "hash": "d7447ffbc86910d6cf5c105627f6d456bbe5f6a5b7255b25d461c233bef34a6e", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 2006, "end_char_idx": 2026, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d683b71-93cf-431d-a4a7-735b762ad821": {"__data__": {"id_": "3d683b71-93cf-431d-a4a7-735b762ad821", "embedding": null, "metadata": {"window": "Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3031bd59-0ec5-4ef1-87f8-68330016e642", "node_type": "1", "metadata": {"window": "A \nOkay.  Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys. ", "original_text": "Please go ahead.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c3f24d6b89b5b9e5f8c1c5142d05a22e6c8711cab2c4dc184f678578533ebf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c924104d-55ef-47c7-a25b-f655f7ff82f6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n", "original_text": "Q \nHey. "}, "hash": "1a13fe4e42e16191988caa8de10eea43aa9ca1e13509fb6fcf5019d9344aa04e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "start_char_idx": 2026, "end_char_idx": 2353, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c924104d-55ef-47c7-a25b-f655f7ff82f6": {"__data__": {"id_": "c924104d-55ef-47c7-a25b-f655f7ff82f6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n", "original_text": "Q \nHey. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d683b71-93cf-431d-a4a7-735b762ad821", "node_type": "1", "metadata": {"window": "Next question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b322c2f42bd597b1ea00e7880eeb607b8dfec034a1a455f5d38083cc683cd42b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f52770d-6dd6-43ab-a39f-7628638b67b3", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n", "original_text": "Good afternoon, guys. "}, "hash": "6030fccc254f2e34dad2910f974a9310583d1c9116b576a4e8ecfffc8593fd4f", "class_name": "RelatedNodeInfo"}}, "text": "Q \nHey. ", "start_char_idx": 2353, "end_char_idx": 2361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f52770d-6dd6-43ab-a39f-7628638b67b3": {"__data__": {"id_": "4f52770d-6dd6-43ab-a39f-7628638b67b3", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n", "original_text": "Good afternoon, guys. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c924104d-55ef-47c7-a25b-f655f7ff82f6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be George Hill with Deutsche Bank.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n", "original_text": "Q \nHey. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4245c07bca8ef133eca43e53aa3adf81cbbb1bcf31be2a3a64f02bc387ee96f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ef8ff38-b85f-4900-9c0d-9f4f0bb19696", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology. ", "original_text": "And thanks for taking the question. "}, "hash": "9f427de89fe4d2bf51f210f78c68eabe94b7737da47da7dcebcc150cdab3e847", "class_name": "RelatedNodeInfo"}}, "text": "Good afternoon, guys. ", "start_char_idx": 2361, "end_char_idx": 2383, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ef8ff38-b85f-4900-9c0d-9f4f0bb19696": {"__data__": {"id_": "2ef8ff38-b85f-4900-9c0d-9f4f0bb19696", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology. ", "original_text": "And thanks for taking the question. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f52770d-6dd6-43ab-a39f-7628638b67b3", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n", "original_text": "Good afternoon, guys. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b15332a7681a8944be64f99b3e9fabb3c317c780cff1702776f06be3eee7d73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aeeff499-e42e-4662-863e-5b822e389029", "node_type": "1", "metadata": {"window": "Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business? ", "original_text": "Britt, first one is just kind of a point of clarification. \n"}, "hash": "60bc94c23fe56c046307bbeb306a63d35932523f34fc0aa0371c1edad35dc347", "class_name": "RelatedNodeInfo"}}, "text": "And thanks for taking the question. ", "start_char_idx": 2383, "end_char_idx": 2419, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aeeff499-e42e-4662-863e-5b822e389029": {"__data__": {"id_": "aeeff499-e42e-4662-863e-5b822e389029", "embedding": null, "metadata": {"window": "Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business? ", "original_text": "Britt, first one is just kind of a point of clarification. \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ef8ff38-b85f-4900-9c0d-9f4f0bb19696", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nGeorge Hill  \nAnalyst, Deutsche Bank Securities, Inc.   Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology. ", "original_text": "And thanks for taking the question. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f675edfecf314931c9979bcf22f979ef72b6f85b195360a0c18517333441e8a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44013258-0b42-40b1-b43b-c16cc36c71aa", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness? ", "original_text": "When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n"}, "hash": "c8062d3a9fe254f3586022a6cdf16f619c6d34545bcfb4a5bc42af16423f88c2", "class_name": "RelatedNodeInfo"}}, "text": "Britt, first one is just kind of a point of clarification. \n", "start_char_idx": 2419, "end_char_idx": 2479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44013258-0b42-40b1-b43b-c16cc36c71aa": {"__data__": {"id_": "44013258-0b42-40b1-b43b-c16cc36c71aa", "embedding": null, "metadata": {"window": "Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness? ", "original_text": "When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aeeff499-e42e-4662-863e-5b822e389029", "node_type": "1", "metadata": {"window": "Q \nHey.  Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business? ", "original_text": "Britt, first one is just kind of a point of clarification. \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "193c740f5dc56628f407e572029f73115f244256f5991841edb06e2da8bf3dfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "429c6ff3-6f4c-4cc7-9a0b-cc6a2bf5bb55", "node_type": "1", "metadata": {"window": "And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n ", "original_text": "And then for Brian, I have a follow -up question on Oncology. "}, "hash": "e9e5917e8c59c75f1ef734ae4a09f6dec5ec03a71e72b4c91b6194276cf2a10b", "class_name": "RelatedNodeInfo"}}, "text": "When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n", "start_char_idx": 2479, "end_char_idx": 2562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "429c6ff3-6f4c-4cc7-9a0b-cc6a2bf5bb55": {"__data__": {"id_": "429c6ff3-6f4c-4cc7-9a0b-cc6a2bf5bb55", "embedding": null, "metadata": {"window": "And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n ", "original_text": "And then for Brian, I have a follow -up question on Oncology. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44013258-0b42-40b1-b43b-c16cc36c71aa", "node_type": "1", "metadata": {"window": "Good afternoon, guys.  And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness? ", "original_text": "When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32d0bf14a4ca8f8439fc9d7f4bc32269dfcf32396e2ee9a8837f79bb37fb0be7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f743523-2224-4b0d-aa03-1adffab55480", "node_type": "1", "metadata": {"window": "Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business? "}, "hash": "dfabee87b82b4faf0c1a65fefd794f25a0e7c0cd3112b2d99f8d0d19db101bb3", "class_name": "RelatedNodeInfo"}}, "text": "And then for Brian, I have a follow -up question on Oncology. ", "start_char_idx": 2562, "end_char_idx": 2624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f743523-2224-4b0d-aa03-1adffab55480": {"__data__": {"id_": "4f743523-2224-4b0d-aa03-1adffab55480", "embedding": null, "metadata": {"window": "Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business? ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "429c6ff3-6f4c-4cc7-9a0b-cc6a2bf5bb55", "node_type": "1", "metadata": {"window": "And thanks for taking the question.  Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n ", "original_text": "And then for Brian, I have a follow -up question on Oncology. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae215a2e648060de2340c54280d91a543bacc1f5cfe4029995aa2c80fc058c44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbab60af-25ec-47f3-8be2-2ab97eb6b2ff", "node_type": "1", "metadata": {"window": "When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on. ", "original_text": "And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness? "}, "hash": "16ff3a036c5e2d97f6ebf85751981a7a585182a100e7b777360f074cb55cf4af", "class_name": "RelatedNodeInfo"}}, "text": "I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business? ", "start_char_idx": 2624, "end_char_idx": 2729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbab60af-25ec-47f3-8be2-2ab97eb6b2ff": {"__data__": {"id_": "dbab60af-25ec-47f3-8be2-2ab97eb6b2ff", "embedding": null, "metadata": {"window": "When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on. ", "original_text": "And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness? ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f743523-2224-4b0d-aa03-1adffab55480", "node_type": "1", "metadata": {"window": "Britt, first one is just kind of a point of clarification. \n When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business? ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "104f6e765187d09c4aee3cdeec250e1737ee48d7aee92ad314945590ad6e78e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4248ce7a-c054-4549-a83d-880a1ddb0ec7", "node_type": "1", "metadata": {"window": "And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business. ", "original_text": "Thank you.  \n "}, "hash": "b5888518c13f345d4e8a6ef097cbd21f1477eae3844842b96e1bb2676e34dfbd", "class_name": "RelatedNodeInfo"}}, "text": "And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness? ", "start_char_idx": 2729, "end_char_idx": 2906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4248ce7a-c054-4549-a83d-880a1ddb0ec7": {"__data__": {"id_": "4248ce7a-c054-4549-a83d-880a1ddb0ec7", "embedding": null, "metadata": {"window": "And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business. ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbab60af-25ec-47f3-8be2-2ab97eb6b2ff", "node_type": "1", "metadata": {"window": "When you say GLP -1s as an EBIT headwind, you mean to margins  not to dollars?  \n \n And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on. ", "original_text": "And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness? ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2eeacca891157e78f504fdabf3996ac0f7135a4fbde90931b98a27abe4cf4f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d0d066a-7d03-4cc5-bedb-cdd98271e426", "node_type": "1", "metadata": {"window": "I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "29a01dd633c2922b9ce823263f7af59d1933040ad6abf4b3b4451279f4c76ee2", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 2906, "end_char_idx": 2920, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d0d066a-7d03-4cc5-bedb-cdd98271e426": {"__data__": {"id_": "1d0d066a-7d03-4cc5-bedb-cdd98271e426", "embedding": null, "metadata": {"window": "I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4248ce7a-c054-4549-a83d-880a1ddb0ec7", "node_type": "1", "metadata": {"window": "And then for Brian, I have a follow -up question on Oncology.  I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business. ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d41c3a41729687119ed7a6aeb0e0a45b08aeeab6ed3532447a094ccd605a5c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ae60f0-7ff0-4e53-8a3a-bf8471f792b6", "node_type": "1", "metadata": {"window": "And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n", "original_text": "A \nI'll start with your second question and then Britt, can come on. "}, "hash": "096d1ef2fc426b564608b96f2141ad2f97332e987d946e0ce6cc5502b50b524e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2920, "end_char_idx": 3264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ae60f0-7ff0-4e53-8a3a-bf8471f792b6": {"__data__": {"id_": "d0ae60f0-7ff0-4e53-8a3a-bf8471f792b6", "embedding": null, "metadata": {"window": "And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n", "original_text": "A \nI'll start with your second question and then Britt, can come on. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d0d066a-7d03-4cc5-bedb-cdd98271e426", "node_type": "1", "metadata": {"window": "I guess, could you just kind of talk about the \ngreenfield opportunity that remains in the USO business?  And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22a385066dbee81027e5a3b2dfac14dee0b719baf849f95a6c5441dcb8806e57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c9e9621c-421e-4905-b6cf-3f5307339fba", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n", "original_text": "So I talked about three ways to drive the US \nOncology business. "}, "hash": "ce4bccb143fd59ae2b6a237659da6d829b8fb86e1cc62798c7ccae9b82c7f639", "class_name": "RelatedNodeInfo"}}, "text": "A \nI'll start with your second question and then Britt, can come on. ", "start_char_idx": 3264, "end_char_idx": 3333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c9e9621c-421e-4905-b6cf-3f5307339fba": {"__data__": {"id_": "c9e9621c-421e-4905-b6cf-3f5307339fba", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n", "original_text": "So I talked about three ways to drive the US \nOncology business. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0ae60f0-7ff0-4e53-8a3a-bf8471f792b6", "node_type": "1", "metadata": {"window": "And do you think more about the opportunity to add \nproviders kind of add regions or add services into the installed base as kind of the way to continue to grow that \nbusiness?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n", "original_text": "A \nI'll start with your second question and then Britt, can come on. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ed0ecb800704e0bd17e1b8a071ab0df8463d5e5a4953de8424a4779bdc14dc6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f65844a-670c-4e70-95c0-af0c398b83a2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us. ", "original_text": "One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography. "}, "hash": "7e7f10c010a4693a824f74177be2361968faa74be319992b9d6eb23007a55c1d", "class_name": "RelatedNodeInfo"}}, "text": "So I talked about three ways to drive the US \nOncology business. ", "start_char_idx": 3333, "end_char_idx": 3398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f65844a-670c-4e70-95c0-af0c398b83a2": {"__data__": {"id_": "0f65844a-670c-4e70-95c0-af0c398b83a2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us. ", "original_text": "One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c9e9621c-421e-4905-b6cf-3f5307339fba", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n", "original_text": "So I talked about three ways to drive the US \nOncology business. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9fbe69b1b5b9fe13a02dfaca7ed60386208b21dbdf5e66824f53bf570f593b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0e1c978-eb3b-4b79-8474-4ac4fff43445", "node_type": "1", "metadata": {"window": "A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n ", "original_text": "And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n"}, "hash": "c51094a14a45b4f239166bd630cf98ba032ba715f92a61919df3dc07905f016d", "class_name": "RelatedNodeInfo"}}, "text": "One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography. ", "start_char_idx": 3398, "end_char_idx": 3508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0e1c978-eb3b-4b79-8474-4ac4fff43445": {"__data__": {"id_": "f0e1c978-eb3b-4b79-8474-4ac4fff43445", "embedding": null, "metadata": {"window": "A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n ", "original_text": "And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f65844a-670c-4e70-95c0-af0c398b83a2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us. ", "original_text": "One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "648479457d505bc4937a65e6e0af93a7f932418fdb8bfbba5e3d7abdec453f9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d995c9b6-e4c5-442d-be02-887694d28f2b", "node_type": "1", "metadata": {"window": "So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We are not afraid to greenfield.  \n \n"}, "hash": "3b5d9c6257bb30251a2439c4fa1f4a2189d6a16b6eae28dd3ae61cd76613ab6e", "class_name": "RelatedNodeInfo"}}, "text": "And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n", "start_char_idx": 3508, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d995c9b6-e4c5-442d-be02-887694d28f2b": {"__data__": {"id_": "d995c9b6-e4c5-442d-be02-887694d28f2b", "embedding": null, "metadata": {"window": "So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We are not afraid to greenfield.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0e1c978-eb3b-4b79-8474-4ac4fff43445", "node_type": "1", "metadata": {"window": "A \nI'll start with your second question and then Britt, can come on.  So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n ", "original_text": "And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18ab6bf5aee4270df0ae842db0a2032aeefd5055e9b1e92c97f2ad7855f59831", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "550410c3-3cfb-4d52-b7ba-c8ba8bd2e43f", "node_type": "1", "metadata": {"window": "One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us. "}, "hash": "24ab488ccd226d78188a964a14b8b53814c6d8998f5caad89b46a2025e7934e9", "class_name": "RelatedNodeInfo"}}, "text": "We are not afraid to greenfield.  \n \n", "start_char_idx": 3721, "end_char_idx": 3758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "550410c3-3cfb-4d52-b7ba-c8ba8bd2e43f": {"__data__": {"id_": "550410c3-3cfb-4d52-b7ba-c8ba8bd2e43f", "embedding": null, "metadata": {"window": "One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d995c9b6-e4c5-442d-be02-887694d28f2b", "node_type": "1", "metadata": {"window": "So I talked about three ways to drive the US \nOncology business.  One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "original_text": "We are not afraid to greenfield.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92e0db0340f591d5b4829c0d280cc4c551ef0e9352c741e45ef07df8f3ddcb5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8641e5e4-24b0-4d3f-8217-c98926e0ffa6", "node_type": "1", "metadata": {"window": "And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n "}, "hash": "6fc5714a0b6b7cff8deab92afef82b5cb98020ca2f20ba5e7feb33d0c221c3a2", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us. ", "start_char_idx": 3758, "end_char_idx": 3961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8641e5e4-24b0-4d3f-8217-c98926e0ffa6": {"__data__": {"id_": "8641e5e4-24b0-4d3f-8217-c98926e0ffa6", "embedding": null, "metadata": {"window": "And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "550410c3-3cfb-4d52-b7ba-c8ba8bd2e43f", "node_type": "1", "metadata": {"window": "One is to acquire a practice in a geography we're not, obviously, to add providers to an \nexisting geography.  And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us. ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6e592c3a691b387c2cf906798a42d4fb9b3039592c5806eacb9278ed472170a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4511b8d2-f5ce-457c-8091-8ef31f786e2e", "node_type": "1", "metadata": {"window": "We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  "}, "hash": "53090be6a036c8e20611599a14c3330d308b618dbdb7cfee59d3ccf2aea5521d", "class_name": "RelatedNodeInfo"}}, "text": "And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n ", "start_char_idx": 3961, "end_char_idx": 4144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4511b8d2-f5ce-457c-8091-8ef31f786e2e": {"__data__": {"id_": "4511b8d2-f5ce-457c-8091-8ef31f786e2e", "embedding": null, "metadata": {"window": "We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8641e5e4-24b0-4d3f-8217-c98926e0ffa6", "node_type": "1", "metadata": {"window": "And in instances where our criteria are met, meaning we think we can attract the right  level of \nscale, we can find oncologists that want to practice consistent with the way we practice oncology in our network. \n We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4d1990386cf40bda0288cad4dd4486274f8db491c6a3ea4754c8f4a0798a927", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36a34f9e-b916-400d-945f-4832084e43f2", "node_type": "1", "metadata": {"window": "Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "A "}, "hash": "a2f67956252f3d53b423a76ae53e3e16235b9051c8290b8e7a4f19c7c8e8f8c3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "start_char_idx": 4144, "end_char_idx": 4504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36a34f9e-b916-400d-945f-4832084e43f2": {"__data__": {"id_": "36a34f9e-b916-400d-945f-4832084e43f2", "embedding": null, "metadata": {"window": "Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "A ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d78783025e3e0e1054fa012d1434beeb15a0e31f0864a32c8e15609db74406c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4511b8d2-f5ce-457c-8091-8ef31f786e2e", "node_type": "1", "metadata": {"window": "We are not afraid to greenfield.  \n \n Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c34fc60eef6c5b374652129cf6503255f5c8abab974bda0969e2a30931e1855", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bed96950-91f5-4f08-aa1b-56d61e02782a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n ", "original_text": "McKesson Corp.  "}, "hash": "5c92fbecd241ac8f2401a0524320efea0a39c18b9004960906481685a0fc9351", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 1637, "end_char_idx": 1639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bed96950-91f5-4f08-aa1b-56d61e02782a": {"__data__": {"id_": "bed96950-91f5-4f08-aa1b-56d61e02782a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36a34f9e-b916-400d-945f-4832084e43f2", "node_type": "1", "metadata": {"window": "Obviously, adding to an existing is faster, acquiring an established practice that we feel fits ou r criteria is probably \nsecond and greenfield would be third, but we have all those avenues open to us.  And so we look at the criteria, \nthe population, the growth, the payer mix, these all kind of go into our formula, as we identify which of those three \navenues is the most viable.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A ", "original_text": "A ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "021819a3f58533f1622f68df9bbdcadda72253ef8cbc0864ac322f633f66cc2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2070b14-125b-4e58-b184-1e1cd015334c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate. "}, "hash": "80b3fa0f50b8cfeb6c25ca77d2fd931d2d2e7273691374f029139d8bbdc9f655", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2070b14-125b-4e58-b184-1e1cd015334c": {"__data__": {"id_": "c2070b14-125b-4e58-b184-1e1cd015334c", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bed96950-91f5-4f08-aa1b-56d61e02782a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5571b2f62e29eb9ec9b55962fab6eacf32bfc2556c7bd29ceb2e4ec1feda8fb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "515f07be-6892-4ffe-aff7-72db5f10be1f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n ", "original_text": "They usually come at a lower margin rate than other products that we distribute. "}, "hash": "f95ab7ef04928ef62fc795b583a9654fdb04694d155a45eb0e5591d75627cc0a", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate. ", "start_char_idx": 16, "end_char_idx": 306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "515f07be-6892-4ffe-aff7-72db5f10be1f": {"__data__": {"id_": "515f07be-6892-4ffe-aff7-72db5f10be1f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n ", "original_text": "They usually come at a lower margin rate than other products that we distribute. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2070b14-125b-4e58-b184-1e1cd015334c", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d4ab9f8af51014afae46780a0be6954198195780f6eb8799dbde94841b97d35a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20544eb7-d992-4557-a73d-56baacdc0a45", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n "}, "hash": "9a3bf8367f88c7cbd3b0fc01cf771542cbb23224a056982d4b7e83660750545a", "class_name": "RelatedNodeInfo"}}, "text": "They usually come at a lower margin rate than other products that we distribute. ", "start_char_idx": 306, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20544eb7-d992-4557-a73d-56baacdc0a45": {"__data__": {"id_": "20544eb7-d992-4557-a73d-56baacdc0a45", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "515f07be-6892-4ffe-aff7-72db5f10be1f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n ", "original_text": "They usually come at a lower margin rate than other products that we distribute. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe3f3ddcfcd9dd0a1a16dc6d52c9829fc00b6b6f24be28713cf0eb175f7e0439", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fa665b3-8706-499b-b0be-087c997ddec8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  "}, "hash": "da42f785b0eeba94cc76f9fe24ab53cad8c183fde33b41cf3e195d19f734eb16", "class_name": "RelatedNodeInfo"}}, "text": "And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n ", "start_char_idx": 387, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fa665b3-8706-499b-b0be-087c997ddec8": {"__data__": {"id_": "5fa665b3-8706-499b-b0be-087c997ddec8", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20544eb7-d992-4557-a73d-56baacdc0a45", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2f7f3e8fa4235ba265c8adc301bc1ecadd6792711513c40f848cb2f7bdc1804", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "271904d0-4b5c-47db-8059-83c3378ac5bb", "node_type": "1", "metadata": {"window": "They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n ", "original_text": "A \nAnd we have time for one more question, please?  \n "}, "hash": "a64e78896cf93dda7b411b9ad64abf4de3070348320b31464840be15a7d60cc6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "start_char_idx": 472, "end_char_idx": 817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "271904d0-4b5c-47db-8059-83c3378ac5bb": {"__data__": {"id_": "271904d0-4b5c-47db-8059-83c3378ac5bb", "embedding": null, "metadata": {"window": "They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n ", "original_text": "A \nAnd we have time for one more question, please?  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fa665b3-8706-499b-b0be-087c997ddec8", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc172c4a75a118157e663b4719ec4e90c8eb8c76fe5033b82d49ead05303df6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51e94653-4f27-446c-a831-cad2cfee06e0", "node_type": "1", "metadata": {"window": "And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "1c3bbc23513218b9d1ce27b989c4cd7ce725cd38cabd4c1e12f65581436d8e4c", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd we have time for one more question, please?  \n ", "start_char_idx": 817, "end_char_idx": 871, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51e94653-4f27-446c-a831-cad2cfee06e0": {"__data__": {"id_": "51e94653-4f27-446c-a831-cad2cfee06e0", "embedding": null, "metadata": {"window": "And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "271904d0-4b5c-47db-8059-83c3378ac5bb", "node_type": "1", "metadata": {"window": "They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n ", "original_text": "A \nAnd we have time for one more question, please?  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22cbb2ec28ba7520dfba13654ffe17ea0ea968b8a4fc0c3cb0263a8da0b00023", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9995193b-c6af-47e1-8f02-a3105d6b18b6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve. ", "original_text": "That question will come from Stephen Baxter with Wells Fargo. "}, "hash": "8d9ebff6a3efb161e198c884ee0a8b2af04a222073512ff289a436f5b790ad5b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 871, "end_char_idx": 1167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9995193b-c6af-47e1-8f02-a3105d6b18b6": {"__data__": {"id_": "9995193b-c6af-47e1-8f02-a3105d6b18b6", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve. ", "original_text": "That question will come from Stephen Baxter with Wells Fargo. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51e94653-4f27-446c-a831-cad2cfee06e0", "node_type": "1", "metadata": {"window": "And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8523baa7a21a88e396f9d84a128da825449572e2be38f94a1d3d90bdc3f51f54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1a53267-2f6a-43f1-acad-f17d46b94ba3", "node_type": "1", "metadata": {"window": "A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1. ", "original_text": "Please go ahead.  \n "}, "hash": "1449bbab8df367528b944ee9f28559432e635995d4651561c1ac0b86adb71b5d", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from Stephen Baxter with Wells Fargo. ", "start_char_idx": 1167, "end_char_idx": 1229, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1a53267-2f6a-43f1-acad-f17d46b94ba3": {"__data__": {"id_": "b1a53267-2f6a-43f1-acad-f17d46b94ba3", "embedding": null, "metadata": {"window": "A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1. ", "original_text": "Please go ahead.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9995193b-c6af-47e1-8f02-a3105d6b18b6", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.   A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve. ", "original_text": "That question will come from Stephen Baxter with Wells Fargo. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72cca365369ef431666b467a281341c683eb6584a0229da8d45282e949955940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6db3cf3-9d22-4d22-b35a-a5977c333e99", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi. "}, "hash": "b260ab6e6563bef0bada8c531ae83fda204685da228e4309375f97abbda7b7f0", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n ", "start_char_idx": 1229, "end_char_idx": 1249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6db3cf3-9d22-4d22-b35a-a5977c333e99": {"__data__": {"id_": "b6db3cf3-9d22-4d22-b35a-a5977c333e99", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1a53267-2f6a-43f1-acad-f17d46b94ba3", "node_type": "1", "metadata": {"window": "A \nAnd we have time for one more question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1. ", "original_text": "Please go ahead.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29bbd1ae6455331943f019b30da7f8ecc43a442743eb320bb5b2ebcce9cd33ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f9acab3-a020-4eae-82a2-d00e2c1d1d22", "node_type": "1", "metadata": {"window": "That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions? ", "original_text": "This is Carol on for Steve. "}, "hash": "784cf54f2191669ca9c8a918ace280e07bbf7747a4b81610aeaa2ba74e183e46", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi. ", "start_char_idx": 1249, "end_char_idx": 1578, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f9acab3-a020-4eae-82a2-d00e2c1d1d22": {"__data__": {"id_": "3f9acab3-a020-4eae-82a2-d00e2c1d1d22", "embedding": null, "metadata": {"window": "That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions? ", "original_text": "This is Carol on for Steve. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6db3cf3-9d22-4d22-b35a-a5977c333e99", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1c52eaa4d480f37652ce60d98cbe6448602d30501d28154985a2a88e45ac5db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb72140c-d03c-406f-a8c1-7c11f8893e18", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s? ", "original_text": "Just a follow -up on the Prescription Technology seg ment of GLP -1. "}, "hash": "c1b78bd450f2dd8856713090211cea82c9c737592fc61e1dd4c162b2169d4186", "class_name": "RelatedNodeInfo"}}, "text": "This is Carol on for Steve. ", "start_char_idx": 1578, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb72140c-d03c-406f-a8c1-7c11f8893e18": {"__data__": {"id_": "eb72140c-d03c-406f-a8c1-7c11f8893e18", "embedding": null, "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s? ", "original_text": "Just a follow -up on the Prescription Technology seg ment of GLP -1. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f9acab3-a020-4eae-82a2-d00e2c1d1d22", "node_type": "1", "metadata": {"window": "That question will come from Stephen Baxter with Wells Fargo.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions? ", "original_text": "This is Carol on for Steve. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6307fc1f45d4dfa8319958dd0ebfc04b3f74d5e90f66c54b09cae687341caab5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e45652d-5860-4fe1-a27a-264e6a0fe16c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n ", "original_text": "Now that we're \nstarting to come up against some harder comps. "}, "hash": "f2bbdeef0fbdc8bbd6ab50ce90fc2d99f5f84899f3aa70b630ed608b140fc9ba", "class_name": "RelatedNodeInfo"}}, "text": "Just a follow -up on the Prescription Technology seg ment of GLP -1. ", "start_char_idx": 1606, "end_char_idx": 1675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e45652d-5860-4fe1-a27a-264e6a0fe16c": {"__data__": {"id_": "5e45652d-5860-4fe1-a27a-264e6a0fe16c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n ", "original_text": "Now that we're \nstarting to come up against some harder comps. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb72140c-d03c-406f-a8c1-7c11f8893e18", "node_type": "1", "metadata": {"window": "Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s? ", "original_text": "Just a follow -up on the Prescription Technology seg ment of GLP -1. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e329ccb0e9859dee38aba4b717dd6317f86a34155142e22c995cfa45494e6f13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f0bb05e-accb-459e-8871-e3124823f339", "node_type": "1", "metadata": {"window": "This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just how should we think about growth for this business tied to \nnew versus renewed prescriptions? "}, "hash": "8ea0dda089736295fd2f29662976a10b1ac9dd109d2f69abcaf222b38f0df0d4", "class_name": "RelatedNodeInfo"}}, "text": "Now that we're \nstarting to come up against some harder comps. ", "start_char_idx": 1675, "end_char_idx": 1738, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f0bb05e-accb-459e-8871-e3124823f339": {"__data__": {"id_": "4f0bb05e-accb-459e-8871-e3124823f339", "embedding": null, "metadata": {"window": "This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just how should we think about growth for this business tied to \nnew versus renewed prescriptions? ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e45652d-5860-4fe1-a27a-264e6a0fe16c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCarol Wong  \nAnalyst, Wells Fargo Securities LLC  Q \nHi.  This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n ", "original_text": "Now that we're \nstarting to come up against some harder comps. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1029ce94f9498bf97e4c1cb73b01ab4828391aa390b33a2d22280ff3eef1c817", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a649ca3b-cce7-4c1a-8324-da8f3e1021b6", "node_type": "1", "metadata": {"window": "Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter. ", "original_text": "And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s? "}, "hash": "431837f9ae6718857f16bae6320cae448ba32460f10be9db857c637aa56913ab", "class_name": "RelatedNodeInfo"}}, "text": "Just how should we think about growth for this business tied to \nnew versus renewed prescriptions? ", "start_char_idx": 1738, "end_char_idx": 1837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a649ca3b-cce7-4c1a-8324-da8f3e1021b6": {"__data__": {"id_": "a649ca3b-cce7-4c1a-8324-da8f3e1021b6", "embedding": null, "metadata": {"window": "Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter. ", "original_text": "And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s? ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f0bb05e-accb-459e-8871-e3124823f339", "node_type": "1", "metadata": {"window": "This is Carol on for Steve.  Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "Just how should we think about growth for this business tied to \nnew versus renewed prescriptions? ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fb9e9f2e7fbdce0d1d0bf675c959df6f208d994b2449f6fddd60c523a6c30ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d85e9ab4-68ec-4228-8219-1f283b933218", "node_type": "1", "metadata": {"window": "Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that. ", "original_text": "Thank you.  \n "}, "hash": "fde92143ce16245237f9c0f0531282fdc2019df72b8911d711604a993797c501", "class_name": "RelatedNodeInfo"}}, "text": "And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s? ", "start_char_idx": 1837, "end_char_idx": 1943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d85e9ab4-68ec-4228-8219-1f283b933218": {"__data__": {"id_": "d85e9ab4-68ec-4228-8219-1f283b933218", "embedding": null, "metadata": {"window": "Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that. ", "original_text": "Thank you.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a649ca3b-cce7-4c1a-8324-da8f3e1021b6", "node_type": "1", "metadata": {"window": "Just a follow -up on the Prescription Technology seg ment of GLP -1.  Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter. ", "original_text": "And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s? ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f22e281b4f4eeb1f7d02ecf161c98ad86eb495af1a273b7185dd75ce050f00d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19354937-ab9e-44ae-81ed-18b9a2bdfdd4", "node_type": "1", "metadata": {"window": "Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "c687642cfaf004a753ebaf917ac6c86d2dd81479e67559ba72be27cf40411acb", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 1943, "end_char_idx": 1957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19354937-ab9e-44ae-81ed-18b9a2bdfdd4": {"__data__": {"id_": "19354937-ab9e-44ae-81ed-18b9a2bdfdd4", "embedding": null, "metadata": {"window": "Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d85e9ab4-68ec-4228-8219-1f283b933218", "node_type": "1", "metadata": {"window": "Now that we're \nstarting to come up against some harder comps.  Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that. ", "original_text": "Thank you.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c33cee6275d771315d3f3ed40ae784f7acdfeea014ec5d60dfd100cc130c0b2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8ead45d-90ec-482e-bbcf-6919c5940a92", "node_type": "1", "metadata": {"window": "And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n ", "original_text": "A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter. "}, "hash": "199655bfd0ac037b25129a0b47d6eb5b46644d2d1c19ecb2b54ded6a2de69d64", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1957, "end_char_idx": 2301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8ead45d-90ec-482e-bbcf-6919c5940a92": {"__data__": {"id_": "d8ead45d-90ec-482e-bbcf-6919c5940a92", "embedding": null, "metadata": {"window": "And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n ", "original_text": "A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19354937-ab9e-44ae-81ed-18b9a2bdfdd4", "node_type": "1", "metadata": {"window": "Just how should we think about growth for this business tied to \nnew versus renewed prescriptions?  And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c5f1ab6ec1b591aef1ca120feb049f2dee772f7cab29341c10ff2892d716ffd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71aba4e5-1f7b-4be1-ac1e-b1fe8c3d7ba5", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.  ", "original_text": "We're going to start \nto lap that. "}, "hash": "d62e7f3cf4ccc860e36775c6a6f33cd72dfd4d996d800c10fc5f83b8c7994c92", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter. ", "start_char_idx": 2301, "end_char_idx": 2400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71aba4e5-1f7b-4be1-ac1e-b1fe8c3d7ba5": {"__data__": {"id_": "71aba4e5-1f7b-4be1-ac1e-b1fe8c3d7ba5", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.  ", "original_text": "We're going to start \nto lap that. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8ead45d-90ec-482e-bbcf-6919c5940a92", "node_type": "1", "metadata": {"window": "And what are some of the other categories we should be focused on as \ngrowth drive rs outside of GLP -1s?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n ", "original_text": "A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4aef134f7406161af9d154b7494046f583a7c64d2fd6b04d272d0b455a6a4ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d0a4343-6a15-4357-930a-268428c6c1c7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment. ", "original_text": "I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products. "}, "hash": "8f2f3e0706ac018a59829a3e137bd7d85b3bd7a8153739251a394fb61105e64e", "class_name": "RelatedNodeInfo"}}, "text": "We're going to start \nto lap that. ", "start_char_idx": 2400, "end_char_idx": 2435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d0a4343-6a15-4357-930a-268428c6c1c7": {"__data__": {"id_": "1d0a4343-6a15-4357-930a-268428c6c1c7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment. ", "original_text": "I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71aba4e5-1f7b-4be1-ac1e-b1fe8c3d7ba5", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.  ", "original_text": "We're going to start \nto lap that. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26ce9d449207453506d316fd4f5daf0d5afa55ee91a103ee575bc74f9029dfe6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fae82da-4155-4a05-b15f-a5bc0c2dcae7", "node_type": "1", "metadata": {"window": "A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good. ", "original_text": "So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n "}, "hash": "c97b2afd4072e96687945439fdc5169100b65b26989c3573c6b992346d07b469", "class_name": "RelatedNodeInfo"}}, "text": "I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products. ", "start_char_idx": 2435, "end_char_idx": 2661, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fae82da-4155-4a05-b15f-a5bc0c2dcae7": {"__data__": {"id_": "5fae82da-4155-4a05-b15f-a5bc0c2dcae7", "embedding": null, "metadata": {"window": "A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good. ", "original_text": "So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d0a4343-6a15-4357-930a-268428c6c1c7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment. ", "original_text": "I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c451ff7e32d256f6381d9c416b753b36886cbebbe3e0f0e032733d575cc084c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af349817-c5ce-458b-bd71-ded040e24caf", "node_type": "1", "metadata": {"window": "We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.  "}, "hash": "abdfb937d12b9c83705d6dda0860fae3e19338dde5367cfd0757674eb4b575bd", "class_name": "RelatedNodeInfo"}}, "text": "So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n ", "start_char_idx": 2661, "end_char_idx": 2890, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af349817-c5ce-458b-bd71-ded040e24caf": {"__data__": {"id_": "af349817-c5ce-458b-bd71-ded040e24caf", "embedding": null, "metadata": {"window": "We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fae82da-4155-4a05-b15f-a5bc0c2dcae7", "node_type": "1", "metadata": {"window": "A \nWell, I think as we think about GLP -1s, obviously, four quarters ago was a big growth quarter.  We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good. ", "original_text": "So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "767d5ce2175a8a939f989abfe946cb4889cd225df542230a5ad57ba2944030f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e4a4794d-210b-47c8-bf78-66e49aee41b8", "node_type": "1", "metadata": {"window": "I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "original_text": "A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment. "}, "hash": "051acee6350cd61f2817413c018e0c6c61eaaa5d0f3bbca269c5633e899d3662", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.  ", "start_char_idx": 2890, "end_char_idx": 3251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e4a4794d-210b-47c8-bf78-66e49aee41b8": {"__data__": {"id_": "e4a4794d-210b-47c8-bf78-66e49aee41b8", "embedding": null, "metadata": {"window": "I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "original_text": "A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af349817-c5ce-458b-bd71-ded040e24caf", "node_type": "1", "metadata": {"window": "We're going to start \nto lap that.  I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9650b09e37d1962c539331009ac2fb652475a0897599202cc055392f3ee4b155", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb1a9918-3bda-4a79-812d-8ec69734ea20", "node_type": "1", "metadata": {"window": "So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call. ", "original_text": "So the momentum in that segment is really good. "}, "hash": "b2c7fc49fc92091fdf61ec74c8e841e3dd0503a0725fe325dc95bd30164b17ea", "class_name": "RelatedNodeInfo"}}, "text": "A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment. ", "start_char_idx": 3251, "end_char_idx": 3504, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb1a9918-3bda-4a79-812d-8ec69734ea20": {"__data__": {"id_": "cb1a9918-3bda-4a79-812d-8ec69734ea20", "embedding": null, "metadata": {"window": "So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call. ", "original_text": "So the momentum in that segment is really good. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e4a4794d-210b-47c8-bf78-66e49aee41b8", "node_type": "1", "metadata": {"window": "I think my characterization is there will continue to be growth, that growth may or may not be linear \ndepending on product launches, uptakes, how commercial, government, other payers adopt policies to manage \nthese products.  So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "original_text": "A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97c0430897cad700c7b79664c9dce33ede62acd5b670157685f52bc6157b9872", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "847b91c3-e3df-405a-8d9c-2d64de6cc33e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions. ", "original_text": "Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n "}, "hash": "1eb38ade4ef607138297908695db256b2782dded2a98423c20e0aa63703cbf21", "class_name": "RelatedNodeInfo"}}, "text": "So the momentum in that segment is really good. ", "start_char_idx": 3504, "end_char_idx": 3552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "847b91c3-e3df-405a-8d9c-2d64de6cc33e": {"__data__": {"id_": "847b91c3-e3df-405a-8d9c-2d64de6cc33e", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions. ", "original_text": "Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb1a9918-3bda-4a79-812d-8ec69734ea20", "node_type": "1", "metadata": {"window": "So I think it's going to be growth, it's go ing to be slowed compared to what it has been historically, \nand it's probably going to be a little bit lumpier than we would typically expect just because of the size of the class.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call. ", "original_text": "So the momentum in that segment is really good. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6ef63ceaf86de247ae6c725c0ed6adb38b805ed302f1fecc46ba9d615664a2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9acaaedf-91d3-4fd0-8254-62231dcd9a06", "node_type": "1", "metadata": {"window": "A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n"}, "hash": "12c6973e26409f033fbc9afa29e36622c976123a3f7bb258951dc49b33fb3dbe", "class_name": "RelatedNodeInfo"}}, "text": "Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n ", "start_char_idx": 3552, "end_char_idx": 3707, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9acaaedf-91d3-4fd0-8254-62231dcd9a06": {"__data__": {"id_": "9acaaedf-91d3-4fd0-8254-62231dcd9a06", "embedding": null, "metadata": {"window": "A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "847b91c3-e3df-405a-8d9c-2d64de6cc33e", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McK esson Corp.   A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions. ", "original_text": "Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d803fd77f3d462dd7b6cd246c827b2d000083beb29e84917fe51482bed0f768b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a6b5b37-b274-4496-bb75-1cdfc3184e8b", "node_type": "1", "metadata": {"window": "So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission. ", "original_text": "Well, thank you again, everyone, for joining our call. "}, "hash": "5f7d4b56c0eb6af3b6efd6641082514b1c79b3a37ca2e858a27d886fe3d77dc5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "start_char_idx": 3707, "end_char_idx": 4053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a6b5b37-b274-4496-bb75-1cdfc3184e8b": {"__data__": {"id_": "7a6b5b37-b274-4496-bb75-1cdfc3184e8b", "embedding": null, "metadata": {"window": "So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission. ", "original_text": "Well, thank you again, everyone, for joining our call. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9acaaedf-91d3-4fd0-8254-62231dcd9a06", "node_type": "1", "metadata": {"window": "A \nAnd I would just remind you that while the growth has been robust, and we do expect the rate of growth to \nmoderate, as we go into future quarters beginning in the fourth quarter, we did increase the guide for the \noperating profit for the seg ment.  So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef7424599fcbbdec4277f660958bd432315fc8c4e46d9de4851dccdaac0818be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "861920fd-4c41-4e09-9443-9d29aee4df3f", "node_type": "1", "metadata": {"window": "Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n", "original_text": "I appreciate, as always, the great questions. "}, "hash": "0aa41e8d12d99e5629b069158b13f9555506353404d6cc1de10cde8df2bb5d8f", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you again, everyone, for joining our call. ", "start_char_idx": 4053, "end_char_idx": 4108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "861920fd-4c41-4e09-9443-9d29aee4df3f": {"__data__": {"id_": "861920fd-4c41-4e09-9443-9d29aee4df3f", "embedding": null, "metadata": {"window": "Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n", "original_text": "I appreciate, as always, the great questions. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a6b5b37-b274-4496-bb75-1cdfc3184e8b", "node_type": "1", "metadata": {"window": "So the momentum in that segment is really good.  Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission. ", "original_text": "Well, thank you again, everyone, for joining our call. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d594f037394b89e135adfae3db63a83b4a2e747a4aa49b71aa671e3d8b1dee0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3b736fa-baec-49a8-8201-c5c2ee68a43b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business. ", "original_text": "I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n"}, "hash": "0ee7737819b203a0abcaa2713fa5d0cb73dfd7600ccf9f3f7d7f6c8137ef0c19", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate, as always, the great questions. ", "start_char_idx": 4108, "end_char_idx": 4154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3b736fa-baec-49a8-8201-c5c2ee68a43b": {"__data__": {"id_": "d3b736fa-baec-49a8-8201-c5c2ee68a43b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business. ", "original_text": "I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "861920fd-4c41-4e09-9443-9d29aee4df3f", "node_type": "1", "metadata": {"window": "Prior authorizations in general, \nGLP-1 specifically, but also seeing good growth across other access and affordability solutions within this \nsegment.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n", "original_text": "I appreciate, as always, the great questions. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "141c5c90925f100ddd86059f8de5d08f16db11552b783747b59ba3d312d78198", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7ace9cb8-cf9e-462d-a180-7191f9d1187a", "node_type": "1", "metadata": {"window": "Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy. ", "original_text": "McKesson continues to make really meaningful progress in advancing our strategy and our mission. "}, "hash": "95c9e667ab52a47efb166b8cca47038e82a8b434dc7373a6f03f5d6ff56dad59", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n", "start_char_idx": 4154, "end_char_idx": 4252, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7ace9cb8-cf9e-462d-a180-7191f9d1187a": {"__data__": {"id_": "7ace9cb8-cf9e-462d-a180-7191f9d1187a", "embedding": null, "metadata": {"window": "Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy. ", "original_text": "McKesson continues to make really meaningful progress in advancing our strategy and our mission. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3b736fa-baec-49a8-8201-c5c2ee68a43b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian Scott Tyler  \nChief Executive Officer & Direct or, McKesson Corp.  \n Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business. ", "original_text": "I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f03153d0a064984c3d1fc480cabbc8ec0a21ff8e1e25043f1d1841657f0f85be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c7db2a64-44e4-453c-b597-18bd43eadcf0", "node_type": "1", "metadata": {"window": "I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter. ", "original_text": "I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n"}, "hash": "e31eb4abdf9724ed6462540d737e9b980fcff61deeb79689ae732daf816d55d0", "class_name": "RelatedNodeInfo"}}, "text": "McKesson continues to make really meaningful progress in advancing our strategy and our mission. ", "start_char_idx": 4252, "end_char_idx": 4349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c7db2a64-44e4-453c-b597-18bd43eadcf0": {"__data__": {"id_": "c7db2a64-44e4-453c-b597-18bd43eadcf0", "embedding": null, "metadata": {"window": "I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter. ", "original_text": "I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7ace9cb8-cf9e-462d-a180-7191f9d1187a", "node_type": "1", "metadata": {"window": "Well, thank you again, everyone, for joining our call.  I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy. ", "original_text": "McKesson continues to make really meaningful progress in advancing our strategy and our mission. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "daf2078fc480b5b624b84569507bb642d102f0a748c3475d57bbef737c8811a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "944b4ef9-838c-478e-b794-f24df46b39bc", "node_type": "1", "metadata": {"window": "I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody. ", "original_text": "I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business. "}, "hash": "5339d80a69f3f7a87aaa14da9fdb77e7dc30f2fb0b46731a75d0d515637c95c7", "class_name": "RelatedNodeInfo"}}, "text": "I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n", "start_char_idx": 4349, "end_char_idx": 4535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "944b4ef9-838c-478e-b794-f24df46b39bc": {"__data__": {"id_": "944b4ef9-838c-478e-b794-f24df46b39bc", "embedding": null, "metadata": {"window": "I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody. ", "original_text": "I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c7db2a64-44e4-453c-b597-18bd43eadcf0", "node_type": "1", "metadata": {"window": "I appreciate, as always, the great questions.  I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter. ", "original_text": "I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73364c2188b971ec59fb492331d55d2a7e8b26bcd1c865e0378b526e19070367", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5bc2959a-84cf-488b-af2a-2a57726a644d", "node_type": "1", "metadata": {"window": "McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "It is one team executing this enterprise strategy. "}, "hash": "68f3dcaca973f2a6231237126feee8d4684e180b13e60042ed87fd4b10992505", "class_name": "RelatedNodeInfo"}}, "text": "I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business. ", "start_char_idx": 4535, "end_char_idx": 4665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5bc2959a-84cf-488b-af2a-2a57726a644d": {"__data__": {"id_": "5bc2959a-84cf-488b-af2a-2a57726a644d", "embedding": null, "metadata": {"window": "McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "It is one team executing this enterprise strategy. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "944b4ef9-838c-478e-b794-f24df46b39bc", "node_type": "1", "metadata": {"window": "I want to thank \nyou, Cynthia, for facilitating the call and maybe just a concluding comment.  \n \n McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody. ", "original_text": "I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae8e51ed53b4898066e020407dd95f938391eb6fb1d8ff8ff0800239d4337366", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20b62843-d733-4c42-9c69-3968ecb0d7b5", "node_type": "1", "metadata": {"window": "I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter. "}, "hash": "e1da29226f711a1a107936946cc9ab656b6aac6394c6fbe2efddfeb090260fae", "class_name": "RelatedNodeInfo"}}, "text": "It is one team executing this enterprise strategy. ", "start_char_idx": 4665, "end_char_idx": 4716, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20b62843-d733-4c42-9c69-3968ecb0d7b5": {"__data__": {"id_": "20b62843-d733-4c42-9c69-3968ecb0d7b5", "embedding": null, "metadata": {"window": "I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5bc2959a-84cf-488b-af2a-2a57726a644d", "node_type": "1", "metadata": {"window": "McKesson continues to make really meaningful progress in advancing our strategy and our mission.  I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "It is one team executing this enterprise strategy. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbff7874cc8bd6b56c718440cacd0d65f5177e0181746179649e6babd21c3816", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37d57c85-c95e-4777-b716-c2c8d875767d", "node_type": "1", "metadata": {"window": "I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "Thanks \nagain, everybody. "}, "hash": "38d0afd3b13cec77e1ef0acbe0d78a75fae45f0b3ae49560349735aa3db39b69", "class_name": "RelatedNodeInfo"}}, "text": "And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter. ", "start_char_idx": 4716, "end_char_idx": 4868, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37d57c85-c95e-4777-b716-c2c8d875767d": {"__data__": {"id_": "37d57c85-c95e-4777-b716-c2c8d875767d", "embedding": null, "metadata": {"window": "I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "Thanks \nagain, everybody. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20b62843-d733-4c42-9c69-3968ecb0d7b5", "node_type": "1", "metadata": {"window": "I couldn't be \nmore pleased with the consistent and solid performance we're delivering, and we remain confident in our ability to \ncontinue to deliver sustainable long -term growth.  \n \n I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1feb6bdeadebea47db5286e865fa78b8beedc2bbd9958b38931415451a2375a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b9798e4-502c-48ea-9fbc-4589239522a0", "node_type": "1", "metadata": {"window": "It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "I hope everyone has a terrific evening.  "}, "hash": "9db248efe2bcca18ed3e0e03429a03dabe01997a22e209a7d4c774f4db4786df", "class_name": "RelatedNodeInfo"}}, "text": "Thanks \nagain, everybody. ", "start_char_idx": 4868, "end_char_idx": 4894, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b9798e4-502c-48ea-9fbc-4589239522a0": {"__data__": {"id_": "4b9798e4-502c-48ea-9fbc-4589239522a0", "embedding": null, "metadata": {"window": "It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "I hope everyone has a terrific evening.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7779d2c4240d5701f9c37027ed4fca8ea6fda6d8a557828e404c958a795e1a1a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37d57c85-c95e-4777-b716-c2c8d875767d", "node_type": "1", "metadata": {"window": "I want to mak e sure I acknowledge the contribution of the McKesson employees, across really all our teams, all of \nour business.  It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "Thanks \nagain, everybody. ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43ddc447fb295fcab5e27500a3d215694bf4969c4c3469dce4fc993acdeec606", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b94e05d0-f254-4879-9178-5a1b7b06d007", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n", "original_text": "McKesson Corp.  "}, "hash": "d6330cbdc328b72ecc3ae430c7f5242cf1b98f45b0675dab19bfb5830d7d2e67", "class_name": "RelatedNodeInfo"}}, "text": "I hope everyone has a terrific evening.  ", "start_char_idx": 4894, "end_char_idx": 4935, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b94e05d0-f254-4879-9178-5a1b7b06d007": {"__data__": {"id_": "b94e05d0-f254-4879-9178-5a1b7b06d007", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b9798e4-502c-48ea-9fbc-4589239522a0", "node_type": "1", "metadata": {"window": "It is one team executing this enterprise strategy.  And I'm proud of what we've been able to achieve \nas a team, and I look forward to sharing more updates and more of our progress with you next quarter.  Thanks \nagain, everybody.  I hope everyone has a terrific evening.  ", "original_text": "I hope everyone has a terrific evening.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0375e4a780679540abf4ef9abb9342fbd0b06749b3de7bf767158341ad554c69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b24c4f9-0c3d-420a-9064-b431d09a0c77", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call. "}, "hash": "e9b9f9994e0fcd5b30a854e0bf411567d98aa4a5a3ba3bd89cfdcc23d6cac063", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b24c4f9-0c3d-420a-9064-b431d09a0c77": {"__data__": {"id_": "3b24c4f9-0c3d-420a-9064-b431d09a0c77", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b94e05d0-f254-4879-9178-5a1b7b06d007", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "783265086dd0fa4a677bc43644f6aa1261c400d78571f2c2650c63444309e4ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "606bc9cb-da41-4851-b08c-bda55cab356a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n"}, "hash": "ab4e1f00021165637afb0019c79ac8ee8708998b98af15cfd0e55825fa2b239c", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 16, "end_char_idx": 241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "606bc9cb-da41-4851-b08c-bda55cab356a": {"__data__": {"id_": "606bc9cb-da41-4851-b08c-bda55cab356a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b24c4f9-0c3d-420a-9064-b431d09a0c77", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information. ", "original_text": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea891b6fb1a4c62e5924dea7aae4056ff71aa05f7431089ebc0c5b31285afa08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87d7c857-0349-4f36-9a49-2711de0ec4ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n"}, "hash": "a2e3c894a6c79ff0c2f8f11ecd42744d192e60db8257ccba5b454c915b95f6d2", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "start_char_idx": 241, "end_char_idx": 310, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87d7c857-0349-4f36-9a49-2711de0ec4ca": {"__data__": {"id_": "87d7c857-0349-4f36-9a49-2711de0ec4ca", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "606bc9cb-da41-4851-b08c-bda55cab356a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eeb5acc89d7b4263101f48e35157329f2a6f6ee060ffd7e12bed1599da541970", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d5dfefa-44f8-434e-9938-7a74d3da89c7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information. "}, "hash": "7ea6d9f3da8b6fbaf848eb3eeb3d63aeccb84b31a1c115a1c35bef78c7435e5f", "class_name": "RelatedNodeInfo"}}, "text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n", "start_char_idx": 310, "end_char_idx": 519, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d5dfefa-44f8-434e-9938-7a74d3da89c7": {"__data__": {"id_": "2d5dfefa-44f8-434e-9938-7a74d3da89c7", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87d7c857-0349-4f36-9a49-2711de0ec4ca", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45836b91da5e4820f898daa5de321eff4d8637aaa5ea64964aa17b91358889b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2758158-decb-462b-9933-d8e1539f2cac", "node_type": "1", "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "1bffbb4372f0a874e9bf69da59c463bbcb7f1aa1df6d7b6b70fac804ac5fef10", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information. ", "start_char_idx": 519, "end_char_idx": 642, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2758158-decb-462b-9933-d8e1539f2cac": {"__data__": {"id_": "d2758158-decb-462b-9933-d8e1539f2cac", "embedding": null, "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d5dfefa-44f8-434e-9938-7a74d3da89c7", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f67be5b211110a6d46548e7422f11d389750bd8d6a1fc3e2553142d6111c149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "01979fb4-6665-48cc-bdbb-7f8a785988b8", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. "}, "hash": "26841c524c85b163f694498f601bc307821760f177e5e14ca45c2eff7117038f", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 642, "end_char_idx": 934, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "01979fb4-6665-48cc-bdbb-7f8a785988b8": {"__data__": {"id_": "01979fb4-6665-48cc-bdbb-7f8a785988b8", "embedding": null, "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2758158-decb-462b-9933-d8e1539f2cac", "node_type": "1", "metadata": {"window": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC. ", "original_text": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c961edee7e43bb09b8177b13a68c20e774096b39f1a7b53f66b515ff43953caa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85777e0b-b710-418e-880b-f5c6ab99149e", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to chang e without notice. "}, "hash": "9e395759c567bb3780a459df24ca3e990243fd11f28708a53a455faba0f83c59", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "start_char_idx": 934, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85777e0b-b710-418e-880b-f5c6ab99149e": {"__data__": {"id_": "85777e0b-b710-418e-880b-f5c6ab99149e", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to chang e without notice. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "01979fb4-6665-48cc-bdbb-7f8a785988b8", "node_type": "1", "metadata": {"window": "Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "58b1a8829c94a5abe768f61a70ebb8a8c97687d55fd7f195cb0e9b6cde42648a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "090d8db1-da83-4d13-b3a3-3da3b5a123bb", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC. "}, "hash": "e1a5dd0b6e5d80b17c319e9d0e2e6aec42fe2144a963380e4101d1d58048c638", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on this date is subject to chang e without notice. ", "start_char_idx": 1296, "end_char_idx": 1381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "090d8db1-da83-4d13-b3a3-3da3b5a123bb": {"__data__": {"id_": "090d8db1-da83-4d13-b3a3-3da3b5a123bb", "embedding": null, "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85777e0b-b710-418e-880b-f5c6ab99149e", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness,  accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on this date is subject to chang e without notice. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3ef38f281c8336794c20609af5a9d99dea3176962b6ca1f2fceb4bd2b06dee64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ec2e95d-a399-4bce-aa1e-2dae5d9e49cb", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n"}, "hash": "5ef5a84daa610c6048fddab32ba8f20445c853b5039bb93675c0b67c8c8cfc29", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC. ", "start_char_idx": 1381, "end_char_idx": 1509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ec2e95d-a399-4bce-aa1e-2dae5d9e49cb": {"__data__": {"id_": "0ec2e95d-a399-4bce-aa1e-2dae5d9e49cb", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "090d8db1-da83-4d13-b3a3-3da3b5a123bb", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks associated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefulness of such informatio n. Th is information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86f65faeba3aa21038f20d69e8603610865e84cd640bea7e4ae57862f9d709c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "985a97ad-feba-4b77-aa7a-fe0fd0fc293e", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "4b47e4914315b4a3813f4ccba7cf7b1a2f3e968381a9e4839a17f832f1fa340a", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "start_char_idx": 1509, "end_char_idx": 1672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "985a97ad-feba-4b77-aa7a-fe0fd0fc293e": {"__data__": {"id_": "985a97ad-feba-4b77-aa7a-fe0fd0fc293e", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ec2e95d-a399-4bce-aa1e-2dae5d9e49cb", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for information purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "906b10cbe90bf63255e4a8992a9dc0925db5f43f115ac0a4d715e055886598b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f64c347-9958-4172-9da4-4bb3dc10283c", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n"}, "hash": "1f3da50a00a559dcc4b50ffcd14aeaaeca3581ac72046eaebad83d31e9222439", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1672, "end_char_idx": 2106, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f64c347-9958-4172-9da4-4bb3dc10283c": {"__data__": {"id_": "4f64c347-9958-4172-9da4-4bb3dc10283c", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "985a97ad-feba-4b77-aa7a-fe0fd0fc293e", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on this date is subject to chang e without notice.  Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3342678fe3221e896f73af1f4d052c5c89ff8a3596bc36d431504ee8c76b11a7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f13d8cff-c3a5-4361-b7eb-6e0e9e1e40fe", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC. "}, "hash": "04e9504d4fc8985cf6f86753000203fccd7361d8d48b70c5a2d291cf88cd400f", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "start_char_idx": 2106, "end_char_idx": 2786, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f13d8cff-c3a5-4361-b7eb-6e0e9e1e40fe": {"__data__": {"id_": "f13d8cff-c3a5-4361-b7eb-6e0e9e1e40fe", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f64c347-9958-4172-9da4-4bb3dc10283c", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the opinions or beliefs of FactSe t \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e1cabf0356337ba6caf438e0a7332d97448491312c6f5b8c3e8eef7eca99a2b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac746f40-0754-4f9d-a603-fe3fd2262d17", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "d6d6aff74aa40530b96589d80cc84f576862bdf33fc31f810fdb4f74c81103f4", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 2786, "end_char_idx": 2976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac746f40-0754-4f9d-a603-fe3fd2262d17": {"__data__": {"id_": "ac746f40-0754-4f9d-a603-fe3fd2262d17", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f13d8cff-c3a5-4361-b7eb-6e0e9e1e40fe", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of this report, may have a po sition in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dbbe28390c22c713d456a154d63e32f06c35c67b7adc8f510928ab93b76fa373", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d20859a5-9180-4394-9b8c-c752ac25e678", "node_type": "1", "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "c1347580e4f1def5dd1e67122d5f39628da075af6f0cbfc036de1182fe7a3b4c", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 2976, "end_char_idx": 3054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d20859a5-9180-4394-9b8c-c752ac25e678": {"__data__": {"id_": "d20859a5-9180-4394-9b8c-c752ac25e678", "embedding": null, "metadata": {"window": "TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bcb5e09cfb4326a804b0039fc3b408a02e3233cd03d4810dcfb0f53ac4a2a74f", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac746f40-0754-4f9d-a603-fe3fd2262d17", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES AND SUPPLIERS DISCLAIM ALL W ARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION ANY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MAXIMUM EXTENT PERMITTED BY A PPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING WITHOU T LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS ADVISED \nOF THE POSSIBILITY O F SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT MATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2024  CallStreet and FactSet CallStreet, LLC are trade marks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5a3af0b1308a1e1c20398cd0278183345cac2d60dc9e169dfc45b9f01b3525f1", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 3054, "end_char_idx": 3076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"1ed17d67-b105-40aa-aa9f-92f69e7243dd": {"doc_hash": "20764046c330094694e1cf7859bdff815f7773b082d7d9de9546f82265296f1d", "ref_doc_id": "d9f2d747-2083-412e-b828-5d8506da8229"}, "da3260e5-2e9b-4e2c-a5ff-594401cd5af5": {"doc_hash": "774f3d5ed0663ffc12a40b00ffbc00d34d0dc42933739f04345125e0e0abc8f8", "ref_doc_id": "d9f2d747-2083-412e-b828-5d8506da8229"}, "5ea85a50-bcbd-4c82-8ae3-ba8e736e8193": {"doc_hash": "049f455c6214dc38fb770aec4c56116bc6fdf2ea3b0a9acde552ad36c728a52a", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "dbae45d9-e504-4467-82cb-d23db27285e7": {"doc_hash": "a12326d7fa1ceb7457ecd4984932808d12e819deceaa0e078c5d0e6ee339b97d", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "b74f7142-7590-42b0-991a-8d033c1dc4c4": {"doc_hash": "29277b49ef8706d6b81bfbb988b1c3d074093fab1c8faa9a2b0f55ebc2c97e92", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "2bdf596e-0915-4c87-84b2-8ee16df4d174": {"doc_hash": "3cad6b37a6d501cd23a53dc1b127f96fb8b4b3466f1984868f37d7cd8aa90847", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "e4577a03-46f1-43a5-aa9e-28b480a738a1": {"doc_hash": "024e1e8ee788830950735d39cbbb2fed68a398c6746eeb7b9f5cf3d97a92df67", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "fb3f2d6a-5c5a-4172-8f8d-0e34d861ce06": {"doc_hash": "91f8836bf35508dd856cbffd163d1a40ef3109b0b476cd121a6a2e80211f0aa8", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "e888fe65-7d3f-4301-a92e-520cc8608087": {"doc_hash": "7da4cb77c63f2d0c60f2125cd27425d084cb6cf09b0aed60fddfe90ab7de719e", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "1a36f826-14c0-4607-b3da-bd4e42c94ae3": {"doc_hash": "1be14693990d71e4d8f7e8a6538c6aa16c5898a580f5d0863c1cf13b1d27b2f4", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "65fa6068-4c5e-40d2-ad15-7d63fcea2345": {"doc_hash": "6f0a15872b9ec8a146ecc861a0bf0335e306540e9edddd9472f82df4e0dd29dc", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "e28b0354-df44-429e-a582-563a61577a78": {"doc_hash": "5d377c7f94226fe235de7c047693c249fc7df729b753fb4c9f96749a724f4ef2", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "e720f6ed-9ac9-41d5-8ddd-de5b90b0130f": {"doc_hash": "ed2294df98cfe4095b0e8032138fd7af23e64de5eb82bb82a162f67dadf5c96c", "ref_doc_id": "25b67b3b-1d81-42c9-ae88-2f190c4d2057"}, "e5d0010e-9a3c-43fe-a561-b6cd258d110d": {"doc_hash": "8d7d4e0942c5633b970c84fe9b436814c16aab7d5a418b7d1da50c23c5342f60", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "2c757f87-efed-4953-8fa4-224d384d9312": {"doc_hash": "121def87f77bdc05a2ffd050ffa3d2ebd37e03fef59111dfa288ae32c3a8d0aa", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "95f1eb72-06f4-4dcc-b928-a9c1af0c7820": {"doc_hash": "bc2b1f0055da9544476c1ea3559f492f9f6a6bc43a5a36d073df19054c20d6cd", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "e20da75a-bcb6-4ed4-ba44-845e57c2a67c": {"doc_hash": "a8f3f103e203eddee5ab43c3414ac4c38a82aeace5d7b6709f80b1de25593fd9", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "470da5ce-1946-4afc-99ca-c859ef20559d": {"doc_hash": "c14866ccf0efdbf6ed9a6ab7a5bfb0ca48d4579a14a6e1ac8478246fc732cb36", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "91e8149b-7c19-43aa-80f3-28bd2601ddce": {"doc_hash": "6f90b98898931a66ce8b81588a4ae9b7580d7f607caf921917fd8d7aaabbc927", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "75b3bbb6-fc6c-439d-963c-b6033cd307ab": {"doc_hash": "67e4d730f0ab4a7012f47a288b3bd3215ae35fa24c4ec3c7b7fa950ec163a3af", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "74b0e77f-54fa-47f1-a17c-41675b580c34": {"doc_hash": "7a8199a09b1da3c6102d099c88455146267bd5ef1a3d84f679a0ebdb8e72c26f", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "e2c0de1b-41a5-4024-bccc-176c141ee85d": {"doc_hash": "214be3038f19241aeb16249ce82f40398e541997c2cae93a903da7ce29e3413d", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "9761ac16-9494-46f1-91b0-41ee90e0fffc": {"doc_hash": "4a389e90ea60d692d28da631c0cecae1d80ae566399f4ce3843d93d5ce1cec4e", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "c3cda2dd-ddb4-4180-9303-64f3fe3e7923": {"doc_hash": "d4544903940da59238839959bf91de383dddc77c2de0023a7ed676451612eb81", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "cc971383-5c5b-4646-a95c-a4ab499a4737": {"doc_hash": "f4fc7c9a906fdfc07c98b2498ee45f9859c35e4b23c511b65453a05e6b6ee19d", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "519a1f76-b821-4d3e-b1eb-094f57ebf349": {"doc_hash": "f37e1fec1f4fac10d398b1923ab4bfb329298bf8f3d742586b4ab9ff908dc7fc", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "8d9026ec-bcc5-4ca8-b15f-bdfd618c355e": {"doc_hash": "7710cffc1fa9efdd6e2c8ba02ebdaa43eb4399f3aaf0b4aada8ece1315e8b935", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "3c096161-6d51-424b-a692-e701dfa2d8be": {"doc_hash": "59b22cfa05261c0c3849855f301163533a4cf98e94086aed70e20c0868245054", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "063e96f4-99e5-4654-a80c-464fe9730301": {"doc_hash": "0b9bac6c9d88f192ee190cd3957bf4b2055f05d13261942128b920a91cd37058", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "958a958d-b042-47a4-9a33-eef8dcf5b2ef": {"doc_hash": "5b71136889d913bfc094fa8429cd7ebbf1713a956e49c1447c4948eb1a1d1222", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "9e8b187a-1724-4a7b-9835-b449aa2ef7a1": {"doc_hash": "d0338485da1617a3fc5b1cd7ec8a8434e3f34c942bb2990de872cdaf93da7cf8", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "1bad560c-29d8-4225-978b-22016fb3e583": {"doc_hash": "f734e4a772d4983a4e48850495e034b1580ce6be7de23a709322746eb2ce5c6a", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "82be3953-bb6f-410d-a593-9c3ec2ce645d": {"doc_hash": "4dfa6ee63dac9bedafcb3770f90d8215aa600d1f5a1d569c55c9eae23159b1fd", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "4c912436-74e2-4b4f-8fab-bde3885c4b53": {"doc_hash": "354bb7c3df1fe03d01e59a3ebdcc96d403c1335b78d169db230c36db336075d6", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "afae947c-0b23-499c-b346-6c07f0a3a5e8": {"doc_hash": "d3cb56fbe5852e5e16df9f466846b3cd457dfaa6ec6471ed0ce51f07bc4e32a0", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "f76a5a03-9f51-4273-8719-fe840b64b2f5": {"doc_hash": "1d1b2367fbf44523a58d87dee5066fdf9a039ba91a5d24820dbaeb691e32ce22", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "898239d1-e0b2-4242-8c6a-57170aa5f562": {"doc_hash": "7d399801069e0cf75d95452c7bf2a99372710a6094dc5f664ffbbd142da93298", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "4583013b-e567-4ee5-a2ad-c94c9445a9d8": {"doc_hash": "09fa2250590e66d52df10a0cc8fd1b13b62a0c84de622d197c8fe79d273b9aa7", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "e89f2dcd-35c4-46b2-bbb2-1e423f793d01": {"doc_hash": "253071682a0ea68ec9452452456efd78156ae8be60a16a1edf39747aafbffe07", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "01be4f8c-2743-4a82-8579-15b18c4c4e39": {"doc_hash": "b5e45655064c211b1cc83d4f6f515bc8ff2a10b7b9bd876f31ec51e2f9b88e62", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "a23c9a20-aea0-4f90-b393-b3a9670685bd": {"doc_hash": "e4a481980f2ded0cad3c7c455bfcb15f253afa0b7d53c099b7a3c02356a150f8", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "068180f1-295f-4acb-a521-2dadae3705d3": {"doc_hash": "eb3e4c1a871ccf66df83cb5fdea59576be9cc9fce68b8daa0a5e3eec7db8e8a0", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "4db31ef3-56d2-414c-9471-ec0981095eba": {"doc_hash": "58c103de413a00c5331defa070b97039d05a7d280a14a1da8b5e701150387c84", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "dcca84c6-b093-4ad6-ae00-1babff4c8db8": {"doc_hash": "3866b5119360ca4f721a0cf96a70ce5c489c49b6803e56256d025cdc64c40f1a", "ref_doc_id": "22e7781e-d2b6-4041-bafb-3755ba7f3bb2"}, "4db949f0-840f-4966-beee-7c6febe725ef": {"doc_hash": "dc3b689795573d110c99ab607d931927033092acf680025e8409f876eda0b74a", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "5ad3adfe-9cf0-4899-8a69-b3ad13a01a94": {"doc_hash": "ef80194d0bcaa5e9ff45718551fcd5afae274e851b639c7027df501e9a0d12df", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "35e0c4e3-de74-4591-b3ee-e5d249885214": {"doc_hash": "7d2a6b3386f1490f72ac3265ab8caf61bb7c50c82ed9aa851ac8fe5d4b35b1e2", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "8583c636-c44e-4f87-ac63-d35a81449456": {"doc_hash": "cdf4d322d038333839069d6830cd9353bcfdec7d4be367f0c880b3f9b5e4e25a", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "712d9ff8-61a9-4909-989d-4433e012db40": {"doc_hash": "cb7ae943ae0221ce3298c3cb0ee2e7a9c101ba1c5bae27d3525a20dc2d351652", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "037a6082-9518-49ce-924b-2e34b3ef60c5": {"doc_hash": "6f747f9d0bf4228f05253016dab8891500820200aa2fb61bf65c27cf9defb775", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "c7ad2ed6-42e1-4f90-a874-114cae606854": {"doc_hash": "e13cf734d048ff9c5136360306af1b2e58e43d6b00acb9107929122879b75c13", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "ad397227-1d53-477a-a010-a50db9c77871": {"doc_hash": "eb957e35a2e3ed5439aa2fd0a12895632e768f8973c41cd04386d1d271d75bfb", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "f6ce17d9-5e19-434c-bbf7-1b3aba146892": {"doc_hash": "cec6b8e234945e37842af166e2e0721a3f11acaab56a43b6dcf60a50d00442af", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "c6689efc-be1d-4cd0-b2be-d262b3599f6e": {"doc_hash": "b136a56d1b3e5ef4215084f28afbd260a5117b80efee1ce9019a856cd5e785c0", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "a5798f00-c3d0-465e-8fde-3f67c3f35802": {"doc_hash": "b851aef36673b4bb62bf9e42404cd62434709ab413fe1e66ea61d5caa75fe4b7", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "47a5dba3-7e33-40af-9803-28d8a7d6d91d": {"doc_hash": "9fcbcc47f8252192f8f4b3ddc1a7281f895cd55803c95f695b34acc41487dd4a", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "04993d82-38a1-4914-a424-13b0e47fd946": {"doc_hash": "c81bbc1b15239e98756b8a4e630e083b562b50014dbf44b065087d4033d9354d", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "d564e149-fd5d-46d4-9025-2c6b6a31bdf9": {"doc_hash": "63295614d497df9f45abbf8205c8c3916bf573091ad8eea8acee38367b5af0bb", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "5a541701-3166-4789-9242-d89259953431": {"doc_hash": "3e3910fbca68eb308388f886997a6442ceb88a1d51cc9884071a97d7d99e8b15", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "320e8bd5-163d-4e4a-97f6-6d674025f9d7": {"doc_hash": "91797f020fe7bec1d1dc8a2ad7a839075522502e1423ae272b4395e45e91f395", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "f8652407-689e-46d3-8749-8c926f811986": {"doc_hash": "e7a76e6a1e3144f48dab3ef85efccb64a3f83e62fd3319c91bd7f91744653417", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "71517e23-39d6-48ed-9c8d-95f8f216a5a1": {"doc_hash": "16fb59d7de1f401f696df1ecd22e01ba630716bc06aeb4b515475b4f117f3a04", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "79d667f6-b30a-465a-bdf1-eed6dfbed2c0": {"doc_hash": "61f7b4f936325d9b9d2c5b8bb9079e0b0ef464ca6bab2d25a157a2a5654e3e5d", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "7bb74e92-c57a-4669-8b83-c2811bcfa0e3": {"doc_hash": "58be8be9a4512a7f12b2c3da5ee49f1b0547f4c699de8b6d76be18b3236a9560", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "035982fd-75f2-4773-9c5b-0b3df67e580b": {"doc_hash": "5056695cfa44503b0ea0c3b228f81a44706a417da70f234515b1e69fb65ef18c", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "1a380c3b-2f8b-431c-ab21-81e73c03c35f": {"doc_hash": "55af3fdea5d713016e7f5107370e5c37ca69337621ec81c386ab9429aeceba6b", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "34b75e51-506b-4bfa-a477-e602afdeb684": {"doc_hash": "273a232b70d8cc0a5f449d7dab8c6f2467fae7405940bd7db3e434de21e4da36", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "e86f015f-7ca3-4947-ba23-f4bc9b913aa7": {"doc_hash": "a62b9806dd9927bccdf0c80b1847303767b453293adb05f3da6ddc1b8463605d", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "0f628593-991d-4694-837e-7906cb5ed7d4": {"doc_hash": "adcca880e90a99dd99050290b0a07e9a840b2e15ad1b4cd66ed833c92f07b7c0", "ref_doc_id": "da4365cb-41d8-4878-b4ba-61000b85cdc4"}, "ffae2788-5f15-4c1c-9393-79530a5fe133": {"doc_hash": "8090e8f12d65c4f2a9b802e62cbead59a924862699e47494bb3b6c3e04ef3c90", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "99436a68-631e-4a04-95aa-9fbe5f9a973d": {"doc_hash": "d2625ab88cc6d912d88154ca4001a34aec4a85b73ae3ecd428c1c68f0d020e63", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "e554f7c3-6e17-4ea5-9700-278a65600992": {"doc_hash": "a38f211b2cee6ca12f930f8352cef0b3cb04b468cd21f67ed74cd74238e77a4d", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "2a197862-7b05-4924-9a6f-a354414e33ee": {"doc_hash": "049a2c9d50532b037f5c905b0f23fc98677ef5a0665de1c6425e8bae7f192c04", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "3167d7df-c3d8-471a-8e38-e1ec89444ea9": {"doc_hash": "4e298e44e05055855be3ea8477326641ea76998b03f9191ed8bd36f584b64d6f", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "222cd9bb-5c56-41e8-b057-2f30e442aa9f": {"doc_hash": "5ad8f1adf9d91b0706f768d364c8b274942de35151b753d6f107501355c4245d", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "34e3a96c-d0c3-4e8a-8930-470dc5744e75": {"doc_hash": "c75c732204010e8d15d79fb838fac4b4daee2a6c02635246527802aedb95bf12", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "d11503ea-f48d-4a2d-8bee-22f85680f970": {"doc_hash": "a0f33d1d30ea4af9c944ac3b6867f33a7f2e6f63f158ead1fd211c25b4754b91", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "de0c0902-e9ee-46cb-82aa-71b79cef44a2": {"doc_hash": "be89a7ca581eb5035c9913b91c9619fa9f6b7f8e56b922df5d22305ac6c62777", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "75600b61-72cc-4079-89bf-2497daac509a": {"doc_hash": "21cfa3726f8190ddc357e57c0d52f6cf963009ab8a48f42f480a62f2f4677db5", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "6dadac7c-e0ed-46aa-b65c-a90064e885a2": {"doc_hash": "2efa74cc9e697b135cf7c6caed1d469407923d67b57c97f6417167a3b217a51a", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "c8fe9881-545d-4160-a14d-542be1f18abf": {"doc_hash": "bbb38e90e7f3761c1ca7c92a40ca66373163438d5d0f128a7b2f73fb272f700d", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "d29241ac-6b04-40cb-b0a5-38ff62295847": {"doc_hash": "6d7e3658702b0aef39a48c6a6642cb4045ed193aabf66e7ef8eb3b8a3d7c6eec", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "17d1e7af-1823-490c-bbd4-88cb0d76b2dd": {"doc_hash": "c9c2e550c38b6f6b05cb8113c2286334905a69a8b450878c2d997186ec9d4059", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "dfc2d861-c65c-4d38-afb1-4fb81553a9fd": {"doc_hash": "ccda1602884f1489b2386b07f335e612356ddd2491a18faf56898568aeaf174b", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "55475d1d-3be2-483f-bb51-8d9959e6f79f": {"doc_hash": "d1eb6d1f2f416e4119bdb9c7b12482d61fc207fe3f508987b15a687a8be2e600", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "b6f8960c-913d-4480-9abb-b237738e4a82": {"doc_hash": "9ff0f45fb03095d2e5d620a233ceaeea5da81f63ffb7ada1375d85bd73a93904", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "a241c94f-c686-409f-8c52-22a361eeb50b": {"doc_hash": "e0b8538c350349900a0c981d4b7d9239139d76ed8a5c140de58eaff306f69271", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "0f49bd3c-0eae-4c88-ab0e-80f98bdc7308": {"doc_hash": "ff5bd6fd244f2c5cb53d34051f13e5eae2de3c7a1f7637c4812c7e354603dae6", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "6842de3b-de2a-478e-81d3-1d0c6f0bd5a8": {"doc_hash": "5b6cfd916c451e9ccce181f952879d5633f659bbf37b7c3502b9698ce798bc6f", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "2427022c-7c88-45d9-adc0-6aa2b66b7e3f": {"doc_hash": "3fca3962aaabdd5ef88680c38503a6e41bb4b389fa73c90c2c651eb5280072ff", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "35f67f53-581c-4b92-bf5f-044f98408cf5": {"doc_hash": "8709d03ae76c2318c9bcdaaa69c5719346a71e472d046762bc8ceb381673e579", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "9b1723d4-d76e-4811-b8d5-393f439a02ef": {"doc_hash": "ec0b8750acd2707b261655b4107dfe31661a3338dccc9e1557c79e5c4d3cf100", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "204be92c-2131-490b-befe-383d4fda4b4f": {"doc_hash": "96f98b463faf96ed9bdcce1a86e8e7b946dc94198c75b8e22183be07c03db324", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "30ba71fb-2fad-42ca-a503-a4ab95311b54": {"doc_hash": "4a2bd165049139c997ee5228de58541257e244d22885db7e382bfcdaa374b154", "ref_doc_id": "5e649478-3ea1-4c36-8443-a80019444b0a"}, "3173be91-082f-4587-bb2f-4b77bd9dbfc2": {"doc_hash": "571fd0d598587dc33629e43e6fb669577ab41954af80fbb669782b3165a346f0", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "b13ca194-4fb8-4105-a3bc-544e7056904f": {"doc_hash": "c5047e881567cd626568ab8009c54a15d0226f58c620aba3f5b522da090f66e2", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "491b8f6f-2aec-43bd-99fe-6fda1c632595": {"doc_hash": "6ab86727a1b5b254ab9b65997dff88cb4663987d189bbc25714e8b9a2264ad8c", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "06c05d55-8657-4a3b-b2a0-486ae50bfe35": {"doc_hash": "3af44261a758e53d3c135a7e4db903bf7fdde8182c701be0cdef4f27c8a61cf9", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "23705095-5507-4f1a-8ef0-f9d552f59e63": {"doc_hash": "c0a4d2904ce2289aba366ddf99409420531630d6cf17a69ada958069e3e2979d", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "da0ff8f5-5b5a-4d0d-921c-901f50cd98c4": {"doc_hash": "15f69015450d7eaf66ec689d4a1ad6d09195750993f5398072aaf6e198adbb2a", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "0b64e846-1dba-41b3-84c6-9a9863e08a31": {"doc_hash": "2de0b6d988ba58b87c4fcd5af2647903acbf69a1e0f16708abef12b2ddb7c4c4", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "fc173576-f139-4566-b7dc-eba168a55a0f": {"doc_hash": "6fb13f1639c1e3e2409505f20ae6a50d91cdde1d36f68feb862df83bc7088b02", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "c67c9e3a-5521-4aa7-b4e9-c9039463bc87": {"doc_hash": "b545711492556c7deabafe73bdc1f6f20a2c8799ba94c5066c9f47bca47c472c", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "1792d35b-94ea-4daf-aedd-ef201cf97cae": {"doc_hash": "e95ec10cdf93851fa4633b66f0c7c9d899ca0a670f8426d7ddcda0da5d89a7cd", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "a5b58d9f-ece3-4bb6-9694-19945f4ade5c": {"doc_hash": "682aef4c1b0ae4d51bbe34ccb5ac7c4af36e93831f1631021ed2efd6c3aa3ffb", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "9a5a28d9-cbdb-4977-aaef-9c709e892c42": {"doc_hash": "45a065a12a8f984595119e16ecbba0de9e09a9292ba69a58962884363e2e6ef9", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "70b43e66-4fcf-4d63-8ca6-91b9bdc7fa16": {"doc_hash": "e3c020bde3cb605b25a2e01013fa1d93f84cfa6d8706e832baab2e3ebdebfebe", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "f2f7f456-25b6-4572-8c37-e50b7ea8906d": {"doc_hash": "82ff9ee9f965443e3284c4b27e0853fbeec2a4135c5b79d6f1f3fb76589be6c6", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "cf393b88-dee1-447b-8dbf-cfa053d97aa5": {"doc_hash": "6c58564c6e933560539ec993be2119130ffbbd9a1b5d8b4da3906a7ed96eef04", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "fcf35293-3157-429b-9751-1143b6c0fd73": {"doc_hash": "986afa3ecc0ecae9e990043131065a39b34be4e7e289b70d9069af87a9bb144b", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "665cf7e8-89fb-4868-b9be-7d0c2cf9301f": {"doc_hash": "535aeb0469c315143eb879ff6ee50912f69ca814050e28b4d352f784a1aa946a", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "eac99e62-aec4-42e7-8c57-bc5d35f8b0e7": {"doc_hash": "ff7555ef6a9afd533998003a461f2bac31b59cdd9d8011153923b1aec7d7c8f5", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "1120bd9d-15b0-403a-bd27-e8c7b04cac0e": {"doc_hash": "caab6d60443f31310974dddfd59c5e475c75d19d90556e22bd8a669cfe7c9165", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "d0de351d-2951-4591-b91d-c98034620de2": {"doc_hash": "36d58d353dd7bc7b8625454f9758e0690c43fbdfe6059732d7d3c9e0b47bab2a", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "74a1bf7e-b0e8-49f5-b8a1-cb1d4b68f263": {"doc_hash": "64ec4f56bde4700a1ab95059fd3e54156c62155a5475ad27bd5233cb92e9472b", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "4b502dc2-3c60-47eb-97e7-e640e95b2d64": {"doc_hash": "75017e421f9d6080bddb2a7aab4facd653d9af4a7a5de9b73615a0d9f4cae930", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "d6430768-3ed5-465d-847a-e7dead00e6d8": {"doc_hash": "84b77f670c6b00a9632125fdf3872f2aee112c09fa384a58e460719320ae1809", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "e3effdc9-1dfc-4d98-8c7f-8c8309bf1a74": {"doc_hash": "8fd89b1023c76ec5a176eeba45b361ff57e13983ae2b11863a3956abfe2b162e", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "7689e6a0-8112-4703-9a2e-575ffef46302": {"doc_hash": "cd1eae3cd448265d4acd429ffe449309974f19f52a92a8a7d7e564831fb818cb", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "513653a4-ea15-4399-94b3-af80946b37c9": {"doc_hash": "354d71876a2c167fcbe4e5058585b662073be256c47e4393c1f49e5b5fb63f04", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "c4429f84-8804-4148-81e7-4359c918f24d": {"doc_hash": "739feb358602e86a5e91da88639f1109233028d3cc7ce507083a7b0351d1eef9", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "62271bad-f2c2-417d-b0b7-05414d3da30e": {"doc_hash": "33374aa8d123d8ffd397386691f978a3246070eb359752b5a8e72ffb2ef10771", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "19a94e8a-ef3e-45fc-8d6e-96c3a86311a2": {"doc_hash": "628072debe41fea75460bce4c23bff63f1d9a01c758f5a1aa76bd546f218986c", "ref_doc_id": "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6"}, "20a396ed-3bf7-44f7-98ed-694dbef7d5a9": {"doc_hash": "20d97d2b555c6daa5c005510f2474f81777083622fdcabdddd1b434bad27c9bc", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "b983867c-e5ba-4bc0-9278-9110bce50b91": {"doc_hash": "5701c1df2284ef1a8d4907993d301aae81a54873510df0bf507f63b16cd20513", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "3e42c2a6-3701-49a8-b5ab-d05ceba2a3fb": {"doc_hash": "a9cc2dd043bad98754acd8f391ac52e5051e5ec05c425d31a787b7103a9f2100", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "71ccbcc8-bf4e-42a5-84e1-bee34cf7c969": {"doc_hash": "bc082fac0337996241153b17876b7955ea089ec804772ad46202c4b0f509e737", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "cbf75c40-582c-4ba2-941a-a89504968425": {"doc_hash": "2e1abc5e682864632963778dab3e42b70cdaddcba23c75746f1b6b7c3ab41b18", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "899baf8b-fd8c-4e87-a7d7-d557e0eaa216": {"doc_hash": "1341eed534c5e18d07b0fdf0711b2732c044df616afb69ce1bf38303598184e3", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "2c6a0561-88a1-4cfc-b4ad-2e9eba58672b": {"doc_hash": "e5d7fe56884410d2e1e25a421d8ac155f60d4d5ac8ab11553ecd5526305d5048", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "751e737b-725b-4bbe-9a2f-16383b276d67": {"doc_hash": "86018f73dfa82f835c818f05cdf48c63dc060e11c7482298fd70b8bfb9db399c", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "491d8362-a3d9-4c13-9b06-df38b594fd11": {"doc_hash": "f1da8db2d664c548913288ba641e6434c250396978455f6ecdef60a755758cb0", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "da0c3082-2360-4434-aa58-5217bb6ccff8": {"doc_hash": "7a61e767e2fbbd7b404d88e5bdbb2ed07b9730705d4251a8945d9b074fc7401c", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "b2b8930a-0ef4-4245-bb55-8892496c03ff": {"doc_hash": "f7e9482cdf0d97d11a1a5f1cf99c06beaa600af2441df73c959e403d484d4351", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "d840a1eb-dde2-44ec-bd0e-bbb65b114dfc": {"doc_hash": "12f1e92db8ee388e2a00ece073d9e43f874a34b33b02d921bf9bfc8631f24e12", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "b92a787c-8ed7-4df3-b1ab-d11caec0f402": {"doc_hash": "fb96035ab3810b66d572ffdae2269c72e8c5d080569403d510a1e40cb269eb03", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "843966ca-8c19-4692-94c8-40a7eed7fd2b": {"doc_hash": "a7b54299a7d1042eb0801f1a0fe98a374ab9074c75a1e1f0bba7c3fcaa3d4bad", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "a4293517-36f2-4a55-b237-54c1b02f0644": {"doc_hash": "ba8298207e3228532506177d6bc01b06b8ab6a8351d688c0a0edaabfde822b29", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "5dacf767-f9d5-4623-b104-7f1525f50024": {"doc_hash": "bbf1a4ce021427673e37e3f7c5f934ab219110292a257dddec85b2d97644454d", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "062fbe2d-a744-46fc-b1dd-f09347836106": {"doc_hash": "2e4f0cdf1127effb1bc2004f36a31f973848fd7c4778f0b23c7232849e6de988", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "52fa35e9-20e7-4103-9da2-82a9cbb8ce0f": {"doc_hash": "5bcf5810b07d7ccd372fd90d9c2227ddb29a0f545e93e491abd0e3c3fe7f205d", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "242fa5c8-78e9-4606-80d8-2a75712314d7": {"doc_hash": "a2a70d8d5cc5530b58953945817169152c42fb23c2b886864243082ecf0cad34", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "f9628cfe-7fda-4b53-abf9-9b9cc8f8c5c1": {"doc_hash": "9e62694a8741e74e0ccfa085fd8b1347b77d87a41dfc407d158ea42c7f08a07a", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "a446bab5-b994-4395-a6a0-eb31d679c11a": {"doc_hash": "41ea9d5d62d342f38a3a98947d5fec2501e7cd69839631e953679a5cdbc06e18", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "d852d842-69f7-45d1-b22c-289ce7de4053": {"doc_hash": "7d5430de75440bcef464d4b8bbec147dd4e67b2cff4879b146ff00e3272dbd0e", "ref_doc_id": "0b5b5c36-ae23-443b-bf1e-021cd9b6b506"}, "a52f991c-01b2-4948-8b45-a0d302cd090f": {"doc_hash": "475d07aed05386493a9d11b8aa9ce39b8c125b007cda57399b75bc765f5b7f17", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "a789fbbc-2669-46ca-b260-dc14fe93d201": {"doc_hash": "1e940584b80c17ee50720c51a4de0300c2a115f59bdef395d369fda7d86684c1", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "30cfd861-e470-4efe-9e42-421f197dd48a": {"doc_hash": "8ae73689811c6dae399270f167a26eaffe807a0a33123a1851ce8aefb84c8400", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "71230ef2-6263-4b8a-9e65-7370e154d3f2": {"doc_hash": "ee7c22418f1533ea599c899e01a8261060c0457a4095c258b1e6ae6f267649db", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "fa92cede-2a2f-4a36-91da-8733190de3f4": {"doc_hash": "b50fd3ab19c6b5ab2717d434531f1a46daee2ce2e87c7f3df823bc3de26ec9c9", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "ecf45a40-31cd-4d81-9215-0fbdcd56e572": {"doc_hash": "8dd60327c889cd749eb427399ec63d969869585c14dcc034ff8a062e643d4a5b", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "1cbc38d9-a9e8-4094-ad35-2d39ff81f323": {"doc_hash": "93b77a91b6c65e91cd30da0a4050e6c219c68f4e6f0d626e5f848636409b8a1b", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "4b2b4d0d-cb8f-49a6-b5a8-c40fe5572343": {"doc_hash": "0ce5afba42c1c25d63ed56add621c4e07318b38bdb68409cde93975a4e50f0d4", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "6f08013b-e61d-4c5f-bd6e-fa502a9f033d": {"doc_hash": "db406c845e84603e8dc63570ae44a3a0277f98ba1d8cf2ad8829135b439ef8fc", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "2c767b56-7b62-42d9-b1e9-7ffc281264c1": {"doc_hash": "574ca3eae815a4aff5d58532ebd05c8f2dd4755eb7a3b4f254b677db4d6bbef3", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "efc30014-e630-4ff2-875f-8948ccc89a4b": {"doc_hash": "8908be9018e243cc72011c0400b64cb76bb91c2da074e78a5c3eea6237a7aa5a", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "bfa9ce56-6cc0-4844-8669-c17fc7079d42": {"doc_hash": "1e78df20a99471c15019bc201806776b208fc22fe5bc816898980b414eb41067", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "c2f8c334-1a77-4776-bb48-7793f9a27b75": {"doc_hash": "a20ea661833c308169304c81169c20b1a2918dabedc9e56fad021be6dd38d809", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "46b62b18-5282-4f87-bd78-77eed74198bc": {"doc_hash": "4964d84074037746381f2e9c73a792b3c2515487ff1d6bb1f7adb91fe153111c", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "8b1ed457-e2bf-4c9d-b0ce-d7482faa50ef": {"doc_hash": "4265f1bc998aea53e7d5b2ef9223d570ced1e5ce27e539f6f318038faa99cc39", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "caf50c72-24dd-4370-ac48-63006587bb6a": {"doc_hash": "e773be0ede0e7aaade698d033d584e327f8355aace04bf43a415d9329a068427", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "7840c024-0340-4942-8c5f-24be3b80d2c8": {"doc_hash": "0bf435af6ec60247905a03be6907907f3f69eed89457ab009a8962553f9ffa66", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "2c398b3f-7f8e-4e76-8cab-6ce339377e97": {"doc_hash": "dce6ae6d16c967b087f5f4c926cb035e02fd95d6e26d980a78e17503451a8c0a", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "37cdb352-03dd-4bb9-8a7b-94a3026a0f41": {"doc_hash": "391a1fcf42e4a7d4de9bb15b08db07b0a712209330c652196c1630164b8ecd93", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "c93a39f9-ac52-48fd-870a-d95afdba63b3": {"doc_hash": "0c067ea2bd050e0660a7b1f4284d885a3fc8a86b2b9a997495a4ed3641c826af", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "f6783836-80c9-4a36-ba1a-3aab6fa3cd21": {"doc_hash": "f978423296352a4756405fb780457a7c0f8521471518807341bdce841d690a11", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "159c8651-4363-4aa6-a544-2f805126ef57": {"doc_hash": "90906742222c5b7a188838f346fb88ee33d54040095e3b7892cac3bf53fb0e28", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "c1c1ae9f-9efc-4f43-8d59-c472ccfbaf62": {"doc_hash": "b7e95a058565595355a1e69028d5dc406238cc3785b8e51a4fbd7efe24336772", "ref_doc_id": "3ddd6190-5ba6-4b66-8202-b675eff1c23a"}, "883cae08-68c1-4732-ae80-597921526fa2": {"doc_hash": "e0d89d385286526bfe0ad274b1d0eb2f4a4a3ca2144ba1da988e60d9f6482952", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "44a12b6f-f703-4b7f-b1d6-f4862864be5c": {"doc_hash": "a77beaa65a34a5de3a2ff0b74ef10c74e9475be179fcd7baf3676d65b76c614b", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "f087ab77-358d-4910-91f7-8b8e87a9c90e": {"doc_hash": "1168138da331da042d5bf91dc4eff9cce18dd7ce721bd16a8a20d154aa750a27", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "91c76271-702d-4985-a8cf-e718aa75f9b7": {"doc_hash": "55abd70dec9f1a4fafa76b2095cac9e1753416b07bcb48f6194be70e4346d1f9", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "fa76678e-9ddd-4d8f-9275-c8bb1a308d61": {"doc_hash": "33d3ba26902b7187f547fe242694db0d61c12fac23246ea916ad773b1c9f3f0a", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "87621a06-e365-4a0a-a039-3fe5fa5c5cba": {"doc_hash": "0c3dcb52c94bf8be29081a516483c9abbb681732099ccd3e840b144a08fcb16d", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "902055b9-356f-4c75-b761-f6861557801b": {"doc_hash": "c769f8716ccd6b61cbd31b043d20ea637babeff58e21b03ccc42cf6cbd68a868", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "f054395b-caef-44a7-a4b5-44db910d6975": {"doc_hash": "95002735050b0811d1db869aaa833a4037e596e05d874db8e755482c5c67da3f", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "8856f700-e7b2-475d-8925-f140aabc79bd": {"doc_hash": "2ddf7132e10ce1715105713b8bc8182440fcdf6401951881988258ee820f205e", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "21a3e320-87f0-44e5-8819-05c675908266": {"doc_hash": "9abddc9debe8d604c702866dc4a0329282346f5cfff4834f27c3288eeb99f2ef", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "559fbe56-ff77-49a9-a436-70700a6195ca": {"doc_hash": "2e35db5f1149ee3882614a7252d5b9635910f487ab98b4edbc5fdc6d5061c07e", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "7c415bbd-aacc-4fc8-b469-177f59ebff25": {"doc_hash": "e939a0b609ccfa66ff44c94e605202f80958daec85b5b1e6cd6ec092661f099d", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "b6acf1b2-b3de-4ec8-b9e8-5e9bd51f18aa": {"doc_hash": "4f8cc3b6ddeebb6777a22921088731138e4c3b0601e0c8eb81438cea30bb033b", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "89889bfe-39da-49c0-845f-c0192d44a1ca": {"doc_hash": "396a0846c0eb9f5312c224020841d552b6cc828c6785490580052544e271ae95", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "e180b470-04c1-45ef-9ade-4b761f198a0b": {"doc_hash": "465f01deee30a657beab3493fae9c980b489050153c339af40cf7e4ea34431c0", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "151f8fe2-bc20-4ccd-9e06-59cc73b12bc3": {"doc_hash": "47152b80c61e7c1a6a3c0ab758f6c8e225c66bba6308a92f27d96597379b09d4", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "80e26d6b-25bd-433a-bb45-1bf0c642da72": {"doc_hash": "177981c803127329387e0260d640a0b4a7d526466e9a9682a9af7ee61332b7dd", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "f8ac13c4-7809-44e4-b07a-4434d45fc8d0": {"doc_hash": "487f134729fbc8311937c2f6e06305c38537ebca9c30008467082c2cad86425a", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "4024b3e0-8117-4081-9dac-e8f69dbac026": {"doc_hash": "b911761fb48441577142e12f1128e69079ea67cf24aa9c51b966bc6838dffce5", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "bc51e0eb-d5d0-406c-b1ce-26ec2403f5a5": {"doc_hash": "a8f4dc8cc7678a01c7d5b358d797336df67f56c121ba9eb33dfddc8576001b1c", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "9faf157b-3eb2-4271-bfd0-2ef1755bdd7b": {"doc_hash": "08bd86bcb6c40329f830a05a03d0f492f62ef25b792ace4e97c0f3795702b440", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "6b961700-7e0f-494a-8885-ddeb62a37605": {"doc_hash": "534ae7696fb1071b48124d5e337b1b0c078b1e034bcf6bc760c7e88be15e9698", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "6dce7fe1-8901-4f16-826f-b8c71db309c6": {"doc_hash": "b5e624efe27696ae6c5a6b57127c8cc0b949a61d17d30c96bab1a55b85d788e9", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "affea702-68ea-490d-975c-51735142810d": {"doc_hash": "0d6475408ad3e6b0ee33751f0f0e8e946e1f7eaa1f1c8148cdadfeaeea5570f9", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "f85fb169-1859-4b6d-a78b-6eb99d2c429b": {"doc_hash": "d0a80b132d9187139cbbabf353151e547a2ef3cdb7882ac3e49d8556c0b30e76", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "30f3bdee-a598-4146-923d-1c2939c1d8ad": {"doc_hash": "5a049b49eec99e81240724eaa945375f62baf30ceea6df203537be0f77183798", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "035ed148-4649-4545-902a-0200e7cf322d": {"doc_hash": "e9c8e97d7216f266c66e4c1b90333b1ded67c679fac9fbbdbaf0a5a97da44680", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "97e07316-73d0-49d8-9ba8-e5543cac8f4a": {"doc_hash": "14f2398793b885da211b2696236f0da1c5c87ab79340f7f4c6cbcef024304eb5", "ref_doc_id": "45ab0081-c570-402d-a250-5c0e531645b1"}, "ce7aad31-f418-4ef5-a685-c83db287d598": {"doc_hash": "5411db9147c10f8c0721917ea385595b5ce65204da5a0f0b9effe09f017bc467", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "4de169e3-40fd-4668-b466-a926e4635f11": {"doc_hash": "c01f018a013add83c772a44d6c018ec0313b282722d0c41c554b17494277b0f5", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "ad81d690-e61b-4db8-b9bf-962fc5755982": {"doc_hash": "8f6ce5f9b17fee9082e031922fa08bcfdfcef4f0ba8257df1f6cda835ab34457", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "eb9511ed-da59-42bc-ae1b-98952d5984f6": {"doc_hash": "df23effac3cc8b9496544b8437d2a05f2dd9fd17d546325a24ba9a0a5ad4e64c", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "f9801e93-7247-426d-a8a1-885d0ab2adce": {"doc_hash": "6a13095a524682bfee8b191b3ac7ea0d4b67b8dc59bd55907fab82f9790e83fe", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "3a928b9c-fb0e-4803-a349-cb3a904a10aa": {"doc_hash": "c2f5581b5c1ded7a5a85f21acc187f64aff92a31e352b73c10bf8ea06740bd1a", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "22882f66-3068-494b-ad2b-95276d733ffc": {"doc_hash": "e183f3ee7bf3e4ec53542d8d033893b4a0df5d2ba74f343d3b151c268629fc7f", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "b1429b3f-4a23-4392-8b6f-03c60ef4f2f5": {"doc_hash": "571b384ac2026013a3db007690ebef3484664ae3fa8412499d03e253bc99e8c9", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "f13dc18e-7dcb-47a8-81de-e29ffe57a362": {"doc_hash": "505c23f889fc2b3a16766391b0996ddc6692c53726b0e0fa58049503e6e8da44", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "f0fb3356-b5f9-4196-971c-2f733b9139f6": {"doc_hash": "b98e32bd029370e539962ce9affe51f3f19c29fb9005927da0afe9094b4a23bc", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "ed4b4a7b-5dfb-4666-92af-a932c0b4dd2e": {"doc_hash": "57feeddd5b3971c29d3bdaa671556064c57a57eb38c1d7bce66919f9e0ebc2c6", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "ad668f9e-ef13-49d0-8af4-f96ee2599d82": {"doc_hash": "6d8e294fb48fe5b41b8b59900a3539c5d676605ed89e7c19b77116aa052fe840", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "3373bff8-3bf0-4276-aa8c-965eb9d53f76": {"doc_hash": "fc85df75db619610c6460c9ceeffed227da720911ee19c333e00dab3f9436128", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "4b0d473c-d0cf-490f-9978-4037cbb53a7a": {"doc_hash": "dbbc66a181e36cc8a5cf94e90cd0ad3114be56c0f80f38d6a5840ecce0f4732a", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "f1fb6397-75be-4bd3-ad46-6dbd42f657a7": {"doc_hash": "f5c14922194aa7df96c26faf783a6b215b28000755c188f547645dce61fad7ec", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "9596ea0c-c036-4da6-805a-9c8c8cabb482": {"doc_hash": "ddc8050a6dcdfb51cc0d577224c5e6eb84296ee92c28a9f1aad9b92d5fabe2fc", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "eda07e90-b480-44ca-b0c3-a112cbd02056": {"doc_hash": "231ead5b38bd2010cab1b47ed2cc4671cd4f45964571d3ad0c563cdf70c96508", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "37a1fe54-8b47-407d-9d6f-396aa3d75f65": {"doc_hash": "ad88ddf6a8bd5edf40b1871e2cfb1c587d9ccd6787e059b7600429f10f3e5961", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "621a75f7-86dd-4ccd-a9a0-8cbd60fe7dcd": {"doc_hash": "22389c6dc977c6242d92d2bcae80cd91d4d8dfc8bdd9ccb17ca90c463242ffcd", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "f27fe77d-1c8b-443b-9cee-f90088dfdf46": {"doc_hash": "c4d9ab18a473c8817795501d0ce2253b8c118f650cfb3fc15cdfbf161cfd8f85", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "31e0f06a-9722-4862-bc8b-ab20212c223e": {"doc_hash": "7863f244d5a08cff8ccb81659beb85c6a1cd5d2b1e3aa8f6c0140922c3d8a04a", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "ab091e24-c383-4c5b-ae56-01749f37546a": {"doc_hash": "b6c92cc793c6bc9c986e9b852e73ae87c25b5cdf8d85ebcc271f600294929350", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "1bb7d1cc-ad05-4d93-b1dc-d29fdb048e53": {"doc_hash": "f62094421e9960cb2b0e165ccdcd1dea3267f45b554bfb594fc6f705bdf4433f", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "aa9d0e97-8232-4ce9-bc64-8846b3af7499": {"doc_hash": "aed7149b44be413eeaa0ed90ca9f144b4db1788d8f997bd42d727de11e0d4d9c", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "227c624f-c3f4-419d-a87f-ed1dc5969c6e": {"doc_hash": "858ad7c611dbc22531b0e25e424169663c942d7a9e3d71a8eca4e720b08d54cf", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "fe25319d-fa0d-4d28-9647-43632a39e877": {"doc_hash": "ddbcf382f1fa9ff7165d6b1cc9de673ad4d1a5eddae0ed33e3b18860a09e4998", "ref_doc_id": "a4a936ec-9813-42cf-9784-48ca5fc9fb38"}, "ccd70c8b-793d-4b03-a76f-109337ae751f": {"doc_hash": "2e0b9adbf6473f28738016f3f538d41dcc0275790c8826585806cf1c170ed87c", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "7c845133-550c-46be-923c-fa953e1892b1": {"doc_hash": "cf27f2d358af31523f6d2906eda37ae6af42deeb14f41f87d6e693a10dad7558", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "b83e1263-40b9-4ba4-bb28-67f2cb2f2d0a": {"doc_hash": "2548999e3c5dd90ee50a44957d3134618a96b5ae36a3b368b2653b582b9eb0ad", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "fa656960-4093-441a-8c79-2f8fa7c173fa": {"doc_hash": "01f62ce5f169415bfdb22d06b2d27a188b9243291e52cf14f3fa53daf6ffc74f", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "d25592e0-d38f-48cb-bf0b-1c2c023db042": {"doc_hash": "1ccf46c20ac7879142391a4013c991995c37faf78bfef3db5bed657e8605a752", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "5e181255-88a3-47ef-a7ea-d292d8fb40ba": {"doc_hash": "d7bd98a7896a08019730c5fbd8392078d000eaadf9ebc4fef92d3342bb2c3d5a", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "f2dccc5f-f2c4-4387-9dd6-c5c24217136b": {"doc_hash": "d4deeca5dbd67aff434cedfaa19594910bb3386d30704a8d7b17d15cb2f21cbe", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "cdb83e0c-8694-440f-bff6-e882ea39ed24": {"doc_hash": "9a9cb4626ebd2bb83b90660124203f3d209451db04c971a0076689d65d0d1bdf", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "c029b9da-ea56-4945-a6bf-59a8a8ba1e73": {"doc_hash": "5e43896fe3c7f94de91da24624f501b3fcc04da464137934fde673b8dfabbe67", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "d5ad4acf-0bf5-4bb8-b357-af0102c2961c": {"doc_hash": "076e506dd4580cc151b7e2a81c6d4de7399d309d876d66abda731b152cc6d1dd", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "ddaf6b65-1b9f-41a0-bfd8-b1664115d9ef": {"doc_hash": "43a2fc59177b73f2100ed764998ece33ad7545e312f37d04c37382d7527f3e7e", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "67c23161-ed9d-454f-b039-dc55772b546b": {"doc_hash": "e0965699dd316434c67d56a585103207aa1510775344e9d0758990a683ff2e03", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "996991c6-87f3-4ba5-aff5-60da497e0e65": {"doc_hash": "ac98b8dfa049f4a964947b95a2a23ecc09d6e7e48b6835c47a1153b048024ef1", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "26e08cb8-8916-4af0-a4cd-2c12594b3f88": {"doc_hash": "87b50ac4d8ddffd7d40674aab719fcbc0b1135fe8068dd3be35e3a39af028702", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "499e7553-45af-4020-8203-06251699cff3": {"doc_hash": "c8579119b009c99752b2e12c8862718c381c791789f71d5135eb349490428f9d", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "5c85f88a-87c9-4aa6-81c0-3e49abf7997d": {"doc_hash": "8c324573e2c0ac1bacc3aea9b2412cbc54a21471b35209f2141948112e5901a4", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "e9d4e460-02c0-456e-8b86-de90ced3d0ee": {"doc_hash": "26069c2ffd8c9b6fa2d445521d8a05ca434e5f99d58d68e2a876b1cfe14895a6", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "4cdfb22f-93d2-4aca-9ba9-915771121140": {"doc_hash": "620705fe7273dd000f61b74d0c43d8f950f89e162fe6cdb84316bb294e91188d", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "49d5c784-db2c-4f95-abcb-5a407c1a1c3e": {"doc_hash": "19afcfcf0c24b7fd1fb3f423116601d340ba55d80b26c3acc2049e02469255da", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "a70dc208-477a-41f6-a2fa-9ac2ad0cc559": {"doc_hash": "21c7d8406de83d7c0f6fa5d149549ae7e70d73485b664a3669979a0112a97ddf", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "abba9a6f-073b-41e6-b9d1-a20290507da1": {"doc_hash": "7b38c9ec860bb0131d75dc12f54cfd62a66cdaf367030ebca615cd041837edbc", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "ece9950d-f9ce-41d4-af4a-020007fa0402": {"doc_hash": "93156508c9bd0b797e102e8ade5222099238bfbe33ac400bd7e5bbf62be48841", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "9af466ba-9b2c-4c0d-8426-09009585e65f": {"doc_hash": "93eed90c05462db8eea85ac1825238b3a3bc16248104d1396295e05d3159c302", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "1068a5e6-977a-4f83-9ca2-7d4f4a603ae4": {"doc_hash": "8d76e392ee3d3b8ae415fba27b53c6bc53c33cc7cf0ef0d05a1c3caf93c00bba", "ref_doc_id": "f9449a7c-e83b-44bb-b578-5cce641bb7e9"}, "4a9042cd-f73f-4124-9546-e7cf90364883": {"doc_hash": "183c1b07f100a2c1809417c7f2533ed87fdc2d1f06dff1cc6297378940db2422", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "7ce3b2b9-35d3-4f86-b3ad-0227fba243a8": {"doc_hash": "8b5621f1bbfbe88685e87439d848a37d52087b10bad30e6684562567958d957e", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "ebdc0639-70a4-47c5-bb06-2e364454de74": {"doc_hash": "5d88216c368a9d1e5b4e8a9d8b03a22149a3ac3cdfc610ae98ed01df796b3bf8", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "c5c6c919-0fd1-4d34-8347-a751c0c628a9": {"doc_hash": "1d7fe2bbcc59f147557073558c9d6b42db849f791516c5998c9e3355dade6651", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "485e67c5-b6ca-4f00-b282-ac3e2c6ec515": {"doc_hash": "aa5d3570cb14024828a7afa9441a2e83b5e8f3a6808199ebdd756b9133db0f63", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "02200d30-20c1-4f1e-8534-d7f10df6afe5": {"doc_hash": "834bd4da0670e6948057f4400c1ba1aadba5cd5d983ececafbea41d6fcaddbdd", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "4a68cbb3-3e91-4600-b70f-3598344f9938": {"doc_hash": "24f393282b2412d3bce4bfc184246bd66e25aaa9c282382f50382580dbad4199", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "37bede98-5749-478f-9332-5115cda2eeae": {"doc_hash": "547e87628526b301aac8481beb6441f7add9aee4c3edf19d2b59c072027ac94d", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "ab47f78a-58f9-483f-a943-43dd3380158e": {"doc_hash": "cebb6a73ab4580da3d59ff7df05510827cfb503291f093c9aa019617009cbdac", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "1ea75706-fd85-4516-a6b0-53e371627819": {"doc_hash": "1273ff3e68db4db835908c84cdcb3d67c02109d299f80290e6ba71c0aad2082f", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "4fd05cd7-2336-465c-aad1-97955cfba4e1": {"doc_hash": "952e80b51d3a06dcb2234eabca0b84ea644af98c10b4a2d435f71923823d6768", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "586549e8-ff46-47cb-8c87-3cf2dbb51506": {"doc_hash": "bbd2fe535d1542951c07096d41cc064a4daf9bc0ca53fd86bc8bad22b0916ad5", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "877ef944-becc-477d-8ce9-401f844a0a36": {"doc_hash": "8652d8db41fe87737f19648d8f6445412a41f93e2da2f43e5363968d01b73832", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "b30a1e8f-7f70-4c44-b25b-dccb908ab33e": {"doc_hash": "59b0f0fdcb610646fb9d081947c43336a5fbbef3b01ccbdee97c94a73c6060e9", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "4f9cf1e1-6852-4164-9dd9-210b0cfa2e42": {"doc_hash": "2977f3070575ed71e75e3785307f0cc88b302cd6d4848ca5519da543dc3b7a18", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "99c516bf-6494-4353-a6fa-4c412d415014": {"doc_hash": "4fa771cbaecbd5dc1d7fc47dc1add8222e0a05bc084ae23919fb43e5cb095e5f", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "2ea82c4b-958a-4ddd-8941-681a5e4b158a": {"doc_hash": "c90323886774566451689a35a1150b7e7fb62976d56f26ba25175e59496a6799", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "bae626ff-b13d-4d64-9808-c4bd9146d008": {"doc_hash": "68f6682a9ce01d1cb3ffb646123fa316aff4a0eef776594626cddd74b03d3b81", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "f0ff796f-1e15-47fd-ab3b-2487a2ad0c23": {"doc_hash": "bedf4e109f5900b0f959b9f47887845ca52c9f3cc61b1482c4516cf12c180712", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "b575f828-5395-4d6d-8650-4dff320822cd": {"doc_hash": "e7519d4203ff3e4ad138543c3b6b753efbffb8411ffe08add19b93f28c980e5b", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "8ec0b957-575e-4964-a929-f273a0733868": {"doc_hash": "7a4022f7d265da094d349393db33934327ee8762659ce86507d0b6d8e33f7ced", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "cc2f6a6c-9dbb-4ca4-816a-7b5670db0fd6": {"doc_hash": "43160ca2f4e10efa6db3be2aadc1ef8404ccf33fe2dd2fc0a10c3079cb3b4877", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "062011cf-a6cf-432a-8c96-b1284fddbbf6": {"doc_hash": "702dfc27129d8f385a48ce64e80af11b115dce5bb63eca31ba21bca4e294bdb1", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "1630b878-5ef6-4df3-bae9-000ad74b14da": {"doc_hash": "80b50a3e269a878303d9842f728c6215098df917550a105989ede47525495d5d", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "8b5e665f-e391-4c56-b861-71fa0acf63db": {"doc_hash": "b0204aead998389bcfda94bc6b7b77e7d2932ad4c0aeda3f8c0c150a652f2456", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "f236f191-e810-4a83-941c-711143ef8219": {"doc_hash": "d0c6c4fed80e9567bf7c9930917f407e985ef3ac4aad34500b4666119be743b4", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "3615b977-0fea-42eb-8809-02ea24aba08f": {"doc_hash": "be00d47d4d7ebda901a9998e125c35ad778051cb185606eb6dd1e251c9b21b30", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "a5408f33-ecf0-4eb9-8c48-1f2ba0db97be": {"doc_hash": "50b524faeeef9f43a85846c46722c5de6f90a93ae32512387281f83acf7e2b31", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "7ac6805d-7b66-4a95-99ef-5e22878970f6": {"doc_hash": "b2255b56025606298bf99687f1b601f54aa4641a3b6bb9787193f14ec8549e3d", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "bc2123af-2550-40b1-a499-61afc35984f0": {"doc_hash": "2014b4632cd526dc7dacb32fbb463f5bbf8fc2f27daab45e6169dd3722a00d16", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "b790c4f7-b807-4a74-a825-84742e25d789": {"doc_hash": "f7dfdb72cdd7f4f0e0d3809ee9b270c18a5fa1c831f1f26790f6394302f5b197", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "fa020700-75cf-4093-8599-9d2adcd23417": {"doc_hash": "89a98076db54a26cf2012ec47a13f80083f50b28c6eb1af0a359b5d028092a18", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "a7f81ed3-1024-4f35-84a5-03ca20328168": {"doc_hash": "161870b37a5e0128a5980f9efa95a959a069f4a951bd960fc5f516f06ed666e7", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "7a3fa3f4-1c9d-44d9-984c-689253acbe07": {"doc_hash": "81f7fd401831245f0a763dc5cd3b4ce0d4f448f17e2bb70ffcf93da90f2c7a2b", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "384b9944-febf-4c10-9ae6-95db51117e04": {"doc_hash": "d0d885211da1c98438bd7bb669ab8a9564ec8939f320bb056c378fcab4dabe18", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "1a6d00be-7887-4b8c-8cbb-d360b5668105": {"doc_hash": "634fa8d8aef245a1013d997829767850bd06a52e78555f9266c6527cec350fac", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "83d06875-b556-42b6-ba2f-07a083cc2554": {"doc_hash": "810cef486a94d95575f89341672e4bde3dc63875c4576092d2aaa7268dfad3b8", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "0746af92-3685-4f8b-a8c0-b17538525f62": {"doc_hash": "558979e02747de122337521bfda7ea209af90cb91095b3b7ed1c79cc8727b9a0", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "45a0c71e-efe6-478a-97d4-93b6ac36eb86": {"doc_hash": "686243db1e0c08eb9c7917bef7376a072969076470d15da64893b1ae2c10da59", "ref_doc_id": "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c"}, "f8fe945d-d14a-4c55-bb23-aa9d79d205f8": {"doc_hash": "9c49b9fb026c06ed8d63b6b0c0913084c626435284d069d1aafcfe802c7b8f0c", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "72848a64-73d5-4cd1-96d6-6143828378d1": {"doc_hash": "8d0aea94f6dba5cf0a29cd4ed7f886d4a2e506bfc1760c3ba53b5ef4730074c2", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "686b4d3d-8845-466e-aae0-6a114365305b": {"doc_hash": "a3eee0cc81cd837f6187fa08857fe9c10270067cef3f10c123b9c593a937d04e", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "97374d8b-bcd0-4dc8-aaa8-01a164f4a184": {"doc_hash": "b18f2ce00b9f1ebc69953b16ac66c06e2c28bf4b0d7c81ed3d535d281353eb39", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "522b9300-5d5f-44fd-95ce-eeaa1401b0c7": {"doc_hash": "4d38e6d171172b717545306a5ec6de369124560bf96ffcf7a7cb9136f597ca03", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "69712870-cb52-4772-b146-1a5b8379cdd4": {"doc_hash": "4117e1c17f781bf7aa8d271f378ec8b3d99ff211b7ca7191522352054ded56fa", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "c730e6f6-b620-46b0-a264-9260bd1cdd03": {"doc_hash": "c29022048a144533c50cf4e7a7a1d9513b91e0371b6254755d9edfc5d426ceaa", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "6463a506-1846-4265-8955-367e2f23ddfa": {"doc_hash": "cd9eac19412db26c55a169a8d02dd34f26a6b4b63ef7801007c99a43d54e4ca7", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "08ea544f-71f6-4fa9-ae9e-8da4e524c8d0": {"doc_hash": "7a246c2bc56da410c6e8b8306420aa44d78d1914eb0c0fb70ea6120da009f67d", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "e1b48df6-2eac-4f46-a0be-0a6c6dfef4dc": {"doc_hash": "0ea83323c444d0deaca049a23f3515d28383ecfaee15716247689f3152bd4e8c", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "6b973d9b-9c36-4658-b67d-8c911a391d3a": {"doc_hash": "1b678e4412b6a5a25eb75f8dbb2fe6c88a5d0c3e9cb6f9c34ee400d23cdb7e6d", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "33738b0e-56a3-4db5-99e8-87c87c813f61": {"doc_hash": "84483b54eb556e0e01b8451eae69813e1c542a93be77a13464ab4ae31c91543d", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "5d834054-eb51-4c51-afae-ec923ce2f9d1": {"doc_hash": "dab714e76ebcbcdd903612d0188e5cd4924d060fbb3b6b5f8da5447800cc3c63", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "caa529e5-0f2b-4cd7-85c0-06c108e659d1": {"doc_hash": "0a32524048a3f0eacfec440af70516c941908621fe573659cf6a2626a5a20f24", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "aa9ca713-b549-42c7-873d-c525fceda67d": {"doc_hash": "68c72131284264d8defc60751e488ba89d58617463d1e937c19fef2498cf16b5", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "dad46a9f-329f-4a97-84e3-92a01ea78c2d": {"doc_hash": "faf0ff40c30099cb1bf25ac3e78a13af3c8dbced61108f322abf94a7f977f709", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "bbdbdf78-f0bc-4b1a-a962-169d8fb83f9a": {"doc_hash": "a340cfb7e77d3a9074a16d9d146eabed7da1f2391497dddcf8c48def3098866c", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "54869ba2-2042-4284-a332-077be571a6c6": {"doc_hash": "c951493db31174b39fcf9ac1e36930dfa1c6fdf91f5efdd7538668d8b903c14d", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "0989a747-b1a3-4d99-8945-0130dea84e27": {"doc_hash": "b7b2d4caddbde3fb97879461d4f704e9119c30496031d099591c3233d58490ce", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "a99188c1-a845-4d1f-982c-ebf516591e1c": {"doc_hash": "d5d511cb371af7590a7ba4ee86a278a07e78c74f8268d5c73693ef8713aff378", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "a3eadd9e-5633-4efb-badc-478e1a8f8c46": {"doc_hash": "d784cf11fef63b6a1f801aa1bd0fe973f25e703cfcb2fbde8c9a879912f4ccdf", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "781ed85b-d11e-4230-bef8-65e8a68f95b5": {"doc_hash": "9f9cc08249fef2d6300441074722eb113a7328090bbff3dc8b51f492bce20162", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "4e570362-54b1-4ef2-8b83-2c40bff2a94b": {"doc_hash": "a0b6280f00d03cd50f2d19002ca825f58a2d3de5c4cc3c7e1a1a82f879273e48", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "af673cb7-8d91-4321-b6bb-98c9dc9ca6c7": {"doc_hash": "95241738764dca95978deff455399f8cf68764e467639515d237da3327c6ee2e", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "c7e5e841-9ee5-4da2-8271-0105321ecabf": {"doc_hash": "677707b12ae8756acad1b23b551bdd419c0b82ccde528f6e540f311b78712d8c", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "3b73661e-01b5-4bc4-99df-eb6d7dd3cbe3": {"doc_hash": "14400d91adb09ad16e2931b0ca227c792cfcc8f520cfb2383ffa34cdc0a1ea69", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "3e290d57-eecd-471b-b8c3-916fca8e95e0": {"doc_hash": "16d19807c2a6e030fb73f051ad728fd393dff33b22549000b0a7e78975fc1b3f", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "283c9132-e416-40f8-805a-f29f17478163": {"doc_hash": "3f30dbe8987aee9d4da2439a34736f1c4db7351c3d5eaa79e5785d7b697865d2", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "8d40bbd1-50a2-4ee6-bb80-16cbf4740d19": {"doc_hash": "852a7ce08ad7e4a964116c1c45c75eb9e73cb750e9880ed5eba822cdc77b8f7f", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "27b8fb36-bde5-4864-812a-e1778230f32b": {"doc_hash": "acc7dff476c323a9dc5058be17d0c597976ac68b1698ee488f5735cf0633d663", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "bedd14e2-c917-4cfe-8371-588f41aa9713": {"doc_hash": "4970b679b82ba392bb6082461a55466caebd5c27e0ad533236573bb5ac271f37", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "97a212c0-4946-45f3-bb11-1d747c6085a0": {"doc_hash": "9b954c65534e836551f3f26eaa6e95edf455ec89ea8e0009fa849bcba5434620", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "a5633219-f734-4f06-adcb-aff02de0aa80": {"doc_hash": "e5586fbb6c825fc1dec6e5e0df80f0bf8661b410840c5826db9632eb3a031026", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "fdec7572-094a-415e-bdf4-975299580e81": {"doc_hash": "5612f8353ce1f6b7f0cf17511a2dc30ae989f4569ecc5a256f6724f5eea67726", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "f583bc9b-f771-4bf0-bb73-5ce69576ab7b": {"doc_hash": "b2bf92330c8ada825647ae5bf1232931f93638a0afefcd8004d4449a1211e921", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "8897a0bf-bc6a-4fe7-a490-d3c7f8c04e4d": {"doc_hash": "166dbcc65a81f4ee7e9a9ca071c7d8773dda2d4a4a511cbbe4d26fa2662d529c", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "0aad1fea-7504-4da9-b590-0a4be0b0045f": {"doc_hash": "8d7ab23f834906faece944d9226f7a902ed0dde72ac7f2d28da6dc1ce5ec546b", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "98004126-7970-4e00-b09f-c6500bd40c39": {"doc_hash": "ceebe20c4707958ef423f49c07fc1fb27de20dc39c2bb2b0f4637ca64d5b14f3", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "362671c4-ce73-4137-a97e-05a88828c1f7": {"doc_hash": "3c228f0a5ccade2378d1126dfa1bd950a18f2110478d6ecc35d3b386929d6c97", "ref_doc_id": "d11dc646-7603-4427-901a-12238153d34f"}, "5c47e179-368c-4f03-b4ad-f51f4840b60f": {"doc_hash": "1d0679c4affcd2286b907b6034c0a1058d6106752f3cdc9444dd296e4a9ffb1a", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "72403bf4-2f52-4b68-8b60-cb0591f05d2a": {"doc_hash": "8adb9878c26a782921d1f8ab3e9530ee5482d2deb0d7ccbd7ca277c7d76e7529", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "61661cc0-44cb-45e3-9a60-43f6b367f69a": {"doc_hash": "edb99d7e650b5c2401f0ff1eb5b1dfa30a02a10e3bc9aaca74d04f0572bd9140", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "23fb7e9d-89a0-47d1-a170-1304ebec53c0": {"doc_hash": "378837212f68c483ef6d26991178e6b56b6e6509d3f4e580fdc678ed1190de0f", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "01799d7c-2e60-4e0f-af4f-dd1e1a6cc5f7": {"doc_hash": "7ed668b0ae762c4fd75786bcb943b82d3e3c900db407372f4bf5e6b76b4fa686", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "8b6f6e93-8d15-46b0-93f0-60997ad34357": {"doc_hash": "ea6169acb4020756788716cb6632f889d60c034113227bee532332df3d346395", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "11677b7e-10ac-4b9b-b85f-5e5b63a32841": {"doc_hash": "d2d93be207bf6852ba8008c87ebe20262854f56090f86d77d92d33499991ab26", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "46014dcd-39a2-417f-b881-36a1d1afc5a1": {"doc_hash": "99d2023ba9afecf5c8a9a474bafda5191a50a51d90c1c83651dc667e1b139fca", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "8522a4d3-15b7-44fc-beb2-11feae32c01a": {"doc_hash": "ca46ac9d9f1f0abd2c22a29376037b469735f9a3eb9d04db1b4464dae2a0d76c", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "dfd97ad7-8ec9-4acd-be2b-7d2eaa6978f1": {"doc_hash": "a155c169868fea39c7cff535d9462fbb88b5a294619058b2749700cfc5861ca3", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "ea576c0f-bb04-4f62-af37-e682f4f220f4": {"doc_hash": "87b436ceca1eb89e99918891839872fa8e51fa1a396f317b8da27c6c8a88c983", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "5d4ca333-badd-40ed-b273-c58429f30a20": {"doc_hash": "2f09e00a630be4abf021a102dd50bca840356deb014aa46e865e6c382544fa5b", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "2317e537-30cc-40e9-a16e-8854fcb95565": {"doc_hash": "003dca23f9367fcb234fe0c83baf547e8d77ba7e2eaa5aa673863b0dd55bde46", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "58d0f5de-f345-4cdf-85f1-99c67e6cd68c": {"doc_hash": "ca3394d8cbb14d3f27e2af6d9210f5857aa520ef15798393509a3a85037b1e0c", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "ba2744fa-c130-4589-a332-467a3df8cf30": {"doc_hash": "81f5a39ea0f300ddf8c9497739528e42a33235aeb7e83f105e34591b59487903", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "ed98c0ff-4c36-45c6-973b-72963b0adefc": {"doc_hash": "0cc185d71bfe67a665e11409b34bfcd92c6d3c6b765564adf794462630a4cfd2", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "19d94678-b7ae-444b-8e5f-7afdf1f2a295": {"doc_hash": "200731d762e334c85fc07aefd312b9232acb812f070caab702f883c5e408c389", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "1a00b9e8-a625-49a1-bb1d-feab29f47269": {"doc_hash": "83a716929de11515a990347c5602a2e830f97225e4941c0771f7eeadce3c3152", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "27fc6ce0-4344-43ff-9a7d-ca476e9bbec4": {"doc_hash": "916b0935b2f79d151521b81b8d045743ec7f60b426dfd68ae7bde03eb940a3ab", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "915be9cd-dfb6-4516-8d17-37b4ab268819": {"doc_hash": "08e50c5142832e15e2b1da2020ea89a14b2b4598513e026dc6ebcad02cabfac4", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "5a8e7c6a-428c-42b7-85d2-f079fe64c881": {"doc_hash": "a15b1d149731a07e289ef1bc7ed4987f52120862158b39ca3c23e4c79366a8cd", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "cf4c9882-2c58-4bf3-bb3a-2f71b9d15bc3": {"doc_hash": "6e6c05827e5257938df93032c595d4202498d6553ac96c48d704f2cbf8138421", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "5dc7d4e8-23a8-4fd7-a924-6d40039f1d70": {"doc_hash": "4d88fa8d5980a057e698a20ac3990f5ce0e1e773946788c0131a6370f3bfaf7e", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "84253701-3332-40cd-a241-5f0738ae4efb": {"doc_hash": "5096cdec34bb3732a6962f6a6b3ecae2bd2389a672297ee37eac7abc0ec47204", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "4fc568ac-6092-485f-8b99-27b69b3c4fbc": {"doc_hash": "57428ad20e14d0ed623c58b571879f3c1a61349c498901dd6f939aaf128e73e8", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "d764a1a0-6f8d-4701-a8c7-3fdb686c46d9": {"doc_hash": "0d3aecf6efc4538e94718e2b96e678d48bb963cc76a0db3bb26a300b4a5093fa", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "b9e85856-3499-44f2-b0bf-1ebac908c0ed": {"doc_hash": "05bca1bd7f83bb6ce5da133b8ed5ee6db14d8cc1f707b2dae547ef54885264f3", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "4c90186b-3801-4a6e-b8cb-d4c7639dd822": {"doc_hash": "0fe52e302507818802f775a04c2065c2235af2bcda0e3dba13e9a30698d25735", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "fb187781-252b-4aa9-b67a-141f0f96be14": {"doc_hash": "9fdd15bb4b5ab00587cefc19c3ec0a88e38c1874fee9af998c04372060a5d8f3", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "ff64538e-d8f3-415d-897a-f2e8ef6d4de9": {"doc_hash": "15f61200e04d1d0e0bdabd5af02cca1e6335e1ab5133fc9023fa82bd3d5e59d9", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "7e155c06-d60e-4f85-80b7-217f88637133": {"doc_hash": "8dd14dcca37203201ef665cd4cb0b91856f39adfe5282cfcff4fda336e82f505", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "9bc4a21a-4a14-4d67-accc-514ba13bd665": {"doc_hash": "eb9e3c301a1642f6ba39b3ff42c0b6f408ee0502d2c012d7e2e59acbf4e94008", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "d4fbc6cf-8f30-44b8-9b28-2d64e9f66fe4": {"doc_hash": "3e2181221e6919f5802a2ca9120f454483009fc7292add6c900916a7a4bac3b9", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "94bce131-e003-4150-8e13-3fb10876599d": {"doc_hash": "dbcb377080d6b14fc015ffa070300f644b18cca1e097d374e22e4d59e05254d9", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "cad26a4d-9a6e-4211-a7bf-7db4da31d213": {"doc_hash": "20670637bad633b1fb8c1fbdbaa84631d8e32c98cc5c3b99a3aa21a6bddfaee2", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "4ecc9347-a8bf-40a8-b623-4dc1dd73fbf0": {"doc_hash": "f8994ed0ab6024a6512af752e0335126fc76da44d268e5cb4cdb222bac60fd6e", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "fcf486cc-f360-431d-a408-bacc5c1887c6": {"doc_hash": "961138c943a8ea05dad97b269e632c27472760eca5cefd2b89f88deb889cb4b5", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "b1953738-709b-4686-a6e2-39823c62894d": {"doc_hash": "316135e71b9c468c1ee2edbe55d42f3f2c9a54372d27055c7516432dddb3c212", "ref_doc_id": "21b2b899-7ba6-4111-9656-0d52d07bc03a"}, "77c4fd4b-1c66-489e-afcf-ace7571a503f": {"doc_hash": "b8cf88b6dc854100e84beb81865106d9fbdb6c410096e3db10d2a6d2daec8c3b", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "65239a86-1c5f-49bd-986f-4e7cd4bfec05": {"doc_hash": "8678f0e4a15512401d2a8ead5c63db7f8d9abad9c722eef528eb3bd065329de3", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "6ba6322c-a72e-46a9-80bd-2448de523907": {"doc_hash": "fd03cd9e6088ff6e7a08bb60c724d521001d909dd2b180b626407e9a32ae3f02", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "37d01b00-c7b9-41a9-9a08-06301c6bbcb1": {"doc_hash": "dcc37c606f995fad2f585599eb60dba066b1cff9849ef08610fc3599827a94fa", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "2d19b3dc-fc9c-492f-a5b2-7e1b815daf98": {"doc_hash": "8dd814c324adf8502e7958854e5884ec529e8853c1881bb72be91ba03d8d83e8", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "6e59eb3b-2de0-4b0e-a1b6-f3fac0a0236c": {"doc_hash": "c5ea50749e3f8ee65f978b09f8a4bf2530c27bd0d614c91ec51e70f6445345d6", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "6ce3ceb8-3b9c-4b1b-9dcb-2de927d9f061": {"doc_hash": "c7c9569fe5e053a1974d7b2c34bedfc64b71f7f0ffdeee7df355787a8cb9f1e7", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "77b8b06a-6575-4058-b578-661e76b490c0": {"doc_hash": "2c8fe586b03259d568475cb8871cc33a4bf3ca546b44784e6c96da1f1bbc90ce", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "a927da81-849f-4158-b599-a373e492d179": {"doc_hash": "6093f4361d24b337b473249cf484131a34485a60ed95ef5425fd9745cf69d577", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "015a2e4a-955b-4eab-8498-a2d1698c650a": {"doc_hash": "e76fafa64b7234922b4418587a60ffb5d46d0a214d742801f0bcc9e4d18b714d", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "11c5f84e-c869-4779-9497-84afacb015cb": {"doc_hash": "50ae0ae9dce54d4645c33b985267de3a12d395bbc9d30b48ee4aa340e7f0ad9f", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "0f0f683c-43b9-4688-a97d-41f323f7edfe": {"doc_hash": "ce4dbf84a7365bc391cb32f93597529a02d247fab174fd76329b759b5421b8b4", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "002da6de-5467-4556-a3ec-ed7fe83e2369": {"doc_hash": "1def52e2de301d2b81c91ed8ccdf141cb379324f80d261e39cb5d5d1370ad758", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "d3096dfd-c280-446e-a05f-c0f0785c6f4e": {"doc_hash": "2224a505dc1d405577efb55387cd762f2e2146df3e4f51a134631fb93b9ed7d0", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "40c65c05-88ad-47c4-9051-cdcb75e99529": {"doc_hash": "322b17a8b1b3c5657559328efdb60510768fe9932ddfd3116f641ce2e65d3649", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "f8347c81-a453-49a7-9462-693e9a89efea": {"doc_hash": "709ec3492db6d49b8fc9638293a5594a257754b83ca2eea7c4b569728681633c", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "420c75e0-7e5a-423d-b803-8bd024909bed": {"doc_hash": "78ed15fd05a3b91ec02744d30158aab57d07e98a3a406c0ea9ecc32d3dd75229", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "b5a81f01-79de-47ab-afef-7a3a4a2404b0": {"doc_hash": "c89791928b647fdc296c6c412910a079729ad1bedae32960d6d97b4f1399d645", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "fbe90bc3-5131-4eb4-a8d0-9ea2e6448f74": {"doc_hash": "75a4dbefc8958986693e66d9969ae7ef9b35cc6fbb40a0fe609323bcc068044c", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "9005e904-c3c2-40e4-bbce-6c20842c9354": {"doc_hash": "aca2fe4ff3543ab5604f6d4523c4b2984a08f079052275e2794b917ad5a38804", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "a7d5b4b9-9869-4431-ae66-b593604f1e88": {"doc_hash": "160272ca45a658b07cf0bb6a173e16062378808d44d9e2ce87dce26b5fc0da01", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "72b405d0-0d3c-4b02-924f-69c609f1e4b2": {"doc_hash": "1de1fd0c08c5689c5f5dc6214a93c36d65f5cfc37dcc0789f1fc441f55da81ce", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "4c070621-89b2-4911-a3ec-c8d9bf440688": {"doc_hash": "5c2c3ce2222586691eb93d1463eda3f239051344940c34a9bb2b9bc5156a373d", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "024f5141-db0b-455b-9ca2-1f54ae63b85b": {"doc_hash": "0272e8c404dc28388245f4356c79c08cf9d2bba2bd4ced60b4946bb6dcec219e", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "ab26f6d4-2297-4ead-86aa-8651d875bf64": {"doc_hash": "c4cb001a7c536b5014088d94fe28240f3fc923dff2714be98daeaec0becc1fa1", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "138ceca5-2ff8-4746-9ca5-41c5e831ba6d": {"doc_hash": "0861c5b6be0582d1b5476c2ad6c65e9d47bb6763d08eb9c7b0d09ad240ad380a", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "e027ad18-6def-47b9-b2b1-044e7bddcdef": {"doc_hash": "6748aaf93e7b40274fe9be4f5d063f12f248a7e6ced75a8a59a10a66a7b31f92", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "9ce3bd24-a664-4157-961a-c0c2ac6caeba": {"doc_hash": "19fbfc9b46c6a69690efabeae61704f69e8cbf2a16d62e70be225b7ea4b66231", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "98e1ef3c-8940-42cb-a06d-749c7efe68ca": {"doc_hash": "88004ed935ca0957fab4fbb27da019a1419d520e467839f203a38cf471e640b4", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "b42c6c7a-a7b3-4398-9e5e-4ed10c44b5d8": {"doc_hash": "f37ab60ea409879eb62e0dbd7d0439432ffb43f3ecf49ed04af16a089f27ce4d", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "e388a5e6-980d-4539-8cf5-57142a953437": {"doc_hash": "0eab3226afd186946bc35265920598da13bdefdc1f20d3535810018208eca283", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "ab6cbccd-d312-4811-b769-3d4a0684edd8": {"doc_hash": "35d6f950fa27aae9deb71b418f665cd8bbfad30c82c8fba05c0116f745cd37b4", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "aa84a815-50b7-4fc8-a006-1484166eba52": {"doc_hash": "6ba7d89302f70f8ae105b192ac897daa85a5f87e952b6dd557ce22b7265482f8", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "16d4b767-b9c9-471e-8808-4972cf43a8ea": {"doc_hash": "6b384041f08aa8945bc3d4c5c7bbbb31308fac84f7880215db4ae04ee7c40cc1", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "52d0be2b-5828-4d19-95a4-55970cc58fd0": {"doc_hash": "d5f5ac8750529a5491eb72563b21cb9e26af673157834c86193135da28c2496c", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "8a9873f8-0a7f-4430-b704-db97a19a8bde": {"doc_hash": "576276325f669491ad2b37b855a5fb3fb73e44f161a1d859842ee190a6a2a360", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "e1172e5a-abc9-463e-9e8f-dae34f2fe017": {"doc_hash": "cc9ed26767b5827d04122262547f7b02371eb4fe57648d389cc3c77ee7316bf9", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "7e41a6e1-fa3a-4585-ab5f-8ddd80e3572f": {"doc_hash": "fb7c967c98fe472124c95d1ee083c8ed96bcee62fcb159e4d876d3fa458bd0ca", "ref_doc_id": "8a2db112-4ca4-486e-a724-ba2acd1ff4ef"}, "ed11d05d-6e96-4908-84ef-ee7131e318be": {"doc_hash": "07957077b792915a09716742e4ce28b18e1ea226e324af462410a2d514fda8da", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "98a27a5d-70ea-459c-a76f-c5b0dda93fde": {"doc_hash": "b74f793fa6336414340e65c41f365dd80448a37d6e81fcf2540c33a177e69b6b", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "b36545ab-e208-43bf-83ed-824c9a1a69c3": {"doc_hash": "577b970cc5707274aaacc0213f2e59d6c464dee3a28a6c118ad1d3680c0c58c7", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "c3220052-24a2-4ca0-8d2c-0455ea769c0e": {"doc_hash": "579a307c8801a09d2f37a07820989797fafc7d2d3191feeb73f942735c25815c", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "0b8fcea1-2114-47c8-bb54-033b4d0ef87a": {"doc_hash": "dc79fc1634485a754581fc819508f487c1f53e009cfb0475c341cb5e83a590c8", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "5b2e4087-281d-4d38-aaf3-90c92e13e5a3": {"doc_hash": "79dd6dd09c5394e960c87d60d4fc5ac485ae73d8fe6e2dd0fa79c254fa1b5720", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "8a3b1ec4-0df0-4491-a456-61129bbbf9cd": {"doc_hash": "7a60d14e65672f7f2c28af559346626ac2775c3427a1802533f0742140860b59", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "6db7766d-49e6-4117-8a03-3cc2d95081bc": {"doc_hash": "1280db7319dab10e1788f6876e6982eaa76f04fafd6e8cb70584aa3a7b6a8c3a", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "ac922c23-7e0c-45f3-991f-2b60bd136a7a": {"doc_hash": "9600169ccb2a2726c3a6c7470e98aa31b5f4b1eb56f9b8415e9f584489b7ea1d", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "c5c4ff7e-7325-459a-b9fc-5d4a6b5d3784": {"doc_hash": "3d709f60163e00d6551f7b322cc485ba66e77bb270467271608d186e3da25360", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "6f597381-71ea-4374-96dc-f9b3177c9afd": {"doc_hash": "cc83a71f62c2c2b0b161f2792b11822a28dbff4d84fcfe8351a7af8af071bb25", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "fa94e81a-9e61-4809-8917-44678930c507": {"doc_hash": "728b3ea574ad8841ab5cabb71dce8cd7258d0843f003459b0dc5329cc393b3c6", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "032c2696-74b9-4c7b-99e4-a38265e5f349": {"doc_hash": "46cabb9a9a5a5d3dc0841cf6f86002b3cba2e7447b28c55e26cb2646a7d512e0", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "3989eac8-ea2d-451f-9109-afe340df7d6e": {"doc_hash": "4a0d98656aa7ae8f8eb0bc28e99a199687d28f81f71d6d06c301662b7181c1ec", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "031a4fcb-ae94-4637-95f8-0230d6da4921": {"doc_hash": "f9ab2b9cc93030f84ae74c855ea17cef1ba20a4b6bc944d4c4f8f3033552edeb", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "5fbd1228-b8a3-4c5c-b1d6-3451cd6f19e2": {"doc_hash": "24571b17ce8e0db8e954bf9653bb59a1be436ee8789229e05599ca1ec5ac3799", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "c6382bd9-385f-4e8d-b837-65d14d717550": {"doc_hash": "4dd946cb5b63decd8e69286ff232c37aeda9bcf6b4ed3dcbcbab7714085696e5", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "afc7339f-e7e8-4803-bab2-f5631c8e8843": {"doc_hash": "b9b4b6bda01293eeb095eb31c6f3c00cfd6cb061b2fbd69a4398f0050c7fcceb", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "f64404fb-007e-420d-9beb-fef94b63d1fe": {"doc_hash": "2ae72f3c08039d6d03ebda786592d91a9e9d5fcf3f1f322d31fced2045b8d3b9", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "f65034ad-b1a7-406e-93b7-0914f880dd8f": {"doc_hash": "33a779b33e58bc1d72e67f5bd34529febe426ff9f9e1aefa2ca3d4ad9e5bd09a", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "ad0d0614-d184-4e55-a467-e9952e98a15b": {"doc_hash": "d346a5b53b2b6e07992e00fc3258fb47ca333951b0e231f2c1c2b708347f9c1a", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "1d09eea6-9749-4fa9-a010-57a20de7e9b6": {"doc_hash": "89bc1149d9c4e11796137facfffbfc4ec16649b309bbb6073a0715e761d2f201", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "b4d1bcdf-8ded-4c2d-a28c-417c586c8bdf": {"doc_hash": "c06daf7b799aa823935bfa31e58b64a664e66a77d594fc5d900057efbc1cb8b7", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "153214a0-b38e-478e-95b3-495089b4ba76": {"doc_hash": "ff7c3115ca5fca7a15ee689db6d44c9debcbfe685eba2c26e7c16fb781d08b20", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "efbd0f9e-76ad-4418-9432-779929b7f4e0": {"doc_hash": "0e179db7376f09cc31b017ebd344aa56d3a76e6954587100bbd8b04ea777bdeb", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "3b5f948b-5a87-494b-91a6-561cf055bb5c": {"doc_hash": "f6198c5693883df31acac05e79d4c20448f9b61ab08daad641bf263984a90033", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "06976a04-633c-4d35-93b0-5dacaf70fa7f": {"doc_hash": "d04413618d520e93a113a2548d4f73d829ec313483a1d94012076b5f79aa4bac", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "5d9bad1a-7570-441f-9d21-31b370dbffbd": {"doc_hash": "7cc42ba7f6d4950bc458de151418858cc1a7babea501ea0b7a0ce46925f4fac7", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "c7c38b92-2266-4456-8fe0-4bcb551c107f": {"doc_hash": "519156f15b2ca457a63456b7a44c62c081aa83efe977586f1e75372766413fce", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "1ac961fe-5511-4cbd-afa7-0329edfae3b7": {"doc_hash": "8689067dbf09ee2728b09cd2c1cec07ae543c18af379ee52106dbfe296a3a3c1", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "4155f242-875a-4f14-8f54-cedfc6f1f47b": {"doc_hash": "6a073d9f3ec5121fe0533dc690d9f88bcdd559733626b34d2ce1dfe2e1695838", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "100e0463-c2c8-426b-a695-59a86af7c4d5": {"doc_hash": "83f67bc40361db1123b64f3a61cb4ef645d33fe23d2d8ed1f29642800986cc2f", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "89aafaae-d0c1-43a5-80ee-437b4117b780": {"doc_hash": "133869b0df97decbd64737832bf6f14c541d84e823be8bfd2547aba49bc82a83", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "d039f5bd-6156-4802-9a84-c035c14ae3ed": {"doc_hash": "fd97e1d39db2072136eb103238d97715b067fef312da3f1041c90d1bf659a9a0", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "64eebb6c-8326-46d4-8cc4-679ba81495fc": {"doc_hash": "8c077bab06a37a3f21d0d49826dfff901fdbaaa6af1356e31be6f982b72142ab", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "14dd76d6-5e2d-4608-83bc-f5583d14564a": {"doc_hash": "eb104b73dbe594a0da2dbda5f7ed5f3a48e82a5f03a304d484a87cb2b7f2819d", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "66042b9d-6a12-4e96-86ce-6de33bca0e68": {"doc_hash": "fbacf92f912439d72dfb5e3f8e8423189bb2c18e683c5a61d3f7500cea330ca7", "ref_doc_id": "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d"}, "d7c36d6d-699d-46e0-af60-243a0ee5491b": {"doc_hash": "e81de4dd67eb74ce18ea861bb2f5ba20c87edb3dbca287f700798ef670ea0dba", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "17ab0b63-1f1e-4d03-9c4c-61a02ee4a570": {"doc_hash": "1539e914e6ddae914f421bff72725e66c194f9f6f8eacc6e88f1a1544a8a83b9", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "39400718-d18c-4896-8b1f-2337ab4e06aa": {"doc_hash": "6f5214d2306102eeb99cc1918da83f52037249f280edb204a96569b3726ce398", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "2eee060e-fd74-428a-ae44-77de237a4bb9": {"doc_hash": "7400a185702783e82eb00d88a51d86c85184dde75fe32fff72ca2cb882912276", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "4d40e250-a51d-4809-b4f6-4a710f5f36df": {"doc_hash": "a3fe304ceb3433cdf02622920758a1d887a1fc946bdb3173bb2e45c0f5000a75", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "d61203e5-3b90-4769-abed-3e66001e6e7d": {"doc_hash": "cde412faaa54cee937c484e9bbcb876664b6f93c05e258f8cc6a2a39f0ed8d8a", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "a12e48b4-2532-4d59-8316-c1443c4b187a": {"doc_hash": "ed292c66fae830206c4b3569884cec41b185156c370b210a16349bee7fad60b8", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "15a15b28-b917-4587-a2a6-f2be1afeed05": {"doc_hash": "d5ee3c30ca3ef11375094b76e776a924cd428e7884e07dc044a08fe8f76648a8", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "4f95b5d0-ad9f-4cb8-b802-83dfa772dcfc": {"doc_hash": "5484fc8a0b782625d44f88c8489567963a5e68390ec520f64bb2b61ded50ee52", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "8048eb50-340f-4db8-b3d5-424cb7539fe6": {"doc_hash": "addf42fa1cf23721224d4cbda44513547f24dd1ae47d13c171118bb95ebfd69b", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "cbea23fa-273a-464a-aaa8-9716b3b65eec": {"doc_hash": "277e8566444dbad99066a0ad7469e8e6755ef323c564bd3aeda8c076898033bd", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "fefe3f2d-4ce0-436f-b027-559a21934059": {"doc_hash": "8e9b52c0d4ccf338629da159d99c0ec69a0fd07c8f047245f8d7f31b40a409f2", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "94d664dd-133c-4229-a1eb-a4a268af6518": {"doc_hash": "65dae1c68f224cf394339f023445986fd059244882bbba90a9197ae88c1cd3f7", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "6e71ba35-0955-48a5-bda4-a62c4badb7a9": {"doc_hash": "553c09a11c39625fe6278a3498f4b14314db4760f635a633672b6ba0147d6866", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "b32e05a9-2f8e-4285-a5cd-df25e99983f0": {"doc_hash": "56b665a6d0645312121da45ca9695fa32762c32551732484822ce0218c452b69", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "6aedcb9c-07d8-47ed-b1b1-87c21f9effee": {"doc_hash": "30818a451649d16b888dd3c8062d6585c31dfd3ce942a3abff41811256453c78", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "29683966-0ecb-48c3-b636-056250b058dc": {"doc_hash": "0f911cbcd2ac900f7809b661f32287ab954ef6ff06da9789cdb433a66db0fa66", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "923f2ae9-b844-49a2-8915-a668219b0a80": {"doc_hash": "16cf58bcebfd8ca59ac435d6b1f84b56527473857a970f831e961629bdc75e5d", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "c07b7018-0b3b-4b1f-b56a-373886187c71": {"doc_hash": "601049c6ba873bd857347f8f20b53992939f06224a230434b8a7a1636d9d5e28", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "bfa669a6-29b9-4bba-a5f5-36572025dfc5": {"doc_hash": "54337bc8d21d30d11b667598a1be37a634d0b2c614b1b236fb022e02c2dc4297", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "762088ac-ca57-4429-900f-c4352de364dc": {"doc_hash": "76bbcf10d60a4df35bef721b3038c7f31cc3624d1c1dcd5e23a028a319d80e4b", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "b74b0705-bc89-41d8-bda7-73275c8632f7": {"doc_hash": "5750148ca47d48bce5c6c459c286e4e1f23880da4dd0c6cc46f30c13d8efda38", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "b1f5d671-653e-4238-a81c-c4640f7d0bcb": {"doc_hash": "9749356c5fcd7f4333723879670acbf64ba654c3e2c56afbeeb806acc6892b6f", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "aeda4c70-ec4e-4ad5-b5cb-d36230339de1": {"doc_hash": "a301a9c60e89fce4f75fe15bfac03f4156ebff7342125283b3e9689d0c42a3ed", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "0f8a9505-745f-4d8e-8c02-08c941c84e30": {"doc_hash": "a1735b71bf085fb1449bd4b69b7f1f232b1e0d6fc9b855a75ab8535f615c95b0", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "d8373dd6-2097-4ab5-9949-866335a5431a": {"doc_hash": "dadea45ed7d22bfccea473128d3143bf6bb2cadc14ce20e938e70d260be24a5d", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "657e2b4d-ca5d-4e21-9d3a-a3ce0a679709": {"doc_hash": "523874a89a05baabf4d4514eaa33e07a0031f483c28bccf64dd5391ec9fbf5e5", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "6bfd5a2e-a1c8-43b0-9e40-b54d6baf617a": {"doc_hash": "bfcb43ffdab836ec982af6b791195b6e375acff1404aee543790e71ced334f2e", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "b7052506-73dd-4125-9548-8d1ad9d917dd": {"doc_hash": "a4fe07fbb14de4799f9faaf94386c1f75802a0b7a2c5a8e03b825bdb5564226b", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "f8843aba-fa42-4789-87f3-fee55d4e2289": {"doc_hash": "1149b120548b3e6a152a4743e60cb6e806b9950d5165a8be815c71a087b7dfeb", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "61147e0a-a7ce-45c0-a71b-e75f00773209": {"doc_hash": "3a7b21c3a373214165d3b3ff4687285a0ab2bce69939cd345d12d143dfef9293", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "30600360-0a5c-4717-a856-87782073dde5": {"doc_hash": "35269b81fed5eea59669d1462bd9b630ae49b5418f528a3e9b1436739de77894", "ref_doc_id": "ddfd9c54-b1c4-4896-aca4-cec04abfeab6"}, "a6802474-0d9d-4c3a-a101-f3364f7cd7b3": {"doc_hash": "f105b1d43d5b79efb2bb9b77a33bb28dd266438cc16e599ef519b79bbe0594dd", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "a879c777-f7fb-4959-af1b-4972d6fc5778": {"doc_hash": "7e6af3dfa5359fa552f923be51cd7f99b43ca5fc4f232be4d28cda618db35ab4", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "28c9736b-373d-40c5-9ad2-6e47e4f57134": {"doc_hash": "3804f19281c65cbc3ef892d3c4f947a8cc5fb78728bfd4faf59f0dd4cc69c79e", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "28006901-5005-4903-840c-bb4f18b6e5fe": {"doc_hash": "7014286c8c1ce865731231b59aa7eb7422554e54bb3b78ad37b917e0e9fa1669", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "7c0a5064-6239-42b6-b0cd-f22c642038d0": {"doc_hash": "1ca41c86963d0f078afa8fad5a5638da6e34ca856671a8a9fa918574c29f2a49", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "77ac81a3-de6c-4b3b-bb4c-2003d08388f6": {"doc_hash": "55a3af231fa2beacc9d6573d917115e4ac6d6ce9a58cbb8b85472dc1b6b0da99", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "19dbb4fe-0a7c-4414-8bb0-1926a8285e44": {"doc_hash": "9a9cc24b39bf394566ece2dfbc1fa67c652f8fc8401af172bca787fb9f6dceaf", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "8ab44665-5995-4972-9439-1869897df317": {"doc_hash": "d9f1600d90783b98c698a4daa7334eae6efd2e1b8c24d4c669c05cb6bc1f2d98", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "840cec52-ceb2-476b-bc5a-2d4fc3a25675": {"doc_hash": "2a71026172129bf5bf1fd1fa64e153c057bb3b5680d33e864b3d10c767fe265c", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "1baf33de-50f2-454e-aefb-f7e9150689d9": {"doc_hash": "0e5689548d5964b584a357d48932048df61ed94afba0a75a99395038f289d98e", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "64868c4e-9cdb-4a77-921f-c2c741156ad8": {"doc_hash": "2454b6c6b675bbbe29264c71eb8791812d70dd6ffaee929679c0bb6f3e7baf1b", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "ca1a504e-1c08-496e-b3c9-5f9f33bcc6c2": {"doc_hash": "07fe4c9e21d91eec7d003ca5d1f41aedd06b36850c3d7e7dd371ae04fc368056", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "8b20bb00-4033-4669-b145-dceeae56c5cf": {"doc_hash": "1690eb2aa2ad05555e6022d3b1f61d0e4a22e616a1717cfbde694d52dcab0617", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "0714e56e-4fda-4287-8f2e-785e88ae9555": {"doc_hash": "aac695593f91cb58fe5f1406468cd7dfffc3860b05c8504565fbe90cff82c6e2", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "95d275ec-bf2e-4e55-bcc0-9115cf6c8eff": {"doc_hash": "d17a88671f430bc277d8e10de96f6bd9b031915094eb2c293d19e12b6e0eb5ff", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "1d86da0f-d520-45f4-939d-a24176ddbc9e": {"doc_hash": "df63847744dd73342c8d8bdedd18dae889df41afd28272e4961f7348179adda6", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "66531c36-360b-4440-a3eb-2b4ed7b4a2fd": {"doc_hash": "83ac9b28620ce32dfbcfde20e2350bc776940dbcf12921cd8b99f051fee8f37c", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "a6e2d79d-81ca-4db1-92f9-7251ac6dca1f": {"doc_hash": "20e615f5032e0a0025c13954af7933956b356e7020872876ccfe49a0b29edea8", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "5084f07c-a65a-4d83-a92d-4d45b7548e47": {"doc_hash": "dcd1048ce6aaf4536a2b108aa8c7bb7815e91e902b76c3ecf35405ba0f2dfb85", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "2fbc4205-307b-4a73-bd15-e03be0e9eafb": {"doc_hash": "c3e37ecf3faabda56ea6eed4dbf153584b629dc786be65584cbb9c9c3019da4d", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "98a05cd2-8be3-4d0e-866b-d99aaa0e83d5": {"doc_hash": "aae29a8614a2b83b275793e53e4e2488a9803bf0aeb1e3ac0ac41331d1c17bc5", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "4f88a1af-763c-4227-ac13-76de9e0c9a9a": {"doc_hash": "1e38ff7c82bdd672d7ee8e187f1f33d96e52d16720ea9ea419cb2ade5304dcb9", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "c5f7921f-8548-414f-8ee6-531f636eedd2": {"doc_hash": "56424c763e778648940ec6f1d4ebfc1416ebb75fccc53d172083aa9ed6221da3", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "b52b05d4-f28d-4768-83fd-9f8a1d4621e0": {"doc_hash": "dc318c5a5a1ba25141e940c7049b1dcf0b09f5180ccc5124c890f778d6d149c5", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "80155aba-3543-4412-abf4-54e91ce284cd": {"doc_hash": "d98a0789484f1f6f249e1e8aee1fc496b80018cceda32fe8dbe798560faab009", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "48f53da9-bc9b-4aae-8ccf-c7b3a5cb5cea": {"doc_hash": "ff6592c234d6221a144f6b547eeabd57fdfa407058f792c7e97ead7243a567c0", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "cdef0dca-05ba-4b80-a246-b6d0423d210c": {"doc_hash": "e2ca2a313f9a61e84978ef2e0191cbc02fdfdd4f5554ef22f89d1a2e68890ea7", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "943e96df-bb67-4d56-8fb0-5d3c991f1834": {"doc_hash": "a92af805c9925a3a8f90f006249570065085ef84fa33bf30b9a5adb76ea81aed", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "772e284a-cf40-4877-92b8-7e38dc0e6e04": {"doc_hash": "d15758630e33b5652a063409f63e2acedb2e1146fb689f986af278172db9c232", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "d0af590c-5992-4fcd-acd9-93267ef4ec8d": {"doc_hash": "bb0c45c17e3159dba8857891c9f07df4726d77bd3986f58a3d5a268eadcd2c1c", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "d5e5fe7d-a9ab-4901-85a8-2ce015295a71": {"doc_hash": "6ef21b2b30a42fb40637419242c90a9d36b1ac7c24bbf47dadc3ed870fc746a3", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "c2551b75-c7eb-4733-8487-521ac3475e15": {"doc_hash": "834593029ab0f30b1ed30fbab63126cf434c606f1594963714b79ccdcd4086de", "ref_doc_id": "b7634b22-25d5-46bf-9b98-d0ab5b13013c"}, "7321ac7b-0ba1-4727-a497-a11fb189bb72": {"doc_hash": "031acca95da200f646fb547c09ef1b2bd393170d80f158c975865d39c30c0e52", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "3c63f137-08d3-4f77-888b-35d9403c830d": {"doc_hash": "d8fe592c7880b7858120b72fc21e6dfa9d26ebd4f4e41e55fb2d001161455c35", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "e22a3cc0-0749-4537-859e-d622a273e69f": {"doc_hash": "3a14fa0c261a3acfc8c761a5c90466829d69ed3310400b1cc26c04a6c346f27b", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "cf7755b7-4064-4e7b-9291-bc26fd269000": {"doc_hash": "712a754355043be1630c5d573e104ad6b1de1ff9de884cb73a3aab438c3d7ea6", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "c352993a-4906-457f-9f67-6fc25e78c459": {"doc_hash": "6c756f8f67ea9c13ad0fd0e606dd3216d46f35d555d2cf09f93f6688c7e44a91", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "88611dc9-2a77-4850-a8b6-c15fe0f9dc85": {"doc_hash": "f2b63ce7d10b6414fa225eab41ba7b000fafb7aefabb6c70aa439255857300c4", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "041eed41-3963-4ecf-8120-f77e8e163be9": {"doc_hash": "dd04b2b9cc1a7416f5df6380c23365edade7ac1f89dd1bc6e16c8e2772b9e064", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "6c30aeba-44e8-4f34-a5ef-a82aa4adbd97": {"doc_hash": "9b813cc3234e1505b2b42ad39d0253618ca0314c36916e8bc22348ed7a9807ac", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "ca776b91-6f0b-4ad6-be7e-6a861f34a227": {"doc_hash": "a0ac420464fe5385c95bcd3e71db6708832d26ebecff20af3f892705f8d24632", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "060fec8e-4535-4e5d-967f-b1e43947b241": {"doc_hash": "417b9fefa1bb2095c41c16050dbbfafafbb71e64f1feba596ad18f046ce44ee6", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "84ef6f33-c9d0-47d0-ae79-224d9339f77d": {"doc_hash": "145c97feca6cf1136dd9c6ccbdc290ca2ac67fe597630741d69e13f7f0dca085", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "3031bd59-0ec5-4ef1-87f8-68330016e642": {"doc_hash": "7c3f24d6b89b5b9e5f8c1c5142d05a22e6c8711cab2c4dc184f678578533ebf3", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "3d683b71-93cf-431d-a4a7-735b762ad821": {"doc_hash": "b322c2f42bd597b1ea00e7880eeb607b8dfec034a1a455f5d38083cc683cd42b", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "c924104d-55ef-47c7-a25b-f655f7ff82f6": {"doc_hash": "4245c07bca8ef133eca43e53aa3adf81cbbb1bcf31be2a3a64f02bc387ee96f9", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "4f52770d-6dd6-43ab-a39f-7628638b67b3": {"doc_hash": "9b15332a7681a8944be64f99b3e9fabb3c317c780cff1702776f06be3eee7d73", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "2ef8ff38-b85f-4900-9c0d-9f4f0bb19696": {"doc_hash": "f675edfecf314931c9979bcf22f979ef72b6f85b195360a0c18517333441e8a2", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "aeeff499-e42e-4662-863e-5b822e389029": {"doc_hash": "193c740f5dc56628f407e572029f73115f244256f5991841edb06e2da8bf3dfa", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "44013258-0b42-40b1-b43b-c16cc36c71aa": {"doc_hash": "32d0bf14a4ca8f8439fc9d7f4bc32269dfcf32396e2ee9a8837f79bb37fb0be7", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "429c6ff3-6f4c-4cc7-9a0b-cc6a2bf5bb55": {"doc_hash": "ae215a2e648060de2340c54280d91a543bacc1f5cfe4029995aa2c80fc058c44", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "4f743523-2224-4b0d-aa03-1adffab55480": {"doc_hash": "104f6e765187d09c4aee3cdeec250e1737ee48d7aee92ad314945590ad6e78e6", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "dbab60af-25ec-47f3-8be2-2ab97eb6b2ff": {"doc_hash": "c2eeacca891157e78f504fdabf3996ac0f7135a4fbde90931b98a27abe4cf4f3", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "4248ce7a-c054-4549-a83d-880a1ddb0ec7": {"doc_hash": "0d41c3a41729687119ed7a6aeb0e0a45b08aeeab6ed3532447a094ccd605a5c4", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "1d0d066a-7d03-4cc5-bedb-cdd98271e426": {"doc_hash": "22a385066dbee81027e5a3b2dfac14dee0b719baf849f95a6c5441dcb8806e57", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "d0ae60f0-7ff0-4e53-8a3a-bf8471f792b6": {"doc_hash": "6ed0ecb800704e0bd17e1b8a071ab0df8463d5e5a4953de8424a4779bdc14dc6", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "c9e9621c-421e-4905-b6cf-3f5307339fba": {"doc_hash": "b9fbe69b1b5b9fe13a02dfaca7ed60386208b21dbdf5e66824f53bf570f593b5", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "0f65844a-670c-4e70-95c0-af0c398b83a2": {"doc_hash": "648479457d505bc4937a65e6e0af93a7f932418fdb8bfbba5e3d7abdec453f9b", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "f0e1c978-eb3b-4b79-8474-4ac4fff43445": {"doc_hash": "18ab6bf5aee4270df0ae842db0a2032aeefd5055e9b1e92c97f2ad7855f59831", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "d995c9b6-e4c5-442d-be02-887694d28f2b": {"doc_hash": "92e0db0340f591d5b4829c0d280cc4c551ef0e9352c741e45ef07df8f3ddcb5d", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "550410c3-3cfb-4d52-b7ba-c8ba8bd2e43f": {"doc_hash": "f6e592c3a691b387c2cf906798a42d4fb9b3039592c5806eacb9278ed472170a", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "8641e5e4-24b0-4d3f-8217-c98926e0ffa6": {"doc_hash": "e4d1990386cf40bda0288cad4dd4486274f8db491c6a3ea4754c8f4a0798a927", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "4511b8d2-f5ce-457c-8091-8ef31f786e2e": {"doc_hash": "0c34fc60eef6c5b374652129cf6503255f5c8abab974bda0969e2a30931e1855", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "36a34f9e-b916-400d-945f-4832084e43f2": {"doc_hash": "021819a3f58533f1622f68df9bbdcadda72253ef8cbc0864ac322f633f66cc2e", "ref_doc_id": "bfaa0a74-fab6-43a0-b29b-309f1d69910c"}, "bed96950-91f5-4f08-aa1b-56d61e02782a": {"doc_hash": "5571b2f62e29eb9ec9b55962fab6eacf32bfc2556c7bd29ceb2e4ec1feda8fb9", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "c2070b14-125b-4e58-b184-1e1cd015334c": {"doc_hash": "d4ab9f8af51014afae46780a0be6954198195780f6eb8799dbde94841b97d35a", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "515f07be-6892-4ffe-aff7-72db5f10be1f": {"doc_hash": "fe3f3ddcfcd9dd0a1a16dc6d52c9829fc00b6b6f24be28713cf0eb175f7e0439", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "20544eb7-d992-4557-a73d-56baacdc0a45": {"doc_hash": "e2f7f3e8fa4235ba265c8adc301bc1ecadd6792711513c40f848cb2f7bdc1804", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "5fa665b3-8706-499b-b0be-087c997ddec8": {"doc_hash": "cc172c4a75a118157e663b4719ec4e90c8eb8c76fe5033b82d49ead05303df6b", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "271904d0-4b5c-47db-8059-83c3378ac5bb": {"doc_hash": "22cbb2ec28ba7520dfba13654ffe17ea0ea968b8a4fc0c3cb0263a8da0b00023", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "51e94653-4f27-446c-a831-cad2cfee06e0": {"doc_hash": "8523baa7a21a88e396f9d84a128da825449572e2be38f94a1d3d90bdc3f51f54", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "9995193b-c6af-47e1-8f02-a3105d6b18b6": {"doc_hash": "72cca365369ef431666b467a281341c683eb6584a0229da8d45282e949955940", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "b1a53267-2f6a-43f1-acad-f17d46b94ba3": {"doc_hash": "29bbd1ae6455331943f019b30da7f8ecc43a442743eb320bb5b2ebcce9cd33ce", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "b6db3cf3-9d22-4d22-b35a-a5977c333e99": {"doc_hash": "e1c52eaa4d480f37652ce60d98cbe6448602d30501d28154985a2a88e45ac5db", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "3f9acab3-a020-4eae-82a2-d00e2c1d1d22": {"doc_hash": "6307fc1f45d4dfa8319958dd0ebfc04b3f74d5e90f66c54b09cae687341caab5", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "eb72140c-d03c-406f-a8c1-7c11f8893e18": {"doc_hash": "e329ccb0e9859dee38aba4b717dd6317f86a34155142e22c995cfa45494e6f13", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "5e45652d-5860-4fe1-a27a-264e6a0fe16c": {"doc_hash": "1029ce94f9498bf97e4c1cb73b01ab4828391aa390b33a2d22280ff3eef1c817", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "4f0bb05e-accb-459e-8871-e3124823f339": {"doc_hash": "2fb9e9f2e7fbdce0d1d0bf675c959df6f208d994b2449f6fddd60c523a6c30ea", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "a649ca3b-cce7-4c1a-8324-da8f3e1021b6": {"doc_hash": "6f22e281b4f4eeb1f7d02ecf161c98ad86eb495af1a273b7185dd75ce050f00d", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "d85e9ab4-68ec-4228-8219-1f283b933218": {"doc_hash": "c33cee6275d771315d3f3ed40ae784f7acdfeea014ec5d60dfd100cc130c0b2d", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "19354937-ab9e-44ae-81ed-18b9a2bdfdd4": {"doc_hash": "2c5f1ab6ec1b591aef1ca120feb049f2dee772f7cab29341c10ff2892d716ffd", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "d8ead45d-90ec-482e-bbcf-6919c5940a92": {"doc_hash": "e4aef134f7406161af9d154b7494046f583a7c64d2fd6b04d272d0b455a6a4ac", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "71aba4e5-1f7b-4be1-ac1e-b1fe8c3d7ba5": {"doc_hash": "26ce9d449207453506d316fd4f5daf0d5afa55ee91a103ee575bc74f9029dfe6", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "1d0a4343-6a15-4357-930a-268428c6c1c7": {"doc_hash": "c451ff7e32d256f6381d9c416b753b36886cbebbe3e0f0e032733d575cc084c1", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "5fae82da-4155-4a05-b15f-a5bc0c2dcae7": {"doc_hash": "767d5ce2175a8a939f989abfe946cb4889cd225df542230a5ad57ba2944030f6", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "af349817-c5ce-458b-bd71-ded040e24caf": {"doc_hash": "9650b09e37d1962c539331009ac2fb652475a0897599202cc055392f3ee4b155", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "e4a4794d-210b-47c8-bf78-66e49aee41b8": {"doc_hash": "97c0430897cad700c7b79664c9dce33ede62acd5b670157685f52bc6157b9872", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "cb1a9918-3bda-4a79-812d-8ec69734ea20": {"doc_hash": "e6ef63ceaf86de247ae6c725c0ed6adb38b805ed302f1fecc46ba9d615664a2a", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "847b91c3-e3df-405a-8d9c-2d64de6cc33e": {"doc_hash": "d803fd77f3d462dd7b6cd246c827b2d000083beb29e84917fe51482bed0f768b", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "9acaaedf-91d3-4fd0-8254-62231dcd9a06": {"doc_hash": "ef7424599fcbbdec4277f660958bd432315fc8c4e46d9de4851dccdaac0818be", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "7a6b5b37-b274-4496-bb75-1cdfc3184e8b": {"doc_hash": "d594f037394b89e135adfae3db63a83b4a2e747a4aa49b71aa671e3d8b1dee0e", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "861920fd-4c41-4e09-9443-9d29aee4df3f": {"doc_hash": "141c5c90925f100ddd86059f8de5d08f16db11552b783747b59ba3d312d78198", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "d3b736fa-baec-49a8-8201-c5c2ee68a43b": {"doc_hash": "f03153d0a064984c3d1fc480cabbc8ec0a21ff8e1e25043f1d1841657f0f85be", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "7ace9cb8-cf9e-462d-a180-7191f9d1187a": {"doc_hash": "daf2078fc480b5b624b84569507bb642d102f0a748c3475d57bbef737c8811a6", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "c7db2a64-44e4-453c-b597-18bd43eadcf0": {"doc_hash": "73364c2188b971ec59fb492331d55d2a7e8b26bcd1c865e0378b526e19070367", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "944b4ef9-838c-478e-b794-f24df46b39bc": {"doc_hash": "ae8e51ed53b4898066e020407dd95f938391eb6fb1d8ff8ff0800239d4337366", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "5bc2959a-84cf-488b-af2a-2a57726a644d": {"doc_hash": "fbff7874cc8bd6b56c718440cacd0d65f5177e0181746179649e6babd21c3816", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "20b62843-d733-4c42-9c69-3968ecb0d7b5": {"doc_hash": "1feb6bdeadebea47db5286e865fa78b8beedc2bbd9958b38931415451a2375a8", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "37d57c85-c95e-4777-b716-c2c8d875767d": {"doc_hash": "43ddc447fb295fcab5e27500a3d215694bf4969c4c3469dce4fc993acdeec606", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "4b9798e4-502c-48ea-9fbc-4589239522a0": {"doc_hash": "0375e4a780679540abf4ef9abb9342fbd0b06749b3de7bf767158341ad554c69", "ref_doc_id": "e90b37c4-c18d-42bd-97dc-36f7f75521b1"}, "b94e05d0-f254-4879-9178-5a1b7b06d007": {"doc_hash": "783265086dd0fa4a677bc43644f6aa1261c400d78571f2c2650c63444309e4ec", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "3b24c4f9-0c3d-420a-9064-b431d09a0c77": {"doc_hash": "ea891b6fb1a4c62e5924dea7aae4056ff71aa05f7431089ebc0c5b31285afa08", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "606bc9cb-da41-4851-b08c-bda55cab356a": {"doc_hash": "eeb5acc89d7b4263101f48e35157329f2a6f6ee060ffd7e12bed1599da541970", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "87d7c857-0349-4f36-9a49-2711de0ec4ca": {"doc_hash": "45836b91da5e4820f898daa5de321eff4d8637aaa5ea64964aa17b91358889b2", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "2d5dfefa-44f8-434e-9938-7a74d3da89c7": {"doc_hash": "1f67be5b211110a6d46548e7422f11d389750bd8d6a1fc3e2553142d6111c149", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "d2758158-decb-462b-9933-d8e1539f2cac": {"doc_hash": "c961edee7e43bb09b8177b13a68c20e774096b39f1a7b53f66b515ff43953caa", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "01979fb4-6665-48cc-bdbb-7f8a785988b8": {"doc_hash": "58b1a8829c94a5abe768f61a70ebb8a8c97687d55fd7f195cb0e9b6cde42648a", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "85777e0b-b710-418e-880b-f5c6ab99149e": {"doc_hash": "3ef38f281c8336794c20609af5a9d99dea3176962b6ca1f2fceb4bd2b06dee64", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "090d8db1-da83-4d13-b3a3-3da3b5a123bb": {"doc_hash": "86f65faeba3aa21038f20d69e8603610865e84cd640bea7e4ae57862f9d709c8", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "0ec2e95d-a399-4bce-aa1e-2dae5d9e49cb": {"doc_hash": "906b10cbe90bf63255e4a8992a9dc0925db5f43f115ac0a4d715e055886598b8", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "985a97ad-feba-4b77-aa7a-fe0fd0fc293e": {"doc_hash": "3342678fe3221e896f73af1f4d052c5c89ff8a3596bc36d431504ee8c76b11a7", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "4f64c347-9958-4172-9da4-4bb3dc10283c": {"doc_hash": "e1cabf0356337ba6caf438e0a7332d97448491312c6f5b8c3e8eef7eca99a2b1", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "f13d8cff-c3a5-4361-b7eb-6e0e9e1e40fe": {"doc_hash": "dbbe28390c22c713d456a154d63e32f06c35c67b7adc8f510928ab93b76fa373", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "ac746f40-0754-4f9d-a603-fe3fd2262d17": {"doc_hash": "5a3af0b1308a1e1c20398cd0278183345cac2d60dc9e169dfc45b9f01b3525f1", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}, "d20859a5-9180-4394-9b8c-c752ac25e678": {"doc_hash": "14db9b6cda304fd1111ffd55ed050f8cad2c6776f820280ad12e55409b16880c", "ref_doc_id": "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61"}}, "docstore/ref_doc_info": {"d9f2d747-2083-412e-b828-5d8506da8229": {"node_ids": ["1ed17d67-b105-40aa-aa9f-92f69e7243dd", "da3260e5-2e9b-4e2c-a5ff-594401cd5af5"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.   (MCK ) \nQ3 2024 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n07-Feb-2024  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "25b67b3b-1d81-42c9-ae88-2f190c4d2057": {"node_ids": ["5ea85a50-bcbd-4c82-8ae3-ba8e736e8193", "dbae45d9-e504-4467-82cb-d23db27285e7", "b74f7142-7590-42b0-991a-8d033c1dc4c4", "2bdf596e-0915-4c87-84b2-8ee16df4d174", "e4577a03-46f1-43a5-aa9e-28b480a738a1", "fb3f2d6a-5c5a-4172-8f8d-0e34d861ce06", "e888fe65-7d3f-4301-a92e-520cc8608087", "1a36f826-14c0-4607-b3da-bd4e42c94ae3", "65fa6068-4c5e-40d2-ad15-7d63fcea2345", "e28b0354-df44-429e-a582-563a61577a78", "e720f6ed-9ac9-41d5-8ddd-de5b90b0130f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nRachel Rodriguez  \nVice President of Investor Relations, McKesson Corp.  \n Brian Scott Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "22e7781e-d2b6-4041-bafb-3755ba7f3bb2": {"node_ids": ["e5d0010e-9a3c-43fe-a561-b6cd258d110d", "2c757f87-efed-4953-8fa4-224d384d9312", "95f1eb72-06f4-4dcc-b928-a9c1af0c7820", "e20da75a-bcb6-4ed4-ba44-845e57c2a67c", "470da5ce-1946-4afc-99ca-c859ef20559d", "91e8149b-7c19-43aa-80f3-28bd2601ddce", "75b3bbb6-fc6c-439d-963c-b6033cd307ab", "74b0e77f-54fa-47f1-a17c-41675b580c34", "e2c0de1b-41a5-4024-bccc-176c141ee85d", "9761ac16-9494-46f1-91b0-41ee90e0fffc", "c3cda2dd-ddb4-4180-9303-64f3fe3e7923", "cc971383-5c5b-4646-a95c-a4ab499a4737", "519a1f76-b821-4d3e-b1eb-094f57ebf349", "8d9026ec-bcc5-4ca8-b15f-bdfd618c355e", "3c096161-6d51-424b-a692-e701dfa2d8be", "063e96f4-99e5-4654-a80c-464fe9730301", "958a958d-b042-47a4-9a33-eef8dcf5b2ef", "9e8b187a-1724-4a7b-9835-b449aa2ef7a1", "1bad560c-29d8-4225-978b-22016fb3e583", "82be3953-bb6f-410d-a593-9c3ec2ce645d", "4c912436-74e2-4b4f-8fab-bde3885c4b53", "afae947c-0b23-499c-b346-6c07f0a3a5e8", "f76a5a03-9f51-4273-8719-fe840b64b2f5", "898239d1-e0b2-4242-8c6a-57170aa5f562", "4583013b-e567-4ee5-a2ad-c94c9445a9d8", "e89f2dcd-35c4-46b2-bbb2-1e423f793d01", "01be4f8c-2743-4a82-8579-15b18c4c4e39", "a23c9a20-aea0-4f90-b393-b3a9670685bd", "068180f1-295f-4acb-a521-2dadae3705d3", "4db31ef3-56d2-414c-9471-ec0981095eba", "dcca84c6-b093-4ad6-ae00-1babff4c8db8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Welcome to McKesson's Third Quarter Fiscal 2024 Earnings Conference Call.  Please be advised that \ntoday's conference is being recorded.  \n \n At this time, I would like to turn the conference over to Rachel Rodriguez, VP of Investor Relations. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "da4365cb-41d8-4878-b4ba-61000b85cdc4": {"node_ids": ["4db949f0-840f-4966-beee-7c6febe725ef", "5ad3adfe-9cf0-4899-8a69-b3ad13a01a94", "35e0c4e3-de74-4591-b3ee-e5d249885214", "8583c636-c44e-4f87-ac63-d35a81449456", "712d9ff8-61a9-4909-989d-4433e012db40", "037a6082-9518-49ce-924b-2e34b3ef60c5", "c7ad2ed6-42e1-4f90-a874-114cae606854", "ad397227-1d53-477a-a010-a50db9c77871", "f6ce17d9-5e19-434c-bbf7-1b3aba146892", "c6689efc-be1d-4cd0-b2be-d262b3599f6e", "a5798f00-c3d0-465e-8fde-3f67c3f35802", "47a5dba3-7e33-40af-9803-28d8a7d6d91d", "04993d82-38a1-4914-a424-13b0e47fd946", "d564e149-fd5d-46d4-9025-2c6b6a31bdf9", "5a541701-3166-4789-9242-d89259953431", "320e8bd5-163d-4e4a-97f6-6d674025f9d7", "f8652407-689e-46d3-8749-8c926f811986", "71517e23-39d6-48ed-9c8d-95f8f216a5a1", "79d667f6-b30a-465a-bdf1-eed6dfbed2c0", "7bb74e92-c57a-4669-8b83-c2811bcfa0e3", "035982fd-75f2-4773-9c5b-0b3df67e580b", "1a380c3b-2f8b-431c-ab21-81e73c03c35f", "34b75e51-506b-4bfa-a477-e602afdeb684", "e86f015f-7ca3-4947-ba23-f4bc9b913aa7", "0f628593-991d-4694-837e-7906cb5ed7d4"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \ndecades of experience in both strategy and finance and will contribute a valuable perspective to our boardroom. \n We look forward to his leadership as we work together to  deliver on our growth initiatives.  \n \n Driving the growth of our company requires a talented and diverse leadership team and equally important, a \ndiverse workforce where each individual is empowered to bring their own opinion, their own ideas and \nperspective s. Our commitment to best talent and inclusion is reflected in every aspect of our operations. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "5e649478-3ea1-4c36-8443-a80019444b0a": {"node_ids": ["ffae2788-5f15-4c1c-9393-79530a5fe133", "99436a68-631e-4a04-95aa-9fbe5f9a973d", "e554f7c3-6e17-4ea5-9700-278a65600992", "2a197862-7b05-4924-9a6f-a354414e33ee", "3167d7df-c3d8-471a-8e38-e1ec89444ea9", "222cd9bb-5c56-41e8-b057-2f30e442aa9f", "34e3a96c-d0c3-4e8a-8930-470dc5744e75", "d11503ea-f48d-4a2d-8bee-22f85680f970", "de0c0902-e9ee-46cb-82aa-71b79cef44a2", "75600b61-72cc-4079-89bf-2497daac509a", "6dadac7c-e0ed-46aa-b65c-a90064e885a2", "c8fe9881-545d-4160-a14d-542be1f18abf", "d29241ac-6b04-40cb-b0a5-38ff62295847", "17d1e7af-1823-490c-bbd4-88cb0d76b2dd", "dfc2d861-c65c-4d38-afb1-4fb81553a9fd", "55475d1d-3be2-483f-bb51-8d9959e6f79f", "b6f8960c-913d-4480-9abb-b237738e4a82", "a241c94f-c686-409f-8c52-22a361eeb50b", "0f49bd3c-0eae-4c88-ab0e-80f98bdc7308", "6842de3b-de2a-478e-81d3-1d0c6f0bd5a8", "2427022c-7c88-45d9-adc0-6aa2b66b7e3f", "35f67f53-581c-4b92-bf5f-044f98408cf5", "9b1723d4-d76e-4811-b8d5-393f439a02ef", "204be92c-2131-490b-befe-383d4fda4b4f", "30ba71fb-2fad-42ca-a503-a4ab95311b54"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nLet me now continue on to talk about our Oncology and Biopharma platforms.  We continue to build on the \nfoundation of our distribution capabilities, but we have strategically assembled a differentiated set of assets in \noncology and biopharma services.  \n \n Within the Oncology business, The US Oncology Network expanded its footprint by entering the state of \nTennessee. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "62a467e4-cbce-4f17-aeb1-4b9756a2b0b6": {"node_ids": ["3173be91-082f-4587-bb2f-4b77bd9dbfc2", "b13ca194-4fb8-4105-a3bc-544e7056904f", "491b8f6f-2aec-43bd-99fe-6fda1c632595", "06c05d55-8657-4a3b-b2a0-486ae50bfe35", "23705095-5507-4f1a-8ef0-f9d552f59e63", "da0ff8f5-5b5a-4d0d-921c-901f50cd98c4", "0b64e846-1dba-41b3-84c6-9a9863e08a31", "fc173576-f139-4566-b7dc-eba168a55a0f", "c67c9e3a-5521-4aa7-b4e9-c9039463bc87", "1792d35b-94ea-4daf-aedd-ef201cf97cae", "a5b58d9f-ece3-4bb6-9694-19945f4ade5c", "9a5a28d9-cbdb-4977-aaef-9c709e892c42", "70b43e66-4fcf-4d63-8ca6-91b9bdc7fa16", "f2f7f456-25b6-4572-8c37-e50b7ea8906d", "cf393b88-dee1-447b-8dbf-cfa053d97aa5", "fcf35293-3157-429b-9751-1143b6c0fd73", "665cf7e8-89fb-4868-b9be-7d0c2cf9301f", "eac99e62-aec4-42e7-8c57-bc5d35f8b0e7", "1120bd9d-15b0-403a-bd27-e8c7b04cac0e", "d0de351d-2951-4591-b91d-c98034620de2", "74a1bf7e-b0e8-49f5-b8a1-cb1d4b68f263", "4b502dc2-3c60-47eb-97e7-e640e95b2d64", "d6430768-3ed5-465d-847a-e7dead00e6d8", "e3effdc9-1dfc-4d98-8c7f-8c8309bf1a74", "7689e6a0-8112-4703-9a2e-575ffef46302", "513653a4-ea15-4399-94b3-af80946b37c9", "c4429f84-8804-4148-81e7-4359c918f24d", "62271bad-f2c2-417d-b0b7-05414d3da30e", "19a94e8a-ef3e-45fc-8d6e-96c3a86311a2"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nI'm pleased to report that we're  on track to deliver another successful blizzard season that is in line with our \nexpectations.  Our products and solutions in both oncology and biopharma services provide significant value to our \ncustomers, as reflected in the continued growth of these busi nesses.  We're excited about the market \nopportunities in both areas, and we're confident in the scale and depth of our assets and expertise. ", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "0b5b5c36-ae23-443b-bf1e-021cd9b6b506": {"node_ids": ["20a396ed-3bf7-44f7-98ed-694dbef7d5a9", "b983867c-e5ba-4bc0-9278-9110bce50b91", "3e42c2a6-3701-49a8-b5ab-d05ceba2a3fb", "71ccbcc8-bf4e-42a5-84e1-bee34cf7c969", "cbf75c40-582c-4ba2-941a-a89504968425", "899baf8b-fd8c-4e87-a7d7-d557e0eaa216", "2c6a0561-88a1-4cfc-b4ad-2e9eba58672b", "751e737b-725b-4bbe-9a2f-16383b276d67", "491d8362-a3d9-4c13-9b06-df38b594fd11", "da0c3082-2360-4434-aa58-5217bb6ccff8", "b2b8930a-0ef4-4245-bb55-8892496c03ff", "d840a1eb-dde2-44ec-bd0e-bbb65b114dfc", "b92a787c-8ed7-4df3-b1ab-d11caec0f402", "843966ca-8c19-4692-94c8-40a7eed7fd2b", "a4293517-36f2-4a55-b237-54c1b02f0644", "5dacf767-f9d5-4623-b104-7f1525f50024", "062fbe2d-a744-46fc-b1dd-f09347836106", "52fa35e9-20e7-4103-9da2-82a9cbb8ce0f", "242fa5c8-78e9-4606-80d8-2a75712314d7", "f9628cfe-7fda-4b53-abf9-9b9cc8f8c5c1", "a446bab5-b994-4395-a6a0-eb31d679c11a", "d852d842-69f7-45d1-b22c-289ce7de4053"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nExcluding the impact of our European business operations, including completed divestitures, revenues increased \n16%.  Gross profit was $3.1 billion for the quarter, an increase of 3%.  When excluding the impact of our European \nbusiness operations, including c ompleted divestitures and the impact from the US government COVID -19 \nprograms in fiscal 2023, gross profit increased 10%.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "3ddd6190-5ba6-4b66-8202-b675eff1c23a": {"node_ids": ["a52f991c-01b2-4948-8b45-a0d302cd090f", "a789fbbc-2669-46ca-b260-dc14fe93d201", "30cfd861-e470-4efe-9e42-421f197dd48a", "71230ef2-6263-4b8a-9e65-7370e154d3f2", "fa92cede-2a2f-4a36-91da-8733190de3f4", "ecf45a40-31cd-4d81-9215-0fbdcd56e572", "1cbc38d9-a9e8-4094-ad35-2d39ff81f323", "4b2b4d0d-cb8f-49a6-b5a8-c40fe5572343", "6f08013b-e61d-4c5f-bd6e-fa502a9f033d", "2c767b56-7b62-42d9-b1e9-7ffc281264c1", "efc30014-e630-4ff2-875f-8948ccc89a4b", "bfa9ce56-6cc0-4844-8669-c17fc7079d42", "c2f8c334-1a77-4776-bb48-7793f9a27b75", "46b62b18-5282-4f87-bd78-77eed74198bc", "8b1ed457-e2bf-4c9d-b0ce-d7482faa50ef", "caf50c72-24dd-4370-ac48-63006587bb6a", "7840c024-0340-4942-8c5f-24be3b80d2c8", "2c398b3f-7f8e-4e76-8cab-6ce339377e97", "37cdb352-03dd-4bb9-8a7b-94a3026a0f41", "c93a39f9-ac52-48fd-870a-d95afdba63b3", "f6783836-80c9-4a36-ba1a-3aab6fa3cd21", "159c8651-4363-4aa6-a544-2f805126ef57", "c1c1ae9f-9efc-4f43-8d59-c472ccfbaf62"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nIn our fiscal third quarter, commercial COVID -19 vaccine distribution peaked in October then declined significantly \nin November and December.  We do not anticipate material contributions from commercial COVID -19 vaccine \ndistribution in our fiscal fourth quarter.  \n \n For the third  quarter, operating profit increased 6% to $828 million, driven by growth in the distribution of specialty \nproducts to providers and health systems. ", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "45ab0081-c570-402d-a250-5c0e531645b1": {"node_ids": ["883cae08-68c1-4732-ae80-597921526fa2", "44a12b6f-f703-4b7f-b1d6-f4862864be5c", "f087ab77-358d-4910-91f7-8b8e87a9c90e", "91c76271-702d-4985-a8cf-e718aa75f9b7", "fa76678e-9ddd-4d8f-9275-c8bb1a308d61", "87621a06-e365-4a0a-a039-3fe5fa5c5cba", "902055b9-356f-4c75-b761-f6861557801b", "f054395b-caef-44a7-a4b5-44db910d6975", "8856f700-e7b2-475d-8925-f140aabc79bd", "21a3e320-87f0-44e5-8819-05c675908266", "559fbe56-ff77-49a9-a436-70700a6195ca", "7c415bbd-aacc-4fc8-b469-177f59ebff25", "b6acf1b2-b3de-4ec8-b9e8-5e9bd51f18aa", "89889bfe-39da-49c0-845f-c0192d44a1ca", "e180b470-04c1-45ef-9ade-4b761f198a0b", "151f8fe2-bc20-4ccd-9e06-59cc73b12bc3", "80e26d6b-25bd-433a-bb45-1bf0c642da72", "f8ac13c4-7809-44e4-b07a-4434d45fc8d0", "4024b3e0-8117-4081-9dac-e8f69dbac026", "bc51e0eb-d5d0-406c-b1ce-26ec2403f5a5", "9faf157b-3eb2-4271-bfd0-2ef1755bdd7b", "6b961700-7e0f-494a-8885-ddeb62a37605", "6dce7fe1-8901-4f16-826f-b8c71db309c6", "affea702-68ea-490d-975c-51735142810d", "f85fb169-1859-4b6d-a78b-6eb99d2c429b", "30f3bdee-a598-4146-923d-1c2939c1d8ad", "035ed148-4649-4545-902a-0200e7cf322d", "97e07316-73d0-49d8-9ba8-e5543cac8f4a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nwhich can vary for each investment.  We remain pleased with the insights and the results that we're obtaining \nthrough this portfolio.  \n \n Excluding the benefit from the early termina tion of the tax receivable agreement in fiscal 2023 and gains and \nlosses within our McKesson Ventures portfolio in fiscal 2023 and 2024, corporate expenses in the third quarter \ndecreased 5% year -over-year.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "a4a936ec-9813-42cf-9784-48ca5fc9fb38": {"node_ids": ["ce7aad31-f418-4ef5-a685-c83db287d598", "4de169e3-40fd-4668-b466-a926e4635f11", "ad81d690-e61b-4db8-b9bf-962fc5755982", "eb9511ed-da59-42bc-ae1b-98952d5984f6", "f9801e93-7247-426d-a8a1-885d0ab2adce", "3a928b9c-fb0e-4803-a349-cb3a904a10aa", "22882f66-3068-494b-ad2b-95276d733ffc", "b1429b3f-4a23-4392-8b6f-03c60ef4f2f5", "f13dc18e-7dcb-47a8-81de-e29ffe57a362", "f0fb3356-b5f9-4196-971c-2f733b9139f6", "ed4b4a7b-5dfb-4666-92af-a932c0b4dd2e", "ad668f9e-ef13-49d0-8af4-f96ee2599d82", "3373bff8-3bf0-4276-aa8c-965eb9d53f76", "4b0d473c-d0cf-490f-9978-4037cbb53a7a", "f1fb6397-75be-4bd3-ad46-6dbd42f657a7", "9596ea0c-c036-4da6-805a-9c8c8cabb482", "eda07e90-b480-44ca-b0c3-a112cbd02056", "37a1fe54-8b47-407d-9d6f-396aa3d75f65", "621a75f7-86dd-4ccd-a9a0-8cbd60fe7dcd", "f27fe77d-1c8b-443b-9cee-f90088dfdf46", "31e0f06a-9722-4862-bc8b-ab20212c223e", "ab091e24-c383-4c5b-ae56-01749f37546a", "1bb7d1cc-ad05-4d93-b1dc-d29fdb048e53", "aa9d0e97-8232-4ce9-bc64-8846b3af7499", "227c624f-c3f4-419d-a87f-ed1dc5969c6e", "fe25319d-fa0d-4d28-9647-43632a39e877"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOur Medical Surgical Solutions segment continues to be a leader across all the alternate sites of care.  We \nanticipate revenues to be approximately flat to 4% growth and operating profit to decrea se 11% to 15%.  \n \n When excluding the impact of COVID -19-related items from fiscal 2023 results, we anticipate operating profit to \nincrease 6% to 8% year -over-year. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f9449a7c-e83b-44bb-b578-5cce641bb7e9": {"node_ids": ["ccd70c8b-793d-4b03-a76f-109337ae751f", "7c845133-550c-46be-923c-fa953e1892b1", "b83e1263-40b9-4ba4-bb28-67f2cb2f2d0a", "fa656960-4093-441a-8c79-2f8fa7c173fa", "d25592e0-d38f-48cb-bf0b-1c2c023db042", "5e181255-88a3-47ef-a7ea-d292d8fb40ba", "f2dccc5f-f2c4-4387-9dd6-c5c24217136b", "cdb83e0c-8694-440f-bff6-e882ea39ed24", "c029b9da-ea56-4945-a6bf-59a8a8ba1e73", "d5ad4acf-0bf5-4bb8-b357-af0102c2961c", "ddaf6b65-1b9f-41a0-bfd8-b1664115d9ef", "67c23161-ed9d-454f-b039-dc55772b546b", "996991c6-87f3-4ba5-aff5-60da497e0e65", "26e08cb8-8916-4af0-a4cd-2c12594b3f88", "499e7553-45af-4020-8203-06251699cff3", "5c85f88a-87c9-4aa6-81c0-3e49abf7997d", "e9d4e460-02c0-456e-8b86-de90ced3d0ee", "4cdfb22f-93d2-4aca-9ba9-915771121140", "49d5c784-db2c-4f95-abcb-5a407c1a1c3e", "a70dc208-477a-41f6-a2fa-9ac2ad0cc559", "abba9a6f-073b-41e6-b9d1-a20290507da1", "ece9950d-f9ce-41d4-af4a-020007fa0402", "9af466ba-9b2c-4c0d-8426-09009585e65f", "1068a5e6-977a-4f83-9ca2-7d4f4a603ae4"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \npreviously provided for the se segments, demonstrating our leading market positions and stable financial \nperformance.  \n \n We anticipate that the strength we're seeing across our solution set and Prescription Technology Solutions, will \nlead to growth at the top end or slightly above the long-term target.  \n \n In US Pharmaceutical, we remain confident in our long -term target of 5% to 7% growth, supported by sustainable \nmomentum in the core distribution business and across our oncology platform, The US Oncology Network, \nOntada and the joint ven ture with Sarah Cannon Research Institute.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "4a0301e8-5a5b-4801-ad2e-08b482cb4c6c": {"node_ids": ["4a9042cd-f73f-4124-9546-e7cf90364883", "7ce3b2b9-35d3-4f86-b3ad-0227fba243a8", "ebdc0639-70a4-47c5-bb06-2e364454de74", "c5c6c919-0fd1-4d34-8347-a751c0c628a9", "485e67c5-b6ca-4f00-b282-ac3e2c6ec515", "02200d30-20c1-4f1e-8534-d7f10df6afe5", "4a68cbb3-3e91-4600-b70f-3598344f9938", "37bede98-5749-478f-9332-5115cda2eeae", "ab47f78a-58f9-483f-a943-43dd3380158e", "1ea75706-fd85-4516-a6b0-53e371627819", "4fd05cd7-2336-465c-aad1-97955cfba4e1", "586549e8-ff46-47cb-8c87-3cf2dbb51506", "877ef944-becc-477d-8ce9-401f844a0a36", "b30a1e8f-7f70-4c44-b25b-dccb908ab33e", "4f9cf1e1-6852-4164-9dd9-210b0cfa2e42", "99c516bf-6494-4353-a6fa-4c412d415014", "2ea82c4b-958a-4ddd-8941-681a5e4b158a", "bae626ff-b13d-4d64-9808-c4bd9146d008", "f0ff796f-1e15-47fd-ab3b-2487a2ad0c23", "b575f828-5395-4d6d-8650-4dff320822cd", "8ec0b957-575e-4964-a929-f273a0733868", "cc2f6a6c-9dbb-4ca4-816a-7b5670db0fd6", "062011cf-a6cf-432a-8c96-b1284fddbbf6", "1630b878-5ef6-4df3-bae9-000ad74b14da", "8b5e665f-e391-4c56-b861-71fa0acf63db", "f236f191-e810-4a83-941c-711143ef8219", "3615b977-0fea-42eb-8809-02ea24aba08f", "a5408f33-ecf0-4eb9-8c48-1f2ba0db97be", "7ac6805d-7b66-4a95-99ef-5e22878970f6", "bc2123af-2550-40b1-a499-61afc35984f0", "b790c4f7-b807-4a74-a825-84742e25d789", "fa020700-75cf-4093-8599-9d2adcd23417", "a7f81ed3-1024-4f35-84a5-03ca20328168", "7a3fa3f4-1c9d-44d9-984c-689253acbe07", "384b9944-febf-4c10-9ae6-95db51117e04", "1a6d00be-7887-4b8c-8cbb-d360b5668105", "83d06875-b556-42b6-ba2f-07a083cc2554", "0746af92-3685-4f8b-a8c0-b17538525f62", "45a0c71e-efe6-478a-97d4-93b6ac36eb86"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructi ons] And our first question will come from Charles Rhyee with TD \nCowen.  Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d11dc646-7603-4427-901a-12238153d34f": {"node_ids": ["f8fe945d-d14a-4c55-bb23-aa9d79d205f8", "72848a64-73d5-4cd1-96d6-6143828378d1", "686b4d3d-8845-466e-aae0-6a114365305b", "97374d8b-bcd0-4dc8-aaa8-01a164f4a184", "522b9300-5d5f-44fd-95ce-eeaa1401b0c7", "69712870-cb52-4772-b146-1a5b8379cdd4", "c730e6f6-b620-46b0-a264-9260bd1cdd03", "6463a506-1846-4265-8955-367e2f23ddfa", "08ea544f-71f6-4fa9-ae9e-8da4e524c8d0", "e1b48df6-2eac-4f46-a0be-0a6c6dfef4dc", "6b973d9b-9c36-4658-b67d-8c911a391d3a", "33738b0e-56a3-4db5-99e8-87c87c813f61", "5d834054-eb51-4c51-afae-ec923ce2f9d1", "caa529e5-0f2b-4cd7-85c0-06c108e659d1", "aa9ca713-b549-42c7-873d-c525fceda67d", "dad46a9f-329f-4a97-84e3-92a01ea78c2d", "bbdbdf78-f0bc-4b1a-a962-169d8fb83f9a", "54869ba2-2042-4284-a332-077be571a6c6", "0989a747-b1a3-4d99-8945-0130dea84e27", "a99188c1-a845-4d1f-982c-ebf516591e1c", "a3eadd9e-5633-4efb-badc-478e1a8f8c46", "781ed85b-d11e-4230-bef8-65e8a68f95b5", "4e570362-54b1-4ef2-8b83-2c40bff2a94b", "af673cb7-8d91-4321-b6bb-98c9dc9ca6c7", "c7e5e841-9ee5-4da2-8271-0105321ecabf", "3b73661e-01b5-4bc4-99df-eb6d7dd3cbe3", "3e290d57-eecd-471b-b8c3-916fca8e95e0", "283c9132-e416-40f8-805a-f29f17478163", "8d40bbd1-50a2-4ee6-bb80-16cbf4740d19", "27b8fb36-bde5-4864-812a-e1778230f32b", "bedd14e2-c917-4cfe-8371-588f41aa9713", "97a212c0-4946-45f3-bb11-1d747c6085a0", "a5633219-f734-4f06-adcb-aff02de0aa80", "fdec7572-094a-415e-bdf4-975299580e81", "f583bc9b-f771-4bf0-bb73-5ce69576ab7b", "8897a0bf-bc6a-4fe7-a490-d3c7f8c04e4d", "0aad1fea-7504-4da9-b590-0a4be0b0045f", "98004126-7970-4e00-b09f-c6500bd40c39", "362671c4-ce73-4137-a97e-05a88828c1f7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Scott Tyler  \nChief Executive  Officer & Director, McKesson Corp.   A \nLet me start.  I guess I'll start where you ended with the practices. ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "21b2b899-7ba6-4111-9656-0d52d07bc03a": {"node_ids": ["5c47e179-368c-4f03-b4ad-f51f4840b60f", "72403bf4-2f52-4b68-8b60-cb0591f05d2a", "61661cc0-44cb-45e3-9a60-43f6b367f69a", "23fb7e9d-89a0-47d1-a170-1304ebec53c0", "01799d7c-2e60-4e0f-af4f-dd1e1a6cc5f7", "8b6f6e93-8d15-46b0-93f0-60997ad34357", "11677b7e-10ac-4b9b-b85f-5e5b63a32841", "46014dcd-39a2-417f-b881-36a1d1afc5a1", "8522a4d3-15b7-44fc-beb2-11feae32c01a", "dfd97ad7-8ec9-4acd-be2b-7d2eaa6978f1", "ea576c0f-bb04-4f62-af37-e682f4f220f4", "5d4ca333-badd-40ed-b273-c58429f30a20", "2317e537-30cc-40e9-a16e-8854fcb95565", "58d0f5de-f345-4cdf-85f1-99c67e6cd68c", "ba2744fa-c130-4589-a332-467a3df8cf30", "ed98c0ff-4c36-45c6-973b-72963b0adefc", "19d94678-b7ae-444b-8e5f-7afdf1f2a295", "1a00b9e8-a625-49a1-bb1d-feab29f47269", "27fc6ce0-4344-43ff-9a7d-ca476e9bbec4", "915be9cd-dfb6-4516-8d17-37b4ab268819", "5a8e7c6a-428c-42b7-85d2-f079fe64c881", "cf4c9882-2c58-4bf3-bb3a-2f71b9d15bc3", "5dc7d4e8-23a8-4fd7-a924-6d40039f1d70", "84253701-3332-40cd-a241-5f0738ae4efb", "4fc568ac-6092-485f-8b99-27b69b3c4fbc", "d764a1a0-6f8d-4701-a8c7-3fdb686c46d9", "b9e85856-3499-44f2-b0bf-1ebac908c0ed", "4c90186b-3801-4a6e-b8cb-d4c7639dd822", "fb187781-252b-4aa9-b67a-141f0f96be14", "ff64538e-d8f3-415d-897a-f2e8ef6d4de9", "7e155c06-d60e-4f85-80b7-217f88637133", "9bc4a21a-4a14-4d67-accc-514ba13bd665", "d4fbc6cf-8f30-44b8-9b28-2d64e9f66fe4", "94bce131-e003-4150-8e13-3fb10876599d", "cad26a4d-9a6e-4211-a7bf-7db4da31d213", "4ecc9347-a8bf-40a8-b623-4dc1dd73fbf0", "fcf486cc-f360-431d-a408-bacc5c1887c6", "b1953738-709b-4686-a6e2-39823c62894d"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nWell, I won't comment, obviously, on rumors.  Let me say this a bout Canada.  We have a very scaled, broad and \nimpactful healthcare services business there. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "8a2db112-4ca4-486e-a724-ba2acd1ff4ef": {"node_ids": ["77c4fd4b-1c66-489e-afcf-ace7571a503f", "65239a86-1c5f-49bd-986f-4e7cd4bfec05", "6ba6322c-a72e-46a9-80bd-2448de523907", "37d01b00-c7b9-41a9-9a08-06301c6bbcb1", "2d19b3dc-fc9c-492f-a5b2-7e1b815daf98", "6e59eb3b-2de0-4b0e-a1b6-f3fac0a0236c", "6ce3ceb8-3b9c-4b1b-9dcb-2de927d9f061", "77b8b06a-6575-4058-b578-661e76b490c0", "a927da81-849f-4158-b599-a373e492d179", "015a2e4a-955b-4eab-8498-a2d1698c650a", "11c5f84e-c869-4779-9497-84afacb015cb", "0f0f683c-43b9-4688-a97d-41f323f7edfe", "002da6de-5467-4556-a3ec-ed7fe83e2369", "d3096dfd-c280-446e-a05f-c0f0785c6f4e", "40c65c05-88ad-47c4-9051-cdcb75e99529", "f8347c81-a453-49a7-9462-693e9a89efea", "420c75e0-7e5a-423d-b803-8bd024909bed", "b5a81f01-79de-47ab-afef-7a3a4a2404b0", "fbe90bc3-5131-4eb4-a8d0-9ea2e6448f74", "9005e904-c3c2-40e4-bbce-6c20842c9354", "a7d5b4b9-9869-4431-ae66-b593604f1e88", "72b405d0-0d3c-4b02-924f-69c609f1e4b2", "4c070621-89b2-4911-a3ec-c8d9bf440688", "024f5141-db0b-455b-9ca2-1f54ae63b85b", "ab26f6d4-2297-4ead-86aa-8651d875bf64", "138ceca5-2ff8-4746-9ca5-41c5e831ba6d", "e027ad18-6def-47b9-b2b1-044e7bddcdef", "9ce3bd24-a664-4157-961a-c0c2ac6caeba", "98e1ef3c-8940-42cb-a06d-749c7efe68ca", "b42c6c7a-a7b3-4398-9e5e-4ed10c44b5d8", "e388a5e6-980d-4539-8cf5-57142a953437", "ab6cbccd-d312-4811-b769-3d4a0684edd8", "aa84a815-50b7-4fc8-a006-1484166eba52", "16d4b767-b9c9-471e-8808-4972cf43a8ea", "52d0be2b-5828-4d19-95a4-55970cc58fd0", "8a9873f8-0a7f-4430-b704-db97a19a8bde", "e1172e5a-abc9-463e-9e8f-dae34f2fe017", "7e41a6e1-fa3a-4585-ab5f-8ddd80e3572f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBrian Tanquilut  \nAnalyst, Jefferies LLC  Q \nHey.  Good afternoon, guys.  Maybe, Britt, just curious what you're seeing on the generic pricing front? ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f52bd9b3-abd1-4134-94d8-aeb5e3d6fd9d": {"node_ids": ["ed11d05d-6e96-4908-84ef-ee7131e318be", "98a27a5d-70ea-459c-a76f-c5b0dda93fde", "b36545ab-e208-43bf-83ed-824c9a1a69c3", "c3220052-24a2-4ca0-8d2c-0455ea769c0e", "0b8fcea1-2114-47c8-bb54-033b4d0ef87a", "5b2e4087-281d-4d38-aaf3-90c92e13e5a3", "8a3b1ec4-0df0-4491-a456-61129bbbf9cd", "6db7766d-49e6-4117-8a03-3cc2d95081bc", "ac922c23-7e0c-45f3-991f-2b60bd136a7a", "c5c4ff7e-7325-459a-b9fc-5d4a6b5d3784", "6f597381-71ea-4374-96dc-f9b3177c9afd", "fa94e81a-9e61-4809-8917-44678930c507", "032c2696-74b9-4c7b-99e4-a38265e5f349", "3989eac8-ea2d-451f-9109-afe340df7d6e", "031a4fcb-ae94-4637-95f8-0230d6da4921", "5fbd1228-b8a3-4c5c-b1d6-3451cd6f19e2", "c6382bd9-385f-4e8d-b837-65d14d717550", "afc7339f-e7e8-4803-bab2-f5631c8e8843", "f64404fb-007e-420d-9beb-fef94b63d1fe", "f65034ad-b1a7-406e-93b7-0914f880dd8f", "ad0d0614-d184-4e55-a467-e9952e98a15b", "1d09eea6-9749-4fa9-a010-57a20de7e9b6", "b4d1bcdf-8ded-4c2d-a28c-417c586c8bdf", "153214a0-b38e-478e-95b3-495089b4ba76", "efbd0f9e-76ad-4418-9432-779929b7f4e0", "3b5f948b-5a87-494b-91a6-561cf055bb5c", "06976a04-633c-4d35-93b0-5dacaf70fa7f", "5d9bad1a-7570-441f-9d21-31b370dbffbd", "c7c38b92-2266-4456-8fe0-4bcb551c107f", "1ac961fe-5511-4cbd-afa7-0329edfae3b7", "4155f242-875a-4f14-8f54-cedfc6f1f47b", "100e0463-c2c8-426b-a695-59a86af7c4d5", "89aafaae-d0c1-43a5-80ee-437b4117b780", "d039f5bd-6156-4802-9a84-c035c14ae3ed", "64eebb6c-8326-46d4-8cc4-679ba81495fc", "14dd76d6-5e2d-4608-83bc-f5583d14564a", "66042b9d-6a12-4e96-86ce-6de33bca0e68"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nNext question, please?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  Please go ahead.  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ddfd9c54-b1c4-4896-aca4-cec04abfeab6": {"node_ids": ["d7c36d6d-699d-46e0-af60-243a0ee5491b", "17ab0b63-1f1e-4d03-9c4c-61a02ee4a570", "39400718-d18c-4896-8b1f-2337ab4e06aa", "2eee060e-fd74-428a-ae44-77de237a4bb9", "4d40e250-a51d-4809-b4f6-4a710f5f36df", "d61203e5-3b90-4769-abed-3e66001e6e7d", "a12e48b4-2532-4d59-8316-c1443c4b187a", "15a15b28-b917-4587-a2a6-f2be1afeed05", "4f95b5d0-ad9f-4cb8-b802-83dfa772dcfc", "8048eb50-340f-4db8-b3d5-424cb7539fe6", "cbea23fa-273a-464a-aaa8-9716b3b65eec", "fefe3f2d-4ce0-436f-b027-559a21934059", "94d664dd-133c-4229-a1eb-a4a268af6518", "6e71ba35-0955-48a5-bda4-a62c4badb7a9", "b32e05a9-2f8e-4285-a5cd-df25e99983f0", "6aedcb9c-07d8-47ed-b1b1-87c21f9effee", "29683966-0ecb-48c3-b636-056250b058dc", "923f2ae9-b844-49a2-8915-a668219b0a80", "c07b7018-0b3b-4b1f-b56a-373886187c71", "bfa669a6-29b9-4bba-a5f5-36572025dfc5", "762088ac-ca57-4429-900f-c4352de364dc", "b74b0705-bc89-41d8-bda7-73275c8632f7", "b1f5d671-653e-4238-a81c-c4640f7d0bcb", "aeda4c70-ec4e-4ad5-b5cb-d36230339de1", "0f8a9505-745f-4d8e-8c02-08c941c84e30", "d8373dd6-2097-4ab5-9949-866335a5431a", "657e2b4d-ca5d-4e21-9d3a-a3ce0a679709", "6bfd5a2e-a1c8-43b0-9e40-b54d6baf617a", "b7052506-73dd-4125-9548-8d1ad9d917dd", "f8843aba-fa42-4789-87f3-fee55d4e2289", "61147e0a-a7ce-45c0-a71b-e75f00773209", "30600360-0a5c-4717-a856-87782073dde5"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nBritt J. Vitalone  \nChief Financial Officer & Executive Vice President, McKesson Corp.   A \nYes.  So let me comment on a couple of things. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "b7634b22-25d5-46bf-9b98-d0ab5b13013c": {"node_ids": ["a6802474-0d9d-4c3a-a101-f3364f7cd7b3", "a879c777-f7fb-4959-af1b-4972d6fc5778", "28c9736b-373d-40c5-9ad2-6e47e4f57134", "28006901-5005-4903-840c-bb4f18b6e5fe", "7c0a5064-6239-42b6-b0cd-f22c642038d0", "77ac81a3-de6c-4b3b-bb4c-2003d08388f6", "19dbb4fe-0a7c-4414-8bb0-1926a8285e44", "8ab44665-5995-4972-9439-1869897df317", "840cec52-ceb2-476b-bc5a-2d4fc3a25675", "1baf33de-50f2-454e-aefb-f7e9150689d9", "64868c4e-9cdb-4a77-921f-c2c741156ad8", "ca1a504e-1c08-496e-b3c9-5f9f33bcc6c2", "8b20bb00-4033-4669-b145-dceeae56c5cf", "0714e56e-4fda-4287-8f2e-785e88ae9555", "95d275ec-bf2e-4e55-bcc0-9115cf6c8eff", "1d86da0f-d520-45f4-939d-a24176ddbc9e", "66531c36-360b-4440-a3eb-2b4ed7b4a2fd", "a6e2d79d-81ca-4db1-92f9-7251ac6dca1f", "5084f07c-a65a-4d83-a92d-4d45b7548e47", "2fbc4205-307b-4a73-bd15-e03be0e9eafb", "98a05cd2-8be3-4d0e-866b-d99aaa0e83d5", "4f88a1af-763c-4227-ac13-76de9e0c9a9a", "c5f7921f-8548-414f-8ee6-531f636eedd2", "b52b05d4-f28d-4768-83fd-9f8a1d4621e0", "80155aba-3543-4412-abf4-54e91ce284cd", "48f53da9-bc9b-4aae-8ccf-c7b3a5cb5cea", "cdef0dca-05ba-4b80-a246-b6d0423d210c", "943e96df-bb67-4d56-8fb0-5d3c991f1834", "772e284a-cf40-4877-92b8-7e38dc0e6e04", "d0af590c-5992-4fcd-acd9-93267ef4ec8d", "d5e5fe7d-a9ab-4901-85a8-2ce015295a71", "c2551b75-c7eb-4733-8487-521ac3475e15"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : And next will be Daniel Grosslight with Citi.  Please go ahead.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nDaniel Grosslight  \nAnalyst, Citigroup Global Markets, Inc.  ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "bfaa0a74-fab6-43a0-b29b-309f1d69910c": {"node_ids": ["7321ac7b-0ba1-4727-a497-a11fb189bb72", "3c63f137-08d3-4f77-888b-35d9403c830d", "e22a3cc0-0749-4537-859e-d622a273e69f", "cf7755b7-4064-4e7b-9291-bc26fd269000", "c352993a-4906-457f-9f67-6fc25e78c459", "88611dc9-2a77-4850-a8b6-c15fe0f9dc85", "041eed41-3963-4ecf-8120-f77e8e163be9", "6c30aeba-44e8-4f34-a5ef-a82aa4adbd97", "ca776b91-6f0b-4ad6-be7e-6a861f34a227", "060fec8e-4535-4e5d-967f-b1e43947b241", "84ef6f33-c9d0-47d0-ae79-224d9339f77d", "3031bd59-0ec5-4ef1-87f8-68330016e642", "3d683b71-93cf-431d-a4a7-735b762ad821", "c924104d-55ef-47c7-a25b-f655f7ff82f6", "4f52770d-6dd6-43ab-a39f-7628638b67b3", "2ef8ff38-b85f-4900-9c0d-9f4f0bb19696", "aeeff499-e42e-4662-863e-5b822e389029", "44013258-0b42-40b1-b43b-c16cc36c71aa", "429c6ff3-6f4c-4cc7-9a0b-cc6a2bf5bb55", "4f743523-2224-4b0d-aa03-1adffab55480", "dbab60af-25ec-47f3-8be2-2ab97eb6b2ff", "4248ce7a-c054-4549-a83d-880a1ddb0ec7", "1d0d066a-7d03-4cc5-bedb-cdd98271e426", "d0ae60f0-7ff0-4e53-8a3a-bf8471f792b6", "c9e9621c-421e-4905-b6cf-3f5307339fba", "0f65844a-670c-4e70-95c0-af0c398b83a2", "f0e1c978-eb3b-4b79-8474-4ac4fff43445", "d995c9b6-e4c5-442d-be02-887694d28f2b", "550410c3-3cfb-4d52-b7ba-c8ba8bd2e43f", "8641e5e4-24b0-4d3f-8217-c98926e0ffa6", "4511b8d2-f5ce-457c-8091-8ef31f786e2e", "36a34f9e-b916-400d-945f-4832084e43f2"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nTalked about a quarter or two ago about some innovations that we've made in RxTS segment and enhancing \nsome of our solutions and frankly, building and innovating and bringing new solutions.  So it's much like our \ninorganic investmen t. We are tied to our strategy and committed to business cases that we think will deliver more \nreturns.  \n \n I think the one area that we probably highlighted more this quarter than we have in the past is investments in \ntechnology AI, machine learning, obvious ly, that the developments and advancements in that field have come on \nfast. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "e90b37c4-c18d-42bd-97dc-36f7f75521b1": {"node_ids": ["bed96950-91f5-4f08-aa1b-56d61e02782a", "c2070b14-125b-4e58-b184-1e1cd015334c", "515f07be-6892-4ffe-aff7-72db5f10be1f", "20544eb7-d992-4557-a73d-56baacdc0a45", "5fa665b3-8706-499b-b0be-087c997ddec8", "271904d0-4b5c-47db-8059-83c3378ac5bb", "51e94653-4f27-446c-a831-cad2cfee06e0", "9995193b-c6af-47e1-8f02-a3105d6b18b6", "b1a53267-2f6a-43f1-acad-f17d46b94ba3", "b6db3cf3-9d22-4d22-b35a-a5977c333e99", "3f9acab3-a020-4eae-82a2-d00e2c1d1d22", "eb72140c-d03c-406f-a8c1-7c11f8893e18", "5e45652d-5860-4fe1-a27a-264e6a0fe16c", "4f0bb05e-accb-459e-8871-e3124823f339", "a649ca3b-cce7-4c1a-8324-da8f3e1021b6", "d85e9ab4-68ec-4228-8219-1f283b933218", "19354937-ab9e-44ae-81ed-18b9a2bdfdd4", "d8ead45d-90ec-482e-bbcf-6919c5940a92", "71aba4e5-1f7b-4be1-ac1e-b1fe8c3d7ba5", "1d0a4343-6a15-4357-930a-268428c6c1c7", "5fae82da-4155-4a05-b15f-a5bc0c2dcae7", "af349817-c5ce-458b-bd71-ded040e24caf", "e4a4794d-210b-47c8-bf78-66e49aee41b8", "cb1a9918-3bda-4a79-812d-8ec69734ea20", "847b91c3-e3df-405a-8d9c-2d64de6cc33e", "9acaaedf-91d3-4fd0-8254-62231dcd9a06", "7a6b5b37-b274-4496-bb75-1cdfc3184e8b", "861920fd-4c41-4e09-9443-9d29aee4df3f", "d3b736fa-baec-49a8-8201-c5c2ee68a43b", "7ace9cb8-cf9e-462d-a180-7191f9d1187a", "c7db2a64-44e4-453c-b597-18bd43eadcf0", "944b4ef9-838c-478e-b794-f24df46b39bc", "5bc2959a-84cf-488b-af2a-2a57726a644d", "20b62843-d733-4c42-9c69-3968ecb0d7b5", "37d57c85-c95e-4777-b716-c2c8d875767d", "4b9798e4-502c-48ea-9fbc-4589239522a0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \nAnd the answer to your first question as we've talked about GLP -1s previously and today, we are talking about \nmargin rate.  They usually come at a lower margin rate than other products that we distribute.  And as I mentioned, \nthey have been an operating profit headwind year -over-year.  \n ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7016fcf0-b3b3-40e7-a8bd-5d1f3e6b0b61": {"node_ids": ["b94e05d0-f254-4879-9178-5a1b7b06d007", "3b24c4f9-0c3d-420a-9064-b431d09a0c77", "606bc9cb-da41-4851-b08c-bda55cab356a", "87d7c857-0349-4f36-9a49-2711de0ec4ca", "2d5dfefa-44f8-434e-9938-7a74d3da89c7", "d2758158-decb-462b-9933-d8e1539f2cac", "01979fb4-6665-48cc-bdbb-7f8a785988b8", "85777e0b-b710-418e-880b-f5c6ab99149e", "090d8db1-da83-4d13-b3a3-3da3b5a123bb", "0ec2e95d-a399-4bce-aa1e-2dae5d9e49cb", "985a97ad-feba-4b77-aa7a-fe0fd0fc293e", "4f64c347-9958-4172-9da4-4bb3dc10283c", "f13d8cff-c3a5-4361-b7eb-6e0e9e1e40fe", "ac746f40-0754-4f9d-a603-fe3fd2262d17", "d20859a5-9180-4394-9b8c-c752ac25e678"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2024 Earnings Call  Corrected Transcript  \n07-Feb-2024   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2024  FactSet  CallStreet, LLC  \n \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n \n \n \n \n Disclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a com plete or error -free statement or summary of the available data. \n", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q3-FY24-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY24-ECT.pdf", "file_type": "application/pdf", "file_size": 317346, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}